"AHC","PY","nTotDoc","meanAUPerArt","meanAU_IN_PerArt","meanArtAU_IN","meanArtPer_AU_IN_FIRST","meanArtPer_AU_IN_LAST","meanArtPer_AU_IN_CORR","ArtOA","singleAuArt","Q1_nSJR","Q2_nSJR","Q3_nSJR","Q4_nSJR","Q1_percSJR","Q2_percSJR","Q3_percSJR","Q4_percSJR","meanTCperArt","mean_NTC","InternCoauthorship","AffCoauthorship","meanCitationTrend","GC_AUIN_wFractional","GC_AUIN_FIRSTname","GC_AUIN_LASTname","GC_AUIN_CORRESP","top_AU","top_AU_freq","top_AU_wFract","top_AU_freq_wFract","top_AUIN","top_AUIN_freq","top_AUIN_wFract","top_AUIN_freq_wFract","topAUbyCit","topAUbyCit_TC","topAUINbyCit","topAUINbyCit_TC","topAUINbyCit_norm_byYear","topAUINbyCit_TC_norm_byYear","topConcept_L0","topFreq_L0","topConcept_L1","topFreq_L1","topConcept_L2","topFreq_L2","topConcept_L3","topFreq_L3","topConcept_L4","topFreq_L4","topMESH","topMESH_n","topprimary_topic.display_name","topprimary_topic.display_name_n","topDE","topDE_n","topTI_TM","topTI_TM_n","topAB_TM","topAB_TM_n","nDoc_wALTM","percDoc_wALTM","medianAltmetricScore","altmetric_score_mean_top25AltmScore","altmetric_score_min_top25AltmScore","altmetric_score_max_top25AltmScore","cited_by_accounts_count_mean_top25AltmScore","cited_by_accounts_count_min_top25AltmScore","cited_by_accounts_count_max_top25AltmScore","cited_by_fbwalls_count_mean_top25AltmScore","cited_by_fbwalls_count_min_top25AltmScore","cited_by_fbwalls_count_max_top25AltmScore","cited_by_feeds_count_mean_top25AltmScore","cited_by_feeds_count_min_top25AltmScore","cited_by_feeds_count_max_top25AltmScore","cited_by_gplus_count_mean_top25AltmScore","cited_by_gplus_count_min_top25AltmScore","cited_by_gplus_count_max_top25AltmScore","cited_by_msm_count_mean_top25AltmScore","cited_by_msm_count_min_top25AltmScore","cited_by_msm_count_max_top25AltmScore","cited_by_patents_count_mean_top25AltmScore","cited_by_patents_count_min_top25AltmScore","cited_by_patents_count_max_top25AltmScore","cited_by_peer_review_sites_count_mean_top25AltmScore","cited_by_peer_review_sites_count_min_top25AltmScore","cited_by_peer_review_sites_count_max_top25AltmScore","cited_by_policies_count_mean_top25AltmScore","cited_by_policies_count_min_top25AltmScore","cited_by_policies_count_max_top25AltmScore","cited_by_posts_count_mean_top25AltmScore","cited_by_posts_count_min_top25AltmScore","cited_by_posts_count_max_top25AltmScore","cited_by_rdts_count_mean_top25AltmScore","cited_by_rdts_count_min_top25AltmScore","cited_by_rdts_count_max_top25AltmScore","cited_by_rh_count_mean_top25AltmScore","cited_by_rh_count_min_top25AltmScore","cited_by_rh_count_max_top25AltmScore","cited_by_tweeters_count_mean_top25AltmScore","cited_by_tweeters_count_min_top25AltmScore","cited_by_tweeters_count_max_top25AltmScore","cited_by_videos_count_mean_top25AltmScore","cited_by_videos_count_min_top25AltmScore","cited_by_videos_count_max_top25AltmScore","cited_by_wikipedia_count_mean_top25AltmScore","cited_by_wikipedia_count_min_top25AltmScore","cited_by_wikipedia_count_max_top25AltmScore","cohorts.com_mean_top25AltmScore","cohorts.com_min_top25AltmScore","cohorts.com_max_top25AltmScore","cohorts.doc_mean_top25AltmScore","cohorts.doc_min_top25AltmScore","cohorts.doc_max_top25AltmScore","cohorts.pub_mean_top25AltmScore","cohorts.pub_min_top25AltmScore","cohorts.pub_max_top25AltmScore","cohorts.sci_mean_top25AltmScore","cohorts.sci_min_top25AltmScore","cohorts.sci_max_top25AltmScore","readers.citeulike_mean_top25AltmScore","readers.citeulike_min_top25AltmScore","readers.citeulike_max_top25AltmScore","readers.connotea_mean_top25AltmScore","readers.connotea_min_top25AltmScore","readers.connotea_max_top25AltmScore","readers.mendeley_mean_top25AltmScore","readers.mendeley_min_top25AltmScore","readers.mendeley_max_top25AltmScore","readers_count_mean_top25AltmScore","readers_count_min_top25AltmScore","readers_count_max_top25AltmScore","n_patentsDistinct","nPatentStatus_Abandoned","nPatentStatus_Granted","nPatentStatus_N/A","nPatentStatus_Pending","nPatentStatus_Active","nPatentStatus_Not-in-force","nPatentStatus_Expired - Fee Related","nPatentStatus_Withdrawn","nPatentStatus_Ceased","nPatentStatus_Revoked","nPatentStatus_Expired - Lifetime","nPatentPubType_Application","nPatentPubType_Grant","nPatentPubType_N/A","avg_citations_Patent","avg_Inventors_Patent","avg_InstitutesInvolved_Patent","nPatent_singleInventor","n_Patents_CoAff","n_Jurisdiction_distinct","nJurisd_AU","nJurisd_CA","nJurisd_EP","nJurisd_IN","nJurisd_CN","nJurisd_US","nJurisd_DE","nJurisd_ES","nJurisd_IT","nJurisd_AT","nJurisd_BR","nJurisd_WO","nJurisd_JP","nJurisd_DK","nJurisd_IL","nJurisd_PT","nJurisd_PL","nJurisd_FR","nJurisd_SA","nJurisd_MY","nJurisd_KR","nJurisd_NL","nJurisd_CO","nJurisd_SM","nJurisd_SI","nJurisd_HR","nJurisd_RU","nJurisd_EA","nJurisd_MX","nJurisd_HK","nPatentKC_A1","nPatentKC_A","nPatentKC_A2","nPatentKC_B1","nPatentKC_D1","nPatentKC_T3","nPatentKC_B2","nPatentKC_T1","nPatentKC_A3","nPatentKC_C","nPatentKC_B","nPatentKC_C2","nPatentKC_C0","nPatentKC_A8","nPatentKC_E","nPatentKC_T4","nPatentKC_D0","nPatentKC_T2","nPatentKC_A0","nPatentKC_B8","nPatentKC_A4","nPatentKC_T8","nPatentKC_C1","nPatentKC_U1","nPatentKC_T5","nPatentKC_B3","nPatentKC_T7","nPatentKC_A9","top_Inventor names_Patent","top_Inventor names_Patent_n","top_Original assignee names_Patent","top_Original assignee names_Patent_n","top_Fields of Research (ANZSRC 2020)_Patent","top_Fields of Research (ANZSRC 2020)_Patent_n","top_RCDC Categories_Patent","top_RCDC Categories_Patent_n","top_HRCS RAC Categories_Patent","top_HRCS RAC Categories_Patent_n","top_IPCR_Patent","top_IPCR_Patent_n","top_CPC_Patent","top_CPC_Patent_n","n_grants","avg_funding_EUR","avg_funding_EUR_perOrganization","avg_durationYear_grant","avg_Organization_per_grant","avg_countries_per_grant","perc_grant_internazionali","avg_ResultingPublications_per_grant","top_Research Organization - standardized_Grants","top_Research Organization - standardized_n_Grants","top_Funder_Grants","top_Funder_n_Grants","top_Funder Group_Grants","top_Funder Group_n_Grants","top_Program_Grants","top_Program_n_Grants","top_Fields of Research (ANZSRC 2020)_Grants","top_Fields of Research (ANZSRC 2020)_n_Grants","top_RCDC Categories_Grants","top_RCDC Categories_n_Grants","top_HRCS HC Categories_Grants","top_HRCS HC Categories_n_Grants","top_HRCS RAC Categories_Grants","top_HRCS RAC Categories_n_Grants","top_Cancer Types_Grants","top_Cancer Types_n_Grants","top_CSO Categories_Grants","top_CSO Categories_n_Grants","top_Units of Assessment_Grants","top_Units of Assessment_n_Grants","top_Sustainable Development Goals_Grants","top_Sustainable Development Goals_n_Grants","n_dataset","top_Repository_Dataset","top_Repository_Dataset_n","top_Fields of Research (ANZSRC 2020)_Dataset","top_Fields of Research (ANZSRC 2020)_Dataset_n","top_RCDC Categories_Dataset","top_RCDC Categories_Dataset_n","top_HRCS HC Categories_Dataset","top_HRCS HC Categories_Dataset_n","top_HRCS RAC Categories_Dataset","top_HRCS RAC Categories_Dataset_n","top_Health Research Areas_Dataset","top_Health Research Areas_Dataset_n","top_Broad Research Areas_Dataset","top_Broad Research Areas_Dataset_n","top_Cancer Types_Dataset","top_Cancer Types_Dataset_n","top_Sustainable Development Goals_Dataset","top_Sustainable Development Goals_Dataset_n","n_clTrial","avg_durationYear_clTrial","avg_participants_clTrial","nClTrial_w_AltmScore","avg_sponsor_clTrial","nclTrialPhase_Phase 1","nclTrialPhase_Phase 1/2","nclTrialPhase_Phase 2","nclTrialPhase_Phase 2/3","nclTrialPhase_Phase 3","nclTrialPhase_Phase 3/4","nclTrialPhase_Phase 4","nclTrialPhase_N/A","nclTrialPhase_Post Authorisation Studies","nclTrial_StudyType_Interventional","nclTrial_StudyType_Observational","nclTrial_StudyType_Other","nclTrial_StudyType_Expanded access","nclTrial_StudyType_Active surveillance","nclTrial_StudyType_Non-interventional","nclTrial_StudyType_RCT","nclTrial_StudyType_CCT","nclTrial_Gender_All","nclTrial_Gender_Female","nclTrial_Gender_Male","nclTrial_Registry_ClinicalTrials.gov","nclTrial_Registry_EU-CTR","nclTrial_Registry_ENCePP","nclTrial_Registry_ISRCTN","nclTrial_Registry_ANZCTR","nclTrial_Registry_GCTR","nclTrial_Registry_PACTR","nclTrial_Registry_CTRI","nclTrial_Registry_ReBEC","nclTrial_Registry_UMIN-CTR","top_funder_country","top_funder_country_n","top_Fields of Research (ANZSRC 2020)_clTrial","top_Fields of Research (ANZSRC 2020)_clTrial_n","top_RCDC Categories_clTrial","top_RCDC Categories_clTrial_n","top_HRCS HC Categories_clTrial","top_HRCS HC Categories_clTrial_n","top_HRCS RAC Categories_clTrial","top_HRCS RAC Categories_clTrial_n","top_Cancer Types_clTrial","top_Cancer Types_clTrial_n","top_CSO Categories_clTrial","top_CSO Categories_clTrial_n"
"AOU_PISANA",2000,34,6.8235294117647,2.5,0.4,0.558823529411765,0.382352941176471,0.205882352941176,0.264705882352941,5,12,11,4,5,0.35,0.32,0.12,0.15,37.74,0.832439450862192,0.0882352941176471,0.735294117647059,0,0.470599801393453,0.203125,0.238636363636364,0.065934065934066,"ALDO PINCHERA;ANDREA PIETRABISSA;FRANCO MOSCA;G. M. PACIFICI;C. GIUNTINI;GIUSEPPE FABIO PARISI;CHIARA DE SANTI;DOMENICO CANALE;PAOLO MICCOLI;MICHELE BERTONI;FRANCESCO MASSEI;MASSIMO TONACCHERA;E. FORNAI;G. BRESCI;A. CAPRIA;GRAZIA SALIMBENI;MARIO MARIANI;PIER LUIGI PAGGIARO;D GANDINI;P. CONIGLI","3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","PIER LUIGI PAGGIARO;FRANCESCO MASSEI;MASSIMO TONACCHERA;GRAZIA SALIMBENI;LUIGI BARTALENA;ANDREA PIETRABISSA;FRANCO MOSCA;G. M. PACIFICI;DOMENICO CANALE;S. PISTOIA;CHIARA DE SANTI;GIUSEPPE FABIO PARISI;MICHELE BERTONI;G. BRESCI;A. CAPRIA;MARIO MARIANI;ALDO PINCHERA;C. GIUNTINI;MARCO DE CARLO;UBERTO BORTOLOTTI","1.17;1.14;1.09;1.06;1;0.7;0.7;0.7;0.67;0.5;0.45;0.42;0.42;0.42;0.42;0.36;0.36;0.35;0.33;0.33","ALDO PINCHERA;ANDREA PIETRABISSA;FRANCO MOSCA;G. M. PACIFICI;C. GIUNTINI;GIUSEPPE FABIO PARISI;DOMENICO CANALE;PAOLO MICCOLI;MICHELE BERTONI;FRANCESCO MASSEI;MASSIMO TONACCHERA;E. FORNAI;G. BRESCI;A. CAPRIA;GRAZIA SALIMBENI;MARIO MARIANI;PIER LUIGI PAGGIARO;D GANDINI;PIERO MARCHETTI;ANTONIO GIUSEPPE NACCARATO","3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1","PIER LUIGI PAGGIARO;FRANCESCO MASSEI;MASSIMO TONACCHERA;GRAZIA SALIMBENI;LUIGI BARTALENA;ANDREA PIETRABISSA;FRANCO MOSCA;G. M. PACIFICI;DOMENICO CANALE;GIUSEPPE FABIO PARISI;MICHELE BERTONI;G. BRESCI;A. CAPRIA;MARIO MARIANI;ALDO PINCHERA;C. GIUNTINI;MARCO DE CARLO;UBERTO BORTOLOTTI;ALDO MILANO;E. FORNAI","1.17;1.14;1.09;1.06;1;0.7;0.7;0.7;0.67;0.42;0.42;0.42;0.42;0.36;0.36;0.35;0.33;0.33;0.33;0.26","ANDREA PIETRABISSA;FRANCO MOSCA;G. M. PACIFICI;CHIARA DE SANTI;LUIGI BARTALENA;ROBERTO SPISNI;ANNAROSA ARCANGELI;BARBARA ROSATI;ENZO WANKE;MARZIA LECCHI;MASSIMO OLIVOTTO;OLIVIA CROCIANI;PIERO MARCHETTI;R LUPI;BARBARA CASTELLOTTI;C. MARCHINI;CARLO ANTOZZI;CATERINA MARIOTTI;CINZIA GELLERA;DANIELA TESTA","317;317;317;273;252;142;131;131;131;131;131;131;131;131;127;127;127;127;127;127","ANDREA PIETRABISSA;G. M. PACIFICI;LUIGI BARTALENA;PIERO MARCHETTI;R LUPI;GABRIELE SICILIANO;MASSIMO TONACCHERA;ALDO PINCHERA;ANNA PERRI;ANTONIO GIUSEPPE NACCARATO;GIOVANNI CECCARINI;LUCA CHIOVATO;PAOLO MICCOLI;PAOLO VIACAVA;PAOLO VITTI;PATRIZIA AGRETTI;V. ROSELLINI;ROBERTO PEDRINELLI;FRANCESCO MESSINA;FRANCO MOSCA","317;273;252;131;131;127;108;103;84;84;84;84;84;84;84;84;84;58;45;44","ANDREA PIETRABISSA;A. CAPRIA;ALDO PINCHERA;DOMENICO CANALE;G. BRESCI;G. M. PACIFICI;GIUSEPPE FABIO PARISI;GRAZIA SALIMBENI;MASSIMO TONACCHERA;MICHELE BERTONI;ALBERTO BALBARINI;ANNA PERRI;ANTONIO GIUSEPPE NACCARATO;BERTONI;BRESCI;CAPRIA;CLAUDIO MARCOCCI;CLAUDIO TRAINO;D GANDINI;E. MARTINO","3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;POLITICAL SCIENCE;SOCIOLOGY","30;11;5;3;2;1;1","INTERNAL MEDICINE;PATHOLOGY;IMMUNOLOGY;SURGERY;BIOCHEMISTRY;ENDOCRINOLOGY;PHARMACOLOGY;GASTROENTEROLOGY;RADIOLOGY;VIROLOGY;CARDIOLOGY;GENETICS;ANESTHESIA;DERMATOLOGY;FAMILY MEDICINE;INTENSIVE CARE MEDICINE;CANCER RESEARCH;CHROMATOGRAPHY;GENDER STUDIES;LAW;NUCLEAR MEDICINE;ONCOLOGY;OPTICS;ORGANIC CHEMISTRY;PALEONTOLOGY;PEDIATRICS;QUANTUM MECHANICS;THERMODYNAMICS;UROLOGY","23;9;8;8;7;6;6;5;4;4;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","DISEASE;GENE;VIRUS;CANCER;CHEMOTHERAPY;ENZYME;INTERFERON;LUNG;THYROID;ANGIOGRAPHY;ANTIBODY;ANTIOXIDANT;ASTHMA;BARTONELLA;BIOAVAILABILITY;HEPATITIS C;HORMONE;LUMBAR;LYMPH NODE;RANDOMIZED CONTROLLED TRIAL;RESVERATROL;TRANSPLANTATION","6;6;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","ALPHA INTERFERON;RECOMBINANT DNA;VIRAL DISEASE;BREAST CANCER;CAT-SCRATCH DISEASE;CHRONIC HEPATITIS;FLAVONOID;GRAVES' DISEASE;MICROSOME;MUTATION;POLYPHENOL;QUERCETIN;SEROLOGY;VIRAL LOAD;AGE OF ONSET;ALLELE;AMLODIPINE;ANDROGEN;ANGIOTENSIN-CONVERTING ENZYME;ARGININE;ATOPY;AZATHIOPRINE;BONE DENSITY;BONE MINERAL;CISPLATIN;COMMON CAROTID ARTERY;CONSTRUCT VALIDITY;CROHN'S DISEASE;DEAD SPACE;DECREASED LIBIDO;DRUG HOLIDAY;ERYTHEMA NODOSUM;ESSENTIAL HYPERTENSION;EXON;FEMORAL NECK;FINGOLIMOD;GEMCITABINE;GENE EXPRESSION;GENOTYPE;GLICLAZIDE;GLUCURONIDE;GOITER;HEPATITIS C VIRUS;HERG;HIPPURIC ACID;IC50;INTIMA-MEDIA THICKNESS;ISLET;LEUKOPENIA;LUMBAR VERTEBRAE;LUPUS NEPHRITIS;LYMPHADENECTOMY;MAINTENANCE THERAPY;METASTASIS;MONONUCLEOSIS;MOTOR NEURON;MYCOPHENOLATE;MYCOPHENOLIC ACID;OCCULT;OCCUPATIONAL ASTHMA;PATCH CLAMP;PERFUSION SCANNING;PROLACTIN;PROSTATE CANCER;PSEUDOANEURYSM;RADICAL SURGERY;REPOLARIZATION;RESPIRATORY DISEASE;RNA;SPINAL MUSCULAR ATROPHY;SPIROMETRY;SPUTUM;TACROLIMUS;THYROID CANCER;THYROID NODULES;THYROIDECTOMY;TITER;TRANSAMINASE","3;3;3;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","APIGENIN;BARTONELLA HENSELAE;FISETIN;GLUCURONIDATION;KAEMPFEROL;RIBAVIRIN;SENTINEL LYMPH NODE;THYROTROPIN RECEPTOR;ALPHA (FINANCE);ANDROGEN RECEPTOR;ANTIRETROVIRAL THERAPY;BRONCHIAL HYPERRESPONSIVENESS;CARDIAC ACTION POTENTIAL;CATECHIN;DNA METHYLATION;ENALAPRIL;FLAVONOLS;GLUCURONOSYLTRANSFERASE;HERPESVIRIDAE;INTERFERON ALFA;LUTEOLIN;METHACHOLINE;MICROMETASTASIS;MULTINODULAR GOITER;PANCREATIC ISLETS;PAPILLARY THYROID CANCER;RNA SPLICING;SENTINEL NODE;SIDA;TERIFLUNOMIDE;TRINUCLEOTIDE REPEAT EXPANSION;VENTILATION PERFUSION MISMATCH","2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;ADULT;MIDDLE AGED;AGED;HEPATITIS C, CHRONIC;LIVER;LYMPH NODES;;ANTIVIRAL AGENTS;MELANOMA;SKIN NEOPLASMS;HIV INFECTIONS;ITALY;METHYLPREDNISOLONE;QUERCETIN;RNA, VIRAL;STILBENES;THYROID NEOPLASMS","26;20;18;17;17;10;9;9;9;8;7;7;7;6;6;6;6;6;6;6","HEPATITIS C INFECTION AND TREATMENT;BARTONELLA INFECTIONS AND ZOONOTIC POTENTIAL;KIDNEY TRANSPLANTATION;LONG-TERM EFFECTS OF TESTOSTERONE ON HEALTH;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;ROLE OF SIRTUINS IN HEALTH AND AGING;ADVANCEMENTS IN LUNG CANCER RESEARCH;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;DIAGNOSIS AND TREATMENT OF SYNOVIAL DISORDERS;EFFICACY AND SAFETY OF ANTIRETROVIRAL THERAPY FOR HIV;EVOLUTION OF CHILD HEALTH SERVICES IN EUROPE;FUNCTIONAL BOWEL DISORDERS AND GASTROINTESTINAL HEALTH;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;MANAGEMENT OF DIFFICULT AIRWAY IN ANESTHESIA PRACTICE;MANAGEMENT OF HYPERTENSION AND CARDIOVASCULAR RISK FACTORS;MELANOMA;MOLECULAR MECHANISMS OF AMYLOIDOSIS;MOLECULAR MECHANISMS OF CARDIAC ARRHYTHMIAS;MOLECULAR MECHANISMS OF NEURODEGENERATIVE DISEASES","3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","TREATMENT;BARTONELLA;CAT-SCRATCH DISEASE;FISETIN;HEPATITIS C;HYPERTHYROIDISM;HYPOTHYROIDISM;MYRICETIN;RESVERATROL;THYROID DYSFUNCTION;THYROID HORMONE;THYROID NODULES;THYROTROPIN RECEPTOR;ADOLESCENTS;ALLERGEN EXPOSURE;ALPHA (FINANCE);AMBULATORY MONITORING;AMLODIPINE;ANTIRETROVIRAL THERAPY;ARTERIAL STIFFNESS","3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","BARTONELLA HENSELAE;CHRONIC HEPATITIS;HENSELAE INFECTION;HUMAN LIVER;THYROTROPIN RECEPTOR;ACID GLUCURONIDATION;ACTIVATING THYROTROPIN;ADVANCED NONSMALL;AMLODIPINE ENALAPRIL;ANDROGEN RECEPTOR;ANTI-INFLAMMATORY DRUGS;ANTIRETROVIRAL THERAPY;ARGININEINDUCED INSULIN;ARTERY DISEASE;AUTONOMOUS MULTINODULAR;B-MODE ULTRASOUND;BICARBONATESULPHATECALCIUM WATER;BONE MINERAL;CAG-REPEAT EXPANSION;CAROTID INTIMA-MEDIA;CELL LUNG;CESSATION CLINIC;CHRONIC HYPOGLYCEMIC;CHRONIC PULMONARY;CLINICAL PRACTICE;CLINICAL SCREENING;CLINICAL SPECTRUM;CLINICAL TRIAL;COMPARATIVE STUDY;CORONARY ARTERY","2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","MG UID;AORTOBRONCHIAL FISTULA;LEG WEIGHT;MONTHS CI;THERMAL WATER;BLOOD FLOW;DR TOKER;FUNCTIONAL DYSPEPSIA;SKIN BLOOD;SURVIVAL RATES;TRIPLE THERAPY;ABDOMINAL SYMPTOMS;AMLODIPINE MG;DAY ARM;DELIVERED DOSES;DOSE INTENSITIES;DRUG WITHDRAWAL;FLUID EXTRAVASATION;HIGHLY SUGGESTIVE;INCREASED LEG;LEFT SUPERIOR;POSTURAL SKIN;POSTURAL VASOCONSTRICTION;RESPONSE RATES;SKIN VASOCONSTRICTION;THYROID SCINTISCAN;TOTAL DELIVERED;ABDOMINALASSOCIATED SYMPTOMS;ABUNDANT FRESH;ACCIDENTAL DISPLACEMENT","6;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1",2,0.06,2.5,4,4,4,2,2,2,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,2,2,2,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,88,88,88,89,89,89,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PISANA",2001,38,6.76315789473684,3.13157894736842,0.319327731092437,0.68421052631579,0.342105263157895,0.184210526315789,0.236842105263158,3,12,5,8,10,0.32,0.13,0.21,0.26,28.39,0.62143198446252,0.0526315789473684,0.605263157894737,0,0.405573437529904,0.307873090481786,0.35,0.107142857142857,"FRANCO FILIPPONI;FRANCO MOSCA;GÍANNI BIANCOFIORE;A VAGELLI;UGO BOGGI;S. VOLIANI;EMANUELE MARCIANO;FERRUCCIO BONINO;D. TEDESCHI;FRANCO MARTELLI;ANGELO GAZZANO;CLAUDIO VILLANI;CARLO DONADIO;P. ROSSI;FRANCESCA GALLUZZI;SILVANO BERTELLONI;JACOPO ROMAGNOLI;E MICHELETTI;CARLO TASCINI;LUCIO URBANI","7;7;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","FRANCESCO MENICHETTI;FRANCO MOSCA;ELISABETTA GIANNESSI MARGHERITA GIORGETTI;MASSIMO TONACCHERA;FRANCO FILIPPONI;ROBERTA DORIA;GÍANNI BIANCOFIORE;F MENICHETTI;CARLOTTA ROSSI;P MALACARNE;UGO BOGGI;A VAGELLI;CARLO DONADIO;M BINDI;MARCO LUCCHI;FRANCESCO GIUNTA;MASSIMO A. MARIANI;VAN OVEN H;JAN G. GRANDJEAN;A. PAOLICCHI","1.11;1.08;1;1;0.96;0.67;0.52;0.5;0.5;0.5;0.43;0.42;0.34;0.34;0.33;0.33;0.33;0.33;0.33;0.33","FRANCO FILIPPONI;FRANCO MOSCA;GÍANNI BIANCOFIORE;A VAGELLI;UGO BOGGI;S. VOLIANI;EMANUELE MARCIANO;FERRUCCIO BONINO;P. ROSSI;SILVANO BERTELLONI;JACOPO ROMAGNOLI;CARLO TASCINI;LUCIO URBANI;ROBERTA DORIA;M. A. BERTOZZI;FRANCESCO MENICHETTI;G CATALANO;M BINDI;PIERO MARCHETTI;MARCO LUCCHI","7;7;4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","FRANCESCO MENICHETTI;FRANCO MOSCA;ELISABETTA GIANNESSI MARGHERITA GIORGETTI;MASSIMO TONACCHERA;FRANCO FILIPPONI;ROBERTA DORIA;GÍANNI BIANCOFIORE;P MALACARNE;UGO BOGGI;A VAGELLI;M BINDI;MARCO LUCCHI;FRANCESCO GIUNTA;MASSIMO A. MARIANI;JAN G. GRANDJEAN;CARLO TASCINI;SILVANO BERTELLONI;EMANUELE MARCIANO;JACOPO ROMAGNOLI;LUCIO URBANI","1.11;1.08;1;1;0.96;0.67;0.52;0.5;0.43;0.42;0.34;0.33;0.33;0.33;0.33;0.28;0.28;0.24;0.24;0.24","FERRUCCIO BONINO;ANDREAS WACK;ANNALISA D’ANDREA;ANNALISA STILLA;FRANCO FILLIPONI;MARTA MOSCA;NICHOLAS M. VALIANTE;R. MAURIZIA BRUNETTO;SANDRA NUTI;SERGIO ABRIGNANI;STEFANIA CROTTA;UGO D’ORO;FRANCO MOSCA;FRANCO FILIPPONI;ANTONIO RISPO;ARRIGO ARRIGONI;BRUNA MALLARDI;CRISTINA COSCO;FABIANA CASTIGLIONE;FRANCESCA DE NIGRIS","457;454;454;454;454;454;454;454;454;454;454;454;150;107;101;101;101;101;101;101","FERRUCCIO BONINO;FRANCO FILLIPONI;MARTA MOSCA;R. MAURIZIA BRUNETTO;G. BRESCI;FRANCO MOSCA;GÍANNI BIANCOFIORE;UGO BOGGI;CARLA CAPPELLI;CARLO BARTOLOZZI;DAVIDE CARAMELLA;L BATTOLLA;LUCA MELAI;MICHELE BERTONI;PAOLA MASOLINO;PATRIZIA GIUSTI;SALVATORE MAZZEO;CARLO TASCINI;A BOLDRINI;A VAGELLI","457;454;454;454;101;78;78;68;67;67;67;67;67;67;67;67;67;66;64;64","FRANCO FILIPPONI;GÍANNI BIANCOFIORE;FRANCO MOSCA;CARLO TASCINI;EMANUELE MARCIANO;FERRUCCIO BONINO;FRANCESCO MENICHETTI;G CATALANO;JACOPO ROMAGNOLI;LUCIO URBANI;M. A. BERTOZZI;P. ROSSI;ROBERTA DORIA;S. VOLIANI;UGO BOGGI;A BOLDRINI;A BURELLI;A CAROBBI;A VAGELLI;A. COSTA","5;4;4;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;ECONOMICS;MATERIALS SCIENCE;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY","36;12;8;3;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;ENDOCRINOLOGY;IMMUNOLOGY;BIOCHEMISTRY;PATHOLOGY;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;ANESTHESIA;GENETICS;ORGANIC CHEMISTRY;UROLOGY;VIROLOGY;DERMATOLOGY;INTENSIVE CARE MEDICINE;RADIOLOGY;ANDROLOGY;CARDIOLOGY;GENERAL SURGERY;MICROBIOLOGY;PEDIATRICS","27;12;10;10;7;6;5;5;4;4;4;4;4;3;3;3;2;2;2;2;2","TRANSPLANTATION;DISEASE;GENE;POPULATION;VIRUS;CANCER;ENZYME;HORMONE;KIDNEY;RENAL FUNCTION;URINE;ANTIFUNGAL;BENZENE;CREATININE;HEPATITIS C;IN VITRO;LIVER DISEASE;OXIDATIVE STRESS;PATIENT SATISFACTION;SEMEN;SPERM;SPERMATOGENESIS;THYROID","8;5;5;5;5;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","LIVER TRANSPLANTATION;VIRAL DISEASE;COLORECTAL CANCER;FLUCONAZOLE;HEPATITIS C VIRUS;MUCONIC ACID;MUTATION;VASCULITIS;ANTIBIOTIC PROPHYLAXIS;ANTIBIOTIC RESISTANCE;ANTIBIOTIC THERAPY;BIOSYNTHESIS;BLOOD–BRAIN BARRIER;BONE MARROW TRANSPLANTATION;BREAST CANCER;BUDESONIDE;CEPHALOSPORIN;CHEMOTAXIS;COLLAGENASE;COLORECTAL SURGERY;CONSTRUCT VALIDITY;CORPUS ALBICANS;CROHN'S DISEASE;CYTOTOXIC T CELL;DEHYDROGENASE;EUTHYROID;EXON;FABRY DISEASE;GENE EXPRESSION;GENOTYPE;HEPATITIS B VIRUS;HUMAN CYTOMEGALOVIRUS;ILEOCECAL VALVE;INTEGRIN;INTEGRIN ALPHA M;INTERCELLULAR ADHESION MOLECULE-1;IOHEXOL;ISLET;ITRACONAZOLE;KIDNEY TRANSPLANTATION;LAPAROSCOPIC SURGERY;LEVOTHYROXINE;LONG QT SYNDROME;MEAN PLATELET VOLUME;MICROCARRIER;NEPHRECTOMY;NEUTROPENIA;NONSENSE;POLYMERASE CHAIN REACTION;PRION PROTEIN;SINUS RHYTHM;SPUTUM;STEROID;T CELL;THYMECTOMY;THYROGLOBULIN;THYROID HORMONE RECEPTOR;THYROID PEROXIDASE;THYROIDITIS;TORSADES DE POINTES;TRANSFECTION;TRIIODOTHYRONINE;TRYPSIN;TYPE 2 DIABETES;VIREMIA;XENOTRANSPLANTATION","5;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","ALPHA (FINANCE);ALPHA-GALACTOSIDASE;ANTIBIOGRAM;AUTOIMMUNE THYROIDITIS;BASILIXIMAB;BONE MARROW TRANSPLANT;BOVINE SPONGIFORM ENCEPHALOPATHY;CD18;CD81;COLONOSCOPY;DOLICHOL;FATAL FAMILIAL INSOMNIA;HBSAG;HEPACIVIRUS;HORMONE RECEPTOR;INTERLEUKIN 21;LIVING DONOR LIVER TRANSPLANTATION;LYMPHOCYTE FUNCTION-ASSOCIATED ANTIGEN 1;MALIC ENZYME;MISSENSE MUTATION;NATURAL KILLER CELL;OPPORTUNISTIC INFECTION;PANCREATIC ISLETS;POLYARTERITIS NODOSA;PROBAND;REPORTER GENE;RETINAL VASCULITIS;RETINITIS;SCRAPIE;SHORT QT SYNDROME;TORQUE TENO VIRUS;TRYPSINIZATION","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;LIVER TRANSPLANTATION;AGED;IMMUNOSUPPRESSIVE AGENTS;CROHN DISEASE;HEPATITIS C;ANIMALS;ITALY;ADOLESCENT;ANTIBODIES, MONOCLONAL;;AMIODARONE;ASTHMA;BARTONELLA INFECTIONS;CANDIDA ALBICANS;CENTRAL NERVOUS SYSTEM DISEASES","29;21;19;18;15;12;9;8;7;7;6;6;5;5;4;4;4;4;4;4","DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;KIDNEY TRANSPLANTATION;MALE REPRODUCTIVE HEALTH;THYROID DISEASE AND HORMONE REGULATION;BARTONELLA INFECTIONS AND ZOONOTIC POTENTIAL;CHRONIC KIDNEY DISEASE AND DIALYSIS TREATMENT;CHRONIC KIDNEY DISEASE AND ITS IMPLICATIONS;COLORECTAL CANCER RESEARCH AND TREATMENT;EMERGING ANIMAL PATHOGENS AND DISEASES;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES;EVOLUTION OF CHILD HEALTH SERVICES IN EUROPE;GENETIC BASIS OF NEUTROPENIA DISORDERS;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;HEALTH EFFECTS OF AIR POLLUTION;HEPATITIS B INFECTION AND TREATMENT;HEPATITIS C INFECTION AND TREATMENT;IMPROVING COMMUNICATION IN REFERRAL PROCESS;INFLAMMATION'S ROLE IN CANCER DEVELOPMENT AND PROGRESSION;LABORATORY MEDICINE AND TESTING PROCEDURES;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS","2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HEPATITIS C;LIVER DISEASE;LIVING DONOR LIVER TRANSPLANTATION;MUCONIC ACID;SEMEN ANALYSIS;THYROID HORMONE;TREATMENT;ACUTE PAIN;ADOLESCENTS;ALPHA (FINANCE);ALPHA-GALACTOSIDASE;ANAL CANCER;ANIMAL MODEL;ANTIBIOGRAM;ANTIBIOTIC RESISTANCE;ANTIBIOTIC THERAPY;ANTIFUNGAL RESISTANCE;ANTIOXIDANT SUPPLEMENTATION;ASTHMA;AUTOIMMUNE THYROIDITIS","2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","LIVER TRANSPLANT;TRANSPLANT RECIPIENTS;HUMAN SEMINAL;SEMINAL PLASMA;TRANS TRANS-MUCONIC;TRANS-MUCONIC ACID;TRANSPLANT PATIENTS;TRANSPLANT RECIPIENT;ACUTE PULMONARY;ACUTE REJECTION;ADHESION CHEMOTAXIS;ADOLESCENT HEALTH;ADOLESCENTOLOGYS STUDY;AIRWAY RESPONSE;ALBICANS INFECTIONS;ANTERIOR RESECTION;ANTIBIOTIC THERAPY;AUTOIMMUNE THYROIDITIS;BARTONELLA HENSELAE;BELLA POLYCHEMOTHERAPY;BODY COMPOSITION;BONE MARROW;BOWEL SPIRAL;BUDESONIDE REDUCES;CADAVERIC KIDNEY;CANDIDA ALBICANS;CENTRAL NERVOUS;CEREBROSPINAL FLUID;CHEMOPROPHYLACTIC PROTOCOLS;CLINICAL EVIDENCE","6;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PUBMED SCOPUS;THYROID HORMONE;NG ML-;NG NA;CROSSREF PUBMED;LEFT EYE;NK CELLS;OPHTHALMOL -ABSTRACT;HCV INFECTION;SERUM TSH;TRACHEAL EXTUBATION;ALOPHTHALMIC MANIFESTATIONS;COSMETIC RESULTS;FANOUS MM;GOLNIK KC;HBV INFECTION;HCV PREVALENCE;HORMONE LEVELS;IGM TITER;IMMUNOMODULATORY DRUGS;KC MAROTTO;NK CELL;OCULAR BARTONELLOSIS;OPHTHALMOL -CROSSREF;ROCHALIMAEA SPECIESAM;SURG -ABSTRACT;THORAC SURG;TSH CONCENTRATION;TT-MA LEVELS;ABSTRACT PUBMED","16;9;6;6;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2",1,0.03,3,3,3,3,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,45,45,45,45,45,45,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PISANA",2002,45,7.57777777777778,2.8,0.357142857142857,0.466666666666667,0.4,0.111111111111111,0.266666666666667,2,14,7,9,13,0.31,0.16,0.2,0.29,30.07,0.544994914420816,0.2,0.777777777777778,0,0.420486425468593,0.25,0.316430020283976,0.333333333333333,"FRANCO MOSCA;ANDREA PIETRABISSA;FRANCO FILIPPONI;G. M. PACIFICI;LUCIO URBANI;GÍANNI BIANCOFIORE;MARIA TERESA VIETRI;MARIO DEL TACCA;ELENA BACCI;BARBARA VAGAGGINI;SILVANA CIANCHETTI;S. CARNEVALI;L BINDI;D. GIANNINI;ENZO PASQUALE SCILINGO;ISABELLA LUPI;MICHELE BERTONI;RENATO VANACORE;FAUSTO BOGAZZI;F. LORUSSI","8;6;5;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2","FRANCO MOSCA;ANDREA PIETRABISSA;G. M. PACIFICI;NICOLINO AMBROSINO;L. CIONINI;MARIA TERESA VIETRI;ALBERTO BALBARINI;FRANCO FILIPPONI;MARIO DEL TACCA;PIERO MARCHETTI;PAUL DE VOS;MARCO NUTI;GÍANNI BIANCOFIORE;LUCIO URBANI;ENZO PASQUALE SCILINGO;F. LORUSSI;P. ORSINI;CARLO TASCINI;ALBERTO MAZZOLDI;DANILO DE ROSSI","1.36;1.26;1.12;1;1;0.87;0.59;0.54;0.53;0.5;0.5;0.5;0.43;0.41;0.4;0.4;0.4;0.4;0.4;0.4","FRANCO MOSCA;ANDREA PIETRABISSA;FRANCO FILIPPONI;G. M. PACIFICI;LUCIO URBANI;GÍANNI BIANCOFIORE;ELENA BACCI;BARBARA VAGAGGINI;SILVANA CIANCHETTI;S. CARNEVALI;L BINDI;D. GIANNINI;ENZO PASQUALE SCILINGO;ISABELLA LUPI;MICHELE BERTONI;RENATO VANACORE;FAUSTO BOGAZZI;PIERFRANCO CONTÉ;P. ORSINI;MAURO FERRARI","8;6;5;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2","FRANCO MOSCA;ANDREA PIETRABISSA;G. M. PACIFICI;NICOLINO AMBROSINO;L. CIONINI;ALBERTO BALBARINI;FRANCO FILIPPONI;PIERO MARCHETTI;GÍANNI BIANCOFIORE;LUCIO URBANI;ENZO PASQUALE SCILINGO;P. ORSINI;CARLO TASCINI;MICHELE BERTONI;ELENA BACCI;BARBARA VAGAGGINI;SILVANA CIANCHETTI;S. CARNEVALI;D. GIANNINI;L BINDI","1.36;1.26;1.12;1;1;0.59;0.54;0.5;0.43;0.41;0.4;0.4;0.4;0.38;0.31;0.31;0.31;0.31;0.31;0.3","A MARMONT;A. KASHYAP;A. KAZIS;ALAN TYNDALL;ALOÏS GRATWOHL;ANDREAS STECK;BERND HERTENSTEIN;ENRIC CARRERAS;EVA HAVRDOVÁ;F. J. ZUAZU NAGORE;FEDERICO PAPINESCHI;FRANCESC GRAUS;GIANLUIGI MANCARDI;GIORGIO LA NASA;HARRY OPENSHAW;J HANSZ;JACOB M. ROWE;JAKOB PASSWEG;JOAN BESALDUCH;L FOUILLARD","263;263;263;263;263;263;263;263;263;263;263;263;263;263;263;263;263;263;263;263","FEDERICO PAPINESCHI;PIERO MARCHETTI;GÍANNI BIANCOFIORE;D GANDINI;E. PARDINI;P BOTTONE;ROBERTO DIMITRI;MICHELE BERTONI;PIERFRANCO CONTÉ;FRANCO FILIPPONI;ANNA SONIA PETRONIO;CARMELA NARDI;G PATERNI;GIUSEPPE MUSUMECI;MARCO DE CARLO;MARIA GRAZIA DELLE DONNE;MARIO MARIANI;PAOLO CARAVELLI;ROBERTO BAGLINI;UGO LIMBRUNO","263;138;88;83;83;83;83;79;71;68;67;67;67;67;67;67;67;67;67;67","FRANCO MOSCA;FRANCO FILIPPONI;GÍANNI BIANCOFIORE;ANDREA PIETRABISSA;CARLO TASCINI;F. MENICHETTI;LUCIO URBANI;MAURO FERRARI;MICHELE BERTONI;P. ORSINI;PIERFRANCO CONTÉ;RENATO VANACORE;A BOLDRINI;A CILOTTI;A PRECISI;A. BIONDA;A. CAPRIA;A. DANELLA;ALDO PINCHERA;ALESSANDRA GENNARI","4;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PHYSICS;ECONOMICS;ENGINEERING;PHILOSOPHY;MATHEMATICS","40;13;10;6;5;3;2;2;1","INTERNAL MEDICINE;SURGERY;GASTROENTEROLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;CHROMATOGRAPHY;IMMUNOLOGY;PATHOLOGY;ANESTHESIA;ARTIFICIAL INTELLIGENCE;COMPUTER VISION;PHARMACOLOGY;RADIOLOGY;ANATOMY;CARDIOLOGY;DERMATOLOGY;ECOLOGY;ECONOMIC GROWTH;EMBEDDED SYSTEM;GENERAL SURGERY;GENETICS;HUMAN–COMPUTER INTERACTION;INTENSIVE CARE MEDICINE;LINGUISTICS;MECHANICAL ENGINEERING;MICROBIOLOGY;ONCOLOGY;OPERATING SYSTEM;OPTICS;PEDIATRICS;PHYSICAL MEDICINE AND REHABILITATION;QUANTUM MECHANICS","31;15;11;9;9;6;6;6;4;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","TRANSPLANTATION;CANCER;DISEASE;ENZYME;ASTHMA;CHEMOTHERAPY;GENE;HORMONE;INFLAMMATION;PHARMACOKINETICS;TUBERCULOSIS;ALTERNATIVE MEDICINE;ANTIFUNGAL;ANTIOXIDANT;DIABETES MELLITUS;DUODENUM;HEALTH CARE;IN VITRO;INSULIN;METABOLISM;NIFLUMIC ACID;STEM CELL;SULFATION;VIRTUAL REALITY;VOMITING;WEARABLE COMPUTER","7;5;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LIVER TRANSPLANTATION;SPUTUM;BREAST CANCER;COLORECTAL CANCER;EOSINOPHIL;FLAVONOID;FLUCONAZOLE;GLUCURONIDE;ITRACONAZOLE;MICROSOME;PLACEBO;ABDOMINAL AORTIC ANEURYSM;AGONIST;AMIODARONE;AMPHOTERICIN B;ANDROGEN;ANTIBACTERIAL AGENT;AORTIC ANEURYSM;AORTIC VALVE STENOSIS;APOLIPOPROTEIN B;AZITHROMYCIN;BIOSYNTHESIS;BONE DENSITY;BONE MINERAL;C-REACTIVE PROTEIN;CARDIOGENIC SHOCK;CHROMOSOME;CUSHING'S DISEASE;CYCLOPHOSPHAMIDE;DIABETIC RETINOPATHY;DIURESIS;DOWNREGULATION AND UPREGULATION;DYSLIPIDEMIA;ECONOMIC SHORTAGE;ENDOTHELIAL STEM CELL;EPIGASTRIC PAIN;FLUOROURACIL;GASTRIC ACID;GASTRIC EMPTYING;GEMCITABINE;GIST;GOITER;GRAVES' DISEASE;GROWTH HORMONE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;IC50;INFLAMMATORY CELL;INSULIN RESISTANCE;ISLET;KETOROLAC;LAPAROSCOPIC SURGERY;LEPTIN;LIPIDOLOGY;LUMBAR PUNCTURE;MATRIGEL;METHYLATION;NEURORADIOLOGY;NEUTROPENIA;PACLITAXEL;PATIENT SAFETY;PEPSIN;PERCUTANEOUS CORONARY INTERVENTION;PERIPHERAL BLOOD MONONUCLEAR CELL;PHARMACODYNAMICS;PORTAL HYPERTENSION;PORTAL VEIN THROMBOSIS;POSTPRANDIAL;PROGENITOR CELL;PROINFLAMMATORY CYTOKINE;PROSTATE CANCER;PULMONARY REHABILITATION;QUERCETIN;RESPIRATORY DISEASE;RESPIRATORY TRACT;REVASCULARIZATION;SALMETEROL;SPIROMETRY;STROMAL TUMOR;SULFOTRANSFERASE;SYNGENIC;TELEOPERATION;THROMBOLYSIS;THYROIDECTOMY;THYROIDITIS;TRAMADOL;TRIIODOTHYRONINE;ULCERATIVE COLITIS;UNDERACTUATION;UPPER BODY;WHITE ADIPOSE TISSUE;XENOTRANSPLANTATION","4;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","GLUCURONIDATION;ABCIXIMAB;ADIPOSE TISSUE MACROPHAGES;APOMORPHINE;BECLOMETASONE DIPROPIONATE;BRCA MUTATION;BRONCHIAL HYPERRESPONSIVENESS;COLONOSCOPY;DEIODINASE;DOLICHOL;ENDOVASCULAR ANEURYSM REPAIR;EOSINOPHIL CATIONIC PROTEIN;EPIRUBICIN;FISETIN;FLUCYTOSINE;KARYOTYPE;MACE;MAMMOGRAPHY;METHACHOLINE;ORTHOTOPIC LIVER TRANSPLANTATION;PANCREATIC ISLETS;POLYCYSTIC OVARY;PROCTITIS;PROSTATE-SPECIFIC ANTIGEN;THYMIDYLATE SYNTHASE;TOTAL BODY IRRADIATION","2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;LIVER TRANSPLANTATION;POSTOPERATIVE COMPLICATIONS;AGED;SPUTUM;ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL;ASTHMA;LIVER DISEASES;LIVER;;BREAST NEOPLASMS;FLUOROURACIL;TREATMENT OUTCOME;DUODENUM;FEVER;HEPATITIS C","36;27;26;25;18;12;12;11;10;9;9;9;8;7;7;7;7;6;6;6","ASTHMA;EPIDEMIOLOGY AND MANAGEMENT OF FUNGAL INFECTIONS;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;NUCLEOTIDE METABOLISM AND ENZYME REGULATION;PANCREATIC ISLET DYSFUNCTION AND REGENERATION;WEARABLE NANOGENERATOR TECHNOLOGY;ABDOMINAL COMPARTMENT SYNDROME AND INTRA-ABDOMINAL HYPERTENSION;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ANALYSIS OF ELECTROMYOGRAPHY SIGNAL PROCESSING;ANESTHESIA AND SEDATION MANAGEMENT;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHOLESTEROL-LOWERING TREATMENT;DETECTION AND MANAGEMENT OF RETINAL DISEASES;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND PATHOGENESIS OF MULTIPLE SCLEROSIS;DIAGNOSIS AND TREATMENT OF GASTROINTESTINAL STROMAL TUMORS;ELECTRIC DISCHARGE PUMPED LASERS;EPIDEMIOLOGY OF MULTIPLE PRIMARY CANCERS;ETHICAL AND MEDICAL ASPECTS OF ORGAN DONATION;FUNCTIONAL BOWEL DISORDERS AND GASTROINTESTINAL HEALTH","3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LIVER TRANSPLANTATION;DRY POWDER INHALERS;GLUCURONIDE;LIVING DONOR LIVER TRANSPLANTATION;NIFLUMIC ACID;STRETCHABLE SENSORS;TREATMENT;WEARABLE;ABCIXIMAB;ABDOMINAL WALL RECONSTRUCTION;ACUTE-ON-CHRONIC LIVER FAILURE;ADIPOSE TISSUE MACROPHAGES;ADVANCED LIFE SUPPORT;ALANINE AMINOTRANSFERASE;ANAL CANCER;ANALYSER;ANEURYSM SCREENING;ANTIFUNGAL RESISTANCE;ANTIFUNGAL THERAPY;AORTIC STENOSIS","3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","HUMAN LIVER;ACID GLUCURONIDATION;CLINICAL MICROBIOLOGICAL;EUCALYPTUS EXTRACT;HEAVY CONSUMER;INDUCED SPUTUM;LIVER MICROSOMES;LIVER TRANSPLANTATION;MYCOPHENOLIC ACID;NIFLUMIC ACID;ABCIXIMAB IMPROVES;ABDOMINAL HYPERTENSION;ABDOMINAL SURGERY;ACID RAPIDLY;ACID SALICYLIC;ACTIVE DRESSWARE;ACUTE LIVER;ACUTE PAIN;ADIPOSE TISSUE;ADVANCED BREAST;AIRWAY INFLAMMATION;ALANINE AMINOTRANSFERASE;AMIODARONE-INDUCED THYROTOXICOSIS;ANEURYSM REPAIRB;ANTIFUNGAL PROPHYLAXIS;AORTIC VALVE;ARTIFICIAL HAND;ASSESS AIRWAY;BECLOMETHASONE DIPROPIONATE;BICARBONATE-ALKALINE MINERAL","5;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","NEOFORMANS VAR;VAR GATTII;CRYPTOCOCCUS NEOFORMANS;CRYPTOCOCCAL MENINGITIS;MM HG;T-TUBE REMOVAL;BONE MINERAL;CEREBROSPINAL FLUID;CROSSREF PUBMED;HOSPITAL STAY;INFECT DIS;PUBMED SCOPUS;RENAL FAILURE;RISK FACTOR;ANTIFUNGAL THERAPY;CYTOKINE LEVELS;DIS -CROSSREF;EPIRUBICIN MGM;EUCALYPTUS EXTRACT;FEMORAL VBMD;HUMAN IMMUNODEFICIENCY;INDUCED SPUTUM;INFECTED CELLS;MINERAL STATUS;PATIENTS TREATED;PUBMED GOOGLE;Z-SCORE NA;AIRWAY INFLAMMATION;ASTHMATIC SUBJECTS;BLOOD CREATININE","12;10;8;6;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2",3,0.07,7.798,20,20,20,3,3,3,0,0,0,0,0,0,0,0,0,2,2,2,0,0,0,0,0,0,0,0,0,3,3,3,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,64,64,64,65,65,65,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ALBERTELLI ROBERTO","1","AZIENDA OSPEDALIERA PISANA","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","2;1","LUNG;PEDIATRIC","1;1",NA,NA,"A61B5/08;A61M15/00;A61M16/06;A61M16/08;A61M16/20;G01T1/161","1;1;1;1;1;1","A61B5/0813;A61M15/02;A61M16/06;A61M16/08;A61M16/0833;A61M16/208","1;1;1;1;1;1",1,553188,55318.8,4,10,7,1,0,"ANTWERP UNIVERSITY HOSPITAL;AZIENDA OSPEDALIERA UNIVERSITARIA PISANA;BISPEBJERG HOSPITAL;KING'S COLLEGE HOSPITAL;KLINIKUM RHEINE;LUND UNIVERSITY;MAASTRICHT UNIVERSITY;SWEDISH INSTITUTE FOR HEALTH ECONOMICS;TAMESIDE HOSPITAL;UNIVERSITY OF ROME TOR VERGATA","1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","CON - COORDINATION OF RESEARCH ACTIONS (FUNDING SCHEME);FP5-LIFE QUALITY - SPECIFIC PROGRAMME FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ON ""QUALITY OF LIFE AND MANAGEMENT OF LIVING RESOURCES"", 1998-2002 (PROGRAMME)","1;1","42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","1;1","CLINICAL RESEARCH;DIABETES;HEALTH SERVICES","1;1;1","METABOLIC AND ENDOCRINE","1",NA,NA,NA,NA,NA,NA,"A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1,0,36,0,9,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,"Belgium","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS","1;1;1","BRAIN CANCER;BRAIN DISORDERS;CANCER;CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;RARE DISEASES","1;1;1;1;1;1;1","CANCER","1","6.1 PHARMACEUTICALS;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","1;1","BRAIN TUMOR","1","5.1 LOCALIZED THERAPIES - DISCOVERY AND DEVELOPMENT;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","1;1;1"
"AOU_PISANA",2003,52,7.01923076923077,3.94230769230769,0.253658536585366,0.673076923076923,0.403846153846154,0.134615384615385,0.25,4,16,9,16,7,0.31,0.17,0.31,0.13,31.54,0.595875908876044,0.115384615384615,0.557692307692308,0,0.470672831362923,0.473916887709991,0.570261437908497,0.564516129032258,"FRANCO FILIPPONI;FRANCO MOSCA;GÍANNI BIANCOFIORE;LUCIO URBANI;L BINDI;G CATALANO;C VIGNALI;MAURIZIA ROSSANA BRUNETTO;P. CICCOROSSI;FILIPPO OLIVERI;M MACCHERONI;FERRUCCIO BONINO;STEFANO DEL PRATO;P PETRUZZI;GABRIELLA CAVALLINI;ROBERTO CIONI;ANDREA PIETRABISSA;MAURO FERRARI;ILARIA PARENTINI;ROBERTO PISATI","17;17;9;7;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3","FRANCO FILIPPONI;FRANCO MOSCA;GÍANNI BIANCOFIORE;NICOLINO AMBROSINO;ANNA SONIA PETRONIO;LUCIO URBANI;ROBERTO PISATI;G CATALANO;JAN G. GRANDJEAN;FILIPPO OLIVERI;L BINDI;STEFANO DEL PRATO;ROBERTO FERRARA;MAURIZIA ROSSANA BRUNETTO;P. CICCOROSSI;C VIGNALI;MARIA TERESA VIETRI;ANDREA PIETRABISSA;PIERO MARCHETTI;A COPPELLI","3.18;2.31;1.91;1;1;0.88;0.67;0.6;0.58;0.55;0.53;0.52;0.5;0.49;0.49;0.46;0.45;0.43;0.42;0.42","FRANCO FILIPPONI;FRANCO MOSCA;GÍANNI BIANCOFIORE;LUCIO URBANI;L BINDI;G CATALANO;C VIGNALI;MAURIZIA ROSSANA BRUNETTO;P. CICCOROSSI;FILIPPO OLIVERI;M MACCHERONI;FERRUCCIO BONINO;STEFANO DEL PRATO;P PETRUZZI;ROBERTO CIONI;ANDREA PIETRABISSA;MAURO FERRARI;ROBERTO PISATI;JAN G. GRANDJEAN;PIERO MARCHETTI","17;17;9;7;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;2","FRANCO FILIPPONI;FRANCO MOSCA;GÍANNI BIANCOFIORE;NICOLINO AMBROSINO;ANNA SONIA PETRONIO;LUCIO URBANI;ROBERTO PISATI;G CATALANO;JAN G. GRANDJEAN;FILIPPO OLIVERI;L BINDI;STEFANO DEL PRATO;ROBERTO FERRARA;MAURIZIA ROSSANA BRUNETTO;P. CICCOROSSI;C VIGNALI;MARIA TERESA VIETRI;ANDREA PIETRABISSA;PIERO MARCHETTI;A COPPELLI","3.18;2.31;1.91;1;1;0.88;0.67;0.6;0.58;0.55;0.53;0.52;0.5;0.49;0.49;0.46;0.45;0.43;0.42;0.42","FRANCO MOSCA;S. CARNEVALI;F. SCATENA;RENATO VANACORE;ALESSANDRO CELI;BIANCAMARIA LONGONI;CARLO GIUNTINI;MONICA CIPOLLINI;PIERLUIGI PAGGIARO;ROBERTO BARALE;STEFANO PETRUZZELLI;GÍANNI BIANCOFIORE;FRANCO FILIPPONI;MAURO FERRARI;C. MANSI;D. VALPIANI;G. BRESCI;G. DʼALBASIO;GABRIELE RIEGLER;MATILDE INGROSSO","324;323;284;284;277;277;277;277;277;277;277;267;254;210;202;202;202;202;202;202","MONICA CIPOLLINI;ROBERTO BARALE;GÍANNI BIANCOFIORE;FRANCO MOSCA;MAURO FERRARI;G. BRESCI;FRANCO FILIPPONI;STEFANO DEL PRATO;A BOLDRINI;A VAGELLI;GIOVANNI CONSANI;M BISÀ;MARIA LUCIA BINDI;ANNA SONIA PETRONIO;A. DI FRANCO;BARBARA VAGAGGINI;D. GIANNINI;ELENA BACCI;M. TACCOLA;PIER LUIGI PAGGIARO","277;277;267;253;210;202;187;114;113;113;113;113;113;89;71;71;71;71;71;71","FRANCO FILIPPONI;FRANCO MOSCA;GÍANNI BIANCOFIORE;G CATALANO;LUCIO URBANI;L BINDI;MAURIZIA ROSSANA BRUNETTO;P. CICCOROSSI;C VIGNALI;FILIPPO OLIVERI;M MACCHERONI;MAURO FERRARI;STEFANO DEL PRATO;A COPPELLI;A. DI FRANCO;A. GIANNOTTI;BARBARA VAGAGGINI;D. GIANNINI;ELENA BACCI;FERRUCCIO BONINO","13;11;9;5;5;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;CHEMISTRY;ECONOMICS;MATHEMATICS;MATERIALS SCIENCE;PHYSICS;POLITICAL SCIENCE;COMPUTER SCIENCE;PSYCHOLOGY","49;11;6;3;3;2;2;2;1;1","INTERNAL MEDICINE;SURGERY;IMMUNOLOGY;CARDIOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;PATHOLOGY;ANESTHESIA;VIROLOGY;RADIOLOGY;GENETICS;CANCER RESEARCH;ECOLOGY;GENERAL SURGERY;LAW;MATHEMATICAL ECONOMICS;NUCLEAR MEDICINE;ORGANIC CHEMISTRY;PHARMACOLOGY;PSYCHIATRY","31;18;11;9;8;8;8;8;8;7;6;5;4;2;2;2;2;2;2;2;2;2","TRANSPLANTATION;ANTIBODY;ENZYME;INTENSIVE CARE UNIT;BLOOD PRESSURE;CIRRHOSIS;DISEASE;VIRUS;ALTERNATIVE MEDICINE;CANCER;HEPATITIS C;RENAL FUNCTION;ANEURYSM;AORTA;ASTHMA;CHEST PAIN;CREATININE;DIABETES MELLITUS;GENE;HEART FAILURE;HEPATITIS;IN VITRO;INTERFERON;KIDNEY;LIVER DISEASE;LUNG;MEDLINE;MONOCYTE;MYOCARDIAL INFARCTION;OUTCOME (GAME THEORY);PLATELET;RECEPTOR;STENOSIS;TUBERCULOSIS","14;5;5;5;4;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LIVER TRANSPLANTATION;HEPATITIS C VIRUS;AORTIC DISSECTION;BIOSYNTHESIS;COLORECTAL CANCER;HEPATITIS B VIRUS;PLACEBO;SEROLOGY;SPUTUM;VIRAL DISEASE;ABDOMINAL AORTIC ANEURYSM;ABDOMINAL COMPARTMENT SYNDROME;AGONIST;ALPHA INTERFERON;ANGINA;AORTIC ANEURYSM;AORTIC VALVE REPLACEMENT;AORTIC VALVE STENOSIS;ARYL;BRACHYTHERAPY;BRADYKININ;BREAST CANCER;BYPASS GRAFTING;CARCINOGENESIS;CARDIAC FUNCTION CURVE;CAT-SCRATCH DISEASE;CATHEPSIN;CCL4;CHLAMYDIACEAE;CHRONIC LIVER DISEASE;COMPUTED TOMOGRAPHY ANGIOGRAPHY;CONVENTIONAL PCI;CRITICAL ILLNESS;DIASTOLE;DIURESIS;DNA DAMAGE;DOSE PROFILE;EJECTION FRACTION;ENDOCRINE SYSTEM;EOSINOPHIL;FRESH FROZEN PLASMA;GENE EXPRESSION;GENERAL HEALTH QUESTIONNAIRE;GLUTATHIONE;HEART RATE;HEMOFILTRATION;HEPATITIS A VIRUS;HUMAN LIVER;HYDROTHORAX;IMMUNOGLOBULIN HEAVY CHAIN;INSULIN RESISTANCE;ISLET;LAPAROSCOPIC SURGERY;LEPTIN;LINEAR PARTICLE ACCELERATOR;LIVER CIRCULATION;LUNG TRANSPLANTATION;LYMPHOPROLIFERATIVE DISORDERS;MACROPHAGE;MINI-INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW;MONTELUKAST;MUTATION;NEURORADIOLOGY;NUCLEOSIDE ANALOGUE;OCCULT;OLEFIN FIBER;OSTEOCLAST;PERCUTANEOUS CORONARY INTERVENTION;PERICARDIAL CAVITY;PLASMAPHERESIS;POSITRON EMISSION;PROGRAMMED CELL DEATH;PROTAMINE;PSEUDOANEURYSM;QUERCETIN;REACTIVE HYPEREMIA;RESPIRATORY DISEASE;SULFOTRANSFERASE;SYNGENIC;THROMBOLYSIS;TRIGLYCERIDE;TYPE 1 DIABETES;TYPE 2 DIABETES;ULCERATIVE COLITIS;VIRAL LOAD;WHITE ADIPOSE TISSUE","12;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","COLONOSCOPY;DOLICHOL;ABCIXIMAB;APOMORPHINE;BARTONELLA HENSELAE;BECLOMETASONE DIPROPIONATE;BENTALL PROCEDURE;BETA CELL;BRONCHIOLITIS OBLITERANS;BUTHIONINE SULFOXIMINE;CATHEPSIN K;CATHEPSIN L;CENTRAL VENOUS PRESSURE;CHLAMYDOPHILA PNEUMONIAE;COMET ASSAY;CRYOGLOBULINEMIA;DIASTOLIC FUNCTION;DNA FRAGMENTATION;ENDOVASCULAR ANEURYSM REPAIR;EOSINOPHIL CATIONIC PROTEIN;FULMINANT HEPATIC FAILURE;GERMLINE MUTATION;HECK REACTION;HEPACIVIRUS;LEUKOTRIENE RECEPTOR;MODEL FOR END-STAGE LIVER DISEASE;PRIMARY ANGIOPLASTY;RIBAVIRIN;SEROPREVALENCE;SUZUKI REACTION;TIMI;TUMOR SUPPRESSOR GENE;ZAFIRLUKAST","2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;LIVER TRANSPLANTATION;MALE;FEMALE;MIDDLE AGED;POSTOPERATIVE COMPLICATIONS;ADULT;HEPATITIS C;AGED;ITALY;TREATMENT OUTCOME;HYPERTENSION;DOLICHOLS;ACUTE KIDNEY INJURY;HEPATITIS B;TISSUE DONORS;;ANEURYSM, DISSECTING;ASTHMA;FOLLOW-UP STUDIES","43;41;30;28;25;22;16;13;12;10;10;9;8;7;7;7;6;6;6;6","LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;HEPATITIS C INFECTION AND TREATMENT;ABDOMINAL COMPARTMENT SYNDROME AND INTRA-ABDOMINAL HYPERTENSION;ASTHMA;;ALLERGIC RHINITIS AND ITS IMPACT ON ASTHMA;ARTERIAL STIFFNESS AND CARDIOVASCULAR HEALTH;BARTONELLA INFECTIONS AND ZOONOTIC POTENTIAL;CANCER OF UNKNOWN PRIMARY SITE;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;EPIDEMIOLOGY AND MANAGEMENT OF SEPSIS AND SEPTIC SHOCK;ETHICAL AND MEDICAL ASPECTS OF ORGAN DONATION;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;HEPATITIS B INFECTION AND TREATMENT;HETEROCYCLIC COMPOUNDS FOR DRUG DISCOVERY;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;IMMUNOLOGICAL MECHANISMS IN ATHEROSCLEROSIS DEVELOPMENT;INTEROCEPTION AND SOMATIC SYMPTOMS;KIDNEY TRANSPLANTATION","8;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","LIVER TRANSPLANTATION;LIVING DONOR LIVER TRANSPLANTATION;TREATMENT;ASTHMA;COUGH REFLEX SENSITIVITY;DOLICHOL;HEPATITIS C;INTRA-ABDOMINAL HYPERTENSION;LIVER BIOPSY;LIVER CIRRHOSIS;LIVER DISEASE;LIVER DISEASES;LUNG FUNCTION;MONOCYTE;OPEN ABDOMEN MANAGEMENT;PORTAL HYPERTENSION;SIGMOIDOSCOPY;TYPE 1 DIABETES;;ABCIXIMAB","8;6;4;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1","LIVER TRANSPLANTATION;LIVER TRANSPLANT;CISANELLO HOSPITAL;CONTINUOUS VENO-VENOUS;DOLICHOL LEVELS;INTRA-ABDOMINAL PRESSURE;LEFT VENTRICULAR;OUTCOME EVALUATION;TRANSPLANT PATIENTS;TRANSPLANT RECIPIENTS;VIRUS INFECTION;ABDOMINAL AORTIC;ACTIVATOR RELEASE;ACUTE INFARCTION;ACUTE LIVER;AD LIBITUM;ADIPOSE TISSUE;AIRWAY INFLAMMATION;ALLERGIC RHINITIS;ANDOR HYDROTHORAX;ANEURYSM -YEARS;ANTIBODIES TOIBARTONELLA;ANTIMICROBIAL THERAPIES;ANTIVIRAL TREATMENT;AORTIC ANEURYSM;AORTIC DISSECTION;AORTIC NECK;AORTIC STENOSIS;AORTIC VALVE;APPRAISED TOPICS","7;5;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","PUBMED SCOPUS;CROSSREF PUBMED;OBLITERANS ORGANIZING;BRONCHIOLITIS OBLITERANS;ORGANIZING PNEUMONIA;LIVER TRANSPLANT;ALBRONCHIOLITIS OBLITERANS;PNEUMONIA BOOP;AVERAGE COST;BONE MARROW;ASTHMA SEVERITY;EPLER GR;MARROW TRANSPLANTATION;MED -CROSSREF;MEDICALLY UNEXPLAINED;UNEXPLAINED PAIN;ALCYTOMEGALOVIRUS PNEUMONIA;ALLOGENIC BONE;CHAN CK;CHEST X-RAY;CK CHAMBERLAIN;GR BRONCHIOLITIS;IMMUNOPATHOLOGIC PROCESSCHEST;LIVER TRANSPLANTATION;LUNG BIOPSY;ORTHOTOPIC LIVER;PATIENT ALIVE;PNEUMOCYSTIS CARINII;PROCESSCHEST -CROSSREF;PUBMED GOOGLE","21;20;19;16;12;9;7;7;6;6;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4",2,0.04,3.5,6,6,6,3,3,3,0,0,0,0,0,0,0,0,0,0,0,0,3,3,3,0,0,0,0,0,0,3,3,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,106,106,106,106,106,106,1,1,0,1,0,0,0,0,0,0,0,0,2,0,0,0,1,1.5,2,1,2,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ALBERTELLI ROBERTO","2","ALBERTELLI ROBERTO;AZIENDA OSPEDALIERA PISANA;AZIENDA OSPEDALIERO UNIVERSITARIA PISANA","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","4;2","LUNG;PEDIATRIC","2;2",NA,NA,"A61B5/08;A61M15/00;A61M16/06;A61M16/08;A61M16/20;G01T1/161","2;2;2;2;2;2","A61B5/0813;A61M15/02;A61M16/06;A61M16/08;A61M16/0833;A61M16/208","2;2;2;2;2;2",1,309415,77353.75,2,4,1,1,6,"AZIENDA OSPEDALIERA UNIVERSITARIA PISANA;CATHOLIC UNIVERSITY OF THE SACRED HEART;CENTRO CARDIOLOGICO MONZINO;UNIVERSITY OF PADUA","1;1;1;1","TELETHON FOUNDATION","1",NA,NA,"TELETHON - UILDM CLINICAL GRANT PROJECTS - 2002 (PROGRAM)","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","1;1","BRAIN DISORDERS;CARDIOVASCULAR;HEART DISEASE;INTELLECTUAL AND DEVELOPMENTAL DISABILITIES (IDD);MUSCULAR DYSTROPHY;MYOTONIC DYSTROPHY;NEUROSCIENCES;RARE DISEASES","1;1;1;1;1;1;1;1","CARDIOVASCULAR","1",NA,NA,NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,4,7,731.33,1,54.75,0,0,0,0,3,0,0,1,0,3,1,0,0,0,0,0,0,3,1,0,4,0,0,0,0,0,0,0,0,0,"Germany;Italy;United States","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","4;2;2;1;1;1","CLINICAL RESEARCH;AGING;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;ARTHRITIS;BRAIN DISORDERS;BREAST CANCER;CHRONIC PAIN;CONTRACEPTION/REPRODUCTION;ESTROGEN;HEMATOLOGY;LYMPHOMA;NEUROSCIENCES;OSTEOARTHRITIS;PAIN RESEARCH;PREVENTION;RARE DISEASES;STROKE","4;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;MUSCULOSKELETAL;STROKE","1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES","3;1","BREAST CANCER;NON-HODGKIN'S LYMPHOMA","1;1","4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","1;1;1"
"AOU_PISANA",2004,94,8.59574468085106,3.21276595744681,0.311258278145695,0.48936170212766,0.319148936170213,0.127659574468085,0.297872340425532,2,40,14,24,13,0.43,0.15,0.26,0.14,30.61,0.650457658668004,0.159574468085106,0.680851063829787,0,0.442692269568236,0.412422360248447,0.475972540045767,0.510489510489511,"FRANCO MOSCA;UGO BOGGI;FABIO VISTOLI;PIERO MARCHETTI;FRANCO FILIPPONI;STEFANO DEL PRATO;S SIGNORI;LUCIO URBANI;GÍANNI BIANCOFIORE;GIUSEPPE RIZZO;L BINDI;L COLETTI;ANDREA PIETRABISSA;MARCO DEL CHIARO;MAURIZIA ROSSANA BRUNETTO;FABIO MOSCA;MARCO DEL CHIARO;G CATALANO;FULVIA BALDINOTTI;T VANADIA BARTOLO","19;17;15;11;11;8;7;7;7;6;6;6;5;5;5;5;5;5;4;4","FRANCO MOSCA;UGO BOGGI;FRANCESCO MENICHETTI;FRANCO FILIPPONI;FABIO VISTOLI;NICOLINO AMBROSINO;CLAUDIO TRAINO;PAOLO DE SIMONE;PIERO MARCHETTI;STEFANO DEL PRATO;ALESSANDRO D’ALFONSO;JAN G. GRANDJEAN;LUCIO URBANI;GÍANNI BIANCOFIORE;S SIGNORI;L BINDI;MAURIZIA ROSSANA BRUNETTO;G. STAMPACCHIA;GIUSEPPE RIZZO;L COLETTI","1.78;1.5;1.49;1.33;1.32;1.29;1;0.97;0.94;0.79;0.77;0.77;0.72;0.7;0.64;0.6;0.59;0.58;0.56;0.56","FRANCO MOSCA;UGO BOGGI;FABIO VISTOLI;FRANCO FILIPPONI;S SIGNORI;LUCIO URBANI;GÍANNI BIANCOFIORE;GIUSEPPE RIZZO;L BINDI;L COLETTI;ANDREA PIETRABISSA;MAURIZIA ROSSANA BRUNETTO;FABIO MOSCA;MARCO DEL CHIARO;G CATALANO;FULVIA BALDINOTTI;NICOLINO AMBROSINO;ALESSANDRO D’ALFONSO;LUCA MORELLI;C. TREGNAGHI","19;17;15;11;7;7;7;6;6;6;5;5;5;5;5;4;4;4;4;4","FRANCO MOSCA;UGO BOGGI;FRANCESCO MENICHETTI;FRANCO FILIPPONI;FABIO VISTOLI;NICOLINO AMBROSINO;CLAUDIO TRAINO;PAOLO DE SIMONE;ALESSANDRO D’ALFONSO;JAN G. GRANDJEAN;LUCIO URBANI;GÍANNI BIANCOFIORE;S SIGNORI;L BINDI;MAURIZIA ROSSANA BRUNETTO;G. STAMPACCHIA;GIUSEPPE RIZZO;L COLETTI;FABIO MOSCA;MARCO DEL CHIARO","1.78;1.5;1.49;1.33;1.32;1.29;1;0.97;0.77;0.77;0.72;0.7;0.64;0.6;0.59;0.58;0.56;0.56;0.54;0.52","STEFANO DEL PRATO;MAURIZIA ROSSANA BRUNETTO;UGO BOGGI;FRANCO MOSCA;PIERO MARCHETTI;P. COLOMBATTO;SERGIO ABRIGNANI;FABIO VISTOLI;ALDO PINCHERA;FRANCO FILIPPONI;MARCO DEL CHIARO;ALESSANDRA GHIO;ANTONIO BOLDRINI;CRISTINA LENCIONI;GIOVANNI PELLEGRINI;GRAZIANO DI CIANNI;ILARIA CUCCURU;KYRIAZOULA CHATZIANAGNOSTOU;LAURA VOLPE;M. G. GIOVANNITTI","704;489;484;480;433;303;303;292;289;278;266;245;245;245;245;245;245;245;245;245","MAURIZIA ROSSANA BRUNETTO;P. COLOMBATTO;ANTONIO BOLDRINI;FRANCO FILIPPONI;P RINDI;UGO BOGGI;MICHELE MARINÒ;R LUPI;RENATO VANACORE;E. PARDINI;GIUSEPPE RIZZO;GÍANNI BIANCOFIORE;FERRUCCIO BONINO;P. CICCOROSSI;FRANCO MOSCA;PAOLO DE SIMONE;FABRIZIO SCATENA;MASSIMO ESPOSITO;M MACCHERONI;G. STAMPACCHIA","326;303;245;203;196;174;163;154;154;119;119;106;104;104;97;94;89;85;84;81","UGO BOGGI;FRANCO MOSCA;FRANCO FILIPPONI;GÍANNI BIANCOFIORE;FABIO VISTOLI;GIUSEPPE RIZZO;L BINDI;LUCIO URBANI;FULVIA BALDINOTTI;M. L. MARIOTTI;MAURIZIA ROSSANA BRUNETTO;NICOLINO AMBROSINO;PAOLO DE SIMONE;N. FOSSATI;G AMORESE;A BOLDRINI;ALESSANDRO D’ALFONSO;FABIO GUARRACINO;G CATALANO;G. STAMPACCHIA","10;9;8;7;7;6;6;5;4;4;4;4;4;4;3;3;3;3;3;3","MEDICINE;BIOLOGY;CHEMISTRY;ENGINEERING;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;PHILOSOPHY;BUSINESS;GEOGRAPHY;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY;ECONOMICS;ENVIRONMENTAL SCIENCE;MATERIALS SCIENCE","82;31;7;7;7;7;6;6;2;2;2;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;IMMUNOLOGY;PATHOLOGY;CARDIOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;UROLOGY;ANESTHESIA;ENVIRONMENTAL HEALTH;GASTROENTEROLOGY;CELL BIOLOGY;OPTICS;LINGUISTICS;MECHANICAL ENGINEERING;MICROBIOLOGY;PEDIATRICS;RADIOLOGY;VIROLOGY","62;36;17;15;13;12;10;10;8;7;7;7;6;6;5;5;5;5;5;5","TRANSPLANTATION;GENE;KIDNEY;POPULATION;DIABETES MELLITUS;PANCREAS;RENAL FUNCTION;COMPLICATION;ANTIBODY;ANTIGEN;CREATININE;INCIDENCE (GEOMETRY);PREGNANCY;RECEPTOR;VIRUS;BACTERIA;BLOOD PRESSURE;CIRRHOSIS;GOVERNMENT (LINGUISTICS);IMMUNE SYSTEM;THYROID","27;14;9;9;7;7;7;6;5;5;5;5;5;5;5;4;4;4;4;4;4","KIDNEY TRANSPLANTATION;LIVER TRANSPLANTATION;ALLELE;ECONOMIC SHORTAGE;ORGAN DONATION;ORGAN TRANSPLANTATION;CHROMOSOME;DIASTOLE;GENOTYPE;HEPATITIS C VIRUS;HUMAN LEUKOCYTE ANTIGEN;MUTATION;TYPE 2 DIABETES;ABDOMINAL AORTIC ANEURYSM;AUTOANTIBODY;BREAST CANCER;BYPASS GRAFTING;C-REACTIVE PROTEIN;EJECTION FRACTION;EOSINOPHIL;HEPATITIS B VIRUS;ISLET;LIVE BIRTH;LOCUS (GENETICS);METHYLATION;NEPHRECTOMY;PLACEBO;PSEUDOMONAS AERUGINOSA;SEROLOGY;SPUTUM;STAPHYLOCOCCUS AUREUS;T CELL;UNIVARIATE ANALYSIS;VASCULITIS","17;8;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PANCREAS TRANSPLANTATION;DOPPLER ECHOCARDIOGRAPHY;EOSINOPHIL CATIONIC PROTEIN;FULMINANT HEPATIC FAILURE;HAPLOTYPE;HBSAG;KARYOTYPE;METHYLTRANSFERASE;OFF-PUMP CORONARY ARTERY BYPASS;PANCREATIC ISLETS;THYROTROPIN RECEPTOR;ADOPTIVE CELL TRANSFER;ALLELE FREQUENCY;AMINO ACID SUBSTITUTION;ANTI-THYROID AUTOANTIBODIES;ASYMPTOMATIC BACTERIURIA;AZOOSPERMIA;BILATERAL NEPHRECTOMY;BREAST CARCINOMA;BUSULFAN;CANADIAN CARDIOVASCULAR SOCIETY;CD3;CD81;CELL CYCLE CHECKPOINT;CONDITIONING REGIMEN;CROSS-PHASE MODULATION;CRYOGLOBULINEMIA;CYSTECTOMY;CYTOGENETICS;DACLIZUMAB;DELETION MAPPING;DNA FRAGMENTATION;DOPAMINE AGONIST;DYNAMIC HYPERINFLATION;ENDOVASCULAR ANEURYSM REPAIR;ENTEROCOCCUS FAECALIS;FENOLDOPAM;FLUORESCENCE IN SITU HYBRIDIZATION;FOLLICLE-STIMULATING HORMONE;GENOTYPING;GERMLINE MUTATION;GESTATIONAL DIABETES;GLUCOSE TOLERANCE TEST;GLYCATED HEMOGLOBIN;HISTOCOMPATIBILITY;HISTOCOMPATIBILITY TESTING;HLA-A;HUMAN GENOME;IL-2 RECEPTOR;IMPAIRED GLUCOSE TOLERANCE;INTERFACE (MATTER);INTERLEUKIN 12;INTERLEUKIN 21;KRAS;LAMIVUDINE;MALE INFERTILITY;MEMBRANOUS NEPHROPATHY;MICROVESICLES;MITOCHONDRIAL PERMEABILITY TRANSITION PORE;MYCOBACTERIUM BOVIS;OPTICAL PERFORMANCE MONITORING;PLASMACYTOID DENDRITIC CELL;POINT MUTATION;POLYARTERITIS NODOSA;PRENATAL DIAGNOSIS;PSEUDOMONADACEAE;PSEUDOMONADALES;RADIOIODINE THERAPY;RESPIRATORY RATE;SELF-PHASE MODULATION;SINGLE-NUCLEOTIDE POLYMORPHISM;TOXIC SHOCK SYNDROME;TRANSITIONAL CELL CARCINOMA;TRICEPS REFLEX;TUMOR SUPPRESSOR GENE;VERESS NEEDLE","7;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;KIDNEY TRANSPLANTATION;AGED;PANCREAS TRANSPLANTATION;POSTOPERATIVE COMPLICATIONS;TREATMENT OUTCOME;ITALY;LIVER TRANSPLANTATION;;TISSUE DONORS;RETROSPECTIVE STUDIES;CORONARY DISEASE;CREATININE;DIABETES MELLITUS, TYPE 1;ADOLESCENT;TIME FACTORS","77;44;42;40;34;27;23;23;23;20;16;15;14;12;11;10;10;10;8;8","ETHICAL AND MEDICAL ASPECTS OF ORGAN DONATION;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;ASTHMA;EFFECTS OF MEDICATION ON PREGNANCY OUTCOMES;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;HEMATOPOIETIC STEM CELL BIOLOGY;HEPATITIS B INFECTION AND TREATMENT;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;MANAGEMENT AND EPIDEMIOLOGY OF INFECTIVE ENDOCARDITIS;NATURAL KILLER CELLS IN IMMUNITY;PANCREATIC ISLET DYSFUNCTION AND REGENERATION;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT;STANDARDISATION AND MANAGEMENT OF COPD;;ABDOMINAL COMPARTMENT SYNDROME AND INTRA-ABDOMINAL HYPERTENSION;BACTERIAL BIOFILMS AND QUORUM SENSING MECHANISMS;BOTULINUM TOXIN IN NEUROLOGY AND MEDICINE;BRAIN LATERALIZATION AND HANDEDNESS IN HUMANS AND ANIMALS;CARDIAC SURGERY AND BYPASS GRAFTING OUTCOMES;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS","10;7;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1","KIDNEY TRANSPLANTATION;LIVER TRANSPLANTATION;LIVING KIDNEY DONORS;PANCREAS TRANSPLANTATION;LIVING DONOR LIVER TRANSPLANTATION;ORGAN DONATION;TRANSPLANTATION;ECONOMIC SHORTAGE;BREAST CANCER;CANCER SUSCEPTIBILITY;CARDIAC SURGERY RISK MODELS;ECHOCARDIOGRAPHY;LIVER DISEASE;ORGAN PRESERVATION;RESPIRATORY;TREATMENT;ASTHMA;BIRTH OUTCOMES;BRCA1;CADAVERIC SPASM","9;7;7;7;6;6;6;4;3;3;3;3;3;3;3;3;2;2;2;2","KIDNEY TRANSPLANTATION;LIVER TRANSPLANTATION;PANCREAS TRANSPLANTATION;BONE MARROW;CHRONIC HEPATITIS;CORONARY SURGERY;DONORS AGED;GUANIDINOACETATE METHYLTRANSFERASE;HPLC ASSAY;KIDNEY DONATION;OFF-PUMP CORONARY;ORGAN DONATION;ORGAN TRANSPLANTATION;PANCREAS-KIDNEY TRANSPLANTATION;PERIPHERAL BENZODIAZEPINE;PORTAL-ENTERIC DRAINAGE;RETROSPECTIVE SURVEY;ABDOMINAL AORTIC;ABDOMINAL ORGANS;ACIDS EVIDENCE;ACUTE LEUKEMIA;ACUTE RESPIRATORY;ADOPTIVE IMMUNITY;ALL-OPTICAL REGENERATOR;ALLELE DPB;ALLELIC GENES;ALLERGEN CHALLENGE;AMINOPYRINE BREATH;AMPLIFIED POLYMORPHIC;ANAESTHESIOLOGISTS PERSPECTIVE","5;4;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1","TAC DAC;TAC STEROIDS;ACUTE REJECTION;BIOPSY-CONFIRMED ACUTE;LIVER TRANSPLANT;LIVER TRANSPLANTATION;DIABETES MELLITUS;ADVERSE EVENTS;AZIENDA OSPEDALIERA;SERUM CREATININE;DACLIZUMAB INDUCTION;PRESSURE SUPPORT;TRANSPLANT PATIENTS;GRAFT SURVIVAL;SPONTANEOUS BREATHING;INTENT-TO-TREAT PATIENTS;ORGAN TRANSPLANTATION;OSPEDALIERA UNIVERSITARIA;PISA ITALY;SERUM HP;SURVIVAL RATES;TACROLIMUS MONOTHERAPY;UNIVERSITARIA PISANA;ACTUARIAL SURVIVAL;ACUTE REJECTIONS;ADULT LIVER;ADVERSE EVENT;COPD PATIENTS;CORTICOSTEROID-RESISTANT ACUTE;DUAL REGIMEN","48;47;31;17;13;13;10;9;9;9;8;8;8;7;7;6;6;6;6;6;6;6;6;5;5;5;5;5;5;5",8,0.09,3,3.16,3,4.25,2.38,1,9,0,0,0,0,0,0,0,0,0,0,0,0,3.5,1,6,0,0,0,1,1,1,2.62,1,9,0,0,0,0,0,0,3,3,3,0,0,0,1.75,1,3,0,0,0,0,0,0,3,3,3,0,0,0,0,0,0,0.12,0,1,43.38,4,140,43.5,4,141,1,0,1,1,0,0,0,0,1,0,0,0,3,0,0,0,1,1.33333333333333,3,1,3,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ALBERTELLI ROBERTO","3","ALBERTELLI ROBERTO;AZIENDA OSPEDALIERA PISANA;AZIENDA OSPEDALIERO UNIVERSITARIA PISANA;INDIVIDUAL","1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;40 ENGINEERING","3;3;3",NA,NA,NA,NA,"A61M16/00;A61M16/06;A61M16/08","3;3;3","A61M16/0066;A61M16/0078;A61M16/06;A61M16/08;A61M2016/0021","3;3;3;3;3",0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,8,2400.38,3,95.89,0,0,2,0,5,0,1,1,0,7,1,0,0,0,0,0,0,6,3,0,8,1,0,0,0,0,0,0,0,0,"United States;Italy;Japan","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;31 BIOLOGICAL SCIENCES;3105 GENETICS;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS","8;6;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;BREAST CANCER;HEMATOLOGY;ORPHAN DRUG;BRAIN DISORDERS;LYMPHOMA;NEUROSCIENCES;PEDIATRIC;PREVENTION;AGING;BIOENGINEERING;BRAIN CANCER;CHILDHOOD LEUKEMIA;ESTROGEN;GENETIC TESTING;GENETICS;HEALTH SERVICES","7;7;6;5;3;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1","CANCER","7","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES","5;1;1;1","BREAST CANCER;NON-HODGKIN'S LYMPHOMA;BRAIN TUMOR;LEUKEMIA / LEUKAEMIA;MYELOMA","3;3;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","5;1;1"
"AOU_PISANA",2005,67,8.25373134328358,3.83582089552239,0.260700389105058,0.597014925373134,0.477611940298507,0.164179104477612,0.26865671641791,0,33,14,14,3,0.49,0.21,0.21,0.04,50.96,0.962441165253222,0.194029850746269,0.701492537313433,0,0.360631588335173,0.329059829059829,0.414285714285714,0.440771349862259,"FRANCO MOSCA;UGO BOGGI;FABIO VISTOLI;PIERO MARCHETTI;G AMORESE;S SIGNORI;MARIA GRAZIA BONGIORNI;STEFANO DEL PRATO;MARCO DEL CHIARO;FRANCO FILIPPONI;GÍANNI BIANCOFIORE;GIUSEPPE ARENA;GIULIO ZUCCHELLI;NICOLINO AMBROSINO;G. GIANNOLA;ALDO PINCHERA;P PETRUZZI;LUCA MORELLI;C. TREGNAGHI;A COPPELLI","12;11;8;7;6;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3","FRANCO MOSCA;UGO BOGGI;ALDO PINCHERA;STEFANO DEL PRATO;FABIO VISTOLI;DANIELE MASELLI;GAETANO MINZIONI;PIERO MARCHETTI;NICOLINO AMBROSINO;FERRUCCIO SANTINI;G AMORESE;FRANCO FILIPPONI;PAOLO DE SIMONE;GIUSEPPE PENNO;MARIA GRAZIA BONGIORNI;VERONICA BERTINI;MAIDO CASTIGLIONI;LUCA BARBANO;MICHELE VITACCA;LUCA BIANCHI","1.14;0.95;0.83;0.68;0.67;0.64;0.64;0.63;0.55;0.5;0.5;0.49;0.48;0.48;0.48;0.45;0.45;0.45;0.45;0.45","FRANCO MOSCA;UGO BOGGI;FABIO VISTOLI;PIERO MARCHETTI;G AMORESE;MARIA GRAZIA BONGIORNI;STEFANO DEL PRATO;FRANCO FILIPPONI;GÍANNI BIANCOFIORE;GIUSEPPE ARENA;GIULIO ZUCCHELLI;NICOLINO AMBROSINO;G. GIANNOLA;ALDO PINCHERA;LUCA MORELLI;C. TREGNAGHI;EZIO SOLDATI;GIULIANO MARIANI;C VIGNALI;PAOLO DE SIMONE","12;11;8;7;6;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","FRANCO MOSCA;UGO BOGGI;ALDO PINCHERA;STEFANO DEL PRATO;FABIO VISTOLI;DANIELE MASELLI;GAETANO MINZIONI;PIERO MARCHETTI;NICOLINO AMBROSINO;FERRUCCIO SANTINI;G AMORESE;FRANCO FILIPPONI;PAOLO DE SIMONE;MARIA GRAZIA BONGIORNI;VERONICA BERTINI;MAIDO CASTIGLIONI;ANGELO VALETTO;JAVIER ROSADA;PAOLO SIMI;MASSIMILIANO PINELLI","1.14;0.95;0.83;0.68;0.67;0.64;0.64;0.63;0.55;0.5;0.5;0.49;0.48;0.48;0.45;0.45;0.45;0.45;0.45;0.45","FRANCO MOSCA;UGO BOGGI;PIERO MARCHETTI;A. DEL FAVERO;ALESSANDRA MICOZZI;ANNAMARIA NOSARI;BERNARDINO ALLIONE;DANIELA CILLONI;DOMENICO D’ANTONIO;ELIANA ZUFFA;FRANCESCO FABBIANO;FRANCESCO LAURIA;FRANCESCO MENICHETTI;GIAMPAOLO BUCANEVE;GIORGINA SPECCHIA;GIORGIO LA NASA;GIOVANNI MARTINELLI;MARCO DIONISI;MAURIZIO BUELLI;PIETRO MARTINO","844;785;683;616;616;616;616;616;616;616;616;616;616;616;616;616;616;616;616;616","FRANCESCO MENICHETTI;NICOLINO AMBROSINO;ANITA K. SIMONDS;BERND SCHOENHOFER;FRANCO MOSCA;UGO BOGGI;STEFANO DEL PRATO;LORELLA MARSELLI;PIERO MARCHETTI;R LUPI;S DEL GUERRA;M. POLLERA;MARCO BUGLIANI;MATILDE MASINI;S TORRI;SILVERIO SBRANA;A CAPRIA;E. TUMINO;G. BRESCI;GIUSEPPE FABIO PARISI","616;590;568;568;566;550;537;532;532;532;532;454;454;454;454;454;159;159;159;159","G AMORESE;FRANCO MOSCA;MARIA GRAZIA BONGIORNI;C. TREGNAGHI;ALDO PINCHERA;GÍANNI BIANCOFIORE;M BARSOTTI;MAURO FERRARI;UGO BOGGI;NICOLINO AMBROSINO;PAOLO DE SIMONE;STEFANO DEL PRATO;ANDREA CAVAZZANA;ANDREA DEL CORSO;CLAUDIO DI CRISTOFANO;CLAUDIO TRAINO;DANIELE MASELLI;FABIO DI MARTINO;FRANCESCO ROMAGNANI;FRANCO FILIPPONI","5;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;ENGINEERING;PHILOSOPHY;GEOGRAPHY;MATERIALS SCIENCE;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY","62;17;4;3;3;3;3;2;2;2;2;2","INTERNAL MEDICINE;SURGERY;ENDOCRINOLOGY;GASTROENTEROLOGY;CARDIOLOGY;PATHOLOGY;RADIOLOGY;GENETICS;ANESTHESIA;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;IMMUNOLOGY;MOLECULAR BIOLOGY;ONCOLOGY;OPTICS;CANCER RESEARCH;MECHANICAL ENGINEERING;MICROBIOLOGY;NUCLEAR MEDICINE;PEDIATRICS;UROLOGY","48;24;14;12;11;10;8;7;6;6;6;5;4;4;4;3;3;3;3;3;3","TRANSPLANTATION;CANCER;GENE;DIABETES MELLITUS;DISEASE;PANCREAS;THYROID;ANASTOMOSIS;CHEMOTHERAPY;IMMUNOHISTOCHEMISTRY;INSULIN;MECHANICAL VENTILATION;ANEURYSM;ANTIBIOTICS;BONE MARROW;ESOPHAGUS;HORMONE;INCIDENCE (GEOMETRY);INTENSIVE CARE UNIT;PERCUTANEOUS;RETROSPECTIVE COHORT STUDY;THROMBOSIS","14;7;7;6;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3","KIDNEY TRANSPLANTATION;LIVER TRANSPLANTATION;ABDOMINAL AORTIC ANEURYSM;AORTIC ANEURYSM;CHROMOSOME;BREAST CANCER;CALCINEURIN;EJECTION FRACTION;GLUCOKINASE;HYPERCAPNIA;INFERTILITY;INSULIN RESISTANCE;ISLET;LEVOTHYROXINE;POLYMERASE CHAIN REACTION;SUPERIOR MESENTERIC VEIN;TACROLIMUS;THYROID FUNCTION;TYPE 2 DIABETES;Y CHROMOSOME","6;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","PANCREAS TRANSPLANTATION;ENDOVASCULAR ANEURYSM REPAIR;AZOOSPERMIA;FLUORESCENCE IN SITU HYBRIDIZATION;INSULIN OSCILLATION;KARYOTYPE;ACCESSORY SPLEEN;ACID-FAST;BARRETT'S ESOPHAGUS;BASILIXIMAB;CARDIAC RESYNCHRONIZATION THERAPY;CARDIAC SKELETON;CELL CYCLE CHECKPOINT;CHROMOSOME 9;CONNECTIVE TISSUE DISEASE;CROSS-PHASE MODULATION;CYTOGENETICS;DEOXYCYTIDINE;DNA FRAGMENTATION;ENTEROBACTER;ESOPHAGECTOMY;ESOPHAGITIS;EXTRAPULMONARY TUBERCULOSIS;FEBRILE NEUTROPENIA;FLUDARABINE;FOUR-WAVE MIXING;GERD;GLIMEPIRIDE;GLUCOSE HOMEOSTASIS;HEPADNAVIRIDAE;HYPERAMYLASEMIA;HYPERINSULINEMIA;IONIZATION CHAMBER;KLEBSIELLA;LOSS OF HETEROZYGOSITY;MALE INFERTILITY;NISSEN FUNDOPLICATION;NITROTYROSINE;NORMOCAPNIA;OPTICAL MODULATION AMPLITUDE;OPTICAL PERFORMANCE MONITORING;PANCREATIC ISLETS;PROTEUS;RADIOIODINE THERAPY;RENAL ARTERY STENOSIS;SENTINEL LYMPH NODE;SPLENIC DISEASE;SPUTUM CULTURE;TESTIS DETERMINING FACTOR;TOTAL BODY IRRADIATION;TRANSSPHENOIDAL SURGERY;VIRILIZATION;WINDOW PERIOD","4;3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;MALE;FEMALE;MIDDLE AGED;ADULT;AGED;PANCREAS TRANSPLANTATION;POSTOPERATIVE COMPLICATIONS;IMMUNOSUPPRESSIVE AGENTS;KIDNEY TRANSPLANTATION;TREATMENT OUTCOME;;FOLLOW-UP STUDIES;GRAFT REJECTION;LIVER TRANSPLANTATION;PROSPECTIVE STUDIES;TIME FACTORS;ISLETS OF LANGERHANS;ITALY;RETROSPECTIVE STUDIES","55;39;36;28;25;25;20;18;11;11;11;10;9;9;9;9;9;8;8;8","KIDNEY TRANSPLANTATION;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;STANDARDISATION AND MANAGEMENT OF COPD;DIAGNOSIS AND MANAGEMENT OF AORTIC DISEASES;MANAGEMENT OF VASCULAR GRAFT INFECTIONS AND ANEURYSMS;PANCREATIC ISLET DYSFUNCTION AND REGENERATION;SEX DETERMINATION AND DIFFERENTIATION IN ORGANISMS;THYROID DISEASE AND HORMONE REGULATION;ANESTHESIA AND SEDATION MANAGEMENT;ASTHMA;ATRIAL FIBRILLATION;BISPHOSPHONATES IN CANCER TREATMENT AND BONE HEALTH;BREAST PATHOLOGY AND IMAGING TECHNIQUES;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;DIAGNOSIS AND MANAGEMENT OF GASTROESOPHAGEAL REFLUX DISEASE;DIAGNOSIS AND MANAGEMENT OF GASTROINTESTINAL BLEEDING;DIAGNOSIS AND TREATMENT OF CAROTID ARTERY DISEASE;DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA","5;4;3;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","TRANSPLANTATION;PANCREAS TRANSPLANTATION;ANEURYSM RUPTURE;AORTIC ANEURYSMS;ENDOVASCULAR ANEURYSM REPAIR;HYPERTHYROIDISM;HYPOTHYROIDISM;INSULIN SIGNALING;LIVER TRANSPLANTATION;LIVING DONOR LIVER TRANSPLANTATION;ANEURYSM SCREENING;AZOOSPERMIA FACTOR;BARRETT'S ESOPHAGUS;CONTINUOUS GLUCOSE MONITORING;COPD;DIABETES;ECHOCARDIOGRAPHY;ENDOVASCULAR REPAIR;GLUCOKINASE;INSULIN OSCILLATION","6;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","PANCREAS TRANSPLANTATION;ABDOMINAL AORTIC;AORTIC ANEURYSM;LEFT VENTRICULAR;ANEURYSM DUE;ANEURYSM REPAIR;AUTOLOGOUS HAEMOPOIETIC;ENDOGRAFT INFECTION;ENDOVASCULAR ANEURYSM;HAEMOPOIETIC SUPPORT;INTENSIVE CARE;LIVER TRANSPLANT;LIVER TRANSPLANTATION;MARROW TRANSPLANTATION;PORTAL-ENTERIC DRAINAGE;REPAIR EVAR;TRANSPLANT RECIPIENTS;VALSALVA GRAFT;ACCESSORY SPLEEN;ACTH-DEPENDENT CUSHINGS;ACTIVITY INDEX;ACUTE MYOCARDIAL;ADDDROP MULTIPLEXER;ADENOCARCINOMA CELL;ADVANCED OVARIAN;ADVANCED PANCREATIC;AFFECTS SERUM;AGENCY ORGANIZZAZIONE;ALLERGENE CHALLENGE;ANTERIOR LEFT","4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1","EFFICIENCY RATE;PRE-LT EVALUATION;THYMUS ALTERATIONS;LIVER TRANSPLANTATION;TYPE DIABETIC;SURGICAL TREATMENT;CDA EXPRESSION;COMPLETE MASCULINIZATION;COPD PATIENTS;DIABETIC ISLETS;EVALUATION EFFICIENCY;GLUCOSE-STIMULATED INSULIN;HMV USERS;ILIAC ARTERY;INSULIN RELEASE;INSULIN SECRETION;MALE PHENOTYPE;MECHANICAL VENTILATION;MUSCLE FUNCTION;PROCESS EFFICIENCY;Q-BANDING FLUORESCENT;RADIOLOGICAL THYMUS;RESPIRATORY MUSCLE;SINOTUBULAR JUNCTION;SITU HYBRIDIZATION;SSC PATIENTS;STATISTICALLY SIGNIFICANT;VALSALVA GRAFT;WAITLISTED PATIENT;ABNORMALLY ENLARGED","8;6;6;5;5;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2",8,0.12,3,8.5,7,10,4,3,5,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,4.5,4,5,0,0,0,1,1,1,0,0,0,0,0,0,2.5,1,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,43,24,62,43,24,62,1,1,2,0,0,0,0,0,0,0,0,0,3,0,0,8,1,1,3,0,3,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ALBERTELLI ROBERTO;ROBERTO ALBERTELLI","2;1","AZIENDA OSPEDALIERO UNIVERSITARIA PISANA","3","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","6;3","LUNG;PEDIATRIC","3;2",NA,NA,"A61B5/08;A61M15/00;A61M16/06;A61M16/08;A61M16/20;G01T1/161;A61B6/00","3;3;3;3;3;3;1","A61B5/0813;A61M15/02;A61M16/06;A61M16/08;A61M16/0833;A61M16/208","3;3;3;3;3;3",1,261250,261250,3,1,1,0,2,"AZIENDA OSPEDALIERA UNIVERSITARIA PISANA","1","TELETHON FOUNDATION","1",NA,NA,"TELETHON CAREER RENEWAL - 2004 (PROGRAM)","1","31 BIOLOGICAL SCIENCES;49 MATHEMATICAL SCIENCES;4904 PURE MATHEMATICS","1;1;1",NA,NA,"METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;STROKE","1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1",NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,4.88,580.12,2,73.67,0,0,0,2,6,0,1,0,0,8,0,0,0,0,0,0,0,7,0,2,8,1,0,0,0,0,0,0,0,0,"Italy;United States","1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3211 ONCOLOGY AND CARCINOGENESIS;3204 IMMUNOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","9;4;3;3;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;HEMATOLOGY;RARE DISEASES;AGING;ASSISTIVE TECHNOLOGY;ATHEROSCLEROSIS;BIOENGINEERING;CARDIOVASCULAR;CHRONIC PAIN;DENTAL/ORAL AND CRANIOFACIAL DISEASE;HEART DISEASE;HEART DISEASE - CORONARY HEART DISEASE;PAIN RESEARCH;PATIENT SAFETY;PROSTATE CANCER;TRANSPLANTATION;UROLOGIC DISEASES","7;5;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;BLOOD;CARDIOVASCULAR;INFECTION","4;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","5;1;1","PROSTATE CANCER;HEAD AND NECK CANCER;LARYNGEAL CANCER;LEUKEMIA / LEUKAEMIA;LIVER CANCER;NON-HODGKIN'S LYMPHOMA;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;SALIVARY GLAND CANCER;STOMACH CANCER","2;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER","4;1"
"AOU_PISANA",2006,74,9.54054054054054,3.82432432432432,0.261484098939929,0.662162162162162,0.391891891891892,0.162162162162162,0.310810810810811,4,40,12,9,10,0.54,0.16,0.12,0.14,59.81,1.17096535122188,0.175675675675676,0.716216216216216,0,0.458161686011673,0.337209302325581,0.387959866220736,0.363636363636364,"MAURIZIA ROSSANA BRUNETTO;FERRUCCIO BONINO;STEFANO DEL PRATO;FRANCO FILIPPONI;CARLO TASCINI;FRANCO MOSCA;FILIPPO OLIVERI;ALDO PINCHERA;RODOLFO SACCO;UGO BOGGI;DANIELE MASELLI;FABIO GUARRACINO;B. COCO;P. CICCOROSSI;ALBERTO BALBARINI;FRANCESCO MENICHETTI;PIERO MARCHETTI;FRANCESCO MASSEI;ALBERTO PIAGGESI;FAUSTO BOGAZZI","7;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3","STEFANO DEL PRATO;G. BARSOTTI;BRESCI GIAMPAOLO;NULL AUTHOR_ID;ALBERTO BALBARINI;MAURIZIA ROSSANA BRUNETTO;CLAUDIO TRAINO;FERRUCCIO BONINO;CARLO TASCINI;FILIPPO OLIVERI;DANIELE MASELLI;ALDO PINCHERA;FRANCESCO MASSEI;FEDERICA MARTINO;ELIO MELILLO;RODOLFO SACCO;B. COCO;P. CICCOROSSI;FRANCO MOSCA;MARCO NUTI","1.4;1;1;1;0.82;0.75;0.75;0.68;0.63;0.62;0.58;0.55;0.51;0.5;0.5;0.49;0.49;0.49;0.47;0.45","MAURIZIA ROSSANA BRUNETTO;FERRUCCIO BONINO;STEFANO DEL PRATO;FRANCO FILIPPONI;CARLO TASCINI;FILIPPO OLIVERI;ALDO PINCHERA;RODOLFO SACCO;UGO BOGGI;DANIELE MASELLI;FABIO GUARRACINO;B. COCO;P. CICCOROSSI;FRANCESCO MENICHETTI;PIERO MARCHETTI;FRANCESCO MASSEI;ALBERTO PIAGGESI;FAUSTO BOGAZZI;ALESSANDRO LEONILDI;DIEGO FLICHMAN","7;6;6;5;5;5;4;4;4;4;4;4;4;4;3;3;3;3;3;3","STEFANO DEL PRATO;G. BARSOTTI;BRESCI GIAMPAOLO;NULL AUTHOR_ID;MAURIZIA ROSSANA BRUNETTO;CLAUDIO TRAINO;FERRUCCIO BONINO;CARLO TASCINI;FILIPPO OLIVERI;DANIELE MASELLI;ALDO PINCHERA;FRANCESCO MASSEI;FEDERICA MARTINO;ELIO MELILLO;RODOLFO SACCO;B. COCO;P. CICCOROSSI;FABIO GUARRACINO;FRANCO FILIPPONI;FRANCESCO MENICHETTI","1.4;1;1;1;0.75;0.75;0.68;0.63;0.62;0.58;0.55;0.51;0.5;0.5;0.49;0.49;0.49;0.44;0.44;0.43","MAURIZIA ROSSANA BRUNETTO;FERRUCCIO BONINO;ALBERTO PIAGGESI;ALEXANDRA JIRKOVSKÁ;DÍDAC MAURICIO;EDWARD B. JUDE;FRITS VAN MERODE;GUNNEL RAGNARSON TENNVALL;HEINRICH REIKE;J. VAN BAAL;JAN APELQVIST;K. BAKKER;K. VAN ACKER;L. PROMPERS;LUIGI UCCIOLI;M. HUIJBERTS;MAXIMILIAN SPRAUL;MICHAEL EDMONDS;NICOLAAS C. SCHAPER;P. HOLSTEIN","1020;975;952;884;884;884;884;884;884;884;884;884;884;884;884;884;884;884;884;884","MAURIZIA ROSSANA BRUNETTO;ALBERTO PIAGGESI;FILIPPO OLIVERI;P. COLOMBATTO;B. COCO;P. CICCOROSSI;RODOLFO SACCO;A.M. MAINA;DANIELE MASELLI;FABIO GUARRACINO;PIERO MARCHETTI;CINZIA ORLANDINI;MAURO IANNOPOLLO;SERGIO RICCI;GIOVANNI PELLEGRINI;GRAZIANO DI CIANNI;ILARIA CUCCURU;S DEL GUERRA;G. MEUCCI;G BORELLI","1020;904;713;694;653;653;653;641;452;412;353;348;348;348;297;241;241;240;219;200","MAURIZIA ROSSANA BRUNETTO;FILIPPO OLIVERI;CARLO TASCINI;B. COCO;FABIO GUARRACINO;P. CICCOROSSI;RODOLFO SACCO;STEFANO DEL PRATO;ALDO PINCHERA;DANIELE MASELLI;FRANCO FILIPPONI;P. COLOMBATTO;FAUSTO BOGAZZI;GIOVANNI PELLEGRINI;MAURIZIO GASPERI;PIERO MARCHETTI;DIEGO FLICHMAN;ALBERTO PIAGGESI;CHIARA COSCI;CHIARA SARDELLA","7;5;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;2;2;2","MEDICINE;BIOLOGY;COMPUTER SCIENCE;MATHEMATICS;PHYSICS;CHEMISTRY;ECONOMICS;MATERIALS SCIENCE;PHILOSOPHY;PSYCHOLOGY;ENGINEERING;ENVIRONMENTAL SCIENCE;GEOLOGY;SOCIOLOGY","70;27;5;5;5;2;2;2;2;2;1;1;1;1","INTERNAL MEDICINE;SURGERY;ENDOCRINOLOGY;GENETICS;VIROLOGY;GASTROENTEROLOGY;CARDIOLOGY;PATHOLOGY;IMMUNOLOGY;ENVIRONMENTAL HEALTH;ANESTHESIA;MICROBIOLOGY;INTENSIVE CARE MEDICINE;ONCOLOGY;PALEONTOLOGY;RADIOLOGY;ANATOMY;BIOCHEMISTRY;COMPUTATIONAL BIOLOGY;MOLECULAR BIOLOGY;OPTICS;UROLOGY","50;24;18;14;12;11;10;10;9;6;5;5;4;4;4;4;3;3;3;3;3;3","DIABETES MELLITUS;GENE;VIRUS;TRANSPLANTATION;DISEASE;POPULATION;THYROID;ALTERNATIVE MEDICINE;ANTIBIOTICS;BACTERIA;CANCER;CHEMOTHERAPY;CONFIDENCE INTERVAL;HORMONE;INSULIN;MYOCARDIAL INFARCTION;ADVERSE EFFECT;ANTIBODY;BLOOD PRESSURE;BODY MASS INDEX;BONE REMODELING;CIRRHOSIS;COMBINATION THERAPY;HEART FAILURE;INCIDENCE (GEOMETRY);OBESITY;OSTEOPOROSIS;PREGNANCY;PROSTACYCLIN;REGIMEN","10;9;9;8;7;6;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","HEPATITIS B VIRUS;LIVER TRANSPLANTATION;CHRONIC HEPATITIS;COLISTIN;DIABETIC FOOT;GENE EXPRESSION;ILOPROST;PSEUDOMONAS AERUGINOSA;TYPE 2 DIABETES;ABSORBED DOSE;ARTERIAL DISEASE;BONE MASS;C-REACTIVE PROTEIN;CISPLATIN;CYCLOPHOSPHAMIDE;DESFLURANE;DIASTOLE;EJECTION FRACTION;GEMCITABINE;GENOME;GENOTYPE;GRAVES' DISEASE;GROWTH HORMONE;HEPATITIS C VIRUS;HUMAN LEUKOCYTE ANTIGEN;INSULIN RESISTANCE;NEUTROPENIA;OSTEOARTHRITIS;THYROID CANCER;TROPONIN;TROPONIN I;TROPONIN T","6;6;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","CRITICAL LIMB ISCHEMIA;HBSAG;LAMIVUDINE;ACROMEGALY;ARTHROPATHY;LIVING DONOR LIVER TRANSPLANTATION;PEAK BONE MASS;RIBAVIRIN;TRANSIENT ELASTOGRAPHY;VINORELBINE;ABDOMINAL OBESITY;ACE INHIBITOR;ALPHA (FINANCE);ANTI-THYROID AUTOANTIBODIES;ANTIVIRAL THERAPY;AUTOSOME;BARTONELLA HENSELAE;CARDIAC RESYNCHRONIZATION THERAPY;CARMUSTINE;CD117;CEFTAZIDIME;CYSTATIN;CYTOGENETICS;DEOXYCYTIDINE;DIABETIC FOOT ULCER;DNA MICROARRAY;FEBRILE NEUTROPENIA;FLUDARABINE;GESTATIONAL DIABETES;GLUCOSE HOMEOSTASIS;HBX;HISTOCOMPATIBILITY;HISTOCOMPATIBILITY TESTING;HUMAN BREAST;HUMAN GENOME;IFOSFAMIDE;IMIPENEM;ISCHEMIC CARDIOMYOPATHY;KARYOTYPE;LASER CAPTURE MICRODISSECTION;MALE INFERTILITY;MILAN CRITERIA;MITRAL ANNULUS;MITRAL VALVE ANNULOPLASTY;NITROTYROSINE;NONALCOHOLIC FATTY LIVER DISEASE;ORTHOTOPIC LIVER TRANSPLANTATION;OSTEOPENIA;PANCREATIC ISLETS;PARASITEMIA;PERCUTANEOUS ETHANOL INJECTION;POLYCYSTIC OVARY;RADIOIODINE THERAPY;SEX HORMONE-BINDING GLOBULIN;SMALL FOR GESTATIONAL AGE;VANCOMYCIN;VINCRISTINE;VIRAL QUASISPECIES;WOLFF–CHAIKOFF EFFECT","3;3;3;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;;TREATMENT OUTCOME;ANTI-BACTERIAL AGENTS;HEPATITIS B VIRUS;ISCHEMIA;PSEUDOMONAS INFECTIONS;LIVER TRANSPLANTATION;VASODILATOR AGENTS;AGED, 80 AND OVER;DIABETES MELLITUS, TYPE 2;DIABETIC FOOT;FOLLOW-UP STUDIES;ITALY;ADOLESCENT","52;40;38;30;24;23;21;13;11;11;11;11;10;10;9;9;9;9;9;8","HEPATITIS B INFECTION AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;HEPATITIS C INFECTION AND TREATMENT;MANAGEMENT AND TREATMENT OF PERIPHERAL ARTERIAL DISEASE;PREVENTION AND MANAGEMENT OF DIABETIC FOOT ULCERS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;MANAGEMENT OF DIABETES MELLITUS AND HYPOGLYCEMIA;PANCREATIC ISLET DYSFUNCTION AND REGENERATION;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT;ADVANCEMENTS IN LUNG CANCER RESEARCH;AGE-RELATED MACULAR DEGENERATION RESEARCH;ANALYSIS OF ELECTROCARDIOGRAM SIGNALS;BARTONELLA INFECTIONS AND ZOONOTIC POTENTIAL;CARDIAC SURGERY AND BYPASS GRAFTING OUTCOMES;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;CLINICAL MANAGEMENT OF TRACHEAL AND AIRWAY DISORDERS;COPPER AND ZINC IN HEALTH AND DISEASE;CYCLOOXYGENASE-2 INHIBITORS IN INFLAMMATION AND CANCER","6;3;3;3;3;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1","DIABETES;LIVER TRANSPLANTATION;TREATMENT;ANTIVIRAL THERAPY;BONE GROWTH;BONE REMODELING;COLISTIN;COMBINATION THERAPY;CONTINUOUS GLUCOSE MONITORING;CRITICAL LIMB ISCHEMIA;HBEAG;HBV INFECTION;ILOPROST;REGIMEN;ACROMEGALY;ARTHROPATHY;C-REACTIVE PROTEIN;CARDIOVASCULAR EVALUATION;DESFLURANE;GESTATIONAL DIABETES MELLITUS","7;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2","LIVER TRANSPLANTATION;COLISTIN THERAPY;LIMB ISCHEMIA;ANTIBIOTIC THERAPY;CARBON DIOXIDE;CHRONIC HEPATITIS;CRITICAL LIMB;DIABETIC FOOT;HBV INFECTION;JOINT ALTERATIONS;MICROBIOLOGICAL EFFICACY;PROSPECTIVE STUDY;THYROID CANCER;TRANSCUTANEOUS OXYGEN;TRANSIENT ELASTOGRAPHY;ABDOMINAL TRAUMA;ACTIVE STEROID-REFRACTORY;ACTIVEINACTIVE ANTI-HBE;ACUTE ANEMIA;ACUTE MYOCARDIAL;ACUTE VIRAL;ADEFOVIR DIPIVOXIL;ADENOSINE -TRIPHOSPHATE-SENSITIVE;ADJUSTMENT DISORDERS;ADMISSION C-REACTIVE;ADVANCED THYROID;ADVANCED-STAGE NON-SMALL-CELL;AERUGINOSA DIABETIC;AERUGINOSA SYSTEMIC;AERUGINOSAIDIABETIC FOOT","4;3;3;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","DIABETIC RETINOPATHY;MITRAL VALVE;PEGINTERFERON ALPHA-A;VALVE ANNULUS;HBV DNA;EMBOLIC EVENTS;BONE METABOLISM;CI KG;CORONARY ARTERY;DISEASE RECURRENCE;FATFREE MASS;HBV RT;HCV RNA;NANDROLONE DECANOATE;PAD INFECTION;PATIENTS RECEIVING;REFERENCE EQUATIONS;ANIMAL MODELS;AORTIC CLAMPING;ARTERY BYPASS;CARDIAC TROPONIN;CHRONIC HEPATITIS;COMBINATION THERAPY;COMBINED RESPONSE;DEVELOPED DISEASE;DONORS WEIGHING;FOOT DISEASE;FOOT ULCERS;HBV GENOME;HBV GENOTYPE","10;10;9;8;6;5;4;4;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3",8,0.11,3.1,5.47,4.95,6,3,2,4,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,3,2,4,0,0,0,0,0,0,3,3,3,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,1,1,0,0,0,0,0,0,66,48,84,66,48,84,2,0,2,2,0,0,0,0,1,0,0,0,3,1,1,21,1,1,5,0,5,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,3,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ALBERTELLI ROBERTO;ROBERTO ALBERTELLI","4;1","AZIENDA OSPEDALIERO UNIVERSITARIA PISANA;AZIENDA OSPEDALIERA PISANA","3;2","32 BIOMEDICAL AND CLINICAL SCIENCES;40 ENGINEERING;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;4012 FLUID MECHANICS AND THERMAL ENGINEERING","5;4;3;1;1;1","LUNG;PEDIATRIC","1;1",NA,NA,"A61M16/06;A61M16/08;A61M16/00;A61B;A61B5/08;A61M;A61M15/00;A61M16/20;A62B7/00;G01T1/161","5;5;4;1;1;1;1;1;1;1","A61M16/06;A61M16/08;A61M16/0066;A61M16/0078;A61M2016/0021;A61B5/0813;A61M15/02;A61M16/0833;A61M16/208","5;5;4;4;4;1;1;1;1",0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12,5.22,488.67,1,59.25,0,0,3,0,3,0,4,2,0,9,1,0,0,0,0,0,0,11,0,1,10,2,0,0,0,0,0,0,0,0,"United States;Germany;Italy","2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS","12;5;4;4;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;HEMATOLOGY;RARE DISEASES;CANCER;LYMPHOMA;PATIENT SAFETY;CARDIOVASCULAR;FIBROMYALGIA;HEART DISEASE;PAIN RESEARCH;BASIC BEHAVIORAL AND SOCIAL SCIENCE;BEHAVIORAL AND SOCIAL SCIENCE;GENETICS;HEALTH SERVICES;INFECTIOUS DISEASES;KIDNEY DISEASE;NEUROSCIENCES;REGENERATIVE MEDICINE;SEPSIS","9;7;5;4;3;3;3;2;2;2;2;1;1;1;1;1;1;1;1;1","CANCER;BLOOD;CARDIOVASCULAR;RENAL AND UROGENITAL","4;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.4 SURVEILLANCE AND DISTRIBUTION","6;3;1","NON-HODGKIN'S LYMPHOMA;GENITAL SYSTEM, MALE;LIVER CANCER;PROSTATE CANCER","3;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY","4;1"
"AOU_PISANA",2007,91,8.37362637362637,3.27472527472528,0.305369127516779,0.637362637362637,0.340659340659341,0.0879120879120879,0.274725274725275,2,41,17,10,20,0.45,0.19,0.11,0.22,57.46,1.08878180093085,0.197802197802198,0.571428571428571,0,0.441411575405169,0.37,0.416842105263158,0.385,"FRANCO FILIPPONI;STEFANO DEL PRATO;GÍANNI BIANCOFIORE;FABRIZIO SCATENA;PAOLO DE SIMONE;ROBERTO MICCOLI;LUCIO URBANI;CINZIA ORLANDINI;MAIDO CASTIGLIONI;ALBERTO PIAGGESI;GIULIANO MARIANI;ALFONSO CRISTAUDO;L BINDI;GIUSEPPE PENNO;CARLO TASCINI;MAURIZIA ROSSANA BRUNETTO;RUDY FODDIS;MASSIMILIANO PINELLI;MASSIMO BINDI;PIERO MARCHETTI","10;7;7;6;6;5;5;4;4;4;4;4;4;4;4;4;4;4;4;3","FRANCO FILIPPONI;CLAUDIO FAVRE;CARLO PASSAGLIA;MAIDO CASTIGLIONI;MASSIMILIANO PINELLI;MASSIMO BINDI;PAOLO DE SIMONE;P MALACARNE;STEFANO DEL PRATO;GÍANNI BIANCOFIORE;FABRIZIO SCATENA;NICOLINO AMBROSINO;ROBERTO MICCOLI;FEDERICA MORONI;FRANCESCO MENICHETTI;CARLO TASCINI;JAVIER ROSADA;FABIO GUARRACINO;LUCIO URBANI;GIAMPIERO I. BARONCELLI","1.35;1;1;0.93;0.93;0.93;0.92;0.9;0.85;0.74;0.73;0.67;0.6;0.6;0.6;0.57;0.54;0.52;0.52;0.5","FRANCO FILIPPONI;STEFANO DEL PRATO;GÍANNI BIANCOFIORE;FABRIZIO SCATENA;PAOLO DE SIMONE;ROBERTO MICCOLI;LUCIO URBANI;CINZIA ORLANDINI;ALBERTO PIAGGESI;GIULIANO MARIANI;L BINDI;GIUSEPPE PENNO;CARLO TASCINI;MAURIZIA ROSSANA BRUNETTO;MASSIMILIANO PINELLI;MASSIMO BINDI;PIERO MARCHETTI;NICOLINO AMBROSINO;M GROSSO;IACOPO DALLAN","10;7;7;6;6;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3","FRANCO FILIPPONI;CLAUDIO FAVRE;CARLO PASSAGLIA;MASSIMILIANO PINELLI;MASSIMO BINDI;PAOLO DE SIMONE;P MALACARNE;STEFANO DEL PRATO;GÍANNI BIANCOFIORE;FABRIZIO SCATENA;NICOLINO AMBROSINO;ROBERTO MICCOLI;FRANCESCO MENICHETTI;CARLO TASCINI;FABIO GUARRACINO;LUCIO URBANI;GIUSEPPE SAGGESE;BEATRICE RAGGIO;IACOPO DALLAN;ALBERTO PIAGGESI","1.35;1;1;0.93;0.93;0.92;0.9;0.85;0.74;0.73;0.67;0.6;0.6;0.57;0.52;0.52;0.5;0.5;0.48;0.46","CINZIA ORLANDINI;SERGIO RICCI;ALFREDO FALCONE;C. BARBARA;CRISTINA GRANETTO;E. PFANNER;ENRICO CORTESI;GIACOMO ALLEGRINI;GIANFRANCO PORCILE;GIANLUCA MASI;GIOVANNI BENEDETTI;I. BRUNETTI;LAURA FANCHINI;LUCIO CRINÓ;LUISA FIORETTO;M. ANDREUCCETTI;S. VITELLO;SILVANA CHIARA;V. PICONE;W. EVANGELISTA","1256;1221;1162;1162;1162;1162;1162;1162;1162;1162;1162;1162;1162;1162;1162;1162;1162;1162;1162;1162","SERGIO RICCI;C. BARBARA;CRISTINA GRANETTO;E. PFANNER;ENRICO CORTESI;GIACOMO ALLEGRINI;GIANFRANCO PORCILE;GIANLUCA MASI;GIOVANNI BENEDETTI;I. BRUNETTI;LAURA FANCHINI;LUCIO CRINÓ;LUISA FIORETTO;M. ANDREUCCETTI;S. VITELLO;V. PICONE;W. EVANGELISTA;DUCCIO VOLTERRANI;UBALDO BONUCCELLI;PIERO MARCHETTI","1221;1162;1162;1162;1162;1162;1162;1162;1162;1162;1162;1162;1162;1162;1162;1162;1162;641;641;434","FABRIZIO SCATENA;FRANCO FILIPPONI;GÍANNI BIANCOFIORE;PAOLO DE SIMONE;STEFANO DEL PRATO;ALESSANDRO MAZZONI;CLAUDIO TRAINO;EDITTA BALDINI;PIERO MARCHETTI;R LUPI;IACOPO DALLAN;MAURIZIA ROSSANA BRUNETTO;STEFANIA PETRUCCELLI;MASSIMILIANO PINELLI;ALBERTO PIAGGESI;ALDO PINCHERA;CLAUDIA CARIELLO;DANIELE MASELLI;ENIO MARTINO;FABIO GUARRACINO","6;6;6;5;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2","MEDICINE;BIOLOGY;PHYSICS;ECONOMICS;ENGINEERING;PHILOSOPHY;CHEMISTRY;POLITICAL SCIENCE;BUSINESS;MATERIALS SCIENCE;PSYCHOLOGY;COMPUTER SCIENCE;GEOLOGY;MATHEMATICS","88;24;8;6;6;4;3;3;2;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;ENDOCRINOLOGY;GASTROENTEROLOGY;PATHOLOGY;CARDIOLOGY;ENVIRONMENTAL HEALTH;GENETICS;IMMUNOLOGY;INTENSIVE CARE MEDICINE;UROLOGY;BIOCHEMISTRY;ONCOLOGY;RADIOLOGY;MICROBIOLOGY;CELL BIOLOGY;FAMILY MEDICINE;NUCLEAR MEDICINE;VIROLOGY;LINGUISTICS;PSYCHIATRY","69;20;18;16;14;13;12;12;12;12;8;7;7;7;6;5;5;5;5;4;4","CANCER;DISEASE;POPULATION;GENE;TRANSPLANTATION;VIRUS;DIABETES MELLITUS;HEART FAILURE;ANTIBIOTICS;RANDOMIZED CONTROLLED TRIAL;URIC ACID;CHEMOTHERAPY;CREATININE;INSULIN;LUNG;LUNG CANCER;RENAL FUNCTION;ADVERSE EFFECT;ANTIBODY;ASYMPTOMATIC;BACTERIA;BLOOD PRESSURE;DEPRESSION (ECONOMICS);IMMUNOSUPPRESSION;MAGNETIC RESONANCE IMAGING;RADIATION THERAPY;SEPSIS;THYROID","11;11;11;9;9;8;7;7;6;6;5;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3","LIVER TRANSPLANTATION;BREAST CANCER;HEPATITIS B VIRUS;INSULIN RESISTANCE;TYPE 2 DIABETES;CHRONIC HEPATITIS;CLINICAL ENDPOINT;EJECTION FRACTION;EXON;MICROALBUMINURIA;ANTIBIOTIC RESISTANCE;COLISTIN;COLORECTAL CANCER;CYSTATIN C;DIABETIC FOOT;DOPAMINERGIC;ENDOSCOPIC ENDONASAL SURGERY;GENOTYPE;HEPATITIS C VIRUS;HYPERURICEMIA;LEVOFLOXACIN;LEVOSIMENDAN;MESOTHELIN;METABOLIC SYNDROME;MUTATION;PSEUDOMONAS AERUGINOSA;RESPIRATORY DISEASE;SEPTIC SHOCK;THYROID CANCER;VENTILATOR-ASSOCIATED PNEUMONIA;VIRAL LOAD","8;4;4;4;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","LAMIVUDINE;ACINETOBACTER BAUMANNII;HBSAG;MAMMOGRAPHY;RADIOIODINE THERAPY;ABDOMINAL OBESITY;ACROMEGALY;ADENOCARCINOMA OF THE LUNG;ADIPONECTIN;AL AMYLOIDOSIS;ANTIGEN-PRESENTING CELL;BETA CELL;CARDIAC INDEX;CARDIAC RESYNCHRONIZATION THERAPY;CATHEPSIN K;CORONARY ARTERY ANEURYSM;CROSSOVER STUDY;CYCLIN;CYSTATIN;DEMENTIA WITH LEWY BODIES;DEPERSONALIZATION;DIHYDROTESTOSTERONE;DOPAMINE TRANSPORTER;DRUG-ELUTING STENT;DUCTAL CARCINOMA;ENDOTHELIAL PROGENITOR CELL;ENTEROBACTERIACEAE;ERLOTINIB;EVANS SYNDROME;EXTRACORPOREAL PHOTOPHERESIS;FEBRILE NEUTROPENIA;FRAMINGHAM HEART STUDY;GEFITINIB;HAPLOTYPE;HORMONE THERAPY;HYPERINSULINEMIA;HYPERINSULINISM;IFOSFAMIDE;IMIPENEM;IMPAIRED GLUCOSE TOLERANCE;INCRETIN;INSULIN OSCILLATION;INSULIN RECEPTOR;INSULIN SENSITIVITY;INTERSTITIAL PNEUMONITIS;IONIZATION CHAMBER;IRINOTECAN;KARYOTYPE;KRAS;MALE INFERTILITY;MANIA;MEROPENEM;MISSENSE MUTATION;MODEL FOR END-STAGE LIVER DISEASE;NATIONAL CHOLESTEROL EDUCATION PROGRAM;NORETHISTERONE;OXALIPLATIN;PANCREATIC ISLETS;PAPILLARY THYROID CANCER;PRIMARY SYSTEMIC AMYLOIDOSIS;RENAL ARTERY STENOSIS;REVERSE TRANSCRIPTASE;RIGHT CORONARY ARTERY;RNA SPLICING;SEMEN ANALYSIS;SIDA;SINGLE-NUCLEOTIDE POLYMORPHISM;STAT PROTEIN;SUBTHRESHOLD CONDUCTION;TARGET LESION;TOTAL BODY IRRADIATION;VANCOMYCIN;VINORELBINE;VIRAL QUASISPECIES","3;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;DIABETES MELLITUS, TYPE 2;HEART FAILURE;ITALY;;LIVER TRANSPLANTATION;CREATININE;AGED, 80 AND OVER;ATHEROSCLEROSIS;TREATMENT OUTCOME;GLYCATED HEMOGLOBIN A;METABOLIC SYNDROME;POSTOPERATIVE COMPLICATIONS;PROSPECTIVE STUDIES;APOPTOSIS","76;50;49;43;34;28;16;14;14;13;12;11;9;9;9;8;8;8;8;7","HEPATITIS B INFECTION AND TREATMENT;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;ADVANCEMENTS IN LUNG CANCER RESEARCH;BREAST MAGNETIC RESONANCE IMAGING IN ONCOLOGY;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;DIAGNOSIS AND TREATMENT OF RENAL ARTERY STENOSIS;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;KIDNEY TRANSPLANTATION;MANAGEMENT OF FEBRILE NEUTROPENIA IN CANCER PATIENTS;MANAGEMENT OF VENTILATOR-ASSOCIATED PNEUMONIA IN ICU PATIENTS;PANCREATIC ISLET DYSFUNCTION AND REGENERATION;PREVENTION AND MANAGEMENT OF DIABETIC FOOT ULCERS;RADIOTHERAPY PHYSICS AND TECHNOLOGY;THYROID DISEASE AND HORMONE REGULATION;;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN PROSTATE CANCER RESEARCH","5;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1","DIABETES;ADEFOVIR;CLINICAL ENDPOINT;IMMUNOSUPPRESSION;LIVER TRANSPLANTATION;MICROALBUMINURIA;TREATMENT;ACINETOBACTER BAUMANNII;ACROMEGALY;ADIPOSE TISSUE;ASBESTOS EXPOSURE;BOLUS (DIGESTION);BREAST IMAGING;BREAST MRI;COLISTIN;COMBINATION THERAPY;CONTINUOUS INFUSION;DEPRESSION (ECONOMICS);ENDOSCOPIC ENDONASAL SURGERY;FOOT (PROSODY)","4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2","LIVER TRANSPLANT;LUNG CANCER;LIVER TRANSPLANTATION;TRANSPLANT RECIPIENTS;TYPE DIABETES;ADEFOVIR MONOTHERAPY;CANCER PATIENTS;CEREBROSPINAL FLUID;CHRONIC HEPATITIS;COMBINATION THERAPY;CORONARY HEART;DIABETIC FOOT;ENDONASAL ENDOSCOPIC;FIRST-LINE TREATMENT;FLUOROURACIL LEUCOVORIN;HEART DISEASE;HEART FAILURE;INFUSIONAL FLUOROURACIL;METABOLIC SYNDROME;PHASE III;PULMONARY ARTERY;RISK FACTORS;SERUM MESOTHELIN;VENTILATOR-ASSOCIATED PNEUMONIA;A- TRIPLETS;ABLATIVE THERAPY;ABO-INCOMPATIBLE LIVER;ABSOLUTE DOSE;ABSORBED DOSE;ACID LEVELS","5;4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1","AORTIC VALVE;CORONARY ARTERY;PUBMED SCOPUS;SINOTUBULAR JUNCTION;TYPE DIABETES;VALVE REIMPLANTATION;ADVERSE EVENTS;INTRAOPERATIVE MEASUREMENTS;STJ SIZE;SURG -ABSTRACT;VALSALVA VASCUTEK;AORTIC LEAFLETS;BETA CELL;RENAL FUNCTION;SERUM SMRP;SINGLE DOSE;THORAC SURG;ANT- EXPRESSION;CHD RISK;CORONARY ARTERIES;ER STRESS;INDUCTION TEST;P-CONTAINING REGIMENS;RCA ANEURYSM;VASCUTEK GRAFT;ANOMALOUS ORIGIN;AORTIC REGURGITATION;AORTIC ROOT;CROSSREF PUBMED;GEMCITABINE MGM","19;12;12;11;9;9;8;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4",11,0.12,4,7.5,6,10.5,4.2,2,7,0,0,0,0,0,0,0,0,0,0,0,0,4.33,2,7,0,0,0,2,2,2,4.6,2,7,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,107.2,33,285,107.2,33,285,2,0,0,3,0,0,0,0,0,0,0,0,1,1,1,1,1.33333333333333,1,2,0,3,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ALBERTELLI ROBERTO;ALBERTELLI;ROBERTO","2;1;1","AZIENDA OSPEDALIERA PISANA","3","40 ENGINEERING;31 BIOLOGICAL SCIENCES;32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;4012 FLUID MECHANICS AND THERMAL ENGINEERING","2;1;1;1;1","ASSISTIVE TECHNOLOGY;BIOENGINEERING","1;1",NA,NA,"A61M16/00;A61M16/06;A61M16/08;A61M;A62B7/00","3;3;3;2;1","A61M16/06;A61M16/08;A61M16/0066;A61M16/0078;A61M2016/0021;A61M16/66;A61M16/78;A61M2016/21","3;3;2;2;2;1;1;1",0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,2,"PUBLIC LIBRARY OF SCIENCE","2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES","2;1",NA,NA,NA,NA,NA,NA,NA,NA,"CLINICAL MEDICINE AND SCIENCE","1",NA,NA,NA,NA,14,3.2,489.4,1,35.21,0,0,4,1,2,0,6,1,0,4,1,0,0,0,0,0,0,12,2,0,5,9,0,0,0,0,0,0,0,0,"United States","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3208 MEDICAL PHYSIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;5203 CLINICAL AND HEALTH PSYCHOLOGY","11;4;3;3;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;AGING;CARDIOVASCULAR;RARE DISEASES;ARTHRITIS;BIPOLAR DISORDER;BRAIN DISORDERS;CHRONIC PAIN;CONTRACEPTION/REPRODUCTION;ESTROGEN;HEART DISEASE;HEMATOLOGY;HYPERTENSION;LYMPHOMA;MENTAL HEALTH;OSTEOARTHRITIS;PAIN RESEARCH;PATIENT SAFETY","5;3;3;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;NEUROLOGICAL;EYE;MENTAL HEALTH;MUSCULOSKELETAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","3;2;2;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS","7;1;1","COLON AND RECTAL CANCER;NON-HODGKIN'S LYMPHOMA;THYROID CANCER","1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","2;1;1;1"
"AOU_PISANA",2008,130,9.41538461538462,3.55384615384615,0.281385281385281,0.5,0.384615384615385,0.1,0.3,2,66,32,16,14,0.51,0.25,0.12,0.11,53.22,0.969811744126757,0.223076923076923,0.684615384615385,0,0.447018546937863,0.410791266861354,0.43380376344086,0.407982261640798,"FRANCO FILIPPONI;MAURIZIA ROSSANA BRUNETTO;PAOLO DE SIMONE;GÍANNI BIANCOFIORE;LUCIO URBANI;FERRUCCIO BONINO;MAIDO CASTIGLIONI;L BINDI;NICOLINO AMBROSINO;LUCA MORELLI;GIULIANO MARIANI;FABRIZIO SCATENA;P. COLOMBATTO;FRANCO MOSCA;FRANCESCO MENICHETTI;MASSIMILIANO PINELLI;MASSIMO BINDI;PAOLO MICCOLI;IRENE BARGELLINI;ALFREDO FALCONE","17;11;10;10;8;6;6;6;5;5;5;5;5;5;5;5;5;4;4;4","FRANCO FILIPPONI;FRANCESCO MENICHETTI;G. BRESCI;GÍANNI BIANCOFIORE;PAOLO DE SIMONE;MAIDO CASTIGLIONI;MASSIMILIANO PINELLI;MASSIMO BINDI;MAURIZIA ROSSANA BRUNETTO;LUCIO URBANI;NICOLINO AMBROSINO;M BINDI;GENEROSO BEVILACQUA;ELEONORA DATI;SILVANO BERTELLONI;GIUSEPPE MAGGIORE;FERRUCCIO BONINO;ALFREDO FALCONE;GIULIANO MARIANI;DANIELA MORUZZO","2.03;1.76;1.53;1.45;1.38;1.32;1.07;1.07;1.01;0.85;0.81;0.8;0.75;0.67;0.67;0.64;0.63;0.61;0.6;0.57","FRANCO FILIPPONI;MAURIZIA ROSSANA BRUNETTO;PAOLO DE SIMONE;GÍANNI BIANCOFIORE;LUCIO URBANI;MAIDO CASTIGLIONI;L BINDI;NICOLINO AMBROSINO;LUCA MORELLI;GIULIANO MARIANI;FABRIZIO SCATENA;P. COLOMBATTO;FRANCO MOSCA;FRANCESCO MENICHETTI;MASSIMILIANO PINELLI;MASSIMO BINDI;PAOLO MICCOLI;IRENE BARGELLINI;ALFREDO FALCONE;GENEROSO BEVILACQUA","17;11;10;10;8;6;6;5;5;5;5;5;5;5;5;5;4;4;4;4","FRANCO FILIPPONI;FRANCESCO MENICHETTI;G. BRESCI;GÍANNI BIANCOFIORE;PAOLO DE SIMONE;MAIDO CASTIGLIONI;MASSIMILIANO PINELLI;MASSIMO BINDI;MAURIZIA ROSSANA BRUNETTO;LUCIO URBANI;NICOLINO AMBROSINO;M BINDI;GENEROSO BEVILACQUA;ELEONORA DATI;SILVANO BERTELLONI;GIUSEPPE MAGGIORE;ALFREDO FALCONE;GIULIANO MARIANI;P. COLOMBATTO;FRANCO MOSCA","2.03;1.76;1.53;1.45;1.38;1.32;1.07;1.07;1.01;0.85;0.81;0.8;0.75;0.67;0.67;0.64;0.61;0.6;0.56;0.54","MAURIZIA ROSSANA BRUNETTO;ALBERTO PIAGGESI;ALEXANDRA JIRKOVSKÁ;DÍDAC MAURICIO;FRITS VAN MERODE;HEINRICH REIKE;K. BAKKER;K. VAN ACKER;L. PROMPERS;LUIGI UCCIOLI;M. HUIJBERTS;MAXIMILIAN SPRAUL;NICOLAAS C. SCHAPER;P. HOLSTEIN;V. URBANČIČ;EDWARD B. JUDE;JAN APELQVIST;J. VAN BAAL;GUNNEL RAGNARSON-TENNVALL;ISABEL FERREIRA","1610;1375;1375;1375;1375;1375;1375;1375;1375;1375;1375;1375;1375;1375;1375;1185;1185;1095;905;905","MAURIZIA ROSSANA BRUNETTO;ALBERTO PIAGGESI;ALDO PINCHERA;AGNESE BIAGINI;CLARA UGOLINI;CRISTIANA LUPI;CRISTINA ROMEI;DAVID VIOLA;FULVIO BASOLO;PAOLO MICCOLI;RICCARDO GIANNINI;ROSSELLA ELISEI;F. MORICONI;FABIO GUARRACINO;GÍANNI BIANCOFIORE;FABIO FALASCHI;FRANCO FILIPPONI;CHETI SPINELLI;L BINDI;FILIPPO OLIVERI","1480;1375;529;515;515;515;515;515;515;515;515;515;465;368;337;333;303;280;269;245","FRANCO FILIPPONI;MAURIZIA ROSSANA BRUNETTO;GÍANNI BIANCOFIORE;L BINDI;PAOLO DE SIMONE;LUCIO URBANI;FABRIZIO SCATENA;FRANCESCO MENICHETTI;ALESSANDRO MAZZONI;C VIGNALI;CARLO TASCINI;FABIO GUARRACINO;FILIPPO OLIVERI;FRANCO MOSCA;GENEROSO BEVILACQUA;LUCA MORELLI;NICOLINO AMBROSINO;P. COLOMBATTO;DANIELA CAMPANI;G CATALANO","13;10;9;6;6;6;5;5;4;4;4;4;4;4;4;4;4;4;4;3","MEDICINE;BIOLOGY;CHEMISTRY;COMPUTER SCIENCE;PSYCHOLOGY;PHYSICS;ECONOMICS;PHILOSOPHY;ENGINEERING;BUSINESS;ENVIRONMENTAL SCIENCE;MATERIALS SCIENCE;MATHEMATICS;POLITICAL SCIENCE;SOCIOLOGY;ART;GEOGRAPHY;GEOLOGY","127;30;9;7;7;6;5;5;4;3;2;2;2;2;2;1;1;1","INTERNAL MEDICINE;SURGERY;PATHOLOGY;GASTROENTEROLOGY;RADIOLOGY;IMMUNOLOGY;CARDIOLOGY;ENDOCRINOLOGY;GENETICS;INTENSIVE CARE MEDICINE;ONCOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;CANCER RESEARCH;EMERGENCY MEDICINE;PALEONTOLOGY;VIROLOGY;ANESTHESIA;NUCLEAR MEDICINE;PSYCHIATRY","100;37;30;23;20;18;16;14;14;13;13;11;9;7;7;7;7;6;6;6","TRANSPLANTATION;CANCER;DISEASE;HEART FAILURE;CHEMOTHERAPY;GENE;VIRUS;BLOOD PRESSURE;LUNG;POPULATION;BIOPSY;HEMODYNAMICS;LUNG CANCER;THYROID;DIABETES MELLITUS;INTENSIVE CARE UNIT;MAGNETIC RESONANCE IMAGING;ALTERNATIVE MEDICINE;CARCINOMA;CONFIDENCE INTERVAL;INFLAMMATION;LYMPH NODE;STAGE (STRATIGRAPHY)","20;16;15;12;11;11;11;8;7;7;6;6;6;6;5;5;5;4;4;4;4;4;4","LIVER TRANSPLANTATION;CHRONIC HEPATITIS;BREAST CANCER;HEPATITIS B VIRUS;EJECTION FRACTION;HEPATITIS C VIRUS;MUTATION;THYROID CANCER;ADENOCARCINOMA;BLEOMYCIN;CALCINEURIN;CHRONIC LIVER DISEASE;DIABETIC FOOT;DIASTOLE;DOXORUBICIN;EPIDERMAL GROWTH FACTOR RECEPTOR;KIDNEY TRANSPLANTATION;ULCERATIVE COLITIS;UNIVARIATE ANALYSIS;ANDROGEN;CARDIAC OUTPUT;CHEMOSENSITIVITY ASSAY;CISPLATIN;COLORECTAL CANCER;CYCLOPHOSPHAMIDE;EPIDERMAL GROWTH FACTOR;ETOPOSIDE;FLUOROURACIL;GEMCITABINE;GRAFT-VERSUS-HOST DISEASE;HAZARD RATIO;HEART RATE;HUMAN GENETICS;INSULIN RESISTANCE;LIVER FIBROSIS;MESOTHELIN;METASTASIS;NATRIURETIC PEPTIDE;ORGAN DONATION;PERCUTANEOUS CORONARY INTERVENTION;PROGRESSIVE DISEASE;RANDOMIZATION;RESTENOSIS;SPUTUM;THYROID CARCINOMA;THYROIDITIS;TRIIODOTHYRONINE;TYPE 2 DIABETES;WHITE MATTER","12;6;5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","RIBAVIRIN;ANAPLASTIC THYROID CANCER;MAMMOGRAPHY;CARDIAC INDEX;CENTRAL VENOUS PRESSURE;DOPPLER ECHOCARDIOGRAPHY;EPIRUBICIN;EXTRACORPOREAL PHOTOPHERESIS;GEFITINIB;HBSAG;STROKE VOLUME;TRANSIENT ELASTOGRAPHY;ACROMEGALY;ADENOCARCINOMA OF THE LUNG;ALPHA (FINANCE);ANAL CARCINOMA;ANDROSTENEDIONE;ANTI-THYROID AUTOANTIBODIES;ANTITHROMBIN III DEFICIENCY;AUTOIMMUNE THYROIDITIS;BREAST CARCINOMA;CANDIDA KRUSEI;CAPECITABINE;CARBOPLATIN;CARDIAC RESYNCHRONIZATION THERAPY;CYSTECTOMY;DIABETIC FOOT ULCER;DIASTOLIC FUNCTION;ENDOANAL ULTRASOUND;ERLOTINIB;ESOPHAGOGASTRIC JUNCTION;EXTRAVERSION AND INTROVERSION;FETAL HEMOGLOBIN;FLAVIVIRIDAE;FRAMESHIFT MUTATION;GASTRIC BYPASS;GENE MUTATION;GERMLINE MUTATION;GLUCOSE TOLERANCE TEST;GONADAL STEROID HORMONES;HEMIMEGALENCEPHALY;HEPACIVIRUS;HYDROXYSTEROID DEHYDROGENASE;IRINOTECAN;JAG1;LAMIVUDINE;LEGIONNAIRES' DISEASE;LIPOTOXICITY;MICROMETASTASIS;MICRONUCLEUS;MILAN CRITERIA;MISSENSE MUTATION;NICOTINE GUM;ONCOGENE;OXALIPLATIN;P38 MITOGEN-ACTIVATED PROTEIN KINASES;PANCREAS TRANSPLANTATION;PIOGLITAZONE;PULMONARY ARTERY CATHETER;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;RF ABLATION;SENTINEL LYMPH NODE;SENTINEL NODE;SEX HORMONE-BINDING GLOBULIN;SEX STEROID;STENOTROPHOMONAS MALTOPHILIA;SYSTEMIC VASCULITIS;TISSUE DONATION;TRANSLOCATOR PROTEIN;VANCOMYCIN;VIRILIZATION;VOXEL-BASED MORPHOMETRY","6;3;3;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;;TREATMENT OUTCOME;LIVER NEOPLASMS;LIVER TRANSPLANTATION;THYROID NEOPLASMS;HEART FAILURE;AGED, 80 AND OVER;ITALY;LUNG NEOPLASMS;YOUNG ADULT;COLITIS, ULCERATIVE;FOLLOW-UP STUDIES;HEPATITIS C;ADOLESCENT","94;69;65;53;42;36;32;25;19;19;19;17;15;15;13;13;12;12;12;11","HEPATITIS B INFECTION AND TREATMENT;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;KIDNEY TRANSPLANTATION;ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF HEART FAILURE;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;HEPATITIS C INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;OPTIMIZATION OF PERIOPERATIVE FLUID THERAPY;PREVENTION AND MANAGEMENT OF DIABETIC FOOT ULCERS;;ABDOMINAL COMPARTMENT SYNDROME AND INTRA-ABDOMINAL HYPERTENSION;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ASTHMA;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;ETHICAL AND MEDICAL ASPECTS OF ORGAN DONATION;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH","6;6;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","TREATMENT;LIVER TRANSPLANTATION;LIVING DONOR LIVER TRANSPLANTATION;CARDIAC OUTPUT;ORGAN DONATION;TRANSPLANTATION;ANAPLASTIC THYROID CANCER;CANCER;CANCER THERAPY;CHRONIC LIVER DISEASE;DIABETES;ECHOCARDIOGRAPHY;FOOT ULCERS;HEMODYNAMIC MONITORING;HEPATITIS B;INTERQUARTILE RANGE;LIVER DISEASE;PEGINTERFERON ALFA-2A;PULMONARY DISEASE;ULCERATIVE COLITIS","10;8;8;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","LIVER TRANSPLANTATION;HEART FAILURE;LIVER TRANSPLANT;CELL CARCINOMA;ABSOLUTE CONTRA-INDICATION;ANAPLASTIC THYROID;CHRONIC HEPATITIS;CORONARY ARTERY;EURODIALE STUDY;EUROPEAN LIVER;FOOT ULCERS;HEPATIC ANGIOSARCOMA;LIVER DISEASE;LT REPORT;LUNG CANCER;PEGINTERFERON ALFA-A;REGISTRY ELTR;THYROID CANCER;TRANSPLANT REGISTRY;TRANSPLANTATION LT;ULCERATIVE COLITIS;ALFA-A KD;BARE-METAL STENTS;CANCER CELLS;CELL LUNG;COLORECTAL CANCER;DIABETIC FOOT;DRUG-ELUTING STENTS;GENE SYMBOL;HBEAG-NEGATIVE CHRONIC","9;6;5;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2","PEGINTERFERON ALFA-A;BRAFVE MUTATION;CHEMOTHERAPEUTIC AGENTS;HBV DNA;PTC PATIENTS;CHRONIC HEPATITIS;DIABETIC FOOT;ESOPHAGOGASTRIC JUNCTION;GROWTH FACTOR;PATIENTS UNDERGOING;ATC PATIENTS;CHRONIC ASTHMA;COPD PATIENTS;DNA COPIESML;EPIDERMAL GROWTH;FACTOR RECEPTOR;HOTTEST NODE;LOG IUML;LUNG FUNCTION;SHORT ESOPHAGUS;TBAS NA;CHRONIC BRONCHITIS;EXPANDED ACCESS;GRAFT ISCHEMIA;GRAFT SALVAGE;HBSAG CLEARANCE;ICU ECHOCARDIOGRAPHY;KINASE INHIBITORS;KPA NA;LYMPH NODE","15;10;10;8;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4",16,0.12,4.5,15.53,8.25,26,5,3,7,1,1,1,1,1,1,0,0,0,1.33,1,2,3,3,3,0,0,0,3,3,3,5.5,3,8,0,0,0,0,0,0,2.33,1,4,0,0,0,0,0,0,0,0,0,1,1,1,1.67,1,3,0,0,0,0,0,0,0,0,0,220.25,58,491,220.25,58,491,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ROBERTO ALBERTELLI","1","AZIENDA OSPEDALIERO UNIVERSITARIA PISANA","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","2;1","LUNG","1",NA,NA,"A61B5/08;A61M15/00;A61M16/06;A61M16/08;A61M16/20;G01T1/161","1;1;1;1;1;1","A61B5/0813;A61M15/02;A61M16/06;A61M16/08;A61M16/0833;A61M16/208","1;1;1;1;1;1",1,8e+05,8e+05,5,1,1,0,24,"AZIENDA OSPEDALIERA UNIVERSITARIA PISANA","1","TELETHON FOUNDATION","1",NA,NA,"TELETHON CAREER RENEWAL - 2007 II (PROGRAM)","1","31 BIOLOGICAL SCIENCES;3105 GENETICS;32 BIOMEDICAL AND CLINICAL SCIENCES","1;1;1","DIABETES;NUTRITION;OBESITY","1;1;1","METABOLIC AND ENDOCRINE","1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,18,6.55,1540,3,29.61,0,2,5,0,5,0,4,2,0,11,2,0,0,0,0,0,0,18,0,0,13,5,0,0,0,0,0,0,0,0,"Italy;United States","2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3210 NUTRITION AND DIETETICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;40 ENGINEERING;4012 FLUID MECHANICS AND THERMAL ENGINEERING","18;8;7;4;2;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;PATIENT SAFETY;DIGESTIVE DISEASES;CARDIOVASCULAR;HEART DISEASE;BIOMEDICAL IMAGING;COLO-RECTAL CANCER;KIDNEY DISEASE;LIVER DISEASE;PREVENTION;RARE DISEASES;ATHEROSCLEROSIS;BIOENGINEERING;BIOTECHNOLOGY;CHRONIC OBSTRUCTIVE PULMONARY DISEASE;COMPARATIVE EFFECTIVENESS RESEARCH;DIABETES;DRUG ABUSE (NIDA ONLY)","12;8;8;6;5;4;4;2;2;2;2;2;2;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;RENAL AND UROGENITAL;MENTAL HEALTH;ORAL AND GASTROINTESTINAL;RESPIRATORY;STROKE","9;6;2;2;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;7.3 MANAGEMENT AND DECISION MAKING;2.4 SURVEILLANCE AND DISTRIBUTION;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;6.7 PHYSICAL","11;3;2;1;1;1;1","COLON AND RECTAL CANCER;NOT SITE-SPECIFIC CANCER;LIVER CANCER;MELANOMA;MYELOMA","2;2;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","6;2;1"
"AOU_PISANA",2009,144,9.26388888888889,2.31944444444444,0.431137724550898,0.444444444444444,0.291666666666667,0.118055555555556,0.319444444444444,6,64,33,25,13,0.44,0.23,0.17,0.09,45.92,0.99278791299857,0.215277777777778,0.763888888888889,0,0.412024633827398,0.390542328042328,0.377894736842105,0.372916666666667,"FRANCO FILIPPONI;PAOLO DE SIMONE;MAURIZIA ROSSANA BRUNETTO;IACOPO DALLAN;CARLO BARTOLOZZI;FABIO GUARRACINO;STANISLAO RIZZO;LEONARDO BOLOGNESE;ALFREDO FALCONE;ANTONIO L. BARTORELLI;IMAD SHEIBAN;GENEROSO BEVILACQUA;ALBERTO BENASSI;FAUSTO BOGAZZI;STEFANO DE SERVI;CATALDO PALMIERI;LUIGI INGLESE;FOTIOS LOUPAKIS;MASSIMO MARGHERI;L. CIONINI","11;8;8;7;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4","MAURIZIA ROSSANA BRUNETTO;FRANCO FILIPPONI;CARLO BARTOLOZZI;PAOLO DE SIMONE;GABRIELLA FONTANINI;STANISLAO RIZZO;ANNA SONIA PETRONIO;IACOPO DALLAN;CLAUDIO TRAINO;FABIO GUARRACINO;ALFONSO CRISTAUDO;RODOLFO BUSELLI;MARCO DE CARLO;ANNA SONIA PETRONIO;FEDERICA GENOVESI-EBERT;MAIDO CASTIGLIONI;MASSIMO BINDI;STEFANO SELLARI‐FRANCESCHINI;LUCA MUSCATELLO;L. CIONINI","2.81;2.56;1.49;1.45;1.22;1.05;1.05;1.04;0.91;0.67;0.61;0.61;0.59;0.55;0.55;0.54;0.54;0.52;0.52;0.51","FRANCO FILIPPONI;PAOLO DE SIMONE;MAURIZIA ROSSANA BRUNETTO;IACOPO DALLAN;CARLO BARTOLOZZI;FABIO GUARRACINO;STANISLAO RIZZO;ALFREDO FALCONE;GENEROSO BEVILACQUA;FAUSTO BOGAZZI;FOTIOS LOUPAKIS;L. CIONINI;MARIA GRAZIA FABRINI;MARIO PETRINI;FEDERICA GENOVESI-EBERT;FRANCO PERRONE;MARIA A. CALIGO;PAOLA COLLECCHI;DAVIDE LAZZERI;ALDO PINCHERA","11;8;8;7;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3","MAURIZIA ROSSANA BRUNETTO;FRANCO FILIPPONI;CARLO BARTOLOZZI;PAOLO DE SIMONE;STANISLAO RIZZO;ANNA SONIA PETRONIO;IACOPO DALLAN;CLAUDIO TRAINO;FABIO GUARRACINO;RODOLFO BUSELLI;MARCO DE CARLO;ANNA SONIA PETRONIO;FEDERICA GENOVESI-EBERT;MASSIMO BINDI;STEFANO SELLARI‐FRANCESCHINI;LUCA MUSCATELLO;L. CIONINI;MARIA GRAZIA FABRINI;FRANCO PERRONE;MARCO GIANNELLI","2.81;2.56;1.49;1.45;1.05;1.05;1.04;0.91;0.67;0.61;0.59;0.55;0.55;0.54;0.52;0.52;0.51;0.51;0.51;0.5","JÉRÔME DUMORTIER;A. WATKINSON;ALBAN DENYS;CHRISTIAN MUELLER;F. PILLEUL;GÉRALDINE SERGENT;HERBERT LANGENBERGER;JOHANNES LÄMMER;KATARINA MALAGARI;M. PITTON;M. SCHUCHMANN;MARIA POMONI;P. CHEVALLIER;RICCARDO LENCIONI;SYLVAIN TERRAZ;THOMAS GRUENBERGER;THOMAS J. VOGL;THOMAS PFAMMATTER;YVES AVAJON;YVES BENHAMOU","1612;1463;1463;1463;1463;1463;1463;1463;1463;1463;1463;1463;1463;1463;1463;1463;1463;1463;1463;1463","RICCARDO LENCIONI;ALFREDO FALCONE;CHIARA CREMOLINI;FOTIOS LOUPAKIS;I. STASI;LISA SALVATORE;GIANLUCA MASI;FABIO GUARRACINO;SERGIO RICCI;FRANCO FILIPPONI;FRANCA MELFI;I. BRUNETTI;IACOPO DALLAN;FABIO FALASCHI;ANDREA PIETRABISSA;LUCA EMANUELE POLLINA;ORLANDO GOLETTI;PAOLO GHIRRI;PAOLO DE SIMONE;ALDO PINCHERA","1463;773;544;544;544;544;536;357;304;290;279;264;264;235;229;229;229;219;198;186","FRANCO FILIPPONI;MAURIZIA ROSSANA BRUNETTO;IACOPO DALLAN;PAOLO DE SIMONE;FABIO GUARRACINO;STANISLAO RIZZO;ANNA SONIA PETRONIO;FEDERICA GENOVESI-EBERT;CARLO BARTOLOZZI;ALDO PINCHERA;CARLO TASCINI;FABIO FALASCHI;FRANCO GUIDETTI;GIOVANNI-BATTISTA MENCHINI-FABRIS;LUDOVICO SBORDONE;MARCO DE CARLO;MARCO GIANNELLI;MARIA GRAZIA FABRINI;PAOLO TOTI;SERGIO RICCI","8;8;6;6;5;5;4;4;3;3;3;3;3;3;3;3;3;3;3;3","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;MATHEMATICS;ENGINEERING;MATERIALS SCIENCE;ECONOMICS;PSYCHOLOGY;BUSINESS;PHILOSOPHY;ART;GEOGRAPHY;POLITICAL SCIENCE","134;39;14;11;7;6;5;5;4;4;3;3;2;1;1","INTERNAL MEDICINE;SURGERY;RADIOLOGY;CARDIOLOGY;ENDOCRINOLOGY;GASTROENTEROLOGY;GENETICS;PATHOLOGY;IMMUNOLOGY;CANCER RESEARCH;INTENSIVE CARE MEDICINE;ENVIRONMENTAL HEALTH;NUCLEAR MEDICINE;ONCOLOGY;ANESTHESIA;CELL BIOLOGY;OPTICS;PEDIATRICS;FAMILY MEDICINE;PALEONTOLOGY;PSYCHIATRY;UROLOGY;VIROLOGY","94;51;23;19;19;18;18;17;16;12;12;10;9;9;7;7;7;7;6;6;6;6;6","CANCER;GENE;TRANSPLANTATION;CHEMOTHERAPY;DISEASE;VIRUS;POPULATION;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;THYROID;ALTERNATIVE MEDICINE;BLOOD PRESSURE;DIABETES MELLITUS;HEART FAILURE;MYOCARDIAL INFARCTION;RADIATION THERAPY;RANDOMIZED CONTROLLED TRIAL;RECEPTOR;ANTIBODY;CARCINOMA;COPD;DISSECTION (MEDICAL);HORMONE;INSULIN;LUNG;LUNG CANCER;STENOSIS;VISUAL ACUITY","21;13;12;11;9;9;8;7;6;6;5;5;5;5;5;5;5;5;4;4;4;4;4;4;4;4;4;4","CHRONIC HEPATITIS;COLORECTAL CANCER;LIVER TRANSPLANTATION;BREAST CANCER;MUTATION;HEPATITIS B VIRUS;CLINICAL ENDPOINT;DIASTOLE;GENOTYPE;PERCUTANEOUS CORONARY INTERVENTION;ALLELE;EXON;HAZARD RATIO;PHENOTYPE;STAPHYLOCOCCUS AUREUS;THYROID CANCER;TOLERABILITY;UNIVARIATE ANALYSIS;VITRECTOMY;ADENOCARCINOMA;AORTIC VALVE REPLACEMENT;AORTIC VALVE STENOSIS;AUTOANTIBODY;AUTOIMMUNE HEPATITIS;BACTEREMIA;BRACHYTHERAPY;CALCINEURIN;CONVENTIONAL PCI;DOXORUBICIN;EJECTION FRACTION;EPIDERMAL GROWTH FACTOR RECEPTOR;GRAVES' DISEASE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEPATITIS C VIRUS;MUTANT;NATRIURETIC PEPTIDE;NEURORADIOLOGY;NEUTROPENIA;OBSTRUCTIVE LUNG DISEASE;PLACEBO;PULMONARY REHABILITATION;RETINAL DETACHMENT;THYROID CARCINOMA","7;7;7;6;6;5;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HBSAG;COLONOSCOPY;DRUG-ELUTING STENT;IRINOTECAN;LAMIVUDINE;VANCOMYCIN;CETUXIMAB;KRAS;MISSENSE MUTATION;OXALIPLATIN;RADIOIODINE THERAPY;RIBAVIRIN;SINGLE-NUCLEOTIDE POLYMORPHISM;SYSTOLE;3T3-L1;ACROMEGALY;AMINO ACID SUBSTITUTION;ANDROGEN RECEPTOR;ANTHRACYCLINE;ANTI-NUCLEAR ANTIBODY;ANTI-THYROID AUTOANTIBODIES;ANTIVIRAL THERAPY;AORTIC VALVULOPLASTY;BCL-2 FAMILY;BETA CELL;BRCA MUTATION;BREAST CARCINOMA;BURST SWITCHING;CAPECITABINE;CARDIAC RESYNCHRONIZATION THERAPY;CARDIAC SKELETON;CCL2;CHEMOKINE RECEPTOR;CLINICAL GLOBAL IMPRESSION;CRYOGLOBULINEMIA;CTL*;CXCL5;CYCLIN D1;DIABETIC MACULAR EDEMA;DIASTOLIC FUNCTION;DOPPLER ECHOCARDIOGRAPHY;DOPPLER IMAGING;EGFR INHIBITORS;ENDOTHELIAL PROGENITOR CELL;ENOS;ENVELOPE DETECTOR;EPIRETINAL MEMBRANE;EPIRUBICIN;EPWORTH SLEEPINESS SCALE;EXHALED NITRIC OXIDE;EZRIN;FINESSE;FLUOXETINE;FRACTIONAL ANISOTROPY;GENETICALLY MODIFIED MOUSE;GERMLINE MUTATION;GONADOTROPIN-RELEASING HORMONE;HAPLOTYPE;HEREDITARY SPASTIC PARAPLEGIA;HORMONE THERAPY;HYPNOTIC SUSCEPTIBILITY;HYPOPNEA;KARYOTYPE;L-GLUCOSE;LASER CAPTURE MICRODISSECTION;LOSS FUNCTION;LOSS OF HETEROZYGOSITY;LUNG VOLUME REDUCTION SURGERY;MACE;MAMMOGRAPHY;MEDIASTINAL LYMPH NODE;MELANOCORTIN 4 RECEPTOR;MERKEL CELL;MODEL FOR END-STAGE LIVER DISEASE;MULTICENTER TRIAL;OPTICAL PERFORMANCE MONITORING;PAPILLARY CARCINOMA;PARATHYROIDECTOMY;PARS PLANA;PENETRANCE;POLOXAMER;POLYSOMNOGRAM;PRENATAL DIAGNOSIS;PROCESSING DELAY;PROGENITOR;RADIOIMMUNOTHERAPY;SECONDARY HYPERPARATHYROIDISM;STAPHYLOCOCCUS EPIDERMIDIS;TARGET LESION;V600E;VARDENAFIL;VINCRISTINE;WILD TYPE","4;3;3;3;3;3;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;TREATMENT OUTCOME;;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;LUNG NEOPLASMS;ITALY;ADENOCARCINOMA;COLORECTAL NEOPLASMS;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;BREAST NEOPLASMS;FOLLOW-UP STUDIES;BIOMARKERS;CAMPTOTHECIN;TIME FACTORS","115;80;72;64;52;42;32;23;23;22;21;19;18;17;17;15;14;13;12;12","HEPATITIS B INFECTION AND TREATMENT;STANDARDISATION AND MANAGEMENT OF COPD;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES;DIAGNOSIS AND TREATMENT OF LUNG CANCER;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;GLOBAL TRENDS IN COLORECTAL CANCER RESEARCH;LYMPHOID NEOPLASMS;MANAGEMENT OF VALVULAR HEART DISEASE;THYROID DISEASE AND HORMONE REGULATION;ADVANCEMENTS IN LUNG CANCER RESEARCH;DIAGNOSIS AND MANAGEMENT OF LIVER DISEASES;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS;DIAGNOSIS AND TREATMENT OF RENAL ARTERY STENOSIS;HEPATITIS C INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;INSULIN-LIKE GROWTH FACTORS IN HEALTH AND DISEASE;KIDNEY TRANSPLANTATION","7;5;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2","TREATMENT;LIVER TRANSPLANTATION;CLINICAL ENDPOINT;DIAGNOSIS;LEFT VENTRICULAR FUNCTION;LIVING DONOR LIVER TRANSPLANTATION;CANCER IMAGING;CARDIAC IMAGING;CLINICAL PRACTICE;COLONOSCOPY;HBEAG;INTERVENTIONAL RADIOLOGY;LIVER DISEASE;METASTATIC COLORECTAL CANCER;PERFUSION IMAGING;PROSTHETIC VALVES EVALUATION;REGIMEN;TEICOPLANIN;TOLERABILITY;UNIVARIATE ANALYSIS","9;5;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3","LIVER TRANSPLANTATION;CHRONIC HEPATITIS;CORONARY ARTERY;COLORECTAL CANCER;LEFT MAIN;METASTATIC COLORECTAL;BREAST CANCER;CLINICAL PRACTICE;COHORT STUDY;HEART FAILURE;ITALIAN REGISTRY;ITALIAN SOCIETY;LEFT VENTRICULAR;LUNG CANCER;MAIN CORONARY;ACTIVATED FACTOR;AORTIC VALVE;ARTERY DISEASE;ARTERY STENOSIS;CALCINEURIN INHIBITOR;CANCER PATIENTS;CELL LUNG;CELL TRANSPLANTATION;CT COLONOGRAPHY;DRUG-ELUTING STENTS;FACTOR VII;GRAVES DISEASE;GRUPPO ITALIANO;HAEMORRHAGE DATA;HEPATOCELLULAR CARCINOMA","6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","AUTOIMMUNE HEPATITIS;EGFR MUTATIONS;LIVER BIOPSY;BREAST CANCER;LAM-EXPERIENCED PATIENTS;LIVER DISEASE;ANTERIOR MOTION;BONE MARROW;CHRONIC HEPATITIS;FA METABOLISM;KRAS CODONS;PRACTICE COMMITTEE;SYSTOLIC ANTERIOR;LAM-NAIVE PATIENTS;LUNG ADENOCARCINOMA;LUNG CANCER;PRACTICE GUIDELINES;QUALITY IMPROVEMENT;SERUM LEVELS;ANTIVIRAL THERAPY;AUTOIMMUNE LIVER;CLINICAL FEATURES;DC BEAD;HBV DNA;INFECTED CELLS;LIVER DAMAGE;WILD-TYPE PATIENTS;CANCER RISK;CELL CARCINOMA;CLINICAL PRACTICE","10;9;9;8;8;8;7;7;7;7;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;4;4;4",18,0.12,3,19.54,3,205,5.69,1,37,0,0,0,0,0,0,0,0,0,29,29,29,4.71,1,13,0,0,0,1.29,1,3,7.77,1,57,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,1,1,1,0,0,0,0.08,0,1,0,0,0,67.15,16,263,67.15,16,263,2,0,0,1,0,0,1,1,0,0,0,2,0,4,1,0,1,1,5,0,5,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ALBERTELLI ROBERTO;ROBERTO ALBERTELLI","4;1","AZIENDA OSPEDALIERO UNIVERSITARIA PISANA;AZIENDA OSPEDALIERA PISANA","4;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3202 CLINICAL SCIENCES;40 ENGINEERING","9;4;1;1","LUNG;PEDIATRIC","4;3",NA,NA,"A61M16/06;A61M16/08;A61B5/08;A61M15/00;A61M16/20;G01T1/161;A61M16/00","5;5;4;4;4;4;1","A61M16/06;A61M16/08;A61B5/0813;A61M15/02;A61M16/0833;A61M16/208;A61M16/0066;A61M16/0078;A61M2016/0021","5;5;4;4;4;4;1;1;1",0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,27,7,756.11,5,56,0,0,7,0,7,0,7,6,0,12,6,0,0,0,0,0,0,23,2,2,18,9,0,0,0,0,0,0,0,0,"United States;Italy;France;Japan","6;3;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;3204 IMMUNOLOGY;3208 MEDICAL PHYSIOLOGY;3215 REPRODUCTIVE MEDICINE;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY","26;15;15;5;2;1;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;RARE DISEASES;DIGESTIVE DISEASES;CARDIOVASCULAR;HEMATOLOGY;PEDIATRIC;BREAST CANCER;COLO-RECTAL CANCER;HEART DISEASE;HYPERTENSION;LYMPHOMA;PANCREATIC CANCER;PATIENT SAFETY;PEDIATRIC RESEARCH INITIATIVE;STEM CELL RESEARCH;AGING;BIOTECHNOLOGY;BRAIN DISORDERS","17;12;9;8;6;4;3;3;2;2;2;2;2;2;2;2;2;1;1;1","CANCER;CARDIOVASCULAR;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","12;4;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","13;2;2;1;1;1;1","BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;BREAST CANCER;COLON AND RECTAL CANCER;NON-HODGKIN'S LYMPHOMA;PANCREATIC CANCER;PROSTATE CANCER;ENDOMETRIAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;GASTROINTESTINAL TRACT;KIDNEY CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;MELANOMA;MYELOMA;NOT SITE-SPECIFIC CANCER;SARCOMA;STOMACH CANCER","2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","12;2;1;1;1"
"AOU_PISANA",2010,153,10.3333333333333,3.1437908496732,0.318087318087318,0.437908496732026,0.352941176470588,0.169934640522876,0.392156862745098,2,69,40,23,13,0.45,0.26,0.15,0.08,45.61,1.00923310539665,0.300653594771242,0.810457516339869,0,0.424292448719252,0.405709342560554,0.395357985837923,0.337744171392565,"FABIO GUARRACINO;ALFREDO FALCONE;UGO BOGGI;FABIO VISTOLI;PIERO MARCHETTI;STEFANO DEL PRATO;FOTIOS LOUPAKIS;RUBIA BALDASSARRI;MARCO DE CARLO;FRANCO FILIPPONI;MAURIZIA ROSSANA BRUNETTO;NICOLINO AMBROSINO;S SIGNORI;IACOPO DALLAN;MARCO DEL CHIARO;G AMORESE;FABRIZIO SCATENA;CHIARA CREMOLINI;ROMANO DANESI;PAOLO SIMI","11;10;10;9;8;7;7;7;6;6;6;5;5;5;5;5;5;5;5;5","FABIO GUARRACINO;G. BRESCI;RUBIA BALDASSARRI;FRANCO FILIPPONI;UGO BOGGI;RODOLFO BUSELLI;FABIO VISTOLI;IACOPO DALLAN;ALFREDO FALCONE;GIOVANNI FEDERICO;PIERO MARCHETTI;STANISLAO RIZZO;FEDERICA GENOVESI-EBERT;NICOLINO AMBROSINO;STEFANO CIANFARANI;PAOLO SIMI;STEFANO DEL PRATO;SALVATORE DE MARCO;PAOLO CASTELNUOVO;MAURIZIO BIGNAMI","1.65;1.14;1.14;1.07;1.04;1;0.96;0.92;0.86;0.83;0.81;0.78;0.78;0.72;0.67;0.63;0.62;0.6;0.59;0.59","FABIO GUARRACINO;ALFREDO FALCONE;UGO BOGGI;FABIO VISTOLI;PIERO MARCHETTI;STEFANO DEL PRATO;FOTIOS LOUPAKIS;RUBIA BALDASSARRI;MARCO DE CARLO;FRANCO FILIPPONI;MAURIZIA ROSSANA BRUNETTO;NICOLINO AMBROSINO;S SIGNORI;IACOPO DALLAN;MARCO DEL CHIARO;G AMORESE;FABRIZIO SCATENA;CHIARA CREMOLINI;ROMANO DANESI;PAOLO SIMI","11;10;10;9;8;7;7;7;6;6;6;5;5;5;5;5;5;5;5;5","FABIO GUARRACINO;G. BRESCI;RUBIA BALDASSARRI;FRANCO FILIPPONI;UGO BOGGI;RODOLFO BUSELLI;FABIO VISTOLI;IACOPO DALLAN;ALFREDO FALCONE;GIOVANNI FEDERICO;PIERO MARCHETTI;STANISLAO RIZZO;FEDERICA GENOVESI-EBERT;NICOLINO AMBROSINO;PAOLO SIMI;STEFANO DEL PRATO;SALVATORE DE MARCO;PAOLO CASTELNUOVO;MAURIZIO BIGNAMI;CLAUDIA BELTING","1.65;1.14;1.14;1.07;1.04;1;0.96;0.92;0.86;0.83;0.81;0.78;0.78;0.72;0.63;0.62;0.6;0.59;0.59;0.58","ALFREDO FALCONE;MAURIZIA ROSSANA BRUNETTO;B. COCO;UGO BOGGI;FERRUCCIO BONINO;FOTIOS LOUPAKIS;AGOSTINO COLLI;MARCO DEL CHIARO;ROMANO DANESI;ELISA GIOVANNETTI;ENRICO VASILE;FILIPPO OLIVERI;DANIELA CAMPANI;GODEFRIDUS J. PETERS;LETICIA G. LEÓN;NICCOLA FUNEL;CHIARA CREMOLINI;LISA SALVATORE;ANNEMIEKE GROEN;HENK M.W. VERHEUL","1069;872;829;752;602;602;571;538;534;505;468;461;455;453;453;453;441;441;438;438","MAURIZIA ROSSANA BRUNETTO;B. COCO;ALFREDO FALCONE;UGO BOGGI;MARCO DEL CHIARO;ENRICO VASILE;FILIPPO OLIVERI;DANIELA CAMPANI;NICCOLA FUNEL;ANNEMIEKE GROEN;ELISA GIOVANNETTI;GODEFRIDUS J. PETERS;HENK M.W. VERHEUL;LETICIA G. LEÓN;LEYLA A. EROZENCI;LUCA EMANUELE POLLINA;ROMANO DANESI;GIANLUCA MASI;FOTIOS LOUPAKIS;GIOVANNA MOSCATO","872;829;808;714;520;468;461;454;452;437;437;437;437;437;437;437;437;435;430;419","FABIO GUARRACINO;ALFREDO FALCONE;UGO BOGGI;MARCO DE CARLO;MAURIZIA ROSSANA BRUNETTO;PIERO MARCHETTI;FOTIOS LOUPAKIS;MARCO DEL CHIARO;IACOPO DALLAN;FABIO VISTOLI;PAOLO SIMI;FABRIZIO SCATENA;B. COCO;CARLO TASCINI;CHIARA CREMOLINI;FRANCESCO MENICHETTI;FRANCO FILIPPONI;G AMORESE;MARCO ANSELMINO;MARGHERITA MAFFEI","10;7;7;6;6;6;6;6;5;5;5;5;4;4;4;4;4;4;4;4","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;PSYCHOLOGY;COMPUTER SCIENCE;ENGINEERING;MATHEMATICS;ECONOMICS;BUSINESS;POLITICAL SCIENCE;MATERIALS SCIENCE;PHILOSOPHY;SOCIOLOGY","143;56;16;10;9;7;7;7;6;5;5;4;4;1","INTERNAL MEDICINE;SURGERY;GENETICS;ENDOCRINOLOGY;CARDIOLOGY;GASTROENTEROLOGY;BIOCHEMISTRY;IMMUNOLOGY;PATHOLOGY;ONCOLOGY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;RADIOLOGY;PSYCHIATRY;NUCLEAR MEDICINE;VIROLOGY;ANATOMY;MECHANICAL ENGINEERING;FAMILY MEDICINE;NURSING","110;47;31;28;26;22;20;18;18;16;14;11;10;9;8;8;7;7;6;6","GENE;CANCER;TRANSPLANTATION;DIABETES MELLITUS;CHEMOTHERAPY;POPULATION;DISEASE;VIRUS;INSULIN;PANCREAS;STENOSIS;HEART FAILURE;HORMONE;MYOCARDIAL INFARCTION;OBESITY;IN VITRO;BLOOD PRESSURE;BODY MASS INDEX;CIRRHOSIS;CONFIDENCE INTERVAL;HEALTH CARE;PREGNANCY;PROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;REGIMEN;STEM CELL","24;20;14;12;11;11;10;9;8;8;8;7;7;7;7;6;5;5;5;5;5;5;5;5;5;5","GENOTYPE;CLINICAL ENDPOINT;COLORECTAL CANCER;MUTATION;AORTIC VALVE REPLACEMENT;EJECTION FRACTION;KIDNEY TRANSPLANTATION;CHEMOKINE;CHRONIC HEPATITIS;EXON;GENE EXPRESSION;HAZARD RATIO;ISLET;PANCREATIC CANCER;PERCUTANEOUS CORONARY INTERVENTION;PHENOTYPE;ALLELE;BREAST CANCER;ENDOCRINE SYSTEM;FLUOROURACIL;GEMCITABINE;HEPATITIS C VIRUS;WEIGHT LOSS","10;7;7;7;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3","SINGLE-NUCLEOTIDE POLYMORPHISM;IRINOTECAN;MISSENSE MUTATION;PANCREAS TRANSPLANTATION;BETA CELL;CXCL10;KRAS;OXALIPLATIN;ABCIXIMAB;CETUXIMAB;CLINICAL PHENOTYPE;FRAMESHIFT MUTATION;GENE MUTATION;GERD;GROWTH HORMONE DEFICIENCY;HBSAG;IMPAIRED GLUCOSE TOLERANCE;MACE;PANCREATIC ISLETS;TRANSIENT ELASTOGRAPHY","6;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;;AGED, 80 AND OVER;TREATMENT OUTCOME;HEART VALVE PROSTHESIS IMPLANTATION;ITALY;COLORECTAL NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;AORTIC VALVE;CORONARY ARTERY DISEASE;CAMPTOTHECIN;PANCREATIC NEOPLASMS;ADOLESCENT;ANTIBODIES, MONOCLONAL;FOLLOW-UP STUDIES","116;75;71;57;51;47;32;27;27;24;23;19;18;17;16;15;15;14;14;13","MANAGEMENT OF VALVULAR HEART DISEASE;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;PANCREATIC ISLET DYSFUNCTION AND REGENERATION;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;EFFECTS OF BARIATRIC SURGERY ON OBESITY AND DIABETES;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES;HEPATITIS B INFECTION AND TREATMENT;INSULIN-LIKE GROWTH FACTORS IN HEALTH AND DISEASE;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;DIAGNOSIS AND TREATMENT OF RENAL ARTERY STENOSIS;GENETIC BASIS OF NEUROPATHIES AND RELATED DISORDERS;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;HEPATOCELLULAR CARCINOMA;LANTHANIDE LUMINESCENCE IN BIOMEDICAL APPLICATIONS;MANAGEMENT OF ACUTE MYOCARDIAL INFARCTION;METABOLIC SYNDROME AND CARDIOVASCULAR DISEASE;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;PANCREATIC CANCER RESEARCH AND TREATMENT;PHYSIOLOGICAL RESPONSES TO HEAT STRESS IN HUMANS","8;6;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2","TREATMENT;CLINICAL ENDPOINT;TRANSCATHETER AORTIC-VALVE REPLACEMENT;TRANSPLANTATION;LIVER DISEASE;PROSTHETIC VALVES EVALUATION;REGIMEN;SURGICAL AORTIC-VALVE REPLACEMENT;ECHOCARDIOGRAPHY;HEART VALVE SURGERY;PANCREAS TRANSPLANTATION;AORTIC ROOT REPLACEMENT;CANCER RISK;DIABETES;ECHO (COMMUNICATIONS PROTOCOL);INTERQUARTILE RANGE;ISLET TRANSPLANTATION;LIMITING;METASTATIC COLORECTAL CANCER;NASOSEPTAL FLAP","9;7;7;6;5;5;5;5;4;4;4;3;3;3;3;3;3;3;3;3","AORTIC VALVE;COLORECTAL CANCER;CANCER PATIENTS;CORONARY ARTERY;TRANSCATHETER AORTIC;VALVE IMPLANTATION;CHRONIC HEPATITIS;CLINICAL OUTCOME;GROWTH HORMONE;HEART FAILURE;HEPATOCELLULAR CARCINOMA;METASTATIC COLORECTAL;PANCREAS TRANSPLANTATION;PANCREATIC CANCER;ADVANCED COLORECTAL;ARTERY BYPASS;ASPECTS UNDERLYING;BREAST CANCER;COHORT STUDY;CONSENSUS DOCUMENT;DE NOVO;DIABETIC FOOT;FIRST-LINE TREATMENT;GASTROESOPHAGEAL REFLUX;GEMCITABINE ACTIVITY;GLUCOSE TOLERANCE;HEALTH CARE;HEALTH WORKERS;HORMONE DEFICIENCY;INTENSIVE CARE","6;5;4;4;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","MINOR AMPUTATION;LIVER STIFFNESS;AORTIC VALVE;CONFIDENCE INTERVAL;EM RATIO;HEALTHY SUBJECTS;HEART FAILURE;LIVER DISEASE;PHOBIC PATIENTS;SERUM OPN;SOCIAL PHOBIC;BETA CELLS;ODDS RATIO;PATIENTS TREATED;PLASMA OPN;TYPE DIABETES;ACEF SCORE;AMPUTATION RATE;AUTHOR INFORMATION;BREAST CANCER;ENDOTHELIAL REPAIR;HEALTHY CONTROLS;MIR- EXPRESSION;MORTALITY RATE;MYOCARDIAL INFARCTION;RATIO CONFIDENCE;REPAIR CAPACITY;Β CELLS;BRCA MUTATION;COMMERCIAL KITS","10;9;7;7;7;7;7;7;7;7;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5;5;5;5;4;4",25,0.16,3,4.36,3,10,2.18,1,7,1,1,1,0,0,0,0,0,0,1,1,1,1.42,1,4,0,0,0,1.25,1,2,2.71,1,15,0,0,0,1,1,1,6,6,6,0,0,0,2,1,3,0,0,0,0,0,0,5,5,5,1,1,1,0.18,0,1,0.06,0,1,61.65,14,182,61.88,14,183,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,49,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ALBERTELLI ROBERTO","1","AZIENDA OSPEDALIERO UNIVERSITARIA PISANA","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY","2;1","LUNG;PEDIATRIC","1;1",NA,NA,"A61B6/02;A61M11/00","1;1","A61B5/0813;A61B6/4258;A61M15/02;A61M16/06;A61M16/08;A61M16/0833;A61M16/208","1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,11,"PUBLIC LIBRARY OF SCIENCE","11","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;49 MATHEMATICAL SCIENCES","21;8;3;1;1;1","CANCER;RARE DISEASES;DIGESTIVE DISEASES;GENETICS;HEMATOLOGY;PANCREATIC CANCER;BIOTECHNOLOGY;COLO-RECTAL CANCER;ORPHAN DRUG","4;4;3;2;2;2;1;1;1","CANCER;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL","7;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS","3;3;3;1;1","BIOMEDICAL","2","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","7;2","PANCREATIC CANCER;COLON AND RECTAL CANCER","2;1",NA,NA,22,5.06,954.53,6,49.64,1,0,6,0,8,0,1,6,0,15,5,0,0,0,0,0,0,19,3,0,19,2,0,0,0,0,0,0,0,1,"Belgium;Germany;Italy;Spain;United States","1;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3213 PAEDIATRICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;3204 IMMUNOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","22;8;7;3;2;2;2;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;NEUROSCIENCES;PATIENT SAFETY;PEDIATRIC;PREVENTION;TRANSPLANTATION;BIOENGINEERING;BRAIN DISORDERS;CARDIOVASCULAR;DIGESTIVE DISEASES;HEART DISEASE;INFANT MORTALITY;LUNG;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;AGING;ARTHRITIS","18;13;9;7;5;3;3;3;3;3;2;2;2;2;2;2;2;2;1;1","CANCER;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;RESPIRATORY;INFECTION;MUSCULOSKELETAL;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;STROKE","8;2;2;2;1;1;1;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;2.4 SURVEILLANCE AND DISTRIBUTION;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;7.1 INDIVIDUAL CARE NEEDS","14;2;1;1;1;1","LEUKEMIA / LEUKAEMIA;BREAST CANCER;COLON AND RECTAL CANCER;LIVER CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA;PARATHYROID CANCER;SARCOMA;STOMACH CANCER","3;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","8;1;1"
"AOU_PISANA",2011,168,11.9761904761905,3.44047619047619,0.290657439446367,0.428571428571429,0.357142857142857,0.208333333333333,0.452380952380952,1,86,31,24,11,0.51,0.18,0.14,0.07,34.25,0.805232729479066,0.25,0.833333333333333,0,0.416567294185902,0.36304347826087,0.376969696969697,0.347041847041847,"ALDO PINCHERA;FABIO GUARRACINO;FRANCO MOSCA;PIERO MARCHETTI;UGO BOGGI;FERRUCCIO SANTINI;STANISLAO RIZZO;MARIA A. CALIGO;PAOLO VITTI;MIRCO COSOTTINI;ROSALIND A. EELES;NICOLINO AMBROSINO;ALFREDO FALCONE;GIOVANNI LANDONI;IACOPO DALLAN;CARLO BARTOLOZZI;FOTIOS LOUPAKIS;CARLO TASCINI;FABIO VISTOLI;D. GARETH EVANS","9;9;8;7;7;6;6;5;5;5;5;5;5;5;5;5;5;5;5;5","FABIO GUARRACINO;STANISLAO RIZZO;NICOLINO AMBROSINO;FRANK LLOYD DINI;GIOVANNI ORLANDI;FRANCO MOSCA;FEDERICA GENOVESI-EBERT;CLAUDIA BELTING;ALDO PINCHERA;IACOPO DALLAN;GABRIELE NALDINI;JACOPO MARTELLUCCI;UGO BOGGI;STEFANO BERRETTINI;PIERO MARCHETTI;PAOLO FUSAR‐POLI;DANIELE FOCOSI;ANDREA PIETRABISSA;A. CARRIERO;CARLO TASCINI","1.36;1.29;1.04;1;1;0.9;0.89;0.73;0.73;0.72;0.71;0.71;0.69;0.69;0.66;0.65;0.65;0.6;0.58;0.58","ALDO PINCHERA;FABIO GUARRACINO;FRANCO MOSCA;PIERO MARCHETTI;UGO BOGGI;FERRUCCIO SANTINI;STANISLAO RIZZO;MARIA A. CALIGO;PAOLO VITTI;MIRCO COSOTTINI;NICOLINO AMBROSINO;ALFREDO FALCONE;GIOVANNI LANDONI;IACOPO DALLAN;FOTIOS LOUPAKIS;CARLO TASCINI;FABIO VISTOLI;DANIELE FOCOSI;FRANCESCO MENICHETTI;STEFANO BERRETTINI","9;9;8;7;7;6;6;5;5;5;5;5;5;5;5;5;5;5;5;4","FABIO GUARRACINO;STANISLAO RIZZO;NICOLINO AMBROSINO;FRANK LLOYD DINI;GIOVANNI ORLANDI;FRANCO MOSCA;FEDERICA GENOVESI-EBERT;CLAUDIA BELTING;ALDO PINCHERA;IACOPO DALLAN;GABRIELE NALDINI;UGO BOGGI;STEFANO BERRETTINI;PIERO MARCHETTI;PAOLO FUSAR‐POLI;DANIELE FOCOSI;ANDREA PIETRABISSA;CARLO TASCINI;FRANCESCO MENICHETTI;MIRCO COSOTTINI","1.36;1.29;1.04;1;1;0.9;0.89;0.73;0.73;0.72;0.71;0.69;0.69;0.66;0.65;0.65;0.6;0.58;0.58;0.56","A. SAINATO;BRUCE D. MINSKY;CLAUS RÖDEL;FRANCK BONNETAIN;GUIDO LAMMERING;J.F. BOSSET;JEAN‐PIERRE GÉRARD;KRZYSZTOF BUJKO;L. CIONINI;LAURENCE COLLETTE;MAREK BĘBENEK;MARIA ANTONIETTA GAMBACORTA;MARTA BARBA;PHILIPPE LAMBIN;ROLF SAUER;RUUD G.P.M. VAN STIPHOUT;VINCENZO VALENTINI;FABIO GUARRACINO;ANDREW K. GODWIN;D. GARETH EVANS","494;494;494;494;494;494;494;494;494;494;494;494;494;494;494;494;494;366;329;329","A. SAINATO;BRUCE D. MINSKY;CLAUS RÖDEL;FRANCK BONNETAIN;GUIDO LAMMERING;J.F. BOSSET;JEAN‐PIERRE GÉRARD;KRZYSZTOF BUJKO;L. CIONINI;LAURENCE COLLETTE;MAREK BĘBENEK;MARIA ANTONIETTA GAMBACORTA;MARTA BARBA;PHILIPPE LAMBIN;ROLF SAUER;RUUD G.P.M. VAN STIPHOUT;VINCENZO VALENTINI;FABIO GUARRACINO;MARIA A. CALIGO;FOTIOS LOUPAKIS","494;494;494;494;494;494;494;494;494;494;494;494;494;494;494;494;494;366;329;283","FABIO GUARRACINO;ALDO PINCHERA;FRANCESCO MENICHETTI;PIERO MARCHETTI;STANISLAO RIZZO;MARIA A. CALIGO;FERRUCCIO SANTINI;FOTIOS LOUPAKIS;ALFREDO FALCONE;CARLO TASCINI;CLAUDIA CARIELLO;FABIO VISTOLI;FRANCO MOSCA;LISA SALVATORE;NICOLINO AMBROSINO;UGO BOGGI;FEDERICA GENOVESI-EBERT;PAOLO VITTI;ENRICO TAGLIAFERRI;MARIA CARLA IORIO","9;7;7;6;6;5;5;5;4;4;4;4;4;4;4;4;4;4;3;3","MEDICINE;BIOLOGY;CHEMISTRY;PHYSICS;MATHEMATICS;PSYCHOLOGY;ENGINEERING;COMPUTER SCIENCE;SOCIOLOGY;MATERIALS SCIENCE;ECONOMICS;POLITICAL SCIENCE;BUSINESS;ENVIRONMENTAL SCIENCE;GEOLOGY;PHILOSOPHY","155;61;20;16;12;10;9;8;6;5;4;4;1;1;1;1","INTERNAL MEDICINE;SURGERY;GENETICS;ENDOCRINOLOGY;BIOCHEMISTRY;PATHOLOGY;IMMUNOLOGY;CARDIOLOGY;GASTROENTEROLOGY;ONCOLOGY;ANESTHESIA;CANCER RESEARCH;INTENSIVE CARE MEDICINE;ENVIRONMENTAL HEALTH;RADIOLOGY;CELL BIOLOGY;PALEONTOLOGY;PSYCHIATRY;PEDIATRICS;PHYSICAL THERAPY","102;56;38;28;25;23;21;19;17;17;14;14;14;13;12;10;9;9;8;8","GENE;CANCER;DISEASE;POPULATION;TRANSPLANTATION;CHEMOTHERAPY;INSULIN;BACTERIA;DIABETES MELLITUS;STEM CELL;ENZYME;HEART FAILURE;MYOCARDIAL INFARCTION;OBESITY;RANDOMIZED CONTROLLED TRIAL;VIRUS;HEPATOCELLULAR CARCINOMA;IMPLANT;IN VITRO;PREGNANCY;RETROSPECTIVE COHORT STUDY;STIMULATION","29;26;14;13;13;11;8;7;7;7;6;6;6;6;6;6;5;5;5;5;5;5","BREAST CANCER;GENOTYPE;ALLELE;COLORECTAL CANCER;CARCINOGENESIS;GENE EXPRESSION;LEPTIN;STAPHYLOCOCCUS AUREUS;EJECTION FRACTION;GEMCITABINE;ISLET;KIDNEY TRANSPLANTATION;MUTATION;PANCREATIC CANCER;PHENOTYPE;SORAFENIB;TRANSCRIPTION FACTOR;BEVACIZUMAB;CARDIAC OUTPUT;FETUS;HEART RATE;HEMATOPOIETIC STEM CELL TRANSPLANTATION;HEPATITIS B VIRUS;INSULIN RESISTANCE;PROGENITOR CELL;PSEUDOMONAS AERUGINOSA;RETINAL DETACHMENT;SINUS (BOTANY);VITRECTOMY","8;8;7;7;5;5;5;5;4;4;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3","SINGLE-NUCLEOTIDE POLYMORPHISM;HBSAG;OXALIPLATIN;PANCREAS TRANSPLANTATION;ASPARTATE TRANSAMINASE;CRITICAL LIMB ISCHEMIA;DNA METHYLATION;ESMOLOL;FAILED BACK SURGERY;HAPLOTYPE;INSULIN RECEPTOR;IRINOTECAN;MACULAR HOLE;PANCREATIC ISLETS;PRIMARY MOTOR CORTEX;SOD1;TUMOR SUPPRESSOR GENE;VANCOMYCIN;ACINETOBACTER BAUMANNII;ACTIVATING TRANSCRIPTION FACTOR;ACUTE LYMPHOCYTIC LEUKEMIA;ADIPOKINE;ADIPONECTIN;ADJUVANT CHEMOTHERAPY;ADULT STEM CELL;AL AMYLOIDOSIS;ALLELE FREQUENCY;AMNION;ANTIRETROVIRAL THERAPY;AP-1 TRANSCRIPTION FACTOR;APOCYNIN;ATRIAL APPENDAGE;AUTOSOME;AZOOSPERMIA;BIOMARKER DISCOVERY;BREAST RECONSTRUCTION;BREAST SURGERY;C2C12;CANADIAN CARDIOVASCULAR SOCIETY;CANNABINOID RECEPTOR;CARDIAC INDEX;CARDIAC RESYNCHRONIZATION THERAPY;CASPASE;CASPOFUNGIN;CETUXIMAB;COPY-NUMBER VARIATION;CORONAVIRUS DISEASE 2019 (COVID-19);CYCLIN D1;DEATH DOMAIN;DIABETIC FOOT ULCER;DORSOLATERAL PREFRONTAL CORTEX;DUCTAL CARCINOMA;ENDOANAL ULTRASOUND;ENTEROCOCCUS FAECALIS;EPIRETINAL MEMBRANE;EPWORTH SLEEPINESS SCALE;ERLOTINIB;ESTROGEN RECEPTOR;FLAVIVIRIDAE;FRACTIONAL ANISOTROPY;GENETICALLY MODIFIED MOUSE;GENOTYPING;GERMLINE MUTATION;GESTATIONAL DIABETES;GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR;GLOBUS PALLIDUS;GLUCOSE HOMEOSTASIS;GROWTH HORMONE DEFICIENCY;HAPLOINSUFFICIENCY;HIATAL HERNIA;HISTOCOMPATIBILITY TESTING;HOUSEKEEPING GENE;HYPOPHYSITIS;HYPOPNEA;INSULIN ASPART;INTERATRIAL SEPTUM;INTRINSIC IMMUNITY;INVASIVE CANDIDIASIS;JUNB;KLEBSIELLA;KLEBSIELLA PNEUMONIAE;LAMIVUDINE;LEUKAPHERESIS;LIVE ATTENUATED INFLUENZA VACCINE;LONG ARM;LOWER MOTOR NEURON;MACULOPATHY;MALE INFERTILITY;MICROCHIMERISM;MICROSATELLITE;MOLECULAR EPIDEMIOLOGY;MOTOR NEURONE DISEASE;MUCINOUS CARCINOMA;MULTIPOTENT STEM CELL;NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;NISSEN FUNDOPLICATION;NUCLEAR RECEPTOR;NUCLEOPLASM;ORAL ANTICOAGULANT;OSWESTRY DISABILITY INDEX;PANCREATIC DUCTAL ADENOCARCINOMA;PARS PLANA;PATTERN RECOGNITION RECEPTOR;PDX1;PENETRANCE;PLACENTAL GROWTH FACTOR;PLEURAL DISEASE;POLYMORPHISM (COMPUTER SCIENCE);PROGENITOR;PROLIFERATIVE VITREORETINOPATHY;PROMOTER;PROTEUS;PULMONARY ARTERY CATHETER;RADIOIODINE THERAPY;REPORTER GENE;SEROTONIN TRANSPORTER;SOX2;SPINDLE APPARATUS;STROKE VOLUME;SYNTHETIC LETHALITY;TAKAYASU ARTERITIS;TESTIS DETERMINING FACTOR;TISSUE DONATION;TORQUE TENO VIRUS;TRANSLOCATOR PROTEIN;VARDENAFIL;WILD TYPE;WWOX","4;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","HUMANS;FEMALE;MALE;MIDDLE AGED;ADULT;AGED;;TREATMENT OUTCOME;AGED, 80 AND OVER;ITALY;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;YOUNG ADULT;FOLLOW-UP STUDIES;ADENOCARCINOMA;ANIMALS;COLORECTAL NEOPLASMS;FLUOROURACIL;PROSPECTIVE STUDIES;RETROSPECTIVE STUDIES;ADOLESCENT","131;91;90;69;61;55;32;25;22;22;21;20;17;15;15;14;14;14;14;13","GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK;NEUROENDOCRINE REGULATION OF APPETITE AND BODY WEIGHT;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;PANCREATIC ISLET DYSFUNCTION AND REGENERATION;STANDARDISATION AND MANAGEMENT OF COPD;VITREORETINAL SURGERY TECHNIQUES;ATRIAL FIBRILLATION;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES;DIAGNOSIS AND TREATMENT OF LUNG CANCER;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;INSULIN-LIKE GROWTH FACTORS IN HEALTH AND DISEASE;MANAGEMENT OF VALVULAR HEART DISEASE;MECHANICAL VENTILATION IN RESPIRATORY FAILURE AND ARDS;SURGICAL SIMULATION AND TRAINING TECHNIQUES;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;COCHLEAR NEUROPATHY AND HEARING LOSS MECHANISMS;COLORECTAL CANCER RESEARCH AND TREATMENT;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES","5;5;4;4;4;4;3;3;3;3;3;3;3;3;3;2;2;2;2;2","TREATMENT;BRCA1;CANCER RISK;DIABETES;LEPTIN;NEURODEGENERATION;ROBOTIC SURGERY;BREAST CANCER;CANCER SUSCEPTIBILITY;CANCER THERAPY;HEARING LOSS;HEMATOPOIETIC CELL TRANSPLANTATION;INNER EAR DEVELOPMENT;LIVER BIOPSY;MEDICAL THERAPY;METASTATIC COLORECTAL CANCER;PANCREAS TRANSPLANTATION;PROSTHETIC VALVES EVALUATION;REFRACTORY (PLANETARY SCIENCE);REGIMEN","8;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3","BRCA MUTATION;LUNG CANCER;MUTATION CARRIERS;BREAST CANCER;CELL TRANSPLANTATION;COLORECTAL CANCER;PANCREAS TRANSPLANTATION;PATIENTS UNDERGOING;STEM CELL;ALLOGENEIC HEMATOPOIETIC;ATRIAL FIBRILLATION;CANCER PATIENTS;CARDIAC SURGERY;CENTRAL NERVOUS;CLINICAL TRIAL;COCHLEAR IMPLANTATION;COLON CANCER;COLORED PERFLUOROCARBON;COMPUTER-BASED SIMULATION;DIABETIC FOOT;EFFICIENT REMOVAL;HAEMORRHAGIC STROKE;HEMATOPOIETIC STEM;HEPATOCELLULAR CARCINOMA;HUMAN PANCREATIC;INCIDENTALLY DETECTED;INTENSIVE CARE;KIDNEY TRANSPLANT;METASTATIC COLORECTAL;MITRAL VALVE","4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","BREAST CANCER;MUTATION CARRIERS;BRCA MUTATION;CONFIDENCE INTERVAL;EJECTION FRACTION;INTENSIVE CARE;CARDIAC OUTPUT;CARE UNIT;GLUCOSE TOLERANCE;PANCREAS TRANSPLANTATION;AGE CREATININE;CANCER RISK;COLORECTAL CANCER;CREATININE EJECTION;DNA VIRUSES;FRACTION SCORE;GROWTH FACTOR;PATIENTS UNDERGOING;STEM CELLS;ADJUVANT CHEMOTHERAPY;BARRETTS OESOPHAGUS;CARDIAC OPERATIVE;EUROPEAN SYSTEM;IMMUNE SYSTEM;IPI LT;LEPTIN EXPRESSION;LEPTIN LEVELS;LOCOMOTOR ACTIVITY;MESENCHYMAL STEM;MORTALITY RATE","19;19;16;11;9;9;8;8;8;8;7;7;7;7;7;7;7;7;7;6;6;6;6;6;6;6;6;6;6;6",30,0.18,3,8.76,5.136,18.08,4.12,1,11,0,0,0,1.33,1,2,0,0,0,1,1,1,3.2,3,4,1,1,1,0,0,0,5.75,1,16,0,0,0,1,1,1,5,1,9,0,0,0,0,0,0,1,1,1,0,0,0,4,1,7,1,1,1,0,0,0,0,0,0,66.5,27,192,66.5,27,192,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,3,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ALBERTELLI;I-56018 TIRRENIA ITALY;ROBERTO","1;1;1","AZIENDA OSPEDALIERA PISANA","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;40 ENGINEERING","1;1;1",NA,NA,NA,NA,"A61M;A61M16/00;A61M16/06;A61M16/08;A62B7/00","1;1;1;1;1","A61M16/06;A61M16/08;A61M16/66;A61M16/78;A61M2016/21","1;1;1;1;1",0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,9,"SPRINGER NATURE;PUBLIC LIBRARY OF SCIENCE;AMERICAN CHEMICAL SOCIETY","5;3;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;52 PSYCHOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;34 CHEMICAL SCIENCES;3401 ANALYTICAL CHEMISTRY;5202 BIOLOGICAL PSYCHOLOGY","13;6;5;5;3;2;1;1;1;1","CANCER;BASIC BEHAVIORAL AND SOCIAL SCIENCE;BEHAVIORAL AND SOCIAL SCIENCE;BIOTECHNOLOGY;BREAST CANCER;CLINICAL RESEARCH;DENTAL/ORAL AND CRANIOFACIAL DISEASE;DIGESTIVE DISEASES;HEMATOLOGY;NUTRITION;OBESITY;PANCREATIC CANCER;PREVENTION;RARE DISEASES","2;1;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;ORAL AND GASTROINTESTINAL;STROKE","5;1;1","5.1 PHARMACEUTICALS","1","BIOMEDICAL","2","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE","1;1","BREAST CANCER;PANCREATIC CANCER","5;1",NA,NA,24,6.2,764.05,6,56.21,1,0,7,0,6,0,1,9,0,16,6,0,0,0,0,0,0,22,2,0,22,2,0,0,0,0,0,0,0,0,"Italy;United States;Netherlands;United Kingdom","2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;42 HEALTH SCIENCES;3203 DENTISTRY;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4202 EPIDEMIOLOGY;4207 SPORTS SCIENCE AND EXERCISE","21;11;10;4;3;3;2;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;CARDIOVASCULAR;PATIENT SAFETY;HEART DISEASE;HEMATOLOGY;DIGESTIVE DISEASES;LUNG;LYMPHOMA;ORPHAN DRUG;AGING;ATHEROSCLEROSIS;BIOENGINEERING;HEART DISEASE - CORONARY HEART DISEASE;LUNG CANCER;ARTHRITIS;ASSISTIVE TECHNOLOGY;AUTOIMMUNE DISEASE","22;13;12;6;5;5;4;4;3;3;3;3;2;2;2;2;2;1;1;1","CANCER;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;STROKE","10;5;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;5.3 MEDICAL DEVICES;6.3 MEDICAL DEVICES;6.7 PHYSICAL","12;3;2;1;1;1;1","NON-HODGKIN'S LYMPHOMA;LUNG CANCER;BLADDER CANCER;BREAST CANCER;COLON AND RECTAL CANCER;GALLBLADDER CANCER;LIVER CANCER;OVARIAN CANCER;STOMACH CANCER","3;2;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS","10"
"AOU_PISANA",2012,237,11.9367088607595,3.09704641350211,0.322888283378747,0.455696202531646,0.316455696202532,0.105485232067511,0.472573839662447,4,141,38,16,26,0.59,0.16,0.07,0.11,42.76,1.02362889109968,0.413502109704641,0.789029535864979,5.1664464993395,0.489890671958534,0.529501362834696,0.587739625026332,0.462301587301587,"ALFREDO FALCONE;FOTIOS LOUPAKIS;MARTA SCHIRRIPA;UGO BOGGI;CHIARA CREMOLINI;ENRICO VASILE;LISA SALVATORE;GIANLUCA MASI;S. CAPONI;FRANCO FILIPPONI;CARLOTTA ANTONIOTTI;WU ZHANG;LAURA GINOCCHI;PAOLO DE SIMONE;CHIARA CAPARELLO;MONICA LENCIONI;M LUCCHESI;IACOPO DALLAN;HEINZ‐JOSEF LENZ;MARCO DE CARLO","45;22;16;15;15;15;13;13;12;11;11;10;9;9;9;8;8;8;8;8","ALFREDO FALCONE;FOTIOS LOUPAKIS;FRANCESCO MENICHETTI;ENRICO VASILE;UGO BOGGI;ALFONSO CRISTAUDO;S. CAPONI;NICOLINO AMBROSINO;MARTA SCHIRRIPA;IACOPO DALLAN;MARCO DE CARLO;DAVIDE LAZZERI;TOMMASO AGOSTINI;CHIARA CAPARELLO;CHIARA CREMOLINI;UBERTO BORTOLOTTI;LAURA GINOCCHI;GIANLUCA MASI;MARIO MEOLA;YAN DU","3.84;2.16;1.78;1.56;1.3;1.25;1.23;1.2;1.19;1.18;1.16;1.16;1.16;1.13;1.11;1.04;1.03;1.03;1;1","ALFREDO FALCONE;FOTIOS LOUPAKIS;MARTA SCHIRRIPA;UGO BOGGI;CHIARA CREMOLINI;ENRICO VASILE;LISA SALVATORE;GIANLUCA MASI;S. CAPONI;FRANCO FILIPPONI;CARLOTTA ANTONIOTTI;LAURA GINOCCHI;PAOLO DE SIMONE;CHIARA CAPARELLO;MONICA LENCIONI;M LUCCHESI;IACOPO DALLAN;MARCO DE CARLO;NELIDE DE LIO;PIERO MARCHETTI","45;22;16;15;15;15;13;13;12;11;11;9;9;9;8;8;8;8;8;7","ALFREDO FALCONE;FOTIOS LOUPAKIS;FRANCESCO MENICHETTI;ENRICO VASILE;UGO BOGGI;ALFONSO CRISTAUDO;S. CAPONI;NICOLINO AMBROSINO;MARTA SCHIRRIPA;IACOPO DALLAN;MARCO DE CARLO;DAVIDE LAZZERI;TOMMASO AGOSTINI;CHIARA CAPARELLO;CHIARA CREMOLINI;UBERTO BORTOLOTTI;LAURA GINOCCHI;GIANLUCA MASI;MARIO MEOLA;YAN DU","3.84;2.16;1.78;1.56;1.3;1.25;1.23;1.2;1.19;1.18;1.16;1.16;1.16;1.13;1.11;1.04;1.03;1.03;1;1","ALFREDO FALCONE;HEINZ‐JOSEF LENZ;ANTOINE ADENIS;AXEL GROTHEY;CARLO BARONE;DANIEL J. SARGENT;DIRK LAURENT;FRANK CIHON;JOSEP TABERNERO;LAURENT MINEUR;MARC YCHOU;OLIVIER BOUCHÉ;RICHARD M. GOLDBERG;SALVATORE SIENA;TAKAYUKI YOSHINO;THIERRY ANDRÉ;LISA CUPIT;YVES HUMBLET;ERIC VAN CUTSEM;ALBERTO SOBRERO","3037;2492;2487;2487;2487;2487;2487;2487;2487;2487;2487;2487;2487;2487;2487;2487;2485;2485;2482;2480","ALFREDO FALCONE;ANNA SONIA PETRONIO;PIERLUIGI PAGGIARO;MONICA LENCIONI;FRANCO FILIPPONI;MAURIZIA ROSSANA BRUNETTO;MARIA GRAZIA BONGIORNI;MARCO DE CARLO;CRISTINA GIANNINI;FRANCESCO MENICHETTI;UGO BOGGI;PAOLO DE SIMONE;CARLO TASCINI;GIULIO ZUCCHELLI;ALESSANDRO LEONILDI;R LUPI;GIANLUCA MASI;ROBERTO CERAVOLO;FERRUCCIO BONINO;FABIO GUARRACINO","3034;660;623;579;496;473;422;382;378;344;318;297;282;256;252;242;225;213;211;205","ALFREDO FALCONE;ENRICO VASILE;MARTA SCHIRRIPA;CHIARA CREMOLINI;FOTIOS LOUPAKIS;GIANLUCA MASI;LISA SALVATORE;CARLOTTA ANTONIOTTI;S. CAPONI;ANNA SONIA PETRONIO;FRANCO FILIPPONI;FRANCESCO MENICHETTI;CHIARA CAPARELLO;PAOLO DE SIMONE;MARIA GRAZIA BONGIORNI;LORENZO FORNARO;LAURA GINOCCHI;MONICA LENCIONI;CARLO TASCINI;MARCO DE CARLO","38;15;15;15;14;13;13;11;10;9;9;8;8;8;8;7;7;7;7;6","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;PSYCHOLOGY;ENGINEERING;MATHEMATICS;PHILOSOPHY;ECONOMICS;POLITICAL SCIENCE;BUSINESS;GEOLOGY;HISTORY;MATERIALS SCIENCE;SOCIOLOGY","228;65;24;17;16;15;12;8;4;3;3;2;2;2;2;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;GASTROENTEROLOGY;CARDIOLOGY;GENETICS;PATHOLOGY;ENDOCRINOLOGY;CANCER RESEARCH;RADIOLOGY;BIOCHEMISTRY;ENVIRONMENTAL HEALTH;INTENSIVE CARE MEDICINE;IMMUNOLOGY;OPTICS;MICROBIOLOGY;UROLOGY;NEUROSCIENCE;ANATOMY;CELL BIOLOGY;PHYSICAL THERAPY","175;80;59;38;31;31;26;24;23;21;20;18;18;17;15;12;12;10;9;9;9","CANCER;GENE;CHEMOTHERAPY;TRANSPLANTATION;POPULATION;RANDOMIZED CONTROLLED TRIAL;DISEASE;DIABETES MELLITUS;MYOCARDIAL INFARCTION;VIRUS;ADVERSE EFFECT;HEPATOCELLULAR CARCINOMA;CLINICAL TRIAL;INCIDENCE (GEOMETRY);KIDNEY;ALTERNATIVE MEDICINE;ANTIBIOTICS;CONFIDENCE INTERVAL;DISSECTION (MEDICAL);INSULIN;RENAL FUNCTION;RETROSPECTIVE COHORT STUDY","60;35;29;19;17;17;13;11;11;11;10;10;8;8;8;7;7;7;7;7;7;7","COLORECTAL CANCER;BEVACIZUMAB;CLINICAL ENDPOINT;GENOTYPE;LIVER TRANSPLANTATION;BREAST CANCER;GENE EXPRESSION;PANCREATIC CANCER;EJECTION FRACTION;GEMCITABINE;HAZARD RATIO;MICRORNA;PERCUTANEOUS CORONARY INTERVENTION;HEPATITIS B VIRUS;KIDNEY TRANSPLANTATION;NEUTROPENIA;PHASES OF CLINICAL RESEARCH;PLACEBO;SORAFENIB;STAPHYLOCOCCUS AUREUS;TACROLIMUS;TOLERABILITY","33;15;15;15;11;10;7;7;6;6;6;6;6;5;5;5;5;5;5;5;5;5","IRINOTECAN;CETUXIMAB;OXALIPLATIN;SINGLE-NUCLEOTIDE POLYMORPHISM;HBSAG;KRAS;CARDIAC RESYNCHRONIZATION THERAPY;VANCOMYCIN;CAPECITABINE;FOLINIC ACID;METASTATIC BREAST CANCER;METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS;PANCREAS TRANSPLANTATION;PANCREATIC ISLETS;REGORAFENIB;STAPHYLOCOCCUS EPIDERMIDIS;ALISKIREN;BASILIXIMAB;FEBRILE NEUTROPENIA;GENE EXPRESSION PROFILING;GENE SIGNATURE;LAMIVUDINE;MACE;MATRIX-ASSISTED LASER DESORPTION/IONIZATION;MICROARRAY;PHARMACOGENETICS;TIOTROPIUM BROMIDE;TRASTUZUMAB","16;9;7;6;5;5;4;4;3;3;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;MALE;FEMALE;MIDDLE AGED;AGED;ADULT;TREATMENT OUTCOME;AGED, 80 AND OVER;ITALY;LIVER NEOPLASMS;RETROSPECTIVE STUDIES;ANTI-BACTERIAL AGENTS;MICRORNAS;COLORECTAL NEOPLASMS;DIABETES MELLITUS, TYPE 2;ADOLESCENT;ANTINEOPLASTIC AGENTS;CARCINOMA, HEPATOCELLULAR;PROSPECTIVE STUDIES","136;100;89;88;73;65;50;30;24;22;22;21;18;18;17;17;15;15;15;15","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;KIDNEY TRANSPLANTATION;PANCREATIC CANCER RESEARCH AND TREATMENT;HEPATOCELLULAR CARCINOMA;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES;LIVER TRANSPLANTATION AND GRAFT SURVIVAL ANALYSIS;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;HEPATITIS B INFECTION AND TREATMENT;MANAGEMENT OF VALVULAR HEART DISEASE;PANCREATIC ISLET DYSFUNCTION AND REGENERATION;ADVANCEMENTS IN LUNG CANCER RESEARCH;MICRORNA REGULATION IN CANCER AND DEVELOPMENT;CLINICAL STUDIES ON CORONARY STENTS AND REVASCULARIZATION;HER2 SIGNALING IN BREAST CANCER TREATMENT;LIVER CIRRHOSIS AND ASSOCIATED COMPLICATIONS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MANAGEMENT AND EPIDEMIOLOGY OF INFECTIVE ENDOCARDITIS;MICROBIAL IDENTIFICATION AND DIAGNOSIS;AGE-RELATED MACULAR DEGENERATION RESEARCH;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA","23;9;8;7;6;6;5;5;5;5;4;4;3;3;3;3;3;3;2;2","CLINICAL ENDPOINT;METASTATIC COLORECTAL CANCER;TREATMENT;LIVER TRANSPLANTATION;FOLFIRI;METASTATIC PANCREATIC CANCER;BREAST CANCER;HEART RHYTHM;LIVING DONOR LIVER TRANSPLANTATION;REGIMEN;ECHOCARDIOGRAPHY;HEPATITIS B;KIDNEY TRANSPLANTATION;LIVER CANCER;LIVER CIRRHOSIS;METASTATIC BREAST CANCER;TOLERABILITY;CANCER RISK;CANCER SUSCEPTIBILITY;CARDIAC IMAGING","16;16;16;9;7;7;6;6;6;6;5;5;5;5;5;5;5;4;4;4","COLORECTAL CANCER;METASTATIC COLORECTAL;CANCER PATIENTS;PATIENTS TREATED;PANCREATIC CANCER;CANCER MCRC;LIVER TRANSPLANTATION;MCRC PATIENTS;PHASE II;BREAST CANCER;FIRST-LINE FOLFIRI;FIRST-LINE TREATMENT;PATIENTS PTS;ADVANCED PANCREATIC;BEVACIZUMAB BV;DE NOVO;EUROPEAN HEART;HEART RHYTHM;HEPATOCELLULAR CARCINOMA;LIVER TRANSPLANT;LUNG CANCER;MODIFIED FOLFOXIRI;NOVO LIVER;PROSPECTIVE STUDY;RANDOMIZED CONTROLLED;RHYTHM ASSOCIATION;RISK FACTORS;TRANSPLANT RECIPIENTS;ADVANCED COLORECTAL;ASSOCIATION SURVEY","19;15;12;10;8;7;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4;4;4;4;4;4;3;3","UNITED KINGDOMSEARCH;UNIVERSITY HOSPITAL;HR CI;BREAST CANCER;BRCA MUTATION;MUTATION CARRIERS;PRIMARY ENDPOINT;CANCER PATIENTS;CLINICAL GENETICS;CANCER CENTER;MEDICAL UNIVERSITY;GENETIC EPIDEMIOLOGY;GRAFT SURVIVAL;PUBLIC HEALTH;RENAL FUNCTION;CAMBRIDGE UNITED;CANCER GENETIC;CARE UNIVERSITY;EPIDEMIOLOGY DEPARTMENT;OVARIAN CANCER;PATIENTS TREATED;PRIMARY CARE;CAMBRIDGE CAMBRIDGE;COLORECTAL CANCER;DE NOVO;MEDICAL CENTER;PROGRESSION-FREE SURVIVAL;SURVIVAL OS;ABSTRACT INTRODUCTION;ACUTE REJECTION","27;24;23;20;18;18;18;17;16;15;15;13;13;13;13;12;12;12;12;12;12;12;11;11;11;11;11;11;10;10",47,0.2,2.85,68.6,4.25,593.3,33.33,3,156,7.8,1,16,1.67,1,2,1.5,1,2,15.6,1,72,5,1,10,1,1,1,2,1,3,42.67,3,211,0,0,0,1,1,1,21.91,2,129,0,0,0,1,1,1,1.4,1,3,7,1,25,16.36,1,95,3,1,6,0.33,0,2,0,0,0,221.92,12,1121,222.25,12,1121,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,2,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ALBERTELLI ROBERTO","1","AZIENDA OSPEDALIERO UNIVERSITARIA PISANA","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;40 ENGINEERING","1;1;1",NA,NA,NA,NA,"A61M16/00;A61M16/06;A61M16/08","1;1;1","A61M16/0066;A61M16/0078;A61M16/06;A61M16/08;A61M2016/0021","1;1;1;1;1",0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,14,"PUBLIC LIBRARY OF SCIENCE","14","32 BIOMEDICAL AND CLINICAL SCIENCES;42 HEALTH SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3001 AGRICULTURAL BIOTECHNOLOGY;3105 GENETICS;3215 REPRODUCTIVE MEDICINE;34 CHEMICAL SCIENCES;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY","19;9;6;4;3;2;1;1;1;1;1;1","CANCER;BREAST CANCER;GENETICS;CLINICAL RESEARCH;PREVENTION;DIGESTIVE DISEASES;HUMAN GENOME;BIOTECHNOLOGY;CHRONIC LIVER DISEASE AND CIRRHOSIS;EMERGING INFECTIOUS DISEASES;ESTROGEN;HEPATITIS;LIVER DISEASE;PANCREATIC CANCER;RARE DISEASES","6;5;5;3;3;2;2;1;1;1;1;1;1;1;1","CANCER","5","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","2","POPULATION & SOCIETY;CLINICAL","3;2","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH;HEALTH SERVICES RESEARCH","6;3;1","BREAST CANCER;PANCREATIC CANCER","5;1",NA,NA,31,6.13,505.7,13,58.84,1,1,9,1,9,0,5,5,0,26,4,0,0,0,0,0,0,29,2,0,30,1,0,0,0,0,0,0,0,0,"United States;Switzerland;Belgium;Germany;Italy;Japan","7;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3207 MEDICAL MICROBIOLOGY;3209 NEUROSCIENCES;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE;42 HEALTH SCIENCES;44 HUMAN SOCIETY;4403 DEMOGRAPHY","31;19;11;5;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;HEMATOLOGY;PREVENTION;DIGESTIVE DISEASES;PATIENT SAFETY;NEURODEGENERATIVE;NEUROSCIENCES;BRAIN DISORDERS;CARDIOVASCULAR;CHRONIC PAIN;COLO-RECTAL CANCER;GENETICS;INFECTIOUS DISEASES;PAIN RESEARCH;TRANSPLANTATION;BREAST CANCER;CHRONIC LIVER DISEASE AND CIRRHOSIS","29;18;15;10;7;7;6;5;4;4;3;3;3;3;3;3;3;3;2;2","CANCER;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL;ORAL AND GASTROINTESTINAL;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY","14;2;2;1;1;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;4.4 POPULATION SCREENING;5.2 CELLULAR AND GENE THERAPIES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","22;8;1;1;1;1","COLON AND RECTAL CANCER;LIVER CANCER;LEUKEMIA / LEUKAEMIA;LUNG CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;BREAST CANCER;OVARIAN CANCER;PANCREATIC CANCER;STOMACH CANCER","3;3;2;2;2;2;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","17;1;1;1;1;1"
"AOU_PISANA",2013,266,11.718045112782,3.2218045112782,0.310385064177363,0.37593984962406,0.334586466165414,0.12781954887218,0.454887218045113,2,157,51,23,19,0.59,0.19,0.09,0.07,32.42,0.929275687176205,0.379699248120301,0.853383458646617,5.30385487528345,0.458741723380672,0.573692448154428,0.507234394377842,0.577450980392157,"ALFREDO FALCONE;FOTIOS LOUPAKIS;CHIARA CREMOLINI;LISA SALVATORE;MARTA SCHIRRIPA;GIANLUCA MASI;CARLOTTA ANTONIOTTI;FEDERICA MARMORINO;GABRIELLA FONTANINI;HEINZ‐JOSEF LENZ;DAVIDE LAZZERI;MARIA GRAZIA BONGIORNI;MAURIZIA ROSSANA BRUNETTO;FRANCESCA BERGAMO;VITTORINA ZAGONEL;GUIDO BOCCI;SARA LONARDI;PAOLO VITTI;FERRUCCIO BONINO;CARINA BLOMSTRÖM‐LUNDQVIST","33;30;23;21;20;17;17;14;11;11;10;10;10;9;9;8;8;7;7;7","ALFREDO FALCONE;FOTIOS LOUPAKIS;CHIARA CREMOLINI;DAVIDE LAZZERI;MAURIZIA ROSSANA BRUNETTO;F. COSENTINO;LISA SALVATORE;MARTA SCHIRRIPA;MARIA GRAZIA BONGIORNI;FERRUCCIO BONINO;CARLOTTA ANTONIOTTI;GIANLUCA MASI;NORA TERRASINI;FEDERICA MARMORINO;FRANCESCO MENICHETTI;ANTONIO BOLDRINI;TOMMASO AGOSTINI;CARINA BLOMSTRÖM‐LUNDQVIST;PAOLO PIAGGI;GABRIELLA FONTANINI","2.31;2.17;1.67;1.58;1.49;1.38;1.3;1.27;1.25;1.24;1.11;1.05;1;0.95;0.94;0.88;0.88;0.87;0.87;0.81","ALFREDO FALCONE;FOTIOS LOUPAKIS;CHIARA CREMOLINI;LISA SALVATORE;MARTA SCHIRRIPA;GIANLUCA MASI;CARLOTTA ANTONIOTTI;FEDERICA MARMORINO;GABRIELLA FONTANINI;DAVIDE LAZZERI;MARIA GRAZIA BONGIORNI;MAURIZIA ROSSANA BRUNETTO;PAOLO VITTI;FERRUCCIO BONINO;CRISTIANA LUPI;ENRICO VASILE;ROMANO DANESI;NICCOLA FUNEL;GRETA ALÌ;CARLO TASCINI","33;30;23;21;20;17;17;14;11;10;10;10;7;7;7;7;7;6;6;6","ALFREDO FALCONE;FOTIOS LOUPAKIS;CHIARA CREMOLINI;DAVIDE LAZZERI;MAURIZIA ROSSANA BRUNETTO;F. COSENTINO;LISA SALVATORE;MARTA SCHIRRIPA;MARIA GRAZIA BONGIORNI;FERRUCCIO BONINO;CARLOTTA ANTONIOTTI;GIANLUCA MASI;NORA TERRASINI;FEDERICA MARMORINO;FRANCESCO MENICHETTI;ANTONIO BOLDRINI;PAOLO PIAGGI;GABRIELLA FONTANINI;ROSA TERESA SCARAMUZZO;ANTONELLA CIARAMELLA","2.31;2.17;1.67;1.58;1.49;1.38;1.3;1.27;1.25;1.24;1.11;1.05;1;0.95;0.94;0.88;0.87;0.81;0.78;0.73","ALFREDO FALCONE;FABIO GUARRACINO;ALESSANDRA ORECCHIONI;ALEXANDER MEBAZAA;ANDREA MORELLI;ANNALIA D’EGIDIO;C RAFFONE;CHRISTIAN ERTMER;FIORELLA D''IPPOLITI;LUIGI TRITAPEPE;MARIO VENDITTI;MARTIN WESTPHAL;MASSIMO GIRARDIS;MERVYN SINGER;P PIETROPAOLI;SANDRA LIGGES;SEBASTIAN REHBERG;TIM KAMPMEIER;FOTIOS LOUPAKIS;CHIARA CREMOLINI","773;618;601;601;601;601;601;601;601;601;601;601;601;601;601;601;601;601;599;587","ALFREDO FALCONE;FABIO GUARRACINO;FOTIOS LOUPAKIS;CARLO TASCINI;FRANCESCO MENICHETTI;CHIARA CREMOLINI;GIANLUCA MASI;LISA SALVATORE;ANNA SONIA PETRONIO;MARIA GRAZIA BONGIORNI;MARIA A. CALIGO;MARTA SCHIRRIPA;ROSSANA BERTA;MARCO GAMBACCIANI;PIERO MARCHETTI;MATTEO ANSELMINO;CARLOTTA ANTONIOTTI;PAOLO SIMI;PAOLO PIAGGI;F. SCATENA","665;618;588;558;558;519;511;478;474;422;406;396;376;302;294;266;225;214;209;201","ALFREDO FALCONE;FOTIOS LOUPAKIS;CHIARA CREMOLINI;LISA SALVATORE;GIANLUCA MASI;MARTA SCHIRRIPA;CARLOTTA ANTONIOTTI;FEDERICA MARMORINO;MARIA GRAZIA BONGIORNI;DAVIDE LAZZERI;MAURIZIA ROSSANA BRUNETTO;ENRICO VASILE;CARLO TASCINI;FRANCESCO MENICHETTI;GRETA ALÌ;ANTONIO CHELLA;IACOPO DALLAN;PAOLO PIAGGI;FERRUCCIO BONINO;GABRIELLA FONTANINI","28;26;21;19;17;17;14;13;10;10;9;7;6;6;6;5;5;5;5;5","MEDICINE;BIOLOGY;PHYSICS;PSYCHOLOGY;ENGINEERING;COMPUTER SCIENCE;CHEMISTRY;MATHEMATICS;ECONOMICS;POLITICAL SCIENCE;BUSINESS;SOCIOLOGY;MATERIALS SCIENCE;ENVIRONMENTAL SCIENCE;GEOLOGY;GEOGRAPHY;PHILOSOPHY","252;64;23;22;15;14;13;10;8;7;4;4;3;2;2;1;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;GENETICS;GASTROENTEROLOGY;CARDIOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;CANCER RESEARCH;PHYSICAL THERAPY;BIOCHEMISTRY;IMMUNOLOGY;PSYCHIATRY;INTENSIVE CARE MEDICINE;NUCLEAR MEDICINE;ANESTHESIA;OPTICS;NEUROSCIENCE","194;71;60;43;37;36;32;32;32;26;24;21;20;17;16;15;15;14;13;12","CANCER;GENE;CHEMOTHERAPY;POPULATION;DISEASE;OBESITY;RANDOMIZED CONTROLLED TRIAL;COHORT;ADVERSE EFFECT;DIABETES MELLITUS;HEPATOCELLULAR CARCINOMA;LUNG CANCER;HEART FAILURE;RECEPTOR;THYROID;VIRUS;ALTERNATIVE MEDICINE;CONFIDENCE INTERVAL;BODY MASS INDEX;INCIDENCE (GEOMETRY);LUNG","71;34;32;27;24;14;14;13;12;12;12;12;10;10;10;10;9;9;8;8;8","COLORECTAL CANCER;BEVACIZUMAB;GENOTYPE;PROGRESSION-FREE SURVIVAL;CLINICAL ENDPOINT;MUTATION;ADENOCARCINOMA;THYROID CANCER;BREAST CANCER;EJECTION FRACTION;EPIDERMAL GROWTH FACTOR RECEPTOR;HAZARD RATIO;HEPATITIS B VIRUS;PHASES OF CLINICAL RESEARCH;METASTASIS;PLACEBO;NEUTROPENIA;UNIVARIATE ANALYSIS;VASCULAR ENDOTHELIAL GROWTH FACTOR;WEIGHT LOSS","46;22;12;11;10;9;8;8;7;7;7;7;7;7;6;6;5;5;5;5","KRAS;IRINOTECAN;SINGLE-NUCLEOTIDE POLYMORPHISM;CETUXIMAB;OXALIPLATIN;HBSAG;LAMIVUDINE;AMPHIREGULIN;CAPECITABINE;RADIOIODINE THERAPY;CARDIAC RESYNCHRONIZATION THERAPY;FEBRILE NEUTROPENIA;REGORAFENIB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;ACROMEGALY;BONE METASTASIS;COLONOSCOPY;DEBULKING;DIABETIC FOOT ULCER;ENOS;EPWORTH SLEEPINESS SCALE;GASTRIC BYPASS;GESTATIONAL DIABETES;IPILIMUMAB;MISSENSE MUTATION;MODIFIED RANKIN SCALE;MOTOR SYMPTOMS;NEUROPEPTIDE Y RECEPTOR;NUCLEOTIDE EXCISION REPAIR;PRIMARY MOTOR CORTEX;RIBAVIRIN;V600E;VANCOMYCIN","19;15;9;7;7;6;6;4;4;4;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;COLORECTAL NEOPLASMS;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;ITALY;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;LUNG NEOPLASMS;AGED, 80 AND OVER;EUROPE;CAMPTOTHECIN;FOLLOW-UP STUDIES;PROGNOSIS;YOUNG ADULT;RISK FACTORS","147;115;113;109;81;70;66;32;31;29;25;24;22;21;19;18;18;18;18;17","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;HEPATITIS B INFECTION AND TREATMENT;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;PANCREATIC CANCER RESEARCH AND TREATMENT;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;GLIOMAS;HEPATOCELLULAR CARCINOMA;ADVANCEMENTS IN LUNG CANCER RESEARCH;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;MANAGEMENT OF VALVULAR HEART DISEASE;PATHOPHYSIOLOGY OF PARKINSON'S DISEASE;ATRIAL FIBRILLATION;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;PREVENTION AND MANAGEMENT OF DIABETIC FOOT ULCERS;ASTHMA;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;DIAGNOSIS AND MANAGEMENT OF PITUITARY DISORDERS","26;8;6;6;5;5;5;4;4;4;4;3;3;3;3;2;2;2;2;2","METASTATIC COLORECTAL CANCER;TREATMENT;PROGRESSION-FREE SURVIVAL;CLINICAL ENDPOINT;ECHOCARDIOGRAPHY;FOLFIRI;DIABETES;EGFR MUTATIONS;BEVACIZUMAB;HEART RHYTHM;HEPATITIS B;HEPATOCELLULAR CARCINOMA;INTERQUARTILE RANGE;LIVER CANCER;REGIMEN;TRANSCATHETER AORTIC-VALVE REPLACEMENT;UNIVARIATE ANALYSIS;BIOMARKER ANALYSIS;BRAF MUTATIONS;CANCER GENOMICS","24;14;11;10;8;8;6;6;5;5;5;5;5;5;5;5;5;4;4;4","COLORECTAL CANCER;METASTATIC COLORECTAL;CANCER MCRC;CANCER PATIENTS;PHASE III;PATIENTS TREATED;ASSOCIATION SURVEY;EUROPEAN HEART;FIRST-LINE TREATMENT;HEART RHYTHM;MCRC PATIENTS;PATIENTS PTS;RHYTHM ASSOCIATION;PHASE II;AORTIC VALVE;BEVACIZUMAB BEV;HEPATOCELLULAR CARCINOMA;RETROSPECTIVE ANALYSIS;BEBYP TRIAL;GENETIC VARIANTS;ITALIAN EXPERIENCE;LUNG CANCER;MULTICENTER STUDY;BEVACIZUMAB BV;CHRONIC HEPATITIS;HUMAN VISUAL;II STUDY;III BEBYP;III CORRECT;KRAS MUTATIONS","34;26;13;12;10;9;7;7;7;7;7;7;7;6;5;5;5;5;4;4;4;4;4;3;3;3;3;3;3;3","PATIENTS TREATED;AORTIC VALVE;TYPE DIABETES;MAGNETIZATION TRANSFER;COLORECTAL CANCER;SLEEP DURATION;ALZHEIMER DISEASE;BRCA CARRIERS;METASTATIC COLORECTAL;TRANSFER RATIO;ATRIAL FIBRILLATION;BCLC STAGE;BETA CELL;BLOOD PRESSURE;INVERSELY RELATED;PATIENTS RECEIVED;BODY MASS;BONE METASTASIS;CONSECUTIVE PATIENTS;MASS INDEX;MEDIAN FOLLOW-UP;MEDIAN PFS;OVARIAN CANCER;SEVERE OBESITY;SLEEP APNEA;STOPPING RULE;WEIGHT CHANGE;ADMINISTRATIVE DATA;AORTIC ANNULUS;AR LEVELS","13;12;12;11;10;10;9;9;9;9;8;8;8;8;8;8;7;7;7;7;7;7;7;7;7;7;7;6;6;6",59,0.22,1.5,28.8,4.6,288.239999999999,33.27,1,408,1.4,1,3,1.5,1,3,0,0,0,1.71,1,6,3.4,1,7,1,1,1,1,1,1,34.47,1,419,0,0,0,1,1,1,40.82,1,399,1,1,1,2,2,2,1.33,1,2,2.12,1,5,42,1,393,1.6,1,2,0,0,0,0,0,0,109.4,26,224,109.4,26,224,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PISANA",2014,301,12.4318936877076,3.41196013289037,0.293086660175268,0.338870431893688,0.299003322259136,0.192691029900332,0.495016611295681,2,174,62,32,16,0.58,0.21,0.11,0.05,40.22,1.06414756947951,0.401993355481728,0.870431893687708,5.57223796033995,0.479760200016952,0.505555555555556,0.519314868804665,0.499228905045164,"ALFREDO FALCONE;FOTIOS LOUPAKIS;CHIARA CREMOLINI;GABRIELLA FONTANINI;GIANLUCA MASI;LISA SALVATORE;MAURIZIA ROSSANA BRUNETTO;LUCA GALLI;FABIO GUARRACINO;CARLOTTA ANTONIOTTI;ALBERTO ZANIBONI;HEINZ‐JOSEF LENZ;LISA DEROSA;DONGYUN YANG;FEDERICO CAPPUZZO;MATTEO SANTONI;MARCO LUCCHI;PAOLO VITTI;FEDERICA MARMORINO;SEBASTIAN STINTZING","40;29;21;19;15;14;13;12;12;12;11;11;11;11;10;10;9;9;9;9","ALFREDO FALCONE;FABIO GUARRACINO;MAURIZIA ROSSANA BRUNETTO;FOTIOS LOUPAKIS;BRUNO ROSSI;PIETRO BERTINI;STEFANIA DALISE;PAOLO PERRINI;FRANCESCO MENICHETTI;CHIARA CREMOLINI;CARMELO CHISARI;GABRIELLA FONTANINI;LUCA GALLI;FERRUCCIO BONINO;FEDERICA BERTOLUCCI;GIANLUCA MASI;PAOLO PIAGGI;FRANCESCO TRAMONTI;PAOLO VITTI;MICHELE CURCIO","2.7;2.27;1.7;1.67;1.51;1.39;1.38;1.33;1.29;1.26;1.25;1.22;1.21;1.19;1.08;0.99;0.98;0.93;0.93;0.91","ALFREDO FALCONE;FOTIOS LOUPAKIS;CHIARA CREMOLINI;GABRIELLA FONTANINI;GIANLUCA MASI;LISA SALVATORE;MAURIZIA ROSSANA BRUNETTO;LUCA GALLI;FABIO GUARRACINO;CARLOTTA ANTONIOTTI;LISA DEROSA;FEDERICO CAPPUZZO;MARCO LUCCHI;PAOLO VITTI;FEDERICA MARMORINO;RODOLFO SACCO;MARTA SCHIRRIPA;ENRICO VASILE;FRANCA MELFI;ELISA SENSI","40;29;21;19;15;14;13;12;12;12;11;10;9;9;9;9;9;9;8;8","ALFREDO FALCONE;FABIO GUARRACINO;MAURIZIA ROSSANA BRUNETTO;FOTIOS LOUPAKIS;BRUNO ROSSI;PIETRO BERTINI;STEFANIA DALISE;PAOLO PERRINI;FRANCESCO MENICHETTI;CHIARA CREMOLINI;CARMELO CHISARI;GABRIELLA FONTANINI;LUCA GALLI;FERRUCCIO BONINO;FEDERICA BERTOLUCCI;GIANLUCA MASI;PAOLO PIAGGI;FRANCESCO TRAMONTI;PAOLO VITTI;MICHELE CURCIO","2.7;2.27;1.7;1.67;1.51;1.39;1.38;1.33;1.29;1.26;1.25;1.22;1.21;1.19;1.08;0.99;0.98;0.93;0.93;0.91","ANNA SONIA PETRONIO;ALFREDO FALCONE;FOTIOS LOUPAKIS;NEIL MOAT;GIANLUCA MASI;CHIARA CREMOLINI;A. GILLAMS;BORIS NIKOLIC;BRADFORD J. WOOD;BYUNG IHN CHOI;CHRISTOPHER L. BRACE;CONSTANTINOS T. SOFOCLEOUS;DAMIAN E. DUPUY;DAVID GIANFELICE;DAVID J. BREEN;DAVID LU;DEBRA A. GERVAIS;EDWARD LEEN;FRED T. LEE;GERALD D. DODD","1415;1244;1220;1219;1180;1167;1151;1151;1151;1151;1151;1151;1151;1151;1151;1151;1151;1151;1151;1151","ANNA SONIA PETRONIO;FOTIOS LOUPAKIS;ALFREDO FALCONE;CHIARA CREMOLINI;GIANLUCA MASI;RICCARDO LENCIONI;LISA SALVATORE;ANTONIO CHELLA;ALESSANDRA CAPODANNO;FABIO GUARRACINO;GABRIELLA FONTANINI;MARCO LUCCHI;MAURIZIA ROSSANA BRUNETTO;RUBIA BALDASSARRI;RODOLFO SACCO;MARCO ANSELMINO;PAOLO PIAGGI;CRISTIANA LUPI;ELISA SENSI;FERRUCCIO BONINO","1377;1218;1212;1165;1165;1151;1107;664;550;531;508;444;416;378;360;269;269;260;260;255","ALFREDO FALCONE;FOTIOS LOUPAKIS;CHIARA CREMOLINI;LISA SALVATORE;GIANLUCA MASI;FABIO GUARRACINO;LUCA GALLI;CARMELO CHISARI;MAURIZIA ROSSANA BRUNETTO;LISA DEROSA;CARLOTTA ANTONIOTTI;GABRIELLA FONTANINI;MARTA SCHIRRIPA;ENRICO VASILE;FEDERICA MARMORINO;MARIA GRAZIA BONGIORNI;BRUNO ROSSI;A. FARNESI;ANNA SONIA PETRONIO;MARCO LUCCHI","32;28;20;13;13;12;12;12;12;11;11;10;9;9;8;8;8;7;7;7","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;PSYCHOLOGY;MATHEMATICS;SOCIOLOGY;ENGINEERING;MATERIALS SCIENCE;ECONOMICS;POLITICAL SCIENCE;PHILOSOPHY;GEOLOGY;BUSINESS;GEOGRAPHY","292;91;19;18;16;16;14;11;10;7;6;6;5;4;2;2","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GASTROENTEROLOGY;GENETICS;PATHOLOGY;CARDIOLOGY;BIOCHEMISTRY;ENDOCRINOLOGY;CANCER RESEARCH;RADIOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;PALEONTOLOGY;PHYSICAL THERAPY;PSYCHIATRY;ANESTHESIA;INTENSIVE CARE MEDICINE;NUCLEAR MEDICINE;NURSING;PHYSICAL MEDICINE AND REHABILITATION;VIROLOGY","230;86;77;49;46;45;33;31;28;27;25;21;19;16;16;16;14;14;14;11;11;11","CANCER;GENE;CHEMOTHERAPY;CONFIDENCE INTERVAL;POPULATION;HEPATOCELLULAR CARCINOMA;ADVERSE EFFECT;COHORT;VIRUS;RANDOMIZED CONTROLLED TRIAL;ALTERNATIVE MEDICINE;DISEASE;LUNG CANCER;MYOCARDIAL INFARCTION;PROPORTIONAL HAZARDS MODEL;STAGE (STRATIGRAPHY);THYROID;MULTIVARIATE ANALYSIS;RADIATION THERAPY;RENAL CELL CARCINOMA","78;56;49;20;18;16;13;13;13;12;11;11;11;11;10;10;10;9;9;9","COLORECTAL CANCER;BEVACIZUMAB;GENOTYPE;HAZARD RATIO;MUTATION;BREAST CANCER;CLINICAL ENDPOINT;METASTASIS;EPIDERMAL GROWTH FACTOR RECEPTOR;SORAFENIB;THYROID CANCER;EJECTION FRACTION;PANCREATIC CANCER;PROGRESSION-FREE SURVIVAL;PROGRESSIVE DISEASE;SUNITINIB;UNIVARIATE ANALYSIS;ADENOCARCINOMA;CHRONIC HEPATITIS;EXON;GEMCITABINE;HEPATITIS B VIRUS;HEPATITIS C VIRUS;NEUTROPENIA;PHASES OF CLINICAL RESEARCH;TEMOZOLOMIDE","36;23;19;13;13;11;9;9;8;7;7;6;6;6;6;6;6;5;5;5;5;5;5;5;5;5","KRAS;IRINOTECAN;SINGLE-NUCLEOTIDE POLYMORPHISM;CETUXIMAB;RIBAVIRIN;HBSAG;OXALIPLATIN;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;ERLOTINIB;MISSENSE MUTATION;PAZOPANIB;ANDROGEN RECEPTOR;BONE METASTASIS;FRAMESHIFT MUTATION;ONCOGENE;PHARMACOGENETICS;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;ANAPLASTIC LYMPHOMA KINASE;ANTHRACYCLINE;CRIZOTINIB;ECHINOCANDIN;EXOME SEQUENCING;FANCONI ANEMIA;FEBRILE NEUTROPENIA;FENOLDOPAM;GEFITINIB;GENOTYPING;HAPLOTYPE;METASTATIC BREAST CANCER;PAPILLARY THYROID CANCER;PROMOTER;REGORAFENIB;RIBOSOME;SENTINEL LYMPH NODE;VASCULAR ENDOTHELIAL GROWTH FACTOR A","17;11;11;9;7;5;5;4;4;4;4;3;3;3;3;3;3;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2;2","HUMANS;FEMALE;MALE;;MIDDLE AGED;AGED;ADULT;TREATMENT OUTCOME;LIVER NEOPLASMS;RETROSPECTIVE STUDIES;LUNG NEOPLASMS;ITALY;AGED, 80 AND OVER;CARCINOMA, HEPATOCELLULAR;YOUNG ADULT;COLORECTAL NEOPLASMS;THYROID NEOPLASMS;FOLLOW-UP STUDIES;ANTIBODIES, MONOCLONAL, HUMANIZED;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS","173;139;136;122;101;90;75;46;44;40;39;38;36;36;31;28;28;27;25;24","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;RENAL CELL CARCINOMA;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;HEPATITIS C INFECTION AND TREATMENT;HEPATOCELLULAR CARCINOMA;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;PANCREATIC CANCER RESEARCH AND TREATMENT;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;MANAGEMENT OF VALVULAR HEART DISEASE;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GLIOMAS;MYASTHENIA GRAVIS AND THYMIC TUMORS RESEARCH;OPTIMIZATION OF PERIOPERATIVE FLUID THERAPY;PRINCIPLES AND INTERVENTIONS IN STROKE REHABILITATION;DENTAL IMPLANTOLOGY AND PERI-IMPLANT DISEASES;HEPATITIS B INFECTION AND TREATMENT;IDIOPATHIC PULMONARY FIBROSIS: DIAGNOSIS AND MANAGEMENT;LYMPHOID NEOPLASMS","24;9;9;8;8;6;6;6;5;5;4;4;4;4;4;4;3;3;3;3","METASTATIC COLORECTAL CANCER;TREATMENT;FOLFIRI;CLINICAL ENDPOINT;KRAS MUTATIONS;CONCOMITANT;EGFR MUTATIONS;CARDIAC IMAGING;ECHOCARDIOGRAPHY;BIOMARKER ANALYSIS;BRAF MUTATIONS;PROGRESSION-FREE SURVIVAL;RENAL CELL CARCINOMA;UNIVARIATE ANALYSIS;HEPATITIS C;HEPATOCELLULAR CARCINOMA;PROSTHETIC VALVES EVALUATION;STROKE (ENGINE);TEMOZOLOMIDE;THYROID NODULES","17;17;11;9;9;8;8;7;7;6;6;6;6;6;5;5;5;5;5;5","COLORECTAL CANCER;METASTATIC COLORECTAL;CANCER MCRC;CANCER PATIENTS;CLINICAL OUTCOME;PATIENTS TREATED;PATIENTS PTS;CELL CARCINOMA;MCRC PATIENTS;RENAL CELL;CHRONIC HEPATITIS;LUNG CANCER;OBSERVATIONAL STUDY;BEVACIZUMAB BEV;CELL LUNG;ELDERLY PATIENTS;HEPATOCELLULAR CARCINOMA;METASTATIC RENAL;PANCREATIC CANCER;PHASE II;THYROID CANCER;BREAST CANCER;NON-SMALL CELL;ACUTE CORONARY;ASSOCIATION SURVEY;CARDIAC SURGERY;CORONARY SYNDROME;EUROPEAN HEART;FIRST-LINE TREATMENT;GENES INVOLVED","25;25;13;11;10;10;9;8;8;8;7;7;7;6;6;6;6;6;6;6;6;5;5;4;4;4;4;4;4;4","PATIENTS TREATED;PATIENTS RECEIVED;ABSTRACT AIM;MEDIAN PFS;RADIATION THERAPY;RISK FACTORS;CARDIAC SURGERY;MEDIAN AGE;MULTIVARIATE ANALYSIS;MUTATIONAL STATUS;WEIGHT LOSS;CLINICAL TRIALS;MEDIAN OS;MONTHS CI;PRETERM INFANTS;RESPONSE RATE;SURVIVAL OS;WT PTS;CONFIDENCE INTERVAL;HR CI;METABOLIC SYNDROME;PATIENTS UNDERGOING;PT PT;PARKINSON DISEASE;PATIENTS RECEIVING;ADJUVANT CHEMOTHERAPY;CLINICAL PRACTICE;FANCONI ANEMIA;IJV DISTENSIBILITY;LEFT VENTRICULAR","21;15;14;14;14;13;12;12;12;12;12;11;11;11;11;11;11;11;10;10;10;10;10;9;9;8;8;8;8;8",102,0.34,2.55,15.85,7,74.558,11.54,1,44,2.07,1,6,1.6,1,4,1,1,1,1.73,1,7,3.71,1,12,0,0,0,1.25,1,2,14.57,1,51,0,0,0,1,1,1,9.43,1,33,1,1,1,1.67,1,3,1.54,1,3,2.92,1,7,6.45,1,18,1.89,1,6,0.04,0,1,0,0,0,129.14,24,581,129.18,24,581,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"ALBERTELLI ROBERTO","1","AZIENDA OSPEDALIERO UNIVERSITARIA PISANA","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;40 ENGINEERING","1;1;1",NA,NA,NA,NA,"A61M16/00;A61M16/06;A61M16/08","1;1;1","A61M16/0066;A61M16/0078;A61M16/06;A61M16/08;A61M2016/0021","1;1;1;1;1",0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,49,"PUBLIC LIBRARY OF SCIENCE;KARGER PUBLISHERS","47;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;31 BIOLOGICAL SCIENCES;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;38 ECONOMICS;3105 GENETICS;3203 DENTISTRY;42 HEALTH SCIENCES;44 HUMAN SOCIETY;49 MATHEMATICAL SCIENCES;4904 PURE MATHEMATICS;50 PHILOSOPHY AND RELIGIOUS STUDIES;5003 PHILOSOPHY;51 PHYSICAL SCIENCES;52 PSYCHOLOGY;3009 VETERINARY SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3213 PAEDIATRICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES","66;20;8;6;3;3;2;2;2;2;2;2;2;2;2;2;1;1;1;1","CLINICAL RESEARCH;PREVENTION;INFECTIOUS DISEASES;PHYSICAL INJURY - ACCIDENTS AND ADVERSE EFFECTS;RARE DISEASES;SLEEP RESEARCH;ANTIMICROBIAL RESISTANCE;BIOTECHNOLOGY;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;DIGESTIVE DISEASES;GENETICS;PATIENT SAFETY;BEHAVIORAL AND SOCIAL SCIENCE;BIOMEDICAL IMAGING;BRAIN DISORDERS;CANCER;CARDIOVASCULAR;DENTAL/ORAL AND CRANIOFACIAL DISEASE;HEART DISEASE;LIVER CANCER","12;8;6;4;4;4;3;3;3;3;2;2;1;1;1;1;1;1;1;1","INFECTION;CARDIOVASCULAR;NEUROLOGICAL;CANCER;METABOLIC AND ENDOCRINE","4;2;2;1;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;3.1 PRIMARY PREVENTION INTERVENTIONS TO MODIFY BEHAVIOURS OR PROMOTE WELLBEING;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS","3;2;1;1;1;1","CLINICAL;BIOMEDICAL","10;1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH","23;1","LIVER CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;NOT SITE-SPECIFIC CANCER","3;1;1","3 GOOD HEALTH AND WELL BEING","2",26,4.46,360.04,15,67,0,1,10,0,7,0,0,8,0,20,6,0,0,0,0,0,0,24,1,1,26,0,0,0,0,0,0,0,0,0,"United States;Italy;Germany","8;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3210 NUTRITION AND DIETETICS;3212 OPHTHALMOLOGY AND OPTOMETRY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","26;17;14;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;DIGESTIVE DISEASES;PATIENT SAFETY;LUNG;LUNG CANCER;AGING;CARDIOVASCULAR;GENETICS;HEMATOLOGY;PREVENTION;ACQUIRED COGNITIVE IMPAIRMENT;AUTOIMMUNE DISEASE;BRAIN DISORDERS;COLO-RECTAL CANCER;DEMENTIA;NEURODEGENERATIVE;NEUROSCIENCES","25;18;16;7;6;6;4;4;3;3;3;3;3;2;2;2;2;2;2;2","CANCER;NEUROLOGICAL;CARDIOVASCULAR;INFECTION;INFLAMMATORY AND IMMUNE SYSTEM;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;RENAL AND UROGENITAL","14;2;1;1;1;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.2 CELLULAR AND GENE THERAPIES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.3 MEDICAL DEVICES","17;3;2;2;1;1;1","LUNG CANCER;COLON AND RECTAL CANCER;PANCREATIC CANCER;BLOOD CANCER;BREAST CANCER;HEAD AND NECK CANCER;LEUKEMIA / LEUKAEMIA;LIVER CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA;ORAL CAVITY AND LIP CANCER;PHARYNGEAL CANCER;PROSTATE CANCER;SALIVARY GLAND CANCER;SARCOMA","4;2;2;1;1;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","12;1;1;1;1"
"AOU_PISANA",2015,369,13.4850948509485,3.11653116531165,0.320869565217391,0.306233062330623,0.254742547425474,0.149051490514905,0.517615176151762,3,218,77,22,32,0.59,0.21,0.06,0.09,34.11,0.915214415413544,0.422764227642276,0.905149051490515,5.70465890183029,0.487255158649458,0.55842659644503,0.556571757262007,0.574193548387097,"ALFREDO FALCONE;FOTIOS LOUPAKIS;CHIARA CREMOLINI;GIUSEPPE APRILE;DANIELE SANTINI;STEFANO CASCINU;GIUSEPPE TONINI;ENRICO VASILE;SARA LONARDI;CATERINA VIVALDI;ANDREA MICHELOTTI;LISA SALVATORE;LISA DEROSA;GABRIELLA FONTANINI;MATTEO SANTONI;FRANCESCA BERGAMO;LORENZO FORNARO;ALBERTO ZANIBONI;MARTA SCHIRRIPA;GIANLUCA MASI","55;40;29;22;19;16;16;16;15;14;14;13;13;12;12;12;12;12;12;12","ALFREDO FALCONE;FOTIOS LOUPAKIS;CARMELO CHISARI;MARCO GAMBACCIANI;CHIARA CREMOLINI;MAURO CERVIGNI;MAURO FERRARI;VINCENZO FERRARI;GIUSEPPE APRILE;ENRICO VASILE;CATERINA VIVALDI;BRUNO ROSSI;MAURIZIA ROSSANA BRUNETTO;LISA DEROSA;ALESSANDRO CELI;GIOVANNI COLUCCIA;CLAUDIO MARCOCCI;PAOLO VITTI;DANIELE SANTINI;PAOLO PIAGGI","3.48;2.22;2.17;1.92;1.49;1.42;1.33;1.21;1.2;1.16;1.14;1.11;1.01;1;1;1;0.99;0.99;0.98;0.94","ALFREDO FALCONE;FOTIOS LOUPAKIS;CHIARA CREMOLINI;ENRICO VASILE;CATERINA VIVALDI;ANDREA MICHELOTTI;LISA SALVATORE;LISA DEROSA;GABRIELLA FONTANINI;LORENZO FORNARO;MARTA SCHIRRIPA;GIANLUCA MASI;G. PASQUINI;LUCA GALLI;DANIELE ROSSINI;GIANNA MUSETTINI;MAURIZIA ROSSANA BRUNETTO;CARLOTTA ANTONIOTTI;CHIARA CAPARELLO;CARMELO CHISARI","55;40;29;16;14;14;13;13;12;12;12;12;11;11;11;10;10;9;9;9","ALFREDO FALCONE;FOTIOS LOUPAKIS;CARMELO CHISARI;MARCO GAMBACCIANI;CHIARA CREMOLINI;MAURO FERRARI;VINCENZO FERRARI;ENRICO VASILE;CATERINA VIVALDI;BRUNO ROSSI;MAURIZIA ROSSANA BRUNETTO;LISA DEROSA;ALESSANDRO CELI;GIOVANNI COLUCCIA;CLAUDIO MARCOCCI;PAOLO VITTI;PAOLO PIAGGI;LORENZO FORNARO;G. PASQUINI;MARIA GRAZIA BONGIORNI","3.48;2.22;2.17;1.92;1.49;1.33;1.21;1.16;1.14;1.11;1.01;1;1;1;0.99;0.99;0.94;0.92;0.88;0.87","ALFREDO FALCONE;FOTIOS LOUPAKIS;CHIARA CREMOLINI;CARLOTTA ANTONIOTTI;SARA LONARDI;SALVATORE SIENA;GIUSEPPE TONINI;GABRIELLA FONTANINI;LUCA BONI;ANDREA SARTORE‐BIANCHI;CALOGERO LAURICELLA;CRISTINA GRANETTO;EMANUELE VALTORTA;PATRIZIA RACCA;SILVIA MARSONI;SILVIO VERONESE;ALBERTO ZANIBONI;ALESSIO AMATU;GIACOMO ALLEGRINI;CRISTIANA LUPI","3296;3036;2737;2078;1795;1696;1603;1485;1477;1392;1360;1241;1213;1213;1213;1213;1204;1105;1103;1093","ALFREDO FALCONE;FOTIOS LOUPAKIS;CHIARA CREMOLINI;CARLOTTA ANTONIOTTI;MARIA GRAZIA BONGIORNI;FRANCESCO MENICHETTI;CARMELO CHISARI;LISA SALVATORE;ANNA SONIA PETRONIO;MARTA SCHIRRIPA;GIANLUCA MASI;GIUSEPPE LAMOLA;NICCOLA FUNEL;CATERINA PROCOPIO;ANDREA MICHELOTTI;MARCO GAMBACCIANI;ANTONIO CHELLA;CARLO TASCINI;MAURIZIA ROSSANA BRUNETTO;ROBERTO MORETTO","3292;3036;2737;2078;932;543;506;456;380;370;350;310;296;286;269;262;257;251;241;236","ALFREDO FALCONE;FOTIOS LOUPAKIS;CHIARA CREMOLINI;ENRICO VASILE;ANDREA MICHELOTTI;CATERINA VIVALDI;LISA SALVATORE;LISA DEROSA;MARTA SCHIRRIPA;GIANLUCA MASI;LORENZO FORNARO;LUCA GALLI;G. PASQUINI;DANIELE ROSSINI;GIANNA MUSETTINI;CARLOTTA ANTONIOTTI;MARIA GRAZIA BONGIORNI;MAURIZIA ROSSANA BRUNETTO;CARMELO CHISARI;CHIARA CAPARELLO","51;40;29;16;14;14;13;13;12;12;11;11;11;10;10;9;9;9;9;9","MEDICINE;BIOLOGY;COMPUTER SCIENCE;CHEMISTRY;PSYCHOLOGY;PHYSICS;ENGINEERING;MATHEMATICS;PHILOSOPHY;ECONOMICS;MATERIALS SCIENCE;SOCIOLOGY;POLITICAL SCIENCE;GEOLOGY;BUSINESS;ENVIRONMENTAL SCIENCE;ART;GEOGRAPHY;HISTORY","358;87;34;24;24;23;18;14;10;6;6;6;4;3;2;2;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GASTROENTEROLOGY;GENETICS;CANCER RESEARCH;PATHOLOGY;ENVIRONMENTAL HEALTH;RADIOLOGY;CARDIOLOGY;PSYCHIATRY;BIOCHEMISTRY;ENDOCRINOLOGY;IMMUNOLOGY;PALEONTOLOGY;PEDIATRICS;PHYSICAL THERAPY;ARTIFICIAL INTELLIGENCE;INTENSIVE CARE MEDICINE;MECHANICAL ENGINEERING;NUCLEAR MEDICINE;PHYSICAL MEDICINE AND REHABILITATION;UROLOGY","289;133;106;75;49;44;39;38;37;33;28;24;22;22;19;16;16;15;15;13;13;13;13","CANCER;CHEMOTHERAPY;GENE;POPULATION;DISEASE;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;MULTIVARIATE ANALYSIS;ADVERSE EFFECT;PROPORTIONAL HAZARDS MODEL;RETROSPECTIVE COHORT STUDY;COHORT;HEPATOCELLULAR CARCINOMA;RADIATION THERAPY;ALTERNATIVE MEDICINE;CLINICAL TRIAL;HEART FAILURE;RECEPTOR;REGIMEN;STAGE (STRATIGRAPHY);THYROID","139;69;51;36;28;27;23;21;20;20;19;18;17;17;16;16;14;13;12;12;12","COLORECTAL CANCER;BREAST CANCER;BEVACIZUMAB;GENOTYPE;CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;HAZARD RATIO;GEMCITABINE;SORAFENIB;PANCREATIC CANCER;UNIVARIATE ANALYSIS;METASTASIS;PLACEBO;CHEMOTHERAPY REGIMEN;HEPATITIS B VIRUS;NEUTROPENIA;SUNITINIB;FLUOROURACIL;MUTATION;PERFORMANCE STATUS","69;30;28;24;23;21;19;13;13;12;12;11;9;8;8;8;8;7;7;7","KRAS;IRINOTECAN;SINGLE-NUCLEOTIDE POLYMORPHISM;METASTATIC BREAST CANCER;REGORAFENIB;CETUXIMAB;TRASTUZUMAB;OXALIPLATIN;HBSAG;PAZOPANIB;TAXANE;ANDROGEN RECEPTOR;BONE METASTASIS;CAPECITABINE;DISCOVERY AND DEVELOPMENT OF MTOR INHIBITORS;GEFITINIB;GENOTYPING;GONADOTROPIN-RELEASING HORMONE;MOLECULAR MEDICINE;ONCOGENE;PHARMACOGENETICS;RIBAVIRIN","24;21;14;13;13;11;9;8;6;5;4;3;3;3;3;3;3;3;3;3;3;3","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;COLORECTAL NEOPLASMS;TREATMENT OUTCOME;ITALY;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;ANTINEOPLASTIC AGENTS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;LIVER NEOPLASMS;YOUNG ADULT;BREAST NEOPLASMS;PROGNOSIS;RISK FACTORS;ADOLESCENT","202;163;158;150;115;110;101;66;54;51;47;46;35;34;34;30;29;25;25;24","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;PANCREATIC CANCER RESEARCH AND TREATMENT;RENAL CELL CARCINOMA;CHOLANGIOCARCINOMA;HEPATITIS B INFECTION AND TREATMENT;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;HEPATOCELLULAR CARCINOMA;HER2 SIGNALING IN BREAST CANCER TREATMENT;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN LUNG CANCER RESEARCH;ATRIAL FIBRILLATION;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;GLIOMAS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;PATHOPHYSIOLOGY AND MANAGEMENT OF GRAVES' OPHTHALMOPATHY;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;GASTRIC CANCER RESEARCH AND TREATMENT;MOLECULAR RESEARCH ON BREAST CANCER;PELVIC FLOOR DISORDERS","33;9;9;7;7;6;6;6;5;5;5;5;5;5;5;5;4;4;4;4","METASTATIC COLORECTAL CANCER;CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;FOLFIRI;TREATMENT;REGORAFENIB;KRAS MUTATIONS;REGIMEN;UNIVARIATE ANALYSIS;BREAST CANCER;CONCOMITANT;STROKE (ENGINE);CHEMOTHERAPY REGIMEN;BEVACIZUMAB;EGFR MUTATIONS;METASTATIC BREAST CANCER;BILIARY TRACT CANCER;GRAVES' OPHTHALMOPATHY;PERFORMANCE STATUS;RENAL CELL CARCINOMA","30;23;22;15;15;13;12;12;12;11;11;10;9;8;8;8;7;7;7;7","COLORECTAL CANCER;METASTATIC COLORECTAL;CANCER PATIENTS;BREAST CANCER;CANCER MCRC;METASTATIC BREAST;PATIENTS PTS;PANCREATIC CANCER;CELL CARCINOMA;RENAL CELL;PHASE III;PATIENTS RECEIVING;PATIENTS TREATED;CLINICAL OUTCOME;ELDERLY PATIENTS;MULTICENTER RETROSPECTIVE;ADVANCED BILIARY;ADVANCED PANCREATIC;ITALIAN ASSOCIATION;MCRC PATIENTS;METASTATIC RENAL;OBSERVATIONAL STUDY;TRIBE STUDY;ATRIAL FIBRILLATION;BILIARY TRACT;CARCINOMA MRCC;EUROPEAN HEART;FIRST-LINE CHEMOTHERAPY;HCC PATIENTS;HEART RHYTHM","49;35;27;22;13;13;13;12;11;11;9;8;8;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5","MARSEILLE FRANCE;HR CI;COLORECTAL CANCER;BREAST CANCER;MEDIAN PFS;VERSUS CTRL;FRANCE SEARCH;MEDIAN AGE;CANCER PATIENTS;CRCM MARSEILLE;SURVIVAL OS;HFD VERSUS;MEDIAN OS;PATIENTS TREATED;MONTHS CI;PROGRESSION-FREE SURVIVAL;ADVERSE EVENTS;CNRS UMR;METASTATIC COLORECTAL;SURVIVAL PFS;ECOG PS;VERSUS HFD;RESPONSE RATE;MEDIAN FOLLOW-UP;NICE FRANCE;CLINICAL OUTCOMES;DISEASE PROGRESSION;PISA ITALY;MCRC PATIENTS;PATIENTS PTS","68;45;44;40;40;40;38;35;34;34;34;32;31;31;30;30;29;28;26;25;24;23;22;21;21;20;20;20;19;19",111,0.3,1.75,30.08,7.05,109.7,24.11,2,91,2.54,1,4,1.25,1,3,1.43,1,2,2.78,1,11,2.17,1,3,0,0,0,1,1,1,27.43,2,97,1,1,1,1,1,1,19.46,1,85,1,1,1,1,1,1,1.93,1,6,4.7,1,15,13.04,1,63,3.79,1,16,0.18,0,3,0,0,0,146.32,0,718,146.5,0,721,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,12,4,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BERRETTINI STEFANO;DANTI SERENA;MARRAZZA STEFANO;STEFANINI CESARE","1;1;1;1","AZIENDA OSPEDALIERO UNIVERSITARIA PISANA","1","40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","2;1","BIOENGINEERING;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN","1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","A61F2/18;C12N5/00;C12N5/0775","1;1;1","A61F2002/183;A61F2240/001;A61L2430/14;A61L27/3604;A61L27/3645;A61L27/58;C12M21/08;C12M35/06;C12N2500/38;C12N2501/15","1;1;1;1;1;1;1;1;1;1",0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,5,"PUBLIC LIBRARY OF SCIENCE","5","32 BIOMEDICAL AND CLINICAL SCIENCES;34 CHEMICAL SCIENCES;3202 CLINICAL SCIENCES;3403 MACROMOLECULAR AND MATERIALS CHEMISTRY;3404 MEDICINAL AND BIOMOLECULAR CHEMISTRY","4;4;2;1;1","CANCER;DIGESTIVE DISEASES;HEPATITIS;HEPATITIS - B;INFECTIOUS DISEASES;KIDNEY DISEASE;LIVER DISEASE","1;1;1;1;1;1;1",NA,NA,"6.1 PHARMACEUTICALS","1","CLINICAL","1","CLINICAL MEDICINE AND SCIENCE","2","KIDNEY CANCER","1",NA,NA,53,4.76,888.35,33,110.43,1,1,8,0,23,0,3,17,0,41,8,0,0,0,0,0,0,52,1,0,49,4,0,0,0,0,0,0,0,0,"United States;Germany;Japan;Italy;Canada","12;5;5;4;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;4203 HEALTH SERVICES AND SYSTEMS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3203 DENTISTRY;3210 NUTRITION AND DIETETICS;3213 PAEDIATRICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4206 PUBLIC HEALTH","47;22;20;5;4;4;3;3;3;2;2;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;DIGESTIVE DISEASES;LUNG;PATIENT SAFETY;RARE DISEASES;CARDIOVASCULAR;LUNG CANCER;HEART DISEASE;NEUROSCIENCES;BRAIN DISORDERS;AUTOIMMUNE DISEASE;BIOENGINEERING;NEURODEGENERATIVE;NUTRITION;TRANSPLANTATION;AGING;BRAIN CANCER;HEMATOLOGY","49;35;22;10;9;9;9;8;8;7;7;6;4;4;4;4;4;3;3;3","CANCER;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;ORAL AND GASTROINTESTINAL;EYE;NEUROLOGICAL;INFLAMMATORY AND IMMUNE SYSTEM;RESPIRATORY;SKIN;STROKE","19;8;3;3;2;2;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.3 MEDICAL DEVICES;6.3 MEDICAL DEVICES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.7 PHYSICAL","36;4;2;2;2;1;1;1","LUNG CANCER;COLON AND RECTAL CANCER;BRAIN TUMOR;LEUKEMIA / LEUKAEMIA;PANCREATIC CANCER;BREAST CANCER;MYELOMA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;STOMACH CANCER","8;4;2;2;2;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","21;1"
"AOU_PISANA",2016,413,14.9418886198547,3.43583535108959,0.291050035236082,0.348668280871671,0.319612590799031,0.196125907990315,0.535108958837772,3,253,85,38,19,0.61,0.21,0.09,0.05,29.24,0.90022847752794,0.387409200968523,0.898305084745763,5.41873669268985,0.497732391118866,0.534025273917457,0.539651649314002,0.532105635046812,"ALFREDO FALCONE;FOTIOS LOUPAKIS;CHIARA CREMOLINI;GIANLUCA MASI;SARA LONARDI;LUCA GALLI;FRANCESCA BERGAMO;LISA SALVATORE;ALBERTO ZANIBONI;HEINZ‐JOSEF LENZ;ENRICO VASILE;ANDREA ANTONUZZO;MARTA SCHIRRIPA;FILIPPO PIETRANTONIO;ANDREA MICHELOTTI;CATERINA VIVALDI;GABRIELLA FONTANINI;FRANCESCA BATTAGLIN;FEDERICA MARMORINO;GIANNA MUSETTINI","66;32;31;28;21;20;19;18;16;15;15;14;14;14;14;13;12;12;12;12","ALFREDO FALCONE;SOHAIL BAKKAR;CHIARA CREMOLINI;GIANLUCA MASI;LUCA GALLI;FOTIOS LOUPAKIS;ANDREA ANTONUZZO;LISA SALVATORE;PAOLO PERRINI;ENRICO VASILE;IACOPO DALLAN;FULVIO BASOLO;PAOLO VITTI;LUCA BRUSCHINI;SARA LONARDI;CLARA UGOLINI;RICCARDO LIGA;CLAUDIO MARCOCCI;FRANCESCA MENICHETTI;CARLO TASCINI","4.88;2.81;1.85;1.78;1.67;1.6;1.45;1.4;1.36;1.27;1.26;1.2;1.1;1.09;1.07;1.07;1.06;1.06;1.05;1.04","ALFREDO FALCONE;FOTIOS LOUPAKIS;CHIARA CREMOLINI;GIANLUCA MASI;LUCA GALLI;LISA SALVATORE;ENRICO VASILE;ANDREA ANTONUZZO;MARTA SCHIRRIPA;ANDREA MICHELOTTI;CATERINA VIVALDI;GABRIELLA FONTANINI;FEDERICA MARMORINO;GIANNA MUSETTINI;PAOLO VITTI;DANIELE ROSSINI;CLAUDIO MARCOCCI;MICHELE MARINÒ;ROBERTO MORETTO;UGO BOGGI","66;32;31;28;20;18;15;14;14;14;13;12;12;12;11;11;11;10;10;10","ALFREDO FALCONE;SOHAIL BAKKAR;CHIARA CREMOLINI;GIANLUCA MASI;LUCA GALLI;FOTIOS LOUPAKIS;ANDREA ANTONUZZO;LISA SALVATORE;PAOLO PERRINI;ENRICO VASILE;IACOPO DALLAN;FULVIO BASOLO;PAOLO VITTI;LUCA BRUSCHINI;CLARA UGOLINI;RICCARDO LIGA;CLAUDIO MARCOCCI;FRANCESCA MENICHETTI;CARLO TASCINI;PAOLO MARZULLO","4.88;2.81;1.85;1.78;1.67;1.6;1.45;1.4;1.36;1.27;1.26;1.2;1.1;1.09;1.07;1.06;1.06;1.05;1.04;1","GIANLUCA MASI;ALESSANDRO GRANITO;ANNETTE BAUMHAUER;G. BODOKY;ISABELLE OLLIVIER‐HOURMAND;JORDI BRUIX;MASATOSHI KUDO;OLIVIER ROSMORDUC;OSAMU YOKOSUKA;PHILIPPE MERLE;RENÉ GÉROLAMI;SHUKUI QIN;TIANQIANG SONG;YI‐HSIANG HUANG;В. В. БРЕДЕР;GUOHONG HAN;PAUL J. ROSS;ANN‐LII CHENG;GEROLD MEINHARDT;JEAN-PIERRE BRONOWICKI","3405;3158;3158;3158;3158;3158;3158;3158;3158;3158;3158;3158;3158;3158;3158;3119;3119;3109;3109;3109","GIANLUCA MASI;ALFREDO FALCONE;CHIARA CREMOLINI;MAURIZIA ROSSANA BRUNETTO;FOTIOS LOUPAKIS;UGO FARAGUNA;ANNA SONIA PETRONIO;LUCA GALLI;ENRICO VASILE;RODOLFO SACCO;RICCARDO LIGA;IACOPO DALLAN;MARIA A. CALIGO;LISA DEROSA;CLAUDIO MARCOCCI;FULVIO BASOLO;MICHELE MARINÒ;PAOLO VITTI;FEDERICA MARMORINO;LUCA BRUSCHINI","3405;649;554;502;340;310;298;293;287;284;266;265;258;252;246;242;230;228;223;214","ALFREDO FALCONE;CHIARA CREMOLINI;GIANLUCA MASI;LUCA GALLI;FOTIOS LOUPAKIS;LISA SALVATORE;ENRICO VASILE;ANDREA ANTONUZZO;ANDREA MICHELOTTI;FEDERICA MARMORINO;GIANNA MUSETTINI;ANNA SONIA PETRONIO;MICHELE MARINÒ;DANIELE ROSSINI;ROBERTO MORETTO;CATERINA VIVALDI;IACOPO DALLAN;ANTONIO CHELLA;RODOLFO SACCO;UGO BOGGI","64;31;28;19;18;18;15;14;14;12;12;11;10;10;10;9;9;9;9;9","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;CHEMISTRY;MATHEMATICS;ENGINEERING;PSYCHOLOGY;MATERIALS SCIENCE;ECONOMICS;POLITICAL SCIENCE;PHILOSOPHY;SOCIOLOGY;ART;GEOLOGY;GEOGRAPHY;HISTORY","398;106;41;27;23;18;16;16;12;10;10;7;6;3;3;2;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GASTROENTEROLOGY;PATHOLOGY;GENETICS;RADIOLOGY;ENVIRONMENTAL HEALTH;CARDIOLOGY;CANCER RESEARCH;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;ENDOCRINOLOGY;IMMUNOLOGY;OPTICS;PEDIATRICS;NUCLEAR MEDICINE;PALEONTOLOGY;ANESTHESIA;FAMILY MEDICINE","320;132;126;91;74;53;48;47;42;32;31;26;25;25;20;19;17;17;16;13","CANCER;CHEMOTHERAPY;GENE;POPULATION;CONFIDENCE INTERVAL;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;CLINICAL TRIAL;ALTERNATIVE MEDICINE;COHORT;THYROID;DISEASE;RETROSPECTIVE COHORT STUDY;REGIMEN;HEPATOCELLULAR CARCINOMA;PROPORTIONAL HAZARDS MODEL;INCIDENCE (GEOMETRY);MULTIVARIATE ANALYSIS;STENOSIS;HEART FAILURE;LUNG;STAGE (STRATIGRAPHY)","156;77;54;46;32;32;28;23;21;21;21;19;19;18;17;17;16;14;14;12;12;12","COLORECTAL CANCER;BEVACIZUMAB;BREAST CANCER;CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;GENOTYPE;PLACEBO;HAZARD RATIO;NEUTROPENIA;PROSTATE CANCER;METASTASIS;THYROID CARCINOMA;EJECTION FRACTION;MUTATION;PHASES OF CLINICAL RESEARCH;THYROID CANCER;UNIVARIATE ANALYSIS;ALLELE;GEMCITABINE;PERFORMANCE STATUS;SORAFENIB","69;35;33;30;23;22;18;17;17;14;12;10;9;9;9;9;8;7;7;7;7","IRINOTECAN;OXALIPLATIN;SINGLE-NUCLEOTIDE POLYMORPHISM;CETUXIMAB;FEBRILE NEUTROPENIA;CAPECITABINE;KRAS;REGORAFENIB;METASTATIC BREAST CANCER;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;TRASTUZUMAB;ANDROGEN RECEPTOR;HORMONAL THERAPY;ANDROGEN DEPRIVATION THERAPY;AROMATASE;FRACTIONAL ANISOTROPY;CARBOPLATIN;EPIRUBICIN;FORMOTEROL;GENOTYPING;GERMLINE MUTATION;GRAVES' OPHTHALMOPATHY;KLEBSIELLA PNEUMONIAE;ONCOGENE;PLEURAL DISEASE;PRIMARY TUMOR;RIBAVIRIN","19;15;15;12;11;10;9;9;7;6;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3","HUMANS;;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;AGED, 80 AND OVER;COLORECTAL NEOPLASMS;TREATMENT OUTCOME;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;RETROSPECTIVE STUDIES;LIVER NEOPLASMS;THYROID NEOPLASMS;PROSPECTIVE STUDIES;LUNG NEOPLASMS;AORTIC VALVE STENOSIS;YOUNG ADULT;BREAST NEOPLASMS","216;195;157;154;116;108;86;66;51;49;49;45;36;34;34;32;30;29;27;25","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;MANAGEMENT OF VALVULAR HEART DISEASE;HEPATOCELLULAR CARCINOMA;EPIDEMIOLOGY AND MANAGEMENT OF NEUROENDOCRINE TUMORS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ADVANCEMENTS IN LUNG CANCER RESEARCH;GASTRIC CANCER RESEARCH AND TREATMENT;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;MOLECULAR RESEARCH ON BREAST CANCER;PANCREATIC CANCER RESEARCH AND TREATMENT;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;DIAGNOSIS AND MANAGEMENT OF FUNGAL INFECTIONS;ENDOSCOPIC SKULL BASE SURGERY TECHNIQUES;PATHOPHYSIOLOGY AND MANAGEMENT OF GRAVES' OPHTHALMOPATHY;RENAL CELL CARCINOMA;CANCER IMMUNOTHERAPY;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;GENETIC RESEARCH ON BRCA MUTATIONS AND CANCER RISK","43;14;13;11;10;7;7;7;6;6;6;5;5;5;5;5;5;4;4;4","METASTATIC COLORECTAL CANCER;CLINICAL ENDPOINT;PROGRESSION-FREE SURVIVAL;BREAST CANCER;TREATMENT;REGIMEN;FOLFIRI;TRANSCATHETER AORTIC-VALVE REPLACEMENT;CARDIAC IMAGING;PROSTHETIC VALVES EVALUATION;CONCOMITANT;EVEROLIMUS;METASTATIC GASTRIC CANCER;METASTATIC PROSTATE CANCER;PANCREATIC NEUROENDOCRINE TUMORS;REFRACTORY (PLANETARY SCIENCE);REGORAFENIB;FOLFOX;LIVER CANCER;METASTATIC PANCREATIC CANCER","43;30;23;19;19;18;11;11;10;10;9;9;9;9;9;9;9;8;8;8","COLORECTAL CANCER;METASTATIC COLORECTAL;BREAST CANCER;CANCER PATIENTS;CANCER MCRC;PATIENTS PTS;PHASE II;PROSTATE CANCER;HEPATOCELLULAR CARCINOMA;PATIENTS TREATED;BEVACIZUMAB BEV;AORTIC VALVE;GASTRIC CANCER;LOCALLY ADVANCED;CLINICAL OUTCOME;POOLED ANALYSIS;RECOURSE TRIAL;TRANSCATHETER AORTIC;CLINICAL PRACTICE;GRAVES ORBITOPATHY;MCRC PATIENTS;METASTATIC RENAL;NEUROENDOCRINE TUMORS;PANCREATIC CANCER;PHASE III;RENAL CELL;ADVANCED GASTRIC;CANCER RISK;CASTRATION-RESISTANT PROSTATE;CELL CARCINOMA","46;43;23;22;18;14;13;13;10;10;9;8;8;8;7;7;7;7;6;6;6;6;6;6;6;6;5;5;5;5","MEDIAN PFS;HR CI;BREAST CANCER;ADVERSE EVENTS;MONTHS NA;PATIENTS PTS;PROGRESSION-FREE SURVIVAL;SURVIVAL PFS;ARM AB;COLORECTAL CANCER;MEDIAN AGE;SURVIVAL OS;MCRC PATIENTS;PTS RECEIVED;LDH LEVELS;PRIMARY ENDPOINT;MEDICAL ONCOLOGY;MEDIAN OS;METASTATIC COLORECTAL;MULTIVARIATE ANALYSIS;ECOG PS;MO CI;USA DEPARTMENT;LUNG METASTASES;RESPONSE RATE;CLINICAL PRACTICE;CONFIDENCE INTERVAL;MONTHS CI;MCRC PTS;NORMOGLYCEMIC PTS","51;48;43;42;33;31;31;29;28;28;28;28;27;27;26;25;24;23;23;22;21;21;21;20;20;19;18;18;17;17",123,0.3,1.6,58.14,7.75,564.066,20.26,3,111,2.06,1,7,2.43,1,10,3,1,7,8.36,1,64,2.6,1,4,0,0,0,1.83,1,4,25.71,3,133,0,0,0,0,0,0,11.7,1,52,1,1,1,1.5,1,3,1.67,1,5,3.22,1,15,8.22,1,32,2.55,1,7,0.1,0,2,0,0,0,144.84,24,1197,144.94,24,1197,4,0,2,4,1,0,0,0,0,0,0,0,6,0,1,6,4.14285714285714,1.42857142857143,0,3,5,0,0,1,0,1,1,0,0,1,0,0,3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,6,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BERRETTINI STEFANO;DANTI SERENA;STEFANINI CESARE;MARRAZZA STEFANO;CEMPINI MARCO;GIOVACCHINI FRANCESCO;VITIELLO NICOLA;BRUSCHINI LUCA;CIREGIA FEDERICA;CORTESE MARIO","4;4;4;3;2;2;2;1;1;1","AZIENDA OSPEDALIERO UNIVERSITARIA PISANA;AZIENDA OSPEDALIERA PISANA;SCUOLA SUPERIORE S ANNA;UNIVERSITÀ DI PISA","5;2;2;1","40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;32 BIOMEDICAL AND CLINICAL SCIENCES;49 MATHEMATICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4904 PURE MATHEMATICS","7;3;2;2;1;1;1;1","BIOENGINEERING;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN;ASSISTIVE TECHNOLOGY;CANCER;RARE DISEASES;REHABILITATION","3;3;2;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);5.3 MEDICAL DEVICES","3;1;1;1","A61F2/18;C12N5/0775;C12N5/00;A61H1/02;A61L27/36;A61L27/58;C12M1/42;C12M3/00;G01N33/574;H04R25/00","3;3;2;1;1;1;1;1;1;1","A61F2002/183;A61F2240/001;A61L2430/14;A61L27/3604;A61L27/3645;A61L27/58;C12M21/08;C12M35/06;C12N2500/38;C12N2501/15","4;3;3;3;3;3;3;3;3;3",0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,21,"PUBLIC LIBRARY OF SCIENCE;TAYLOR & FRANCIS GROUP","20;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;3213 PAEDIATRICS;40 ENGINEERING;4203 HEALTH SERVICES AND SYSTEMS;44 HUMAN SOCIETY;4403 DEMOGRAPHY;51 PHYSICAL SCIENCES;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY","18;8;4;4;4;2;1;1;1;1;1;1;1;1","CANCER;GENETICS;RARE DISEASES;BREAST CANCER;CLINICAL RESEARCH;DIGESTIVE DISEASES;HUMAN GENOME;INFANT MORTALITY;LIVER CANCER;LIVER DISEASE;LUNG;NEONATAL RESPIRATORY DISTRESS;OVARIAN CANCER;PEDIATRIC;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;PRETERM, LOW BIRTH WEIGHT AND HEALTH OF THE NEWBORN;PREVENTION","3;3;3;2;2;1;1;1;1;1;1;1;1;1;1;1;1","CANCER;REPRODUCTIVE HEALTH AND CHILDBIRTH","2;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.1 PHARMACEUTICALS","4;2;1","BIOMEDICAL","1","BASIC SCIENCE;CLINICAL MEDICINE AND SCIENCE;HEALTH SERVICES RESEARCH","2;2;1","OVARIAN CANCER;BREAST CANCER;GENITAL SYSTEM, FEMALE;LIVER CANCER","3;2;1;1","14 LIFE BELOW WATER;3 GOOD HEALTH AND WELL BEING","1;1",46,4.47,574.42,22,63.72,1,0,10,1,14,0,5,15,0,28,8,0,0,0,0,0,0,43,3,0,36,10,0,0,0,0,0,0,0,0,"United States;Italy;Switzerland;Germany;Japan;United Kingdom","8;5;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3203 DENTISTRY;42 HEALTH SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;4201 ALLIED HEALTH AND REHABILITATION SCIENCE;4203 HEALTH SERVICES AND SYSTEMS;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3215 REPRODUCTIVE MEDICINE;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;46 INFORMATION AND COMPUTING SCIENCES;51 PHYSICAL SCIENCES;5105 MEDICAL AND BIOLOGICAL PHYSICS","42;21;13;7;7;5;4;3;2;2;2;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;NEUROSCIENCES;RARE DISEASES;DIGESTIVE DISEASES;DENTAL/ORAL AND CRANIOFACIAL DISEASE;BRAIN DISORDERS;INFECTIOUS DISEASES;NEURODEGENERATIVE;ASSISTIVE TECHNOLOGY;AUTOIMMUNE DISEASE;BIOENGINEERING;CARDIOVASCULAR;PATIENT SAFETY;DIABETES;REHABILITATION;AGING;BEHAVIORAL AND SOCIAL SCIENCE;BREAST CANCER","37;26;10;8;8;7;6;5;5;5;4;4;4;4;4;3;3;2;2;2","CANCER;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;INFLAMMATORY AND IMMUNE SYSTEM;STROKE;RENAL AND UROGENITAL;RESPIRATORY;SKIN","11;5;4;4;3;2;2;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.3 MEDICAL DEVICES;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;6.7 PHYSICAL;8.1 ORGANISATION AND DELIVERY OF SERVICES","27;3;2;2;1;1;1;1;1","BREAST CANCER;LIVER CANCER;BRAIN TUMOR;COLON AND RECTAL CANCER;HEAD AND NECK CANCER;LUNG CANCER;MELANOMA;ORAL CAVITY AND LIP CANCER;PANCREATIC CANCER;PHARYNGEAL CANCER;SARCOMA;STOMACH CANCER","4;2;1;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;1.4 CANCER PROGRESSION AND METASTASIS;2.2 ENDOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","7;2;1;1;1;1;1;1"
"AOU_PISANA",2017,429,14.3752913752914,3.18181818181818,0.314285714285714,0.319347319347319,0.305361305361305,0.172494172494172,0.606060606060606,1,261,85,40,24,0.61,0.2,0.09,0.06,20.81,0.705903568351032,0.34032634032634,0.916083916083916,5.65579937304076,0.476702383198562,0.517743192300402,0.516674897119342,0.518236074270557,"ALFREDO FALCONE;GABRIELLA FONTANINI;CHIARA CREMOLINI;LORENZO FORNARO;FILIPPO PIETRANTONIO;DANIELE SANTINI;FOTIOS LOUPAKIS;ENRICO VASILE;DANIELE ROSSINI;ANTONIO CHELLA;LUCA GALLI;UGO DE GIORGI;CATERINA VIVALDI;GRETA ALÌ;PAOLO VITTI;SARA LONARDI;GIANLUCA MASI;FEDERICA MORANO;CARLOTTA ANTONIOTTI;CHIARA CAPARELLO","53;27;25;18;18;18;17;17;16;15;15;14;13;13;12;12;12;12;12;12","ALFREDO FALCONE;GABRIELLA FONTANINI;FABIO GUARRACINO;LORENZO FORNARO;ALFREDO MUSSI;GRETA ALÌ;PAOLO VITTI;ANTONIO CHELLA;PAOLO MICCOLI;ENRICO VASILE;RICCARDO LIGA;CHIARA CREMOLINI;CLAUDIO MARCOCCI;ROSSELLA BRUNO;MARCO LUCCHI;FRANCA MELFI;CHIARA CAPARELLO;GABRIELE NALDINI;SOHAIL BAKKAR;ALESSANDRO ANTONELLI","3.45;2.55;1.79;1.66;1.52;1.51;1.45;1.43;1.41;1.34;1.29;1.22;1.21;1.16;1.14;1.13;1.07;1.06;1.04;1","ALFREDO FALCONE;GABRIELLA FONTANINI;CHIARA CREMOLINI;LORENZO FORNARO;FOTIOS LOUPAKIS;ENRICO VASILE;DANIELE ROSSINI;ANTONIO CHELLA;LUCA GALLI;CATERINA VIVALDI;GRETA ALÌ;PAOLO VITTI;GIANLUCA MASI;CARLOTTA ANTONIOTTI;CHIARA CAPARELLO;ALFREDO MUSSI;FEDERICA MARMORINO;MARTA SCHIRRIPA;ANNA SONIA PETRONIO;CLAUDIO MARCOCCI","53;27;25;18;17;17;16;15;15;13;13;12;12;12;12;12;11;11;10;10","ALFREDO FALCONE;GABRIELLA FONTANINI;FABIO GUARRACINO;LORENZO FORNARO;ALFREDO MUSSI;GRETA ALÌ;PAOLO VITTI;ANTONIO CHELLA;PAOLO MICCOLI;ENRICO VASILE;RICCARDO LIGA;CHIARA CREMOLINI;CLAUDIO MARCOCCI;MARCO LUCCHI;FRANCA MELFI;CHIARA CAPARELLO;GABRIELE NALDINI;SOHAIL BAKKAR;ALESSANDRO ANTONELLI;LAURA CARROZZI","3.45;2.55;1.79;1.66;1.52;1.51;1.45;1.43;1.41;1.34;1.29;1.22;1.21;1.14;1.13;1.07;1.06;1.04;1;0.97","MARIA A. CALIGO;ANDERS BOJESEN;ANGELA BROOKS‐WILSON;ANGELA R. BRADBURY;BERNARDO BONANNI;CAROLE BREWER;CORA M. AALFS;DANIEL BARROWDALE;HODA ANTON‐CULVER;IAN CAMPBELL;IRENE L. ANDRULIS;JACKIE COOK;JACOPO AZZOLLINI;JAVIER BENÍTEZ;JOAN BRUNET;JOCELYNE CHIQUETTE;JOE DENNIS;JONATHAN BEESLEY;JUDITH BALMAÑÀ;JULIAN ADLARD","787;770;770;770;770;770;770;770;770;770;770;770;770;770;770;770;770;770;770;770","MARIA A. CALIGO;CHIARA CREMOLINI;ALFREDO FALCONE;ANNA SONIA PETRONIO;MARIA GRAZIA BONGIORNI;FABIO GUARRACINO;SIMONE LORENZO ROMANO;CARLOTTA ANTONIOTTI;CARMELO CHISARI;FRANCESCO MENICHETTI;CRISTINA GIANNINI;PIERO MARCHETTI;IACOPO DALLAN;CHIARA FANCIULLACCI;FABIO FALASCHI;FRANCESCO PISTELLI;LAURA CARROZZI;MAURIZIA ROSSANA BRUNETTO;FEDERICA BERTOLUCCI;MARCO BUGLIANI","787;691;450;436;415;395;390;388;381;324;297;291;289;287;287;287;287;280;279;266","ALFREDO FALCONE;CHIARA CREMOLINI;LORENZO FORNARO;ENRICO VASILE;ANNA SONIA PETRONIO;LUCA GALLI;ANTONIO CHELLA;DANIELE ROSSINI;CARLOTTA ANTONIOTTI;GIANLUCA MASI;FEDERICA MARMORINO;ALFREDO MUSSI;GRETA ALÌ;CHIARA CAPARELLO;FRANCA MELFI;ROBERTO MORETTO;BEATRICE BORELLI;CLAUDIO MARCOCCI;MARCO DE CARLO;MAURIZIA ROSSANA BRUNETTO","47;25;18;17;15;15;15;14;12;12;11;10;10;9;9;9;9;9;9;9","MEDICINE;BIOLOGY;PHYSICS;CHEMISTRY;COMPUTER SCIENCE;PSYCHOLOGY;ENGINEERING;MATHEMATICS;MATERIALS SCIENCE;PHILOSOPHY;ECONOMICS;GEOLOGY;POLITICAL SCIENCE;SOCIOLOGY;ART;HISTORY;GEOGRAPHY;ENVIRONMENTAL SCIENCE","404;119;31;26;26;24;19;16;9;6;5;5;4;4;3;3;2;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GENETICS;CARDIOLOGY;GASTROENTEROLOGY;PATHOLOGY;CANCER RESEARCH;BIOCHEMISTRY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;PSYCHIATRY;RADIOLOGY;IMMUNOLOGY;INTENSIVE CARE MEDICINE;NEUROSCIENCE;OPTICS;PALEONTOLOGY;PEDIATRICS;PHYSICAL THERAPY","329;144;106;68;65;65;58;48;37;34;28;24;24;21;21;18;17;17;16;15","CANCER;GENE;CHEMOTHERAPY;ADVERSE EFFECT;CLINICAL TRIAL;POPULATION;COHORT;LUNG CANCER;CONFIDENCE INTERVAL;DISEASE;HEPATOCELLULAR CARCINOMA;RANDOMIZED CONTROLLED TRIAL;OVERALL SURVIVAL;MYOCARDIAL INFARCTION;REGIMEN;PROPORTIONAL HAZARDS MODEL;ALTERNATIVE MEDICINE;HEART FAILURE;INCIDENCE (GEOMETRY);RECEPTOR;RETROSPECTIVE COHORT STUDY;STENOSIS;THYROID","147;68;47;27;27;27;26;24;23;20;20;19;17;16;16;15;13;13;13;13;13;13;13","COLORECTAL CANCER;BREAST CANCER;ADENOCARCINOMA;PROGRESSION-FREE SURVIVAL;CLINICAL ENDPOINT;GENOTYPE;BEVACIZUMAB;MUTATION;HAZARD RATIO;PROSTATE CANCER;GENE EXPRESSION;PANCREATIC CANCER;SORAFENIB;DOCETAXEL;PLACEBO;MICRORNA;PHASES OF CLINICAL RESEARCH;VALVE REPLACEMENT;THYROID CANCER;EJECTION FRACTION;EPIDERMAL GROWTH FACTOR RECEPTOR;PREDICTIVE MARKER","63;25;20;20;19;18;16;15;14;12;11;11;11;10;10;9;9;9;8;7;7;7","IRINOTECAN;KRAS;CETUXIMAB;OXALIPLATIN;REGORAFENIB;ROS1;ANDROGEN RECEPTOR;METASTATIC BREAST CANCER;SINGLE-NUCLEOTIDE POLYMORPHISM;ANDROGEN DEPRIVATION THERAPY;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;CRIZOTINIB;CAPECITABINE;EGFR INHIBITORS;NIVOLUMAB;PHARMACOGENETICS;RIBAVIRIN;TRANSCRIPTOME;TRASTUZUMAB;CARBOPLATIN;GENOTYPING;GERMLINE MUTATION;MEK INHIBITOR;MICROSATELLITE;MISSENSE MUTATION;ONCOGENE;PANCREATIC DUCTAL ADENOCARCINOMA;PAPILLARY THYROID CANCER;PARATHYROIDECTOMY;POINT MUTATION;SANGER SEQUENCING;TAXANE;TRAMETINIB;VEMURAFENIB","20;12;11;11;11;11;10;10;10;7;7;5;4;4;4;4;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3;3;3;3",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;AGED, 80 AND OVER;COLORECTAL NEOPLASMS;RETROSPECTIVE STUDIES;POSTOPERATIVE COMPLICATIONS;TREATMENT OUTCOME;LIVER NEOPLASMS;LUNG NEOPLASMS;AORTIC VALVE STENOSIS;CARCINOMA, HEPATOCELLULAR;PROGNOSIS;PROSPECTIVE STUDIES;RISK FACTORS","228;197;155;145;106;97;70;61;49;43;39;37;36;34;33;29;29;29;27;27","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;MANAGEMENT OF VALVULAR HEART DISEASE;ADVANCEMENTS IN LUNG CANCER RESEARCH;HEPATOCELLULAR CARCINOMA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;DIAGNOSIS AND TREATMENT OF LUNG CANCER;GASTRIC CANCER RESEARCH AND TREATMENT;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;HEPATITIS C INFECTION AND TREATMENT;PANCREATIC CANCER RESEARCH AND TREATMENT;CEREBELLAR CONTRIBUTIONS TO NEUROLOGICAL DISORDERS AND FUNCTIONS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;PERIOPERATIVE CARDIAC RISK ASSESSMENT AND MANAGEMENT;ATRIAL FIBRILLATION;PATHOPHYSIOLOGY AND MANAGEMENT OF GRAVES' OPHTHALMOPATHY;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;RENAL CELL CARCINOMA;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ANORECTAL SURGICAL PROCEDURES","31;16;12;11;10;8;8;8;7;7;7;6;6;6;5;5;5;5;4;4","METASTATIC COLORECTAL CANCER;PROGRESSION-FREE SURVIVAL;CLINICAL ENDPOINT;TREATMENT;REGIMEN;TRANSCATHETER AORTIC-VALVE REPLACEMENT;EGFR MUTATIONS;PROSTHETIC VALVES EVALUATION;REGORAFENIB;BREAST CANCER;CARDIAC IMAGING;ENZALUTAMIDE;FOLFIRI;HEPATOCELLULAR CARCINOMA;MALIGNANT PLEURAL MESOTHELIOMA;VALVE REPLACEMENT;FOLFIRINOX;METASTATIC PANCREATIC CANCER;STROKE (ENGINE);SURGICAL AORTIC-VALVE REPLACEMENT","25;20;19;17;16;15;11;11;11;10;10;9;9;9;9;9;8;8;8;8","COLORECTAL CANCER;METASTATIC COLORECTAL;PATIENTS PTS;CANCER PATIENTS;BREAST CANCER;AORTIC VALVE;CANCER MCRC;LUNG CANCER;PATIENTS TREATED;PROSTATE CANCER;HEPATOCELLULAR CARCINOMA;TRANSCATHETER AORTIC;CELL CARCINOMA;LEFT VENTRICULAR;PANCREATIC CANCER;VALVE REPLACEMENT;CANCER MCRPC;CASTRATION-RESISTANT PROSTATE;CLINICAL OUTCOMES;METASTATIC BREAST;METASTATIC CASTRATION-RESISTANT;ADVANCED PANCREATIC;LUNG ADENOCARCINOMA;SECOND-LINE TREATMENT;CLINICAL OUTCOME;CLINICAL PRACTICE;COHORT STUDY;EXPANDED ACCESS;GASTRIC CANCER;METASTATIC RENAL","35;30;22;19;17;16;13;13;13;13;12;11;9;9;9;9;8;8;8;8;8;7;7;7;6;6;6;6;6;6","HR CI;LUNG CANCER;SURVIVAL OS;ADVERSE EVENTS;COLORECTAL CANCER;PROGRESSION-FREE SURVIVAL;PATIENTS TREATED;MCRC PATIENTS;PTS TREATED;METASTATIC COLORECTAL;BREAST CANCER;RESPONSE RATE;MEDIAN AGE;SURVIVAL PFS;CLINICAL PRACTICE;PATIENTS PTS;PATIENTS RECEIVING;CANCER PATIENTS;VERSUS MONTHS;EGFR GCN;GENE EXPRESSION;DISEASE CONTROL;IVS GA;MEDIAN OS;PRIMARY ENDPOINT;SIGNIFICANT DIFFERENCE;STATISTICALLY SIGNIFICANT;LIVER DISEASE;RISK FACTORS;UNIVERSITY HOSPITAL","46;33;33;30;29;29;26;25;25;22;21;21;20;20;19;19;19;17;17;16;16;15;15;15;15;15;15;14;14;14",131,0.31,1.85,30.13,5.7,289.66,25.48,2,278,4.53,1,28,1.25,1,2,1.2,1,2,4.86,1,19,1.67,1,3,0,0,0,1.25,1,2,29.76,2,330,1,1,1,1,1,1,24.89,1,227,1,1,1,1,1,1,1.85,1,5,4.95,1,40,17.41,1,160,4.11,1,21,0.12,0,2,0,0,0,90.64,12,301,90.76,12,301,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PISANA",2018,491,16.091649694501,3.18940936863544,0.313537675606641,0.289205702647658,0.30142566191446,0.181262729124236,0.543788187372709,1,264,116,39,33,0.54,0.24,0.08,0.07,24.53,0.804096098247508,0.380855397148676,0.90224032586558,5.43592552026286,0.477922141659222,0.514670868347339,0.503037792194419,0.515523752733055,"ALFREDO FALCONE;CHIARA CREMOLINI;GIANLUCA MASI;FOTIOS LOUPAKIS;FILIPPO PIETRANTONIO;SARA LONARDI;CARLOTTA ANTONIOTTI;DANIELE SANTINI;MARIA GRAZIA BONGIORNI;FRANCESCA BERGAMO;VITTORINA ZAGONEL;DANIELE ROSSINI;LUCA SEGRETI;MAURIZIA ROSSANA BRUNETTO;PAOLO VITTI;FEDERICA MARMORINO;LORENZO FORNARO;CATERINA VIVALDI;FEDERICA MORANO;ENRICO VASILE","54;37;24;23;22;21;19;18;17;17;15;15;15;15;14;14;14;14;14;14","ALFREDO FALCONE;CHIARA CREMOLINI;PAOLO VITTI;LUCA SEGRETI;FOTIOS LOUPAKIS;FRANCA MELFI;SIMONA BARNINI;MARIA GRAZIA BONGIORNI;DAVIDE CARAMELLA;ALESSIA GIULIANO;ANDREA FONTANA;GIANLUCA MASI;SARA RICCIARDI;NICCOLA FUNEL;FILIPPO PIETRANTONIO;GABRIELE NALDINI;LUCA MORELLI;ENRICO VASILE;SARA LONARDI;FULVIO BASOLO","3.3;2.02;1.64;1.39;1.36;1.32;1.27;1.26;1.22;1.2;1.19;1.16;1.12;1.11;1.1;1.1;1.07;1.05;1.04;1.03","ALFREDO FALCONE;CHIARA CREMOLINI;GIANLUCA MASI;FOTIOS LOUPAKIS;CARLOTTA ANTONIOTTI;MARIA GRAZIA BONGIORNI;DANIELE ROSSINI;LUCA SEGRETI;MAURIZIA ROSSANA BRUNETTO;PAOLO VITTI;FEDERICA MARMORINO;LORENZO FORNARO;CATERINA VIVALDI;ENRICO VASILE;GIULIO ZUCCHELLI;LUCA MORELLI;LUCA GALLI;NICCOLA FUNEL;GABRIELLA FONTANINI;ROBERTO MORETTO","54;37;24;23;19;17;15;15;15;14;14;14;14;14;13;13;12;12;11;11","ALFREDO FALCONE;CHIARA CREMOLINI;PAOLO VITTI;LUCA SEGRETI;FOTIOS LOUPAKIS;FRANCA MELFI;SIMONA BARNINI;MARIA GRAZIA BONGIORNI;DAVIDE CARAMELLA;ALESSIA GIULIANO;ANDREA FONTANA;GIANLUCA MASI;SARA RICCIARDI;NICCOLA FUNEL;GABRIELE NALDINI;LUCA MORELLI;ENRICO VASILE;FULVIO BASOLO;GIULIO ZUCCHELLI;RICCARDO MORGANTI","3.3;2.02;1.64;1.39;1.36;1.32;1.27;1.26;1.22;1.2;1.19;1.16;1.12;1.11;1.1;1.07;1.05;1.03;1.01;1","EINAT SHACHAM‐SHMUELI;ERAY GOEKKURT;ALFREDO FALCONE;GIUSEPPE APRILE;MARIA DI BARTOLOMEO;LORENZO FORNARO;NIALL C. TEBBUTT;EVARISTO MAIELLO;CHARLES S. FUCHS;ATSUSHI OHTSU;CHRISTIAN CAGLEVIC;HYUN CHEOL CHUNG;KEI MURO;KOHEI SHITARA;MARIO MANDALÁ;MIN‐HEE RYU;MUSTAFA ÖZGÜROĞLU;RAY MCDERMOTT;SOONMO PETER KANG;TOMASZ OLESIŃSKI","2206;2206;1941;1607;1285;1222;1145;1133;1131;1128;1128;1128;1128;1128;1128;1128;1128;1128;1128;1128","LORENZO FORNARO;GIANLUCA MASI;FRANCESCO MENICHETTI;ALFREDO FALCONE;CHIARA CREMOLINI;MARIA GRAZIA BONGIORNI;ANNA SONIA PETRONIO;PAOLO DE SIMONE;CHIARA CAPARELLO;FRANCESCO PASQUALETTI;DANIELE ROSSINI;MARIA A. CALIGO;PAOLO VITTI;FEDERICA MARMORINO;FRANCESCO AMADORI;CARLOTTA ANTONIOTTI;MAURIZIA ROSSANA BRUNETTO;MICHELE MARINÒ;CLAUDIO MARCOCCI;ELENA SABINI","1222;1067;1016;823;786;615;489;393;384;381;379;379;359;340;302;286;273;270;249;228","ALFREDO FALCONE;CHIARA CREMOLINI;GIANLUCA MASI;CARLOTTA ANTONIOTTI;ANNA SONIA PETRONIO;MARIA GRAZIA BONGIORNI;MAURIZIA ROSSANA BRUNETTO;DANIELE ROSSINI;LORENZO FORNARO;LUCA SEGRETI;FEDERICA MARMORINO;GIULIO ZUCCHELLI;CATERINA VIVALDI;ENRICO VASILE;LUCA GALLI;STEFANO VIANI;ROBERTO MORETTO;FRANCA MELFI;PAOLO VITTI;BEATRICE BORELLI","44;31;24;19;16;16;15;15;14;14;14;13;12;12;11;11;10;10;10;10","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;MATHEMATICS;CHEMISTRY;PSYCHOLOGY;ENGINEERING;MATERIALS SCIENCE;PHILOSOPHY;POLITICAL SCIENCE;GEOLOGY;ECONOMICS;SOCIOLOGY;BUSINESS;ART;GEOGRAPHY;HISTORY","471;132;43;40;24;22;20;17;11;10;9;8;7;7;3;1;1;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;GASTROENTEROLOGY;GENETICS;CARDIOLOGY;PATHOLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;CANCER RESEARCH;BIOCHEMISTRY;INTENSIVE CARE MEDICINE;NUCLEAR MEDICINE;PHYSICAL THERAPY;PALEONTOLOGY;ENDOCRINOLOGY;MICROBIOLOGY;OPTICS;PEDIATRICS","380;153;143;77;73;71;70;59;42;39;37;33;28;27;21;20;19;19;19;19","CANCER;CHEMOTHERAPY;GENE;COHORT;DISEASE;POPULATION;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;CLINICAL TRIAL;CONFIDENCE INTERVAL;HEART FAILURE;MULTIVARIATE ANALYSIS;RETROSPECTIVE COHORT STUDY;REGIMEN;PROPORTIONAL HAZARDS MODEL;ANTIBIOTICS;MAGNETIC RESONANCE IMAGING;STENOSIS;INCIDENCE (GEOMETRY);ALTERNATIVE MEDICINE;ATRIAL FIBRILLATION;HEPATOCELLULAR CARCINOMA;LUNG CANCER;PROSPECTIVE COHORT STUDY","175;67;64;40;39;37;36;26;25;24;21;21;19;18;17;16;16;16;15;14;14;14;14;14","COLORECTAL CANCER;CLINICAL ENDPOINT;BREAST CANCER;BEVACIZUMAB;GENOTYPE;PANCREATIC CANCER;PROGRESSION-FREE SURVIVAL;HAZARD RATIO;UNIVARIATE ANALYSIS;PHASES OF CLINICAL RESEARCH;EJECTION FRACTION;IMMUNOTHERAPY;ADENOCARCINOMA;GEMCITABINE;METASTASIS;MUTATION;PROSTATE CANCER;TEMOZOLOMIDE;GENE EXPRESSION;ALLELE;NEUTROPENIA;PLACEBO;PSEUDOMONAS AERUGINOSA","78;34;27;26;23;21;18;16;15;14;13;13;11;11;11;11;10;10;9;8;8;8;8","IRINOTECAN;OXALIPLATIN;KRAS;REGORAFENIB;SINGLE-NUCLEOTIDE POLYMORPHISM;CETUXIMAB;METASTATIC BREAST CANCER;CAPECITABINE;NIVOLUMAB;KLEBSIELLA PNEUMONIAE;HBSAG;PEMBROLIZUMAB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;MICROSATELLITE;PRIMARY TUMOR;SANGER SEQUENCING;V600E;VINCRISTINE","25;21;14;14;14;13;10;8;7;6;5;5;5;4;4;4;4;4;4;4",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;ITALY;TREATMENT OUTCOME;AGED, 80 AND OVER;RETROSPECTIVE STUDIES;COLORECTAL NEOPLASMS;LIVER NEOPLASMS;YOUNG ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;POSTOPERATIVE COMPLICATIONS;PROSPECTIVE STUDIES;AORTIC VALVE STENOSIS;CARCINOMA, HEPATOCELLULAR;RISK FACTORS","254;235;180;169;139;129;95;81;59;57;56;42;38;32;31;30;30;29;29;28","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;MANAGEMENT OF VALVULAR HEART DISEASE;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;PANCREATIC CANCER RESEARCH AND TREATMENT;HEPATOCELLULAR CARCINOMA;GLIOMAS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ATRIAL FIBRILLATION;CANCER IMMUNOTHERAPY;DIAGNOSIS AND TREATMENT OF LUNG CANCER;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;HEPATITIS B INFECTION AND TREATMENT;HEPATITIS C INFECTION AND TREATMENT;ANORECTAL SURGICAL PROCEDURES;GASTRIC CANCER RESEARCH AND TREATMENT;MALIGNANT PLEURAL MESOTHELIOMA RESEARCH;PATHOPHYSIOLOGY AND MANAGEMENT OF GRAVES' OPHTHALMOPATHY","37;19;17;17;14;11;9;9;9;8;8;7;6;6;6;6;5;5;5;5","CLINICAL ENDPOINT;METASTATIC COLORECTAL CANCER;PROGRESSION-FREE SURVIVAL;REGIMEN;TREATMENT;FOLFIRI;PROSTHETIC VALVES EVALUATION;TRANSCATHETER AORTIC-VALVE REPLACEMENT;REGORAFENIB;UNIVARIATE ANALYSIS;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;PANCREATIC CANCER;TEMOZOLOMIDE;BREAST CANCER;CANCER IMAGING;METASTATIC PANCREATIC CANCER;STROKE (ENGINE);CARDIOVASCULAR RISK ASSESSMENT;FOLFIRINOX;GLIOBLASTOMA","35;27;19;18;18;16;16;16;14;14;10;10;10;9;9;9;9;8;8;8","COLORECTAL CANCER;METASTATIC COLORECTAL;CANCER PATIENTS;CANCER MCRC;PATIENTS PTS;BREAST CANCER;PANCREATIC CANCER;PATIENTS TREATED;AORTIC VALVE;CLINICAL PRACTICE;HEPATOCELLULAR CARCINOMA;PHASE II;CLINICAL TRIAL;TRANSCATHETER AORTIC;ATRIAL FIBRILLATION;LEAD EXTRACTION;PROSTATE CANCER;HEART FAILURE;PHASE III;PREVIOUSLY TREATED;VALVE REPLACEMENT;ADVANCED BREAST;ADVANCED GASTRIC;ARTERY DISEASE;CELL CARCINOMA;CHRONIC HEPATITIS;CLINICAL OUTCOMES;CORONARY ARTERY;FINAL RESULTS;GRAVES ORBITOPATHY","43;40;29;16;16;15;15;13;12;12;11;10;9;9;8;8;8;7;6;6;6;5;5;5;5;5;5;5;5;5","PUBMED SCOPUS;CROSSREF PUBMED;HR CI;CANCER PATIENTS;CONFIDENCE INTERVAL;PROGRESSION-FREE SURVIVAL;ADVERSE EVENTS;BREAST CANCER;HAZARD RATIO;MEDIAN OS;MEDIAN PFS;RESPONSE RATE;ATRIAL FIBRILLATION;COLORECTAL CANCER;PATIENTS TREATED;RISK FACTORS;MCRC PATIENTS;MEDIAN AGE;METASTATIC COLORECTAL;ADVANCED CANCER;DISEASE PROGRESSION;PRIMARY ENDPOINT;SURVIVAL OS;CONSECUTIVE PATIENTS;ECOG PS;SURVIVAL PFS;CLINICAL TRIAL;ELDERLY PATIENTS;LUNG CANCER;MULTIVARIATE ANALYSIS","85;75;57;35;31;31;25;24;24;24;24;24;23;23;23;23;22;22;21;20;18;18;18;17;17;17;16;16;16;16",154,0.31,2.05,34.86,7,275.6,31.93,1,264,2.27,1,5,1,1,1,1.25,1,2,3.27,1,18,2.25,1,6,0,0,0,1.33,1,2,37.61,1,301,0,0,0,1,1,1,35.03,2,245,1,1,1,0,0,0,2.12,1,5,6.79,1,35,23.24,1,164,5.55,1,42,0.05,0,1,0,0,0,116.8,8,546,116.85,8,546,1,0,2,0,0,0,0,0,0,0,0,0,2,0,0,3,5,2.5,0,2,2,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CEMPINI MARCO;CORTESE MARIO;GIOVACCHINI FRANCESCO;VITIELLO NICOLA;MOISE MATTEO;MOISÉ MATTEO","2;2;2;2;1;1","AZIENDA OSPEDALIERO UNIVERSITARIA PISANA;SCUOLA SUPERIORE DI STUDI UNIV E DI PERFEZIONAMENTO SANT'ANNA DI PISA;SCUOLA SUPERIORE DI STUDI UNIVERSITARI E DI PERFEZIONAMENTO SANT'ANNA DI PISA;SCUOLA SUPERIORE DI STUDI UNIVERSITARI E DI PERFEZIONAMENTO SANTANNA","2;1;1;1","49 MATHEMATICAL SCIENCES;4904 PURE MATHEMATICS","4;2",NA,NA,NA,NA,"A61H1/02","2","A61H1/0277;A61H1/0281;A61H2201/0157;A61H2201/1215;A61H2201/14;A61H2201/1481;A61H2201/1616;A61H2201/1638;A61H2201/1671;A61H2201/1676","2;2;2;2;2;2;2;2;2;2",2,138929.5,138929.5,1,1,1,0,0,"AZIENDA OSPEDALIERA UNIVERSITARIA PISANA","2","EUROPEAN COMMISSION","2","COALITION S;EC & ERC - EUROPEAN UNION","2;2","3RD HEALTH PROGRAMME (PROGRAMME);CONNECTING EUROPE FACILITY (PROGRAMME)","1;1","42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;46 INFORMATION AND COMPUTING SCIENCES","2;2;1","CLINICAL RESEARCH;HEALTH SERVICES","1;1",NA,NA,"7.1 INDIVIDUAL CARE NEEDS","1","NOT SITE-SPECIFIC CANCER","1","1.5 RESOURCES AND INFRASTRUCTURE;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE;6.9 RESOURCES AND INFRASTRUCTURE RELATED TO CANCER CONTROL, SURVIVORSHIP, AND OUTCOMES RESEARCH","1;1;1;1","A01 CLINICAL MEDICINE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY","1;1","3 GOOD HEALTH AND WELL BEING","1",29,"PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;FRONTIERS;KARGER PUBLISHERS","13;8;6;2","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;31 BIOLOGICAL SCIENCES;3202 CLINICAL SCIENCES;3105 GENETICS;42 HEALTH SCIENCES;52 PSYCHOLOGY;3208 MEDICAL PHYSIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;5202 BIOLOGICAL PSYCHOLOGY","47;14;10;8;7;2;2;1;1;1;1;1","CLINICAL RESEARCH;CANCER;BREAST CANCER;GENETICS;RARE DISEASES;OVARIAN CANCER;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN;BEHAVIORAL AND SOCIAL SCIENCE;DIGESTIVE DISEASES;HUMAN GENOME;MENTAL HEALTH;NEUROSCIENCES;ORPHAN DRUG;PREVENTION;BASIC BEHAVIORAL AND SOCIAL SCIENCE;BIOMEDICAL IMAGING;BIOTECHNOLOGY;BRAIN DISORDERS;COMPLEMENTARY AND INTEGRATIVE HEALTH","9;8;4;4;4;3;3;3;2;2;2;2;2;2;2;1;1;1;1;1","CANCER;MENTAL HEALTH;NEUROLOGICAL","14;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.1 PHARMACEUTICALS;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING;6.1 PHARMACEUTICALS","9;3;1;1","CLINICAL;BIOMEDICAL","6;4","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE;PUBLIC HEALTH","12;6;1","OVARIAN CANCER;BREAST CANCER;GENITAL SYSTEM, FEMALE;COLON AND RECTAL CANCER;STOMACH CANCER","9;4;2;1;1",NA,NA,52,4.71,1176.29,35,120.92,1,0,10,0,29,0,1,10,1,44,8,0,0,0,0,0,0,49,3,0,51,0,1,0,0,0,0,0,0,0,"United States;Japan;Italy;Finland;Germany;United Kingdom","25;3;2;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3204 IMMUNOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;31 BIOLOGICAL SCIENCES;3101 BIOCHEMISTRY AND CELL BIOLOGY;3207 MEDICAL MICROBIOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3215 REPRODUCTIVE MEDICINE","52;23;19;10;9;3;2;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;DIGESTIVE DISEASES;RARE DISEASES;PATIENT SAFETY;LIVER DISEASE;INFECTIOUS DISEASES;AUTOIMMUNE DISEASE;EMERGING INFECTIOUS DISEASES;HEMATOLOGY;INFLAMMATORY BOWEL DISEASE;PREVENTION;AGING;BRAIN DISORDERS;CARDIOVASCULAR;LUNG;NEURODEGENERATIVE;NEUROSCIENCES;NUTRITION","47;40;24;13;11;10;6;5;4;4;4;4;4;3;3;3;3;3;3;3","CANCER;INFECTION;ORAL AND GASTROINTESTINAL;INFLAMMATORY AND IMMUNE SYSTEM;SKIN;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;NEUROLOGICAL","14;4;4;3;3;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;5.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.3 MEDICAL DEVICES;5.9 RESOURCES AND INFRASTRUCTURE (TREATMENT DEVELOPMENT);6.4 SURGERY;8.1 ORGANISATION AND DELIVERY OF SERVICES","37;5;3;1;1;1;1;1;1","LIVER CANCER;LUNG CANCER;MELANOMA;NON-HODGKIN'S LYMPHOMA;STOMACH CANCER;BLADDER CANCER;BREAST CANCER;CERVICAL CANCER;COLON AND RECTAL CANCER;LEUKEMIA / LEUKAEMIA;KIDNEY CANCER;MYELOMA;OVARIAN CANCER;PANCREATIC CANCER","3;3;3;3;3;2;2;2;2;2;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;1.4 CANCER PROGRESSION AND METASTASIS;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.7 RESOURCES AND INFRASTRUCTURE RELATED TO TREATMENT AND THE PREVENTION OF RECURRENCE","20;3;1;1;1;1;1"
"AOU_PISANA",2019,469,16.6055437100213,3.32835820895522,0.300448430493274,0.336886993603412,0.292110874200426,0.247334754797441,0.537313432835821,0,271,94,27,31,0.58,0.2,0.06,0.07,24.35,1.00143624921105,0.353944562899787,0.918976545842217,5.6690856313498,0.496709996669158,0.51517094017094,0.576188448985384,0.553808097312999,"ALFREDO FALCONE;CHIARA CREMOLINI;SARA LONARDI;DANIELE SANTINI;FILIPPO PIETRANTONIO;MARIA GRAZIA BONGIORNI;DANIELE ROSSINI;GIANLUCA MASI;BEATRICE BORELLI;CARLOTTA ANTONIOTTI;FILIPPO DE BRAUD;VITTORINA ZAGONEL;FOTIOS LOUPAKIS;FEDERICA MARMORINO;FRANCESCA BERGAMO;ANTONIO CHELLA;GABRIELLA FONTANINI;GIULIO ZUCCHELLI;MICHELE EMDIN;ROBERTO MORETTO","63;44;26;22;21;20;20;17;17;17;16;16;16;15;15;14;14;13;13;13","ALFREDO FALCONE;CHIARA CREMOLINI;FABIO GUARRACINO;MARIA GRAZIA BONGIORNI;DAVIDE CARAMELLA;FRANCA MELFI;ALESSIA GIMELLI;MAURO FERRARI;SARA LONARDI;MARCO LUCCHI;ANTONIO CHELLA;LUCA SEGRETI;FILIPPO PIETRANTONIO;PAOLO VITTI;PIETRO BERTINI;MICHELE EMDIN;SARA RICCIARDI;FULVIO BASOLO;GABRIELLA FONTANINI;RAFFAELLA BERCHIOLLI","3.86;2.4;1.91;1.45;1.39;1.26;1.19;1.18;1.18;1.17;1.14;1.14;1.13;1.12;1.1;1.1;1.09;1.06;1.06;0.98","ALFREDO FALCONE;CHIARA CREMOLINI;MARIA GRAZIA BONGIORNI;DANIELE ROSSINI;GIANLUCA MASI;BEATRICE BORELLI;CARLOTTA ANTONIOTTI;FOTIOS LOUPAKIS;FEDERICA MARMORINO;ANTONIO CHELLA;GABRIELLA FONTANINI;GIULIO ZUCCHELLI;ROBERTO MORETTO;LORENZO FORNARO;CATERINA VIVALDI;ENRICO VASILE;MARIA A. CALIGO;DAVIDE CARAMELLA;MARCO LUCCHI;PAOLO VITTI","63;44;20;20;17;17;17;16;15;14;14;13;13;13;13;13;12;12;11;11","ALFREDO FALCONE;CHIARA CREMOLINI;FABIO GUARRACINO;MARIA GRAZIA BONGIORNI;DAVIDE CARAMELLA;FRANCA MELFI;ALESSIA GIMELLI;MAURO FERRARI;MARCO LUCCHI;ANTONIO CHELLA;LUCA SEGRETI;PAOLO VITTI;PIETRO BERTINI;SARA RICCIARDI;FULVIO BASOLO;GABRIELLA FONTANINI;RAFFAELLA BERCHIOLLI;CARLOTTA ANTONIOTTI;DANIELE ROSSINI;MARCO GAMBACCIANI","3.86;2.4;1.91;1.45;1.39;1.26;1.19;1.18;1.17;1.14;1.14;1.12;1.1;1.09;1.06;1.06;0.98;0.98;0.97;0.91","PAOLA ANNA ERBA;ALDO P. MAGGIONI;BERNARD COSYNS;BERNARD IUNG;BERNARD PRENDERGAST;BOGDAN A. POPESCU;GILBERT HABIB;MARTA MOSCA;ANDREA DORIA;ANN E. CLARKE;BERNADETT HALDA-KISS;BETTY DIAMOND;BEVRA HAHN;BIMBA F. HOYER;BRANIMIR ANIĆ;CARLOS VASCONCELOS;CHIARA TANI;DAFNA D. GLADMAN;DANIEL J. WALLACE;DAVID DAIKH","1791;1772;1725;1725;1725;1725;1725;1652;1623;1460;1460;1460;1460;1460;1460;1460;1460;1460;1460;1460","CHIARA TANI;ALFREDO FALCONE;PAOLA ANNA ERBA;CHIARA CREMOLINI;MARIA GRAZIA BONGIORNI;NORA NABILA ALI TATAR-CHENTIR;ROSSELLA ELISEI;MARCO DE CARLO;DAVID VIOLA;ANNA SONIA PETRONIO;LIBORIO TORREGROSSA;VALERIA BOTTICI;VIRGINIA CAPPAGLI;FULVIO BASOLO;BEATRICE BORELLI;MARIA A. CALIGO;FABIO GUARRACINO;ANTONIO CHELLA;CLARA UGOLINI;GRETA ALÌ","1460;1291;1163;869;856;575;455;388;342;340;340;318;318;306;290;278;271;254;218;201","ALFREDO FALCONE;CHIARA CREMOLINI;MARIA GRAZIA BONGIORNI;DANIELE ROSSINI;GIANLUCA MASI;BEATRICE BORELLI;CARLOTTA ANTONIOTTI;FEDERICA MARMORINO;CATERINA VIVALDI;GIULIO ZUCCHELLI;LORENZO FORNARO;ROBERTO MORETTO;ENRICO VASILE;ANTONIO CHELLA;LUCA SEGRETI;IRENE PECORA;ALBERTO AIMO;FABIO GUARRACINO;G. PASQUINI;LUCA GALLI","54;39;21;19;16;16;16;14;13;12;12;12;12;11;11;11;10;9;9;9","MEDICINE;BIOLOGY;COMPUTER SCIENCE;CHEMISTRY;PHYSICS;PSYCHOLOGY;ENGINEERING;MATHEMATICS;SOCIOLOGY;ECONOMICS;POLITICAL SCIENCE;MATERIALS SCIENCE;GEOLOGY;PHILOSOPHY;BUSINESS;HISTORY;ART","449;114;31;30;30;24;18;18;16;11;11;9;7;7;3;3;1","INTERNAL MEDICINE;ONCOLOGY;SURGERY;CARDIOLOGY;GENETICS;PATHOLOGY;RADIOLOGY;GASTROENTEROLOGY;CANCER RESEARCH;BIOCHEMISTRY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;PSYCHIATRY;IMMUNOLOGY;INTENSIVE CARE MEDICINE;NUCLEAR MEDICINE;PALEONTOLOGY;PEDIATRICS;PHARMACOLOGY;NURSING","374;140;133;76;62;58;56;53;38;37;32;30;28;26;26;20;20;17;17;16","CANCER;GENE;CHEMOTHERAPY;COHORT;CONFIDENCE INTERVAL;HEART FAILURE;DISEASE;CLINICAL TRIAL;POPULATION;ADVERSE EFFECT;RANDOMIZED CONTROLLED TRIAL;MYOCARDIAL INFARCTION;ATRIAL FIBRILLATION;PROPORTIONAL HAZARDS MODEL;PROSPECTIVE COHORT STUDY;LUNG;RETROSPECTIVE COHORT STUDY;THYROID;MULTIVARIATE ANALYSIS;QUALITY OF LIFE (HEALTHCARE)","153;57;50;39;35;33;32;30;29;28;21;20;19;18;18;17;17;17;16;16","COLORECTAL CANCER;BREAST CANCER;CLINICAL ENDPOINT;BEVACIZUMAB;EJECTION FRACTION;HAZARD RATIO;MUTATION;GENOTYPE;ADENOCARCINOMA;IMMUNOTHERAPY;PROSTATE CANCER;UNIVARIATE ANALYSIS;PHENOTYPE;THYROID CANCER;TOLERABILITY;GENE EXPRESSION;METASTASIS;PHASES OF CLINICAL RESEARCH;PANCREATIC CANCER;PROGRESSION-FREE SURVIVAL;PROGRESSIVE DISEASE;WARFARIN","69;31;24;21;21;16;16;13;12;12;11;10;9;9;9;8;8;8;7;7;7;7","IRINOTECAN;OXALIPLATIN;CARDIAC RESYNCHRONIZATION THERAPY;METASTATIC BREAST CANCER;REGORAFENIB;SINGLE-NUCLEOTIDE POLYMORPHISM;CETUXIMAB;KRAS;PEMBROLIZUMAB;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;CAPECITABINE;NIVOLUMAB;GEFITINIB;GERMLINE MUTATION;TRANSCRIPTOME;ANDROGEN DEPRIVATION THERAPY;ANDROGEN RECEPTOR;ENDOVASCULAR ANEURYSM REPAIR;ENOS;FEBRILE NEUTROPENIA;GESTATIONAL DIABETES;MAMMOGRAPHY;MICROVESICLES;PAPILLARY THYROID CANCER;PEMETREXED;TAXANE;VITAMIN K ANTAGONIST","16;15;9;9;9;9;8;6;6;6;5;5;4;4;4;3;3;3;3;3;3;3;3;3;3;3;3",";HUMANS;FEMALE;MALE;AGED;MIDDLE AGED;ADULT;ITALY;RETROSPECTIVE STUDIES;AGED, 80 AND OVER;LUNG NEOPLASMS;TREATMENT OUTCOME;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;COLORECTAL NEOPLASMS;BREAST NEOPLASMS;POSTOPERATIVE COMPLICATIONS;PROGNOSIS;FOLLOW-UP STUDIES;HEART FAILURE;PROSPECTIVE STUDIES","237;230;169;161;126;119;101;65;61;50;45;45;43;39;36;33;32;31;31;27","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;MANAGEMENT OF VALVULAR HEART DISEASE;PANCREATIC CANCER RESEARCH AND TREATMENT;HEPATOCELLULAR CARCINOMA;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;DIAGNOSIS AND TREATMENT OF LUNG CANCER;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ATRIAL FIBRILLATION;CANCER IMMUNOTHERAPY;CYCLIN-DEPENDENT KINASE 4/6 INHIBITORS IN BREAST CANCER;DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;RADIOMICS IN MEDICAL IMAGING ANALYSIS;RECOMMENDATIONS FOR CARDIAC CHAMBER QUANTIFICATION BY ECHOCARDIOGRAPHY;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;CHOLANGIOCARCINOMA;COLORECTAL CANCER RESEARCH AND TREATMENT","31;20;13;10;10;9;7;7;6;6;6;6;5;5;5;5;5;4;4;4","METASTATIC COLORECTAL CANCER;CLINICAL ENDPOINT;TREATMENT;BREAST CANCER;FOLFIRI;CARDIAC IMAGING;REGIMEN;INTERQUARTILE RANGE;TRANSCATHETER AORTIC-VALVE REPLACEMENT;CARDIOVASCULAR RISK ASSESSMENT;EGFR MUTATIONS;MEDULLARY THYROID CANCER;PROSTHETIC VALVES EVALUATION;STROKE (ENGINE);UNIVARIATE ANALYSIS;CARDIAC RESYNCHRONIZATION THERAPY;REGORAFENIB;THYROID NODULES;TOLERABILITY;ECHOCARDIOGRAPHY","31;24;16;13;13;12;12;11;11;10;10;10;10;10;10;9;9;9;9;8","COLORECTAL CANCER;METASTATIC COLORECTAL;CANCER PATIENTS;BREAST CANCER;CANCER MCRC;PATIENTS PTS;PATIENTS TREATED;HEART FAILURE;PHASE II;LEAD EXTRACTION;PHASE III;LUNG CANCER;HEART RHYTHM;CLINICAL TRIAL;EUROPEAN SOCIETY;POOLED ANALYSIS;CONSENSUS DOCUMENT;ITALIAN MULTICENTER;MCRC DATA;OBSERVATIONAL STUDY;PROSTATE CANCER;RHYTHM SOCIETY;TRIBE STUDIES;CARDIAC IMPLANTABLE;CLINICAL IMPACT;CLINICAL OUTCOMES;EUROPEAN LEAD;EXTRACTION CONTROLLED;HEALTH-RELATED QUALITY;III TRIALS","44;38;18;15;15;14;13;12;12;11;11;10;9;7;7;7;6;6;6;6;6;6;6;5;5;5;5;5;5;5","ADVISORY CONSULTANCY;ACCOMMODATION EXPENSES;TRAVEL ACCOMMODATION;BUREAU EXPERT;EXPERT TESTIMONY;SPEAKER BUREAU;GRANT FUNDING;RESEARCH GRANT;CONSULTANCY SPEAKER;FUNDING INSTITUTION;HR CI;DISEASE PROGRESSION;COLORECTAL CANCER;CONSULTANCY TRAVEL;PATIENTS TREATED;ADVERSE EVENTS;BREAST CANCER;ECOG PS;GENE EXPRESSION;INSTITUTION TRAVEL;PROGRESSION-FREE SURVIVAL;CROSSREF PUBMED;MEDIAN OS;MULTIVARIATE ANALYSIS;PUBMED SCOPUS;ROCHE HONORARIA;SURVIVAL OS;CONSULTANCY RESEARCH;MCRC PATIENTS;MEDIAN AGE","157;74;74;70;70;70;50;50;49;49;48;31;27;27;27;25;24;23;22;21;21;20;20;20;20;20;19;18;18;18",175,0.37,2.85,49.19,10.304,403.61,51.25,2,338,2.4,1,12,1.3,1,4,1,1,1,4.35,1,30,2.5,1,4,0,0,0,1,1,1,62.02,2,382,1,1,1,1,1,1,53.03,1,295,1,1,1,2,2,2,2.85,1,9,9.03,1,37,36.53,1,193,8.76,1,105,0.02,0,1,0,0,0,134.84,11,1569,134.36,11,1569,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,4,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BERRETTINI STEFANO;DANTI SERENA;MARRAZZA STEFANO;STEFANINI CESARE","1;1;1;1","AZIENDA OSPEDALIERO UNIVERSITARIA PISANA","1","40 ENGINEERING;4003 BIOMEDICAL ENGINEERING","2;1","BIOENGINEERING;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN","1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1","A61F2/18;A61L27/36;A61L27/58;C12M1/42;C12M3/00;C12N5/0775","1;1;1;1;1;1","A61F2002/183;A61F2240/001;A61L2430/14;A61L27/3604;A61L27/3645;A61L27/58;C12M21/08;C12M35/06;C12N2500/38;C12N2501/15","1;1;1;1;1;1;1;1;1;1",3,18581000,356084.58,3.33333333333333,46.6666666666667,11.3333333333333,0.333333333333333,120.5,"AZIENDA OSPEDALIERA UNIVERSITARIA PISANA;ACADEMIC MEDICAL CENTER;ACADEMY OF FINLAND;ACIBADEM UNIVERSITY;AGENCE NATIONALE DE LA RECHERCHE;AGENZIA PER LA PROMOZIONE DELLA RICERCA EUROPEA;AIX-MARSEILLE UNIVERSITY;ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;AUSTRIAN INSTITUTE OF TECHNOLOGY;AZIENDA OSPEDALIERA UNIVERSITARIA SENESE;AZIENDA SANITARIA UNIVERSITARIA FRIULI CENTRALE;BAMBINO GESÙ CHILDREN'S HOSPITAL;BARCELONA SUPERCOMPUTING CENTER;BIOBANKING AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE - ERIC;CANADIAN INSTITUTES OF HEALTH RESEARCH;CENTER FOR ADVANCED STUDIES RESEARCH AND DEVELOPMENT IN SARDINIA;CENTER OF MEDICAL GENETICS AND PRIMARY HEALTH CARE;CENTRE FOR GENOMIC REGULATION;CENTRE LÉON BÉRARD;CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","3","COALITION S;EC & ERC - EUROPEAN UNION","3;3","3RD HEALTH PROGRAMME (PROGRAMME);COFUND-EJP - COFUND (EUROPEAN JOINT PROGRAMME) (FUNDING SCHEME);CONNECTING EUROPE FACILITY (PROGRAMME);H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME)","1;1;1;1","42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;46 INFORMATION AND COMPUTING SCIENCES;4610 LIBRARY AND INFORMATION STUDIES","2;2;1;1",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"A02 PUBLIC HEALTH, HEALTH SERVICES AND PRIMARY CARE;A03 ALLIED HEALTH PROFESSIONS, DENTISTRY, NURSING AND PHARMACY;B11 COMPUTER SCIENCE AND INFORMATICS","1;1;1",NA,NA,30,"PUBLIC LIBRARY OF SCIENCE;SAGE JOURNALS;FRONTIERS;TAYLOR & FRANCIS GROUP;SPRINGER NATURE;KARGER PUBLISHERS","15;6;3;3;2;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3105 GENETICS;3212 OPHTHALMOLOGY AND OPTOMETRY;42 HEALTH SCIENCES;46 INFORMATION AND COMPUTING SCIENCES;52 PSYCHOLOGY;3001 AGRICULTURAL BIOTECHNOLOGY;3101 BIOCHEMISTRY AND CELL BIOLOGY;3208 MEDICAL PHYSIOLOGY;3215 REPRODUCTIVE MEDICINE;41 ENVIRONMENTAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;43 HISTORY, HERITAGE AND ARCHAEOLOGY;4301 ARCHAEOLOGY;4612 SOFTWARE ENGINEERING;49 MATHEMATICAL SCIENCES","32;12;10;5;2;2;2;2;2;2;1;1;1;1;1;1;1;1;1;1","CANCER;RARE DISEASES;DIGESTIVE DISEASES;PANCREATIC CANCER;BRAIN DISORDERS;CLINICAL RESEARCH;GENETICS;NEUROSCIENCES;BIOTECHNOLOGY;HUMAN GENOME;AGING;BRAIN CANCER;ACQUIRED COGNITIVE IMPAIRMENT;ALZHEIMER'S DISEASE;ALZHEIMER'S DISEASE INCLUDING ALZHEIMER'S DISEASE RELATED DEMENTIAS (AD/ADRD);AUTOIMMUNE DISEASE;BASIC BEHAVIORAL AND SOCIAL SCIENCE;BEHAVIORAL AND SOCIAL SCIENCE;BIOMEDICAL IMAGING;BIPOLAR DISORDER","9;8;7;6;4;4;4;4;3;3;2;2;1;1;1;1;1;1;1;1","CANCER;CARDIOVASCULAR;EYE;GENERIC HEALTH RELEVANCE;INFECTION;MENTAL HEALTH;NEUROLOGICAL","7;2;1;1;1;1;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;6.1 PHARMACEUTICALS;6.4 SURGERY;3.4 VACCINES;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;7.1 INDIVIDUAL CARE NEEDS;7.3 MANAGEMENT AND DECISION MAKING","3;2;2;1;1;1;1","BIOMEDICAL;CLINICAL","3;3","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","17;2","PANCREATIC CANCER;BRAIN TUMOR;BLADDER CANCER;NOT SITE-SPECIFIC CANCER","6;2;1;1","3 GOOD HEALTH AND WELL BEING","3",61,4.62,877.8,33,103.67,0,1,15,1,23,0,1,19,1,50,11,0,0,0,0,0,0,55,5,1,60,0,1,0,0,0,0,0,0,0,"United States;Italy;Finland;Germany;Japan","21;3;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;42 HEALTH SCIENCES;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE;4203 HEALTH SERVICES AND SYSTEMS;3203 DENTISTRY;3210 NUTRITION AND DIETETICS;3212 OPHTHALMOLOGY AND OPTOMETRY","59;33;22;7;6;4;3;3;2;2;2;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;RARE DISEASES;DIGESTIVE DISEASES;PATIENT SAFETY;PREVENTION;LIVER DISEASE;NEURODEGENERATIVE;AGING;BRAIN DISORDERS;CARDIOVASCULAR;NEUROSCIENCES;CHRONIC LIVER DISEASE AND CIRRHOSIS;AUTOIMMUNE DISEASE;BREAST CANCER;HEART DISEASE;HEMATOLOGY;HEPATITIS;NUTRITION","57;43;27;19;16;14;13;9;9;8;8;8;8;7;6;6;4;4;4;4","CANCER;ORAL AND GASTROINTESTINAL;NEUROLOGICAL;CARDIOVASCULAR;INFECTION;METABOLIC AND ENDOCRINE;SKIN;INFLAMMATORY AND IMMUNE SYSTEM;STROKE;EYE;RENAL AND UROGENITAL;REPRODUCTIVE HEALTH AND CHILDBIRTH","17;6;4;3;3;3;3;2;2;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);6.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES;7.1 INDIVIDUAL CARE NEEDS","46;6;6;2;1;1;1;1;1","LIVER CANCER;BREAST CANCER;LUNG CANCER;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;COLON AND RECTAL CANCER;PANCREATIC CANCER;BLADDER CANCER;BLOOD CANCER;ENDOMETRIAL CANCER;GALLBLADDER CANCER;KIDNEY CANCER;LEUKEMIA / LEUKAEMIA;PROSTATE CANCER;STOMACH CANCER","7;5;3;3;3;2;2;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.4 RESOURCES AND INFRASTRUCTURE RELATED TO DETECTION, DIAGNOSIS, OR PROGNOSIS;3.3 CHEMOPREVENTION;6.2 SURVEILLANCE","19;4;3;2;2;1;1"
"AOU_PISANA",2020,668,15.9790419161677,3.13323353293413,0.319159101767797,0.320359281437126,0.296407185628743,0.26497005988024,0.567365269461078,4,345,151,49,43,0.52,0.23,0.07,0.06,19.47,0.772546558788757,0.357784431137725,0.914670658682635,6.49689440993788,0.493492501770117,0.48467158712748,0.42916068866571,0.492498875393612,"ALFREDO FALCONE;CHIARA CREMOLINI;DANIELE SANTINI;GIULIO ZUCCHELLI;SARA LONARDI;LUCA SEGRETI;FILIPPO PIETRANTONIO;MARIA GRAZIA BONGIORNI;FEDERICO COCCOLINI;RICCARDO MORGANTI;ANDREA DI CORI;LUCA ANSALONI;ANDREA SBRANA;CATERINA VIVALDI;FOTIOS LOUPAKIS;CARLOTTA ANTONIOTTI;R DE LUCIA;FERRUCCIO SANTINI;STEFANO VIANI;GIANLUCA MASI","44;36;27;25;25;22;22;21;20;19;18;17;16;16;16;16;15;15;15;15","ALFREDO FALCONE;FERRUCCIO SANTINI;RICCARDO MORGANTI;LUCA SEGRETI;GIULIO ZUCCHELLI;CHIARA CREMOLINI;ALFONSO CRISTAUDO;MARIA GRAZIA BONGIORNI;GABRIELE NALDINI;ALESSANDRO STURIALE;NICOLA MONTEMURRO;ANDREA DI CORI;FEDERICO COCCOLINI;ANDREA SBRANA;FABIO GUARRACINO;MARCO GAMBACCIANI;VALENTINA BARLETTA;STEFANO MASI;R DE LUCIA;DIEGO PERONI","2.69;2.28;2.15;2.12;2.09;1.94;1.88;1.83;1.77;1.73;1.67;1.66;1.58;1.55;1.4;1.38;1.38;1.31;1.31;1.28","ALFREDO FALCONE;CHIARA CREMOLINI;GIULIO ZUCCHELLI;LUCA SEGRETI;MARIA GRAZIA BONGIORNI;FEDERICO COCCOLINI;RICCARDO MORGANTI;ANDREA DI CORI;ANDREA SBRANA;CATERINA VIVALDI;FOTIOS LOUPAKIS;CARLOTTA ANTONIOTTI;R DE LUCIA;FERRUCCIO SANTINI;STEFANO VIANI;GIANLUCA MASI;VALENTINA BARLETTA;ROBERTO MORETTO;DANIELE ROSSINI;ROSSELLA ELISEI","44;36;25;22;21;20;19;18;16;16;16;16;15;15;15;15;15;14;14;13","ALFREDO FALCONE;FERRUCCIO SANTINI;RICCARDO MORGANTI;LUCA SEGRETI;GIULIO ZUCCHELLI;CHIARA CREMOLINI;ALFONSO CRISTAUDO;MARIA GRAZIA BONGIORNI;GABRIELE NALDINI;ALESSANDRO STURIALE;NICOLA MONTEMURRO;ANDREA DI CORI;FEDERICO COCCOLINI;ANDREA SBRANA;FABIO GUARRACINO;MARCO GAMBACCIANI;VALENTINA BARLETTA;STEFANO MASI;R DE LUCIA;DIEGO PERONI","2.69;2.28;2.15;2.12;2.09;1.94;1.88;1.83;1.77;1.73;1.67;1.66;1.58;1.55;1.4;1.38;1.38;1.31;1.31;1.28","FRANCESCO MENICHETTI;ALFREDO FALCONE;MARCO FALCONE;GIUSY TISEO;DANIELE SANTINI;CHIARA CREMOLINI;SARA LONARDI;CESIRA GIORDANO;FERRUCCIO SANTINI;SIMONA BARNINI;LORENZO GHIADONI;ALESSANDRO LEONILDI;CARLOTTA ANTONIOTTI;GIUSEPPE APRILE;FRANCESCO FORFORI;LAURA CARROZZI;GIANLUCA TOMASELLO;ALBERTO ZANIBONI;FILIPPO PIETRANTONIO;AGOSTINO VIRDIS","1630;1359;1279;1218;1147;942;936;831;829;813;803;789;768;762;743;735;720;711;710;687","ALFREDO FALCONE;CHIARA CREMOLINI;FERRUCCIO SANTINI;SIMONA BARNINI;FRANCESCO MENICHETTI;CESIRA GIORDANO;DANIELE ROSSINI;GIANLUCA MASI;ROBERTO MORETTO;ALESSANDRO LEONILDI;CARLOTTA ANTONIOTTI;FRANCESCO LATROFA;MARIA GRAZIA BONGIORNI;DEBORA RICCI;ALESSANDRO BRANCATELLA;DANIELE SGRÒ;NICOLA VIOLA;FEDERICO COCCOLINI;ALFONSO CRISTAUDO;FABIO GUARRACINO","1241;883;826;813;758;656;612;611;600;595;593;577;572;565;557;521;521;518;507;488","ALFREDO FALCONE;CHIARA CREMOLINI;GIULIO ZUCCHELLI;LUCA SEGRETI;MARIA GRAZIA BONGIORNI;FEDERICO COCCOLINI;ANDREA DI CORI;ANNA SONIA PETRONIO;RICCARDO MORGANTI;VALENTINA BARLETTA;R DE LUCIA;STEFANO VIANI;ANDREA SBRANA;ROBERTO MORETTO;FERRUCCIO SANTINI;CARLOTTA ANTONIOTTI;DANIELE ROSSINI;GIANLUCA MASI;LORENZO FORNARO;LUCA GALLI","35;35;24;22;21;19;18;18;15;15;15;15;14;14;14;12;12;12;12;12","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;PSYCHOLOGY;ENGINEERING;CHEMISTRY;POLITICAL SCIENCE;ECONOMICS;MATHEMATICS;SOCIOLOGY;GEOLOGY;MATERIALS SCIENCE;BUSINESS;PHILOSOPHY;ART;GEOGRAPHY;HISTORY;ENVIRONMENTAL SCIENCE","645;135;63;42;41;36;29;27;26;26;14;13;13;11;11;6;5;3;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;CARDIOLOGY;GASTROENTEROLOGY;RADIOLOGY;GENETICS;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;NUCLEAR MEDICINE;INTENSIVE CARE MEDICINE;OPTICS;PSYCHIATRY;CANCER RESEARCH;VIROLOGY;BIOCHEMISTRY;GENERAL SURGERY;PALEONTOLOGY;PEDIATRICS","504;220;137;119;108;91;79;72;55;55;49;40;39;38;37;33;33;30;30;30;30","CANCER;DISEASE;GENE;CHEMOTHERAPY;POPULATION;CONFIDENCE INTERVAL;COHORT;HEART FAILURE;RETROSPECTIVE COHORT STUDY;CLINICAL TRIAL;RANDOMIZED CONTROLLED TRIAL;OUTBREAK;ADVERSE EFFECT;DIABETES MELLITUS;INCIDENCE (GEOMETRY);PROPORTIONAL HAZARDS MODEL;ATRIAL FIBRILLATION;OBSERVATIONAL STUDY;LUNG;ANTIBODY;HEALTH CARE;PROSPECTIVE COHORT STUDY","169;117;65;53;51;50;39;39;37;35;34;32;30;26;26;23;22;22;21;20;20;20","COLORECTAL CANCER;INFECTIOUS DISEASE (MEDICAL SPECIALTY);HAZARD RATIO;CLINICAL ENDPOINT;EJECTION FRACTION;BREAST CANCER;2019-20 CORONAVIRUS OUTBREAK;BEVACIZUMAB;IMMUNOTHERAPY;GENOTYPE;PROGRESSION-FREE SURVIVAL;CATHETER ABLATION;ADENOCARCINOMA;MUTATION;THYROID CANCER;PANCREATIC CANCER;PROSTATE CANCER;GEMCITABINE;LIVER TRANSPLANTATION;GESTATION;INSULIN RESISTANCE;UNIVARIATE ANALYSIS","66;63;36;35;29;27;25;23;22;20;17;16;13;12;12;11;10;9;9;8;8;8","CORONAVIRUS DISEASE 2019 (COVID-19);OXALIPLATIN;IRINOTECAN;NIVOLUMAB;SINGLE-NUCLEOTIDE POLYMORPHISM;CETUXIMAB;KRAS;REGORAFENIB;METASTATIC BREAST CANCER;ANDROGEN RECEPTOR;GESTATIONAL DIABETES;PEMBROLIZUMAB;KLEBSIELLA PNEUMONIAE;MEDULLARY THYROID CANCER;MISSENSE MUTATION;RIVAROXABAN;TRANSCRIPTOME;HEART FAILURE WITH PRESERVED EJECTION FRACTION;MAMMOGRAPHY;MANIA;VO2 MAX","63;24;17;13;12;11;10;8;7;6;6;6;5;5;5;5;5;4;4;4;4",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ITALY;ADULT;COLORECTAL NEOPLASMS;TREATMENT OUTCOME;RETROSPECTIVE STUDIES;COVID-19;CORONAVIRUS INFECTIONS;PNEUMONIA, VIRAL;AGED, 80 AND OVER;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;AORTIC VALVE STENOSIS;PROSPECTIVE STUDIES;YOUNG ADULT;PANDEMICS","389;274;157;145;111;105;86;77;66;66;61;52;48;48;45;37;31;30;27;26","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;PANCREATIC CANCER RESEARCH AND TREATMENT;MANAGEMENT OF VALVULAR HEART DISEASE;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;CORONAVIRUS DISEASE 2019;CANCER IMMUNOTHERAPY;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;RENAL CELL CARCINOMA;ATRIAL FIBRILLATION;HEPATOCELLULAR CARCINOMA;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;DIAGNOSIS AND TREATMENT OF LUNG CANCER;GLOBAL CHALLENGE OF ANTIBIOTIC RESISTANCE IN BACTERIA;ANORECTAL SURGICAL PROCEDURES;GASTRIC CANCER RESEARCH AND TREATMENT;IMPACT OF GESTATIONAL DIABETES MELLITUS ON PREGNANCY;CHOLANGIOCARCINOMA;DIAGNOSIS AND MANAGEMENT OF SJÖGREN'S SYNDROME;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE","32;22;21;15;13;13;12;11;11;10;10;10;8;8;7;7;7;6;6;6","CLINICAL ENDPOINT;PANDEMIC;METASTATIC COLORECTAL CANCER;2019-20 CORONAVIRUS OUTBREAK;TREATMENT;ECHOCARDIOGRAPHY;INTERQUARTILE RANGE;PROGRESSION-FREE SURVIVAL;BIOMARKERS FOR IMMUNOTHERAPY;FOLFIRI;RADIOFREQUENCY ABLATION;TRANSCATHETER AORTIC-VALVE REPLACEMENT;CARDIOVASCULAR RISK ASSESSMENT;REGIMEN;TUMOR MICROENVIRONMENT;CARDIAC IMAGING;PROSTHETIC VALVES EVALUATION;STROKE (ENGINE);CONCOMITANT;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR","37;30;28;24;22;18;18;18;15;15;15;15;14;14;13;12;12;12;11;11","COLORECTAL CANCER;METASTATIC COLORECTAL;CANCER PATIENTS;PATIENTS TREATED;AORTIC VALVE;BREAST CANCER;HEART FAILURE;HEPATOCELLULAR CARCINOMA;LEAD EXTRACTION;MULTICENTER STUDY;CELL CARCINOMA;COVID- PANDEMIC;METASTATIC RENAL;PANCREATIC CANCER;TRANSCATHETER AORTIC;EJECTION FRACTION;ITALIAN ASSOCIATION;MAGNETIC RESONANCE;PATIENTS PTS;ATRIAL FIBRILLATION;CLINICAL PRACTICE;ELDERLY PATIENTS;LUNG CANCER;RENAL CELL;RETROSPECTIVE STUDY;CANCER MCRC;CLINICAL OUTCOME;CLINICAL OUTCOMES;COMPUTED TOMOGRAPHY;COVID- PATIENTS","39;32;22;15;13;12;11;10;10;10;9;9;9;9;9;8;8;8;8;7;7;7;7;7;7;6;6;6;6;6","HR CI;PUBMED SCOPUS;CROSSREF PUBMED;COLORECTAL CANCER;HAZARD RATIO;PROGRESSION-FREE SURVIVAL;ADVERSE EVENTS;CLINICAL PRACTICE;PATIENTS TREATED;MALIGNANT PLEURAL;METASTATIC COLORECTAL;MEDIAN AGE;SARS-COV- INFECTION;SURVIVAL OS;DISEASE PROGRESSION;GENE EXPRESSION;CONFIDENCE INTERVAL;SURVIVAL PFS;COVID- PANDEMIC;COVID- PATIENTS;PLEURAL MESOTHELIOMA;PATIENTS RECEIVED;ADJUVANT CHEMOTHERAPY;EJECTION FRACTION;HEART FAILURE;MONTHS CI;PATIENTS UNDERGOING;COHORT STUDY;CORONAVIRUS DISEASE;DAY MORTALITY","77;73;61;36;29;28;27;27;27;26;26;25;25;24;23;23;22;22;21;21;21;20;19;19;19;19;19;18;18;18",284,0.43,2.55,48.9,7.7,937.690000000002,46.27,2,741,1.69,1,7,1.88,1,4,0,0,0,5.76,1,67,2.25,1,4,1,1,1,1,1,1,52.72,2,815,2,1,3,1,1,1,44.97,1,662,1,1,1,1.5,1,4,2.62,1,13,7.95,1,47,32.52,1,535,6.78,1,67,0,0,0,0,0,0,86.86,8,516,86.86,8,516,1,0,1,0,0,2,0,0,0,0,0,0,1,2,0,2,5,2.66666666666667,0,3,2,0,0,1,0,0,2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CEMPINI MARCO;CORTESE MARIO;GIOVACCHINI FRANCESCO;VITIELLO NICOLA;MOISE MATTEO;MOISÉ MATTEO","3;3;3;3;2;1","AZIENDA OSPEDALIERO UNIVERSITARIA PISANA;SCUOLA SUPERIORE DI STUDI UNIVERSITARI E DI PERFEZIONAMENTO SANTANNA;AZIENDA OSPEDALIERA UNIVERSITARIA PISANA;SCUOLA SUPERIORE DI STUDI UNIV E DI PERFEZIONAMENTO SANTANNA DI PISA;SCUOLA SUPERIORE DI STUDI UNIVERSITARI E DI PERFEZIONAMENTO SANT'ANNA DI PISA","3;2;1;1;1","49 MATHEMATICAL SCIENCES;4904 PURE MATHEMATICS","4;2",NA,NA,NA,NA,"A61H1/02;B25J9/00;F16H25/20","3;1;1","A61H1/0277;A61H1/0281;A61H2201/0157;A61H2201/1215;A61H2201/14;A61H2201/1481;A61H2201/1616;A61H2201/1638;A61H2201/1671;A61H2201/1676","3;3;3;3;3;3;3;3;3;3",1,199950,66650,3,3,1,1,1,"AZIENDA OSPEDALIERA UNIVERSITARIA PISANA;ISTITUTO SUPERIORE DI SANITÀ;SANT'ANNA SCHOOL OF ADVANCED STUDIES","1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","3RD HEALTH PROGRAMME (PROGRAMME)","1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;42 HEALTH SCIENCES","1;1;1","CLINICAL RESEARCH;RARE DISEASES","1;1","MUSCULOSKELETAL","1",NA,NA,NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,28,"PUBLIC LIBRARY OF SCIENCE;FRONTIERS;UNIVERSITY COLLEGE LONDON;ZENODO;SCIELO JOURNALS;SPRINGER NATURE","14;8;2;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;3105 GENETICS;42 HEALTH SCIENCES;3202 CLINICAL SCIENCES;49 MATHEMATICAL SCIENCES;41 ENVIRONMENTAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;4105 POLLUTION AND CONTAMINATION;4202 EPIDEMIOLOGY;4905 STATISTICS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3204 IMMUNOLOGY;3215 REPRODUCTIVE MEDICINE;34 CHEMICAL SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4206 PUBLIC HEALTH","24;13;11;6;5;5;3;2;2;2;2;1;1;1;1;1;1","GENETICS;CLINICAL RESEARCH;LUNG;CANCER;NEUROSCIENCES;PATIENT SAFETY;RARE DISEASES;BRAIN CANCER;BRAIN DISORDERS;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;VACCINE RELATED;AUTOIMMUNE DISEASE;HEMATOLOGY;MYASTHENIA GRAVIS;STEM CELL RESEARCH;STEM CELL RESEARCH - NONEMBRYONIC - HUMAN;STEM CELL RESEARCH - NONEMBRYONIC - NON-HUMAN","8;5;5;3;3;3;3;2;2;2;2;1;1;1;1;1;1","CANCER;INFLAMMATORY AND IMMUNE SYSTEM","2;1","2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.1 PHARMACEUTICALS;2.4 SURVEILLANCE AND DISTRIBUTION;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;1.1 NORMAL BIOLOGICAL DEVELOPMENT AND FUNCTIONING","7;6;3;3;3;2;2;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS","3;1;1","CLINICAL MEDICINE AND SCIENCE;PUBLIC HEALTH;BASIC SCIENCE","14;2;1","LUNG CANCER;BRAIN TUMOR;NOT SITE-SPECIFIC CANCER","5;2;1",NA,NA,51,4.21,980.66,30,84.06,2,3,17,2,14,0,0,12,1,37,10,0,0,0,0,0,0,47,2,2,46,4,1,0,0,0,0,0,0,0,"United States;Italy;Germany;Japan;Netherlands;Switzerland","15;4;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;3204 IMMUNOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;31 BIOLOGICAL SCIENCES;3107 MICROBIOLOGY;3207 MEDICAL MICROBIOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;35 COMMERCE, MANAGEMENT, TOURISM AND SERVICES;3505 HUMAN RESOURCES AND INDUSTRIAL RELATIONS;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;46 INFORMATION AND COMPUTING SCIENCES","49;34;21;5;4;3;2;2;2;1;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;RARE DISEASES;DIGESTIVE DISEASES;AUTOIMMUNE DISEASE;LUNG;PREVENTION;BIOMEDICAL IMAGING;BRAIN DISORDERS;GENETICS;HEMATOLOGY;INFECTIOUS DISEASES;LIVER DISEASE;PEDIATRIC;UROLOGIC DISEASES;AGING;COLO-RECTAL CANCER;EMERGING INFECTIOUS DISEASES","44;36;21;14;13;11;6;5;5;4;4;4;4;4;4;4;4;3;3;3","CANCER;INFLAMMATORY AND IMMUNE SYSTEM;INFECTION;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;MUSCULOSKELETAL;NEUROLOGICAL;SKIN;STROKE","17;5;4;3;1;1;1;1;1","6.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;4.5 RESOURCES AND INFRASTRUCTURE (DETECTION);5.2 CELLULAR AND GENE THERAPIES;6.3 MEDICAL DEVICES;6.4 SURGERY;6.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.1 INDIVIDUAL CARE NEEDS","36;5;4;4;1;1;1;1;1;1;1;1","BREAST CANCER;COLON AND RECTAL CANCER;BLADDER CANCER;LEUKEMIA / LEUKAEMIA;LIVER CANCER;LUNG CANCER;PANCREATIC CANCER;PROSTATE CANCER;BLOOD CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;GENITAL SYSTEM, MALE;HODGKIN'S DISEASE;MYELOMA;NON-HODGKIN'S LYMPHOMA;NOT SITE-SPECIFIC CANCER;OVARIAN CANCER;THYROID CANCER","5;4;3;2;2;2;2;2;1;1;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.1 TECHNOLOGY DEVELOPMENT AND/OR MARKER DISCOVERY;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;4.2 TECHNOLOGY AND/OR MARKER EVALUATION WITH RESPECT TO FUNDAMENTAL PARAMETERS OF METHOD;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES","17;2;1;1;1;1"
"AOU_PISANA",2021,636,18.0157232704403,2.80817610062893,0.356103023516237,0.242138364779874,0.227987421383648,0.182389937106918,0.672955974842767,2,308,138,51,29,0.48,0.22,0.08,0.05,14.01,0.908583648907847,0.388364779874214,0.955974842767296,6.62587168758717,0.460989306159774,0.419225543478261,0.416698475199389,0.446904534352766,"SARA LONARDI;CHIARA CREMOLINI;ALFREDO FALCONE;FILIPPO PIETRANTONIO;UGO BOGGI;GIANLUCA MASI;RICCARDO MORGANTI;CATERINA VIVALDI;LUCA ANSALONI;FEDERICO COCCOLINI;ANDREA CASADEI‐GARDINI;DANIELE SANTINI;MARZIA DEL RE;GIULIO ZUCCHELLI;MICHELE EMDIN;LORENZO FORNARO;MARCO FALCONE;FEDERICA MORANO;FABIO GUARRACINO;MARTA MOSCA","29;27;24;22;20;20;20;17;16;16;16;16;15;14;14;13;13;13;13;12","RICCARDO MORGANTI;RAFFAELE DE CATERINA;FABIO GUARRACINO;CHIARA CREMOLINI;ANGELO BAGGIANI;ALBERTO AIMO;RICCARDO MARCONCINI;ALFREDO FALCONE;NICOLA MONTEMURRO;ALESSANDRO STURIALE;SARA LONARDI;PIETRO BERTINI;MICHELE EMDIN;MARGHERITA BARBUTI;GIULIO PERUGI;GABRIELE NALDINI;UGO BOGGI;MARZIA DEL RE;FERRUCCIO SANTINI;FRANCA MELFI","1.9;1.78;1.64;1.47;1.46;1.36;1.35;1.34;1.32;1.29;1.29;1.25;1.24;1.22;1.22;1.16;1.11;1.08;1.07;1.05","CHIARA CREMOLINI;ALFREDO FALCONE;UGO BOGGI;GIANLUCA MASI;RICCARDO MORGANTI;CATERINA VIVALDI;FEDERICO COCCOLINI;MARZIA DEL RE;GIULIO ZUCCHELLI;MICHELE EMDIN;LORENZO FORNARO;MARCO FALCONE;FABIO GUARRACINO;MARTA MOSCA;ROSSELLA ELISEI;FERRUCCIO SANTINI;FRANCESCO MENICHETTI;GIUSY TISEO;LUCA GALLI;FRANCESCO FORFORI","27;24;20;20;20;17;16;15;14;14;13;13;13;12;12;12;12;11;11;11","RICCARDO MORGANTI;RAFFAELE DE CATERINA;FABIO GUARRACINO;CHIARA CREMOLINI;ANGELO BAGGIANI;ALBERTO AIMO;RICCARDO MARCONCINI;ALFREDO FALCONE;NICOLA MONTEMURRO;ALESSANDRO STURIALE;PIETRO BERTINI;MICHELE EMDIN;MARGHERITA BARBUTI;GIULIO PERUGI;GABRIELE NALDINI;UGO BOGGI;MARZIA DEL RE;FERRUCCIO SANTINI;FRANCA MELFI;GIULIO ZUCCHELLI","1.9;1.78;1.64;1.47;1.46;1.36;1.35;1.34;1.32;1.29;1.25;1.24;1.22;1.22;1.16;1.11;1.08;1.07;1.05;1.03","ANTONIO CHELLA;ALEX MARTÍNEZ‐MARTÍ;ALEXANDER LUFT;BARBARA J. GITLITZ;CAICUN ZHOU;ELIZABETH BENNETT;ENRIQUETA FELIP;FAN WU;HEATHER A. WAKELEE;HIROTSUGU KENMOTSU;IHOR VYNNYCHENKO;JING YI;MARK L. MCCLELAND;NASSER K. ALTORKI;OLEKSANDR GOLOBORODKO;SHUNICHI SUGAWARA;TIBOR CSÖSZI;YU DENG;YUH‐MIN CHEN;А. Л. АКОПОВ","1094;1079;1079;1079;1079;1079;1079;1079;1079;1079;1079;1079;1079;1079;1079;1079;1079;1079;1079;1079","ANTONIO CHELLA;FRANCESCO MENICHETTI;MARCO FALCONE;GIUSY TISEO;GIANLUCA MASI;CHIARA CREMOLINI;ALFREDO FALCONE;LORENZO FORNARO;MARTA MOSCA;FEDERICO COCCOLINI;DANIELE ROSSINI;RICCARDO MORGANTI;P MALACARNE;CLAUDIO MARCOCCI;MARZIA DEL RE;MICHELE MARINÒ;NICOLA MONTEMURRO;CATERINA VIVALDI;BEATRICE BORELLI;L SUARDI","1094;497;352;340;313;272;271;268;264;258;216;213;212;199;195;192;177;172;165;160","CHIARA CREMOLINI;ALFREDO FALCONE;GIANLUCA MASI;RICCARDO MORGANTI;FEDERICO COCCOLINI;UGO BOGGI;CATERINA VIVALDI;ANNA SONIA PETRONIO;GIULIO ZUCCHELLI;LORENZO FORNARO;FABIO GUARRACINO;MARZIA DEL RE;ROSSELLA ELISEI;FRANCESCO MENICHETTI;LUCA GALLI;MARTA MOSCA;CARLOTTA ANTONIOTTI;MARCO LUCCHI;FERRUCCIO SANTINI;GABRIELE NALDINI","24;23;18;18;16;16;15;13;13;13;12;12;11;11;11;10;10;10;10;10","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;ENGINEERING;MATHEMATICS;CHEMISTRY;ECONOMICS;PSYCHOLOGY;SOCIOLOGY;POLITICAL SCIENCE;PHILOSOPHY;MATERIALS SCIENCE;BUSINESS;GEOLOGY;HISTORY;ENVIRONMENTAL SCIENCE;GEOGRAPHY;ART","618;141;56;40;34;33;30;29;29;23;21;13;10;9;5;5;2;2;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;CARDIOLOGY;PATHOLOGY;GASTROENTEROLOGY;RADIOLOGY;ENVIRONMENTAL HEALTH;GENETICS;INTENSIVE CARE MEDICINE;ENDOCRINOLOGY;PSYCHIATRY;BIOCHEMISTRY;IMMUNOLOGY;CANCER RESEARCH;PALEONTOLOGY;FAMILY MEDICINE;NUCLEAR MEDICINE;GENERAL SURGERY;VIROLOGY","483;200;159;100;87;82;73;62;57;55;51;47;41;41;36;34;32;30;29;28","CANCER;DISEASE;CHEMOTHERAPY;POPULATION;COHORT;GENE;CONFIDENCE INTERVAL;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;CLINICAL TRIAL;HEART FAILURE;RANDOMIZED CONTROLLED TRIAL;ATRIAL FIBRILLATION;OUTBREAK;HEALTH CARE;PROPORTIONAL HAZARDS MODEL;DIABETES MELLITUS;HEPATOCELLULAR CARCINOMA;PROSPECTIVE COHORT STUDY;INCIDENCE (GEOMETRY);LUNG;MYOCARDIAL INFARCTION;TRANSPLANTATION","157;113;63;58;57;56;52;51;34;32;31;30;25;25;22;22;21;21;21;20;20;20;20","COLORECTAL CANCER;INFECTIOUS DISEASE (MEDICAL SPECIALTY);CLINICAL ENDPOINT;HAZARD RATIO;BREAST CANCER;IMMUNOTHERAPY;2019-20 CORONAVIRUS OUTBREAK;EJECTION FRACTION;BEVACIZUMAB;PANCREATIC CANCER;ALLELE;CATHETER ABLATION;GENOTYPE;SORAFENIB;ADENOCARCINOMA;GEMCITABINE;METASTASIS;PHASES OF CLINICAL RESEARCH;LIVER TRANSPLANTATION;NEUTROPENIA;PROGRESSION-FREE SURVIVAL","64;56;32;31;28;26;21;21;17;17;16;16;14;14;13;11;10;10;9;9;9","CORONAVIRUS DISEASE 2019 (COVID-19);IRINOTECAN;CETUXIMAB;KRAS;MICROSATELLITE;NIVOLUMAB;OXALIPLATIN;PEMBROLIZUMAB;METASTATIC BREAST CANCER;REGORAFENIB;SINGLE-NUCLEOTIDE POLYMORPHISM;LENVATINIB;ANTIRETROVIRAL THERAPY;ATRIAL TACHYCARDIA;CAPECITABINE;DABIGATRAN;DNA MISMATCH REPAIR;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;HEART FAILURE WITH PRESERVED EJECTION FRACTION;IPILIMUMAB;NEOADJUVANT THERAPY;STEATOHEPATITIS","56;14;12;12;12;11;11;10;9;8;8;7;6;5;5;5;5;5;4;4;4;4",";HUMANS;FEMALE;MALE;AGED;MIDDLE AGED;RETROSPECTIVE STUDIES;COVID-19;ITALY;COLORECTAL NEOPLASMS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ADULT;TREATMENT OUTCOME;PROGNOSIS;LIVER NEOPLASMS;SARS-COV-2;POSTOPERATIVE COMPLICATIONS;PROSPECTIVE STUDIES;AGED, 80 AND OVER;BREAST NEOPLASMS","348;285;129;114;82;82;77;71;71;65;57;54;46;40;36;34;33;33;29;27","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;PANCREATIC CANCER RESEARCH AND TREATMENT;HEPATOCELLULAR CARCINOMA;MANAGEMENT OF VALVULAR HEART DISEASE;ATRIAL FIBRILLATION;CANCER IMMUNOTHERAPY;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;ADVANCED CARDIAC IMAGING TECHNIQUES AND DIAGNOSTICS;CORONAVIRUS DISEASE 2019;DIAGNOSIS AND TREATMENT OF LUNG CANCER;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;RENAL CELL CARCINOMA;ADVANCEMENTS IN PROSTATE CANCER RESEARCH;ANORECTAL SURGICAL PROCEDURES;CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN CANCER TREATMENT;IMPACT OF COVID-19 ON MENTAL HEALTH;PATHOPHYSIOLOGY AND MANAGEMENT OF GRAVES' OPHTHALMOPATHY","27;26;18;14;13;13;13;12;10;10;8;8;7;7;7;6;6;6;6;6","CLINICAL ENDPOINT;METASTATIC COLORECTAL CANCER;PANDEMIC;2019-20 CORONAVIRUS OUTBREAK;RADIOFREQUENCY ABLATION;STROKE (ENGINE);TREATMENT;HEPATOCELLULAR CARCINOMA;INTERQUARTILE RANGE;MICROSATELLITE INSTABILITY;PANCREATIC CANCER;CONCORDANCE;PROGRESSION-FREE SURVIVAL;TRANSCATHETER AORTIC-VALVE REPLACEMENT;CARDIAC IMAGING;CARDIOVASCULAR RISK ASSESSMENT;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;TUMOR HETEROGENEITY;UNIVARIATE ANALYSIS;ATRIAL FIBRILLATION","34;29;25;19;17;16;15;12;12;12;12;11;11;11;10;10;10;10;10;9","COLORECTAL CANCER;METASTATIC COLORECTAL;CANCER PATIENTS;BREAST CANCER;HEPATOCELLULAR CARCINOMA;ATRIAL FIBRILLATION;COVID- PANDEMIC;HEART FAILURE;LUNG CANCER;PATIENTS TREATED;CELL CARCINOMA;MULTICENTER STUDY;PHASE II;RETROSPECTIVE STUDY;CHECKPOINT INHIBITORS;COHORT STUDY;PANCREATIC CANCER;CELL LUNG;METASTATIC RENAL;PROGNOSTIC FACTORS;CANCER MCRC;HEALTHCARE WORKERS;IMMUNE CHECKPOINT;LIVER TRANSPLANTATION;METASTATIC BREAST;NON-SMALL CELL;RENAL CELL;ADVANCED HEPATOCELLULAR;CLINICAL OUTCOME;CLINICAL PRACTICE","37;35;28;18;16;12;12;12;11;11;10;10;10;10;9;9;9;8;8;8;7;7;7;7;7;7;7;6;6;6","PUBMED SCOPUS;HR CI;PATIENTS TREATED;CLINICAL PRACTICE;CROSSREF PUBMED;SURVIVAL OS;COVID- PANDEMIC;COVID- PATIENTS;MONTHS CI;FUNDING SOURCES;PROGRESSION-FREE SURVIVAL;PATIENTS UNDERGOING;CONFIDENCE INTERVAL;PRIMARY ENDPOINT;STATISTICALLY SIGNIFICANT;HAZARD RATIO;SPEAKERS BUREAU;SURVIVAL PFS;AORTIC VALVE;BREAST CANCER;RESPONSE RATE;CORONAVIRUS DISEASE;COLORECTAL CANCER;MASS INDEX;MEDIAN AGE;MONTHS NA;RISK FACTORS;BODY MASS;MCRC PATIENTS;MEDIAN OS","88;74;65;59;54;48;44;43;41;38;38;37;34;33;33;31;31;31;29;29;28;27;26;26;26;26;26;25;25;25",289,0.45,2.5,40.51,7.8,505.2,45.88,2,638,1.52,1,6,1.64,1,5,0,0,0,3.75,1,23,0,0,0,0,0,0,1.5,1,2,54.92,3,717,1,1,1,1,1,1,45.7,2,612,3,3,3,1,1,1,1.83,1,5,6.93,1,36,34.76,1,573,6.14,1,27,0,0,0,0,0,0,47.55,5,415,47.55,5,415,2,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,5,1.5,0,1,2,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"BERRETTINI STEFANO;DANTI SERENA;STEFANINI CESARE;DE VITO ANDREA;FORLI FRANCESCA;MARRAZZA STEFANO;MILAZZO MARIO","2;2;2;1;1;1;1","AZIENDA OSPEDALIERO UNIV PISANA;AZIENDA OSPEDALIERO UNIVERSITARIA PISANA;UNIV PISA","1;1;1",NA,NA,NA,NA,NA,NA,"A61F;A61F2/18;C12N5/00;C12N5/0775","1;1;1;1","A61F2002/183;A61F2/18;A61F2240/001;A61L2430/14;A61L27/3604;A61L27/3645;A61L27/58;C12M21/08;C12M35/06;C12N2500/38","2;1;1;1;1;1;1;1;1;1",3,853994,113575.12,2.33333333333333,9,2.66666666666667,0.333333333333333,6,"AZIENDA OSPEDALIERA UNIVERSITARIA PISANA;ACADEMIC MEDICAL CENTER;ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS;AZIENDA SANITARIA UNIVERSITARIA FRIULI CENTRALE;CENTRE LÉON BÉRARD;DÉLÉGATION PARIS 11;ERASMUS MC;EUROPEAN ADVANCED TRANSLATIONAL RESEARCH INFRASTRUCTURE - ERIC;HOSPICES CIVILS DE LYON;HOSPITAL UNIVERSITARIO LA PAZ;HÔPITAUX UNIVERSITAIRES DE STRASBOURG;ISTITUTO ORTOPEDICO RIZZOLI;LEIDEN UNIVERSITY MEDICAL CENTER;MADRID HEALTH SERVICE;MAPI RESEARCH TRUST;RADBOUD UNIVERSITY NIJMEGEN;RADBOUD UNIVERSITY NIJMEGEN MEDICAL CENTRE;ST ANNA CHILDREN'S HOSPITAL;UNIVERSITY HOSPITAL FRANKFURT;UNIVERSITY HOSPITAL HEIDELBERG","3;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION;TELETHON FOUNDATION","2;1","COALITION S;EC & ERC - EUROPEAN UNION","2;2","CONNECTING EUROPE FACILITY (PROGRAMME);CSA - COORDINATION AND SUPPORT ACTION (FUNDING SCHEME);H2020-EU.3.1. - SOCIETAL CHALLENGES - HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING (PROGRAMME);SEED GRANT SPRING 2021 KARTAGENER (PROGRAM)","1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3206 MEDICAL BIOTECHNOLOGY;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;46 INFORMATION AND COMPUTING SCIENCES","2;1;1;1;1;1","BIOTECHNOLOGY;GENE THERAPY;GENETICS;LUNG;RARE DISEASES","1;1;1;1;1",NA,NA,"5.2 CELLULAR AND GENE THERAPIES","1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE;B11 COMPUTER SCIENCE AND INFORMATICS","2;1","3 GOOD HEALTH AND WELL BEING","1",36,"FRONTIERS;PUBLIC LIBRARY OF SCIENCE;AMERICAN ASSOCIATION FOR CANCER RESEARCH;ZENODO;KARGER PUBLISHERS;SPRINGER NATURE;TAYLOR & FRANCIS GROUP","15;8;5;4;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;51 PHYSICAL SCIENCES;3202 CLINICAL SCIENCES;31 BIOLOGICAL SCIENCES;42 HEALTH SCIENCES;5105 MEDICAL AND BIOLOGICAL PHYSICS;52 PSYCHOLOGY;40 ENGINEERING;30 AGRICULTURAL, VETERINARY AND FOOD SCIENCES;3006 FOOD SCIENCES;3105 GENETICS;4202 EPIDEMIOLOGY;5203 CLINICAL AND HEALTH PSYCHOLOGY;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;3206 MEDICAL BIOTECHNOLOGY;4003 BIOMEDICAL ENGINEERING;3102 BIOINFORMATICS AND COMPUTATIONAL BIOLOGY;3210 NUTRITION AND DIETETICS;4203 HEALTH SERVICES AND SYSTEMS","54;14;11;10;8;6;6;6;4;3;3;3;3;3;2;2;2;1;1;1","CANCER;CLINICAL RESEARCH;RARE DISEASES;DIGESTIVE DISEASES;BIOTECHNOLOGY;GENETICS;HUMAN GENOME;LUNG;BEHAVIORAL AND SOCIAL SCIENCE;LIVER DISEASE;LUNG CANCER;MENTAL HEALTH;MIND AND BODY;NEUROSCIENCES;PREVENTION;AUTOIMMUNE DISEASE;BIOMEDICAL IMAGING;CHRONIC LIVER DISEASE AND CIRRHOSIS;REGENERATIVE MEDICINE;STEM CELL RESEARCH","10;9;6;5;4;4;4;4;3;3;3;3;3;3;3;2;2;2;2;2","CANCER;CARDIOVASCULAR;INFECTION;METABOLIC AND ENDOCRINE","12;3;1;1","4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;5.2 CELLULAR AND GENE THERAPIES;6.1 PHARMACEUTICALS;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.1 PHARMACEUTICALS;5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES","5;3;2;2;1;1;1","BIOMEDICAL;CLINICAL","10;8","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","22;5","COLON AND RECTAL CANCER;LIVER CANCER;LUNG CANCER;NOT SITE-SPECIFIC CANCER;PANCREATIC CANCER;THYROID CANCER","5;4;4;3;1;1","3 GOOD HEALTH AND WELL BEING;7 AFFORDABLE AND CLEAN ENERGY","5;1",62,3.66,692.97,31,76.15,2,2,13,1,16,0,2,23,3,41,20,0,0,0,0,0,0,60,2,0,58,1,3,0,0,0,0,0,0,0,"United States;Italy;Germany;Japan;Switzerland;France;Ireland;Portugal;United Kingdom","15;11;4;2;2;1;1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3203 DENTISTRY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;46 INFORMATION AND COMPUTING SCIENCES;31 BIOLOGICAL SCIENCES;3204 IMMUNOLOGY;3210 NUTRITION AND DIETETICS;3213 PAEDIATRICS;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4602 ARTIFICIAL INTELLIGENCE","60;31;17;8;8;8;2;2;2;2;1;1;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;RARE DISEASES;HEMATOLOGY;PREVENTION;DIGESTIVE DISEASES;CARDIOVASCULAR;HEART DISEASE;INFECTIOUS DISEASES;AUTOIMMUNE DISEASE;BRAIN DISORDERS;LYMPHOMA;BIOENGINEERING;NEUROSCIENCES;PEDIATRIC;BREAST CANCER;NEURODEGENERATIVE;ORPHAN DRUG","60;45;19;19;19;11;11;10;8;7;7;6;6;6;5;5;5;4;4;4","CANCER;CARDIOVASCULAR;INFLAMMATORY AND IMMUNE SYSTEM;NEUROLOGICAL;ORAL AND GASTROINTESTINAL;INFECTION;METABOLIC AND ENDOCRINE;SKIN;BLOOD;REPRODUCTIVE HEALTH AND CHILDBIRTH;RESPIRATORY;STROKE","16;6;4;4;4;2;2;2;1;1;1;1","6.1 PHARMACEUTICALS;6.2 CELLULAR AND GENE THERAPIES;6.4 SURGERY;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.2 CELLULAR AND GENE THERAPIES;7.1 INDIVIDUAL CARE NEEDS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.2 FACTORS RELATING TO THE PHYSICAL ENVIRONMENT;4.1 DISCOVERY AND PRECLINICAL TESTING OF MARKERS AND TECHNOLOGIES;5.3 MEDICAL DEVICES;7.3 MANAGEMENT AND DECISION MAKING","43;7;5;4;2;2;2;1;1;1;1;1","NON-HODGKIN'S LYMPHOMA;LEUKEMIA / LEUKAEMIA;BREAST CANCER;NOT SITE-SPECIFIC CANCER;BONE CANCER, OSTEOSARCOMA / MALIGNANT FIBROUS HISTIOCYTOMA;SARCOMA;COLON AND RECTAL CANCER;HODGKIN'S DISEASE;LIVER CANCER;BLADDER CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;LUNG CANCER;MYELOMA;STOMACH CANCER","9;7;4;4;3;3;2;2;2;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;5.3 SYSTEMIC THERAPIES - DISCOVERY AND DEVELOPMENT;2.1 EXOGENOUS FACTORS IN THE ORIGIN AND CAUSE OF CANCER;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES;3.3 CHEMOPREVENTION;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS","18;6;2;2;1;1"
"AOU_PISANA",2022,634,17.6324921135647,3.20031545741325,0.312469196648595,0.293375394321767,0.26813880126183,0.235015772870662,0.733438485804416,4,304,152,29,36,0.48,0.24,0.05,0.06,8.53,0.955191758992046,0.3801261829653,0.93217665615142,6.35644191199748,0.476924246995498,0.474798106377054,0.483945347485565,0.50359168241966,"CHIARA CREMOLINI;SARA LONARDI;GIANLUCA MASI;FILIPPO PIETRANTONIO;LUCA GALLI;RICCARDO MORGANTI;GIULIO ZUCCHELLI;MAURIZIA ROSSANA BRUNETTO;NICOLA MONTEMURRO;FEDERICO COCCOLINI;MIRCO COSOTTINI;FERRUCCIO SANTINI;CRISTINA GIANNINI;LORENZO ANTONUZZO;MARIO SCARTOZZI;STEFANO VIANI;MASSIMO SARTELLI;UGO DE GIORGI;CARLOTTA ANTONIOTTI;SEBASTIANO BUTI","41;32;27;23;20;20;19;18;17;16;14;14;14;13;13;13;13;13;13;12","CHIARA CREMOLINI;NICOLA MONTEMURRO;PAOLO BONGIOANNI;RICCARDO MORGANTI;LORENZO GHIADONI;GIULIO ZUCCHELLI;GIANLUCA MASI;SARA LONARDI;MAURIZIA ROSSANA BRUNETTO;GÍANNI BIANCOFIORE;MIRCO COSOTTINI;RAFFAELE DE CATERINA;STEFANO TADDEI;FERRUCCIO SANTINI;STEFANO GENNAI;STEFANO DEL PRATO;MARCO GAMBACCIANI;ANDREA SBRANA;LUCA GALLI;FILIPPO PIETRANTONIO","2.43;2.18;1.93;1.87;1.71;1.49;1.4;1.38;1.35;1.32;1.29;1.27;1.19;1.18;1.17;1.13;1.08;1.07;1.05;1.02","CHIARA CREMOLINI;GIANLUCA MASI;LUCA GALLI;RICCARDO MORGANTI;GIULIO ZUCCHELLI;MAURIZIA ROSSANA BRUNETTO;NICOLA MONTEMURRO;FEDERICO COCCOLINI;MIRCO COSOTTINI;FERRUCCIO SANTINI;CRISTINA GIANNINI;STEFANO VIANI;CARLOTTA ANTONIOTTI;FEDERICA MARMORINO;STEFANO TADDEI;ROBERTO MORETTO;ALESSANDRA BOCCACCINO;ALESSANDRO ORSINI;ANDREA DI CORI;MARTA MOSCA","41;27;20;20;19;18;17;16;14;14;14;13;13;12;12;12;12;12;12;11","CHIARA CREMOLINI;NICOLA MONTEMURRO;PAOLO BONGIOANNI;RICCARDO MORGANTI;LORENZO GHIADONI;GIULIO ZUCCHELLI;GIANLUCA MASI;MAURIZIA ROSSANA BRUNETTO;GÍANNI BIANCOFIORE;MIRCO COSOTTINI;RAFFAELE DE CATERINA;STEFANO TADDEI;FERRUCCIO SANTINI;STEFANO GENNAI;STEFANO DEL PRATO;MARCO GAMBACCIANI;ANDREA SBRANA;LUCA GALLI;ANTONIO DORE;CINZIA MARZUOLO","2.43;2.18;1.93;1.87;1.71;1.49;1.4;1.35;1.32;1.29;1.27;1.19;1.18;1.17;1.13;1.08;1.07;1.05;1;1","SARA LONARDI;CHIARA CREMOLINI;GIANLUCA MASI;FILIPPO PIETRANTONIO;MARCO FALCONE;EMILIANO TAMBURINI;GIUSY TISEO;FRANCESCA BERGAMO;LORENZO ANTONUZZO;FEDERICA MARMORINO;LISA SALVATORE;MASATOSHI KUDO;TIZIANA PRESSIANI;GIOVANNI RANDON;HONG JAE CHON;JAEKYUNG CHEON;LORENZA RIMASSA;NAOSHI NISHIDA;VERONICA CONCA;FRANCESCO MENICHETTI","704;584;558;525;457;374;344;335;321;305;301;296;296;289;289;289;289;289;280;272","CHIARA CREMOLINI;GIANLUCA MASI;MARCO FALCONE;FEDERICA MARMORINO;GIUSY TISEO;VERONICA CONCA;FRANCESCO MENICHETTI;ROBERTO MORETTO;ALESSANDRA BOCCACCINO;CARLOTTA ANTONIOTTI;DANIELE ROSSINI;BEATRICE BORELLI;SIMONA BARNINI;NICOLA MONTEMURRO;CATERINA VIVALDI;CRISTINA GIANNINI;LEONARDO DELLA SALA;ANNA SONIA PETRONIO;FEDERICO COCCOLINI;ALESSANDRA VECCHIONE","551;534;406;304;294;280;272;254;250;224;223;211;204;185;176;168;159;146;144;140","CHIARA CREMOLINI;GIANLUCA MASI;FEDERICO COCCOLINI;GIULIO ZUCCHELLI;LUCA GALLI;NICOLA MONTEMURRO;ANNA SONIA PETRONIO;RICCARDO MORGANTI;CRISTINA GIANNINI;STEFANO VIANI;CARLOTTA ANTONIOTTI;ALESSANDRA BOCCACCINO;ALESSANDRO ORSINI;MAURIZIA ROSSANA BRUNETTO;ANDREA DI CORI;ROBERTO MORETTO;FABIO GUARRACINO;FERRUCCIO SANTINI;LUCA SEGRETI;FEDERICA MARMORINO","33;23;21;19;19;17;14;14;13;13;12;12;12;12;12;11;11;11;11;11","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;PSYCHOLOGY;CHEMISTRY;ENGINEERING;MATHEMATICS;ECONOMICS;SOCIOLOGY;MATERIALS SCIENCE;PHILOSOPHY;POLITICAL SCIENCE;BUSINESS;GEOGRAPHY;GEOLOGY;ART;HISTORY;ENVIRONMENTAL SCIENCE","612;154;60;41;37;36;29;27;26;15;12;11;10;8;6;6;2;2;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;PATHOLOGY;CARDIOLOGY;GASTROENTEROLOGY;GENETICS;RADIOLOGY;ENVIRONMENTAL HEALTH;IMMUNOLOGY;BIOCHEMISTRY;PSYCHIATRY;ENDOCRINOLOGY;CANCER RESEARCH;INTENSIVE CARE MEDICINE;NURSING;NUCLEAR MEDICINE;PEDIATRICS;PALEONTOLOGY;OPTICS","483;176;138;108;88;86;76;71;63;55;48;44;42;40;34;32;29;28;26;24","CANCER;DISEASE;GENE;POPULATION;CHEMOTHERAPY;COHORT;CONFIDENCE INTERVAL;CLINICAL TRIAL;RETROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;ADVERSE EFFECT;HEART FAILURE;PROPORTIONAL HAZARDS MODEL;OBSERVATIONAL STUDY;HEPATOCELLULAR CARCINOMA;PROSPECTIVE COHORT STUDY;ATRIAL FIBRILLATION;MAGNETIC RESONANCE IMAGING;MULTIVARIATE ANALYSIS;ODDS RATIO","146;97;77;61;59;55;52;39;38;36;33;26;23;22;21;20;19;19;19;18","COLORECTAL CANCER;INFECTIOUS DISEASE (MEDICAL SPECIALTY);HAZARD RATIO;IMMUNOTHERAPY;CLINICAL ENDPOINT;BEVACIZUMAB;BREAST CANCER;MUTATION;CATHETER ABLATION;EJECTION FRACTION;SORAFENIB;UNIVARIATE ANALYSIS;PROGRESSION-FREE SURVIVAL;GENE EXPRESSION;ALLELE;GENOTYPE;PROGRESSIVE DISEASE;2019-20 CORONAVIRUS OUTBREAK;LIVER TRANSPLANTATION;PHENOTYPE;PROSTATE CANCER","55;44;36;35;34;20;20;16;13;13;13;13;12;11;10;10;10;9;9;9;9","CORONAVIRUS DISEASE 2019 (COVID-19);NIVOLUMAB;KRAS;RESPONSE EVALUATION CRITERIA IN SOLID TUMORS;CETUXIMAB;OXALIPLATIN;PEMBROLIZUMAB;MICROSATELLITE;IRINOTECAN;IPILIMUMAB;REGORAFENIB;LENVATINIB;SINGLE-NUCLEOTIDE POLYMORPHISM;ANTIRETROVIRAL THERAPY;ATRIAL TACHYCARDIA;CYTOREDUCTIVE SURGERY;HBSAG;IDH1;MEDULLARY THYROID CANCER;METASTATIC BREAST CANCER;PANCREATIC DUCTAL ADENOCARCINOMA;PRIMARY TUMOR","44;21;15;12;10;9;9;8;7;6;6;5;5;4;4;4;4;4;4;4;4;4","HUMANS;;RETROSPECTIVE STUDIES;FEMALE;MALE;COLORECTAL NEOPLASMS;TREATMENT OUTCOME;COVID-19;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;ADULT;COLONIC NEOPLASMS;PROSPECTIVE STUDIES;AGED;LIVER NEOPLASMS;PROGNOSIS;CARCINOMA, HEPATOCELLULAR;MAGNETIC RESONANCE IMAGING;MIDDLE AGED;BREAST NEOPLASMS;DIABETES MELLITUS, TYPE 2","329;295;77;70;57;55;52;48;40;39;37;36;31;31;28;24;24;24;23;23","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;MANAGEMENT OF VALVULAR HEART DISEASE;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;HEPATOCELLULAR CARCINOMA;PANCREATIC CANCER RESEARCH AND TREATMENT;ATRIAL FIBRILLATION;CORONAVIRUS DISEASE 2019;RENAL CELL CARCINOMA;CANCER IMMUNOTHERAPY;CATHETER ABLATION OF CARDIAC ARRHYTHMIAS;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA;CHOLANGIOCARCINOMA;CORONAVIRUS DISEASE 2019 RESEARCH;GENOMIC LANDSCAPE OF CANCER AND MUTATIONAL SIGNATURES;IMPACT OF COVID-19 ON CANCER PATIENTS AND CARE;IMPACT OF COVID-19 ON MENTAL HEALTH;PANCREATIC ISLET DYSFUNCTION AND REGENERATION;ROLE OF LUNG ULTRASOUND IN CRITICAL CARE;SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME","26;22;19;16;15;10;9;9;8;8;8;6;6;6;6;6;6;6;6;6","CLINICAL ENDPOINT;METASTATIC COLORECTAL CANCER;TREATMENT;TRANSCATHETER AORTIC-VALVE REPLACEMENT;PANDEMIC;PROSTHETIC VALVES EVALUATION;CATHETER ABLATION;RADIOFREQUENCY ABLATION;UNIVARIATE ANALYSIS;PROGRESSION-FREE SURVIVAL;STROKE (ENGINE);ATEZOLIZUMAB;REGIMEN;DISCONTINUATION;ECHOCARDIOGRAPHY;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;2019-20 CORONAVIRUS OUTBREAK;CARDIOVASCULAR RISK ASSESSMENT;MITRAL REGURGITATION;PANITUMUMAB","34;27;24;20;16;15;14;14;13;12;12;11;11;10;10;10;9;9;9;9","COLORECTAL CANCER;METASTATIC COLORECTAL;HEPATOCELLULAR CARCINOMA;CELL CARCINOMA;CANCER PATIENTS;BREAST CANCER;AORTIC VALVE;CLINICAL PRACTICE;RENAL CELL;TRANSCATHETER AORTIC;METASTATIC RENAL;MITRAL VALVE;OBSERVATIONAL STUDY;HEART FAILURE;LIVER TRANSPLANTATION;PATIENTS TREATED;PROSTATE CANCER;SINGLE CENTER;ATRIAL FIBRILLATION;CLINICAL TRIAL;ITALIAN SOCIETY;MULTICENTER STUDY;PHASE III;TYPE DIABETES;VALVE IMPLANTATION;VALVE REPLACEMENT;CLINICAL OUTCOMES;COHORT STUDY;COVID- PANDEMIC;CROSS-SECTIONAL STUDY","33;30;18;14;13;12;11;11;11;11;10;9;9;8;8;8;8;8;7;7;7;7;7;7;7;7;6;6;6;6","HR CI;PATIENTS TREATED;PATIENTS UNDERGOING;PROGRESSION-FREE SURVIVAL;INTENSIVE CARE;ADVERSE EVENTS;PUBMED SCOPUS;FUNDING SOURCES;CLINICAL PRACTICE;SURVIVAL OS;CONSECUTIVE PATIENTS;SIGNIFICANT DIFFERENCES;STATISTICALLY SIGNIFICANT;MONTHS CI;RESPONSE RATE;RISK FACTORS;SURVIVAL PFS;COLORECTAL CANCER;MEDIAN AGE;CONFIDENCE INTERVAL;CORONAVIRUS DISEASE;CROSSREF PUBMED;DISEASE ACTIVITY;MEDIAN FOLLOW-UP;PATIENTS RECEIVED;HAZARD RATIO;PRIMARY ENDPOINT;LOW VOLTAGE;METASTATIC COLORECTAL;BREAST CANCER","54;53;51;47;43;42;42;37;36;34;33;32;30;29;29;29;29;28;28;25;25;25;25;25;25;24;24;23;22;21",306,0.48,2.25,37.86,8.9,404.900000000001,43.97,2,718,1.08,1,2,1.28,1,3,0,0,0,3.08,1,30,1,1,1,1,1,1,1,1,1,52.32,2,784,1,1,1,1,1,1,42.46,1,718,0,0,0,1,1,1,1.85,1,6,6.76,1,24,32.68,1,698,5.53,1,45,0,0,0,0,0,0,25.39,2,107,25.39,2,107,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"AOU_PISANA",2023,675,19.5451851851852,3.13333333333333,0.319148936170213,0.281481481481481,0.272592592592593,0.179259259259259,0.712592592592593,3,317,129,28,45,0.47,0.19,0.04,0.07,4.13,0.942004253845788,0.437037037037037,0.933333333333333,5.96521243227827,0.482841116249251,0.463591463982853,0.468009402369913,0.490684629638904,"CHIARA CREMOLINI;SARA LONARDI;GIANLUCA MASI;FILIPPO PIETRANTONIO;CATERINA VIVALDI;FRANCESCA BERGAMO;DANIELE ROSSINI;NICOLA MONTEMURRO;GIULIO ZUCCHELLI;LUCA SEGRETI;MAURIZIA ROSSANA BRUNETTO;RICCARDO MORGANTI;VERONICA CONCA;FEDERICO COCCOLINI;CARLOTTA ANTONIOTTI;R DE LUCIA;LORENZO FORNARO;ANDREA DI CORI;MARCO LUCCHI;GABRIELLA FONTANINI","52;41;37;31;26;23;22;22;20;20;20;20;18;18;18;17;17;17;16;16","CHIARA CREMOLINI;NICOLA MONTEMURRO;SARA LONARDI;RICCARDO MORGANTI;GIANLUCA MASI;FILIPPO PIETRANTONIO;LORENZO GHIADONI;GIULIO ZUCCHELLI;LUCA SEGRETI;MARCO LUCCHI;GABRIELE MATERAZZI;ANDREA DI CORI;R DE LUCIA;RAFFAELE DE CATERINA;ROSSELLA ELISEI;M PAROLLO;VALENTINA BARLETTA;MARCO FALCONE;GABRIELLA FONTANINI;ELEONORA RUSSO","2.55;2.03;1.86;1.8;1.72;1.54;1.5;1.48;1.46;1.42;1.32;1.31;1.31;1.28;1.27;1.24;1.24;1.23;1.23;1.18","CHIARA CREMOLINI;GIANLUCA MASI;CATERINA VIVALDI;DANIELE ROSSINI;NICOLA MONTEMURRO;GIULIO ZUCCHELLI;LUCA SEGRETI;MAURIZIA ROSSANA BRUNETTO;RICCARDO MORGANTI;VERONICA CONCA;FEDERICO COCCOLINI;CARLOTTA ANTONIOTTI;R DE LUCIA;LORENZO FORNARO;ANDREA DI CORI;MARCO LUCCHI;GABRIELLA FONTANINI;M PAROLLO;VALENTINA BARLETTA;MARCO MARIA GERMANI","52;37;26;22;22;20;20;20;20;18;18;18;17;17;17;16;16;16;16;15","CHIARA CREMOLINI;NICOLA MONTEMURRO;RICCARDO MORGANTI;GIANLUCA MASI;LORENZO GHIADONI;GIULIO ZUCCHELLI;LUCA SEGRETI;MARCO LUCCHI;GABRIELE MATERAZZI;ANDREA DI CORI;R DE LUCIA;RAFFAELE DE CATERINA;ROSSELLA ELISEI;M PAROLLO;VALENTINA BARLETTA;MARCO FALCONE;GABRIELLA FONTANINI;ELEONORA RUSSO;RENAT NURMUKHAMETOV;DANIELE FOCOSI","2.55;2.03;1.8;1.72;1.5;1.48;1.46;1.42;1.32;1.31;1.31;1.28;1.27;1.24;1.24;1.23;1.23;1.18;1.14;1.12","CHIARA CREMOLINI;SARA LONARDI;ELENA ÉLEZ;ERIC VAN CUTSEM;THIERRY ANDRÉ;HEINZ‐JOSEF LENZ;ADEL KARDOSH;ANDREA CERCEK;ANDREW L. COVELER;ANDREW SCOTT PAULSON;CHRISTINA WU;CHRISTOS FOUNTZILAS;DAVID L. BAJOR;FEDERICO SANCHEZ;JOHN H. STRICKLER;JOLEEN M. HUBBARD;KIMMIE NG;KRISTEN K. CIOMBOR;PASHTOON MURTAZA KASI;SALVATORE SIENA","386;276;265;210;207;201;198;198;198;198;198;198;198;198;198;198;198;198;198;198","CHIARA CREMOLINI;MAURIZIA ROSSANA BRUNETTO;NICOLA MONTEMURRO;CATERINA VIVALDI;FEDERICO COCCOLINI;MARCO FALCONE;GIANLUCA MASI;MARIA GRAZIA BONGIORNI;GIUSY TISEO;FRANCESCA SALANI;LORENZO FORNARO;FRANCESCO MENICHETTI;DANIELE ROSSINI;MARCO LUCCHI;CRYSTAL MARRUGANTI;VERONICA CONCA;LUCA GALLI;VERONICA SECCIA;ALESSANDRA BOCCACCINO;CARLOTTA ANTONIOTTI","345;148;140;136;133;123;122;112;105;85;83;76;74;74;71;65;62;62;61;56","CHIARA CREMOLINI;GIANLUCA MASI;DANIELE ROSSINI;NICOLA MONTEMURRO;MAURIZIA ROSSANA BRUNETTO;GIULIO ZUCCHELLI;LUCA SEGRETI;RICCARDO MORGANTI;VERONICA CONCA;CARLOTTA ANTONIOTTI;FEDERICO COCCOLINI;LORENZO FORNARO;ANDREA DI CORI;ANNA SONIA PETRONIO;R DE LUCIA;MARCO LUCCHI;M PAROLLO;MARCO MARIA GERMANI;VALENTINA BARLETTA;CATERINA VIVALDI","48;26;22;22;20;19;19;18;18;18;18;17;16;16;16;15;15;15;15;15","MEDICINE;BIOLOGY;PHYSICS;COMPUTER SCIENCE;ENGINEERING;CHEMISTRY;PSYCHOLOGY;ECONOMICS;MATHEMATICS;SOCIOLOGY;POLITICAL SCIENCE;MATERIALS SCIENCE;PHILOSOPHY;GEOLOGY;ART;BUSINESS;GEOGRAPHY;ENVIRONMENTAL SCIENCE;HISTORY","652;150;58;56;40;39;35;21;20;17;15;11;10;6;4;4;4;3;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;CARDIOLOGY;GASTROENTEROLOGY;PATHOLOGY;ENVIRONMENTAL HEALTH;GENETICS;RADIOLOGY;IMMUNOLOGY;PEDIATRICS;PSYCHIATRY;INTENSIVE CARE MEDICINE;CANCER RESEARCH;ENDOCRINOLOGY;BIOCHEMISTRY;GENERAL SURGERY;OPTICS;FAMILY MEDICINE;PALEONTOLOGY","505;206;162;99;96;96;81;71;69;55;53;51;46;41;39;37;34;34;32;31","CANCER;POPULATION;CHEMOTHERAPY;DISEASE;COHORT;GENE;CONFIDENCE INTERVAL;RETROSPECTIVE COHORT STUDY;RANDOMIZED CONTROLLED TRIAL;HEART FAILURE;CLINICAL TRIAL;OBSERVATIONAL STUDY;HEPATOCELLULAR CARCINOMA;THYROID;ADVERSE EFFECT;ATRIAL FIBRILLATION;MYOCARDIAL INFARCTION;PROSPECTIVE COHORT STUDY;ALTERNATIVE MEDICINE;INCIDENCE (GEOMETRY)","171;76;71;68;65;60;53;44;42;34;32;29;26;25;23;23;23;23;22;22","COLORECTAL CANCER;IMMUNOTHERAPY;CLINICAL ENDPOINT;HAZARD RATIO;BEVACIZUMAB;BREAST CANCER;EJECTION FRACTION;ALLELE;INFECTIOUS DISEASE (MEDICAL SPECIALTY);MUTATION;METASTASIS;SORAFENIB;HEPATITIS B VIRUS;UNIVARIATE ANALYSIS;GEMCITABINE;PANCREATIC CANCER;PROGRESSION-FREE SURVIVAL;THYROID CANCER;HEART RATE;PHASES OF CLINICAL RESEARCH;THYROID CARCINOMA;TUMOR MICROENVIRONMENT;TYPE 2 DIABETES","71;48;37;32;31;28;24;18;16;15;14;13;11;11;9;9;9;9;8;8;8;8;8","NIVOLUMAB;CORONAVIRUS DISEASE 2019 (COVID-19);MICROSATELLITE;PEMBROLIZUMAB;CETUXIMAB;HBSAG;OXALIPLATIN;IRINOTECAN;LENVATINIB;KRAS;METASTATIC BREAST CANCER;BILIARY TRACT CANCER;NEOADJUVANT THERAPY;DNA MISMATCH REPAIR;IPILIMUMAB;MODIFIED RANKIN SCALE;REGORAFENIB;VENETOCLAX;ANTIRETROVIRAL THERAPY;BRADYCARDIA;CYTOREDUCTIVE SURGERY;PAPILLARY THYROID CANCER;PLACENTA;PRIMARY TUMOR;RIVAROXABAN;SINGLE-NUCLEOTIDE POLYMORPHISM","29;16;12;12;11;10;9;8;8;7;7;6;6;5;5;5;5;5;4;4;4;4;4;4;4;4",";HUMANS;RETROSPECTIVE STUDIES;FEMALE;TREATMENT OUTCOME;COLORECTAL NEOPLASMS;MALE;ADULT;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;MIDDLE AGED;COLONIC NEOPLASMS;RECTAL NEOPLASMS;STROKE;COVID-19;LIVER NEOPLASMS;PROGNOSIS;AGED;AORTIC VALVE STENOSIS;LUNG NEOPLASMS;BRAIN ISCHEMIA","364;305;83;72;57;47;44;35;30;27;26;26;25;24;24;24;23;23;23;21","ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;MANAGEMENT OF VALVULAR HEART DISEASE;HEPATOCELLULAR CARCINOMA;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;PANCREATIC CANCER RESEARCH AND TREATMENT;ATRIAL FIBRILLATION;CARDIAC RESYNCHRONIZATION THERAPY IN HEART FAILURE;CHOLANGIOCARCINOMA;HEPATITIS B INFECTION AND TREATMENT;CANCER IMMUNOTHERAPY;GENOMIC ABERRATIONS AND TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA;MOLECULAR CHARACTERIZATION OF COLORECTAL CANCER;RENAL CELL CARCINOMA;EPIDEMIOLOGY AND MANAGEMENT OF STROKE;MYASTHENIA GRAVIS AND THYMIC TUMORS RESEARCH;DIAGNOSIS AND TREATMENT OF LUNG CANCER;COLORECTAL CANCER RESEARCH AND TREATMENT;GENETIC AND CLINICAL ASPECTS OF HEMOGLOBIN DISORDERS;PELVIC FLOOR DISORDERS;SARCOMA RESEARCH AND TREATMENT","33;22;15;13;13;12;12;12;11;10;9;9;9;8;8;7;6;6;6;6","CLINICAL ENDPOINT;METASTATIC COLORECTAL CANCER;TREATMENT;ATEZOLIZUMAB;TRANSCATHETER AORTIC-VALVE REPLACEMENT;STROKE (ENGINE);TUMOR MICROENVIRONMENT;BIOMARKERS FOR IMMUNOTHERAPY;PROSTHETIC VALVES EVALUATION;IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR;MICROSATELLITE INSTABILITY;DISCONTINUATION;REGIMEN;ATRIAL FIBRILLATION;PROGRESSION-FREE SURVIVAL;THYROID NODULES;UNIVARIATE ANALYSIS;CONCOMITANT;REFRACTORY (PLANETARY SCIENCE);BILIARY TRACT CANCER","44;37;34;21;19;17;17;14;14;13;13;12;12;11;11;11;11;10;10;9","COLORECTAL CANCER;METASTATIC COLORECTAL;HEPATOCELLULAR CARCINOMA;CANCER PATIENTS;CHRONIC HEPATITIS;OBSERVATIONAL STUDY;AORTIC VALVE;CELL CARCINOMA;BREAST CANCER;PATIENTS PTS;RENAL CELL;RETROSPECTIVE STUDY;CANCER MCRC;LUNG CANCER;ATRIAL FIBRILLATION;BILIARY TRACT;CLINICAL PRACTICE;HEART FAILURE;IMMUNE CHECKPOINT;PATIENTS TREATED;TYPE DIABETES;CHECKPOINT INHIBITORS;PROGNOSTIC IMPACT;TRANSCATHETER AORTIC;COHORT STUDY;MULTICENTER STUDY;PHASE II;PRELIMINARY RESULTS;ADVANCED HEPATOCELLULAR;CLINICAL OUTCOMES","45;42;22;15;13;13;12;12;11;11;11;11;10;10;9;9;9;9;9;9;9;8;8;8;7;7;7;7;6;6","HR CI;PATIENTS TREATED;MONTHS CI;STATISTICALLY SIGNIFICANT;CONSECUTIVE PATIENTS;PROGRESSION-FREE SURVIVAL;SURVIVAL OS;MEDIAN FOLLOW-UP;MONTHS NA;ADVERSE EVENTS;SURVIVAL PFS;CLINICAL PRACTICE;RESPONSE RATE;ASCENDIS PHARMA;PATIENTS UNDERWENT;CONFIDENCE INTERVAL;MEDIAN AGE;SIGNIFICANT DIFFERENCES;AF ABLATION;COLORECTAL CANCER;DISEASE CONTROL;LI DROP;OBSERVATIONAL STUDY;RISK FACTORS;BREAST CANCER;EJECTION FRACTION;HAZARD RATIO;PATIENTS UNDERGOING;SIGNIFICANT DIFFERENCE;MULTIVARIATE ANALYSIS","88;60;57;44;34;34;32;30;30;29;29;28;28;27;27;26;25;25;23;23;23;23;23;23;22;22;22;22;22;21",244,0.36,2.55,85.63,9.75,1112.48,75.57,2,1074,1.56,1,4,1.55,1,3,0,0,0,15.21,1,137,1,1,1,1,1,1,4,4,4,92.3,2,1437,1,1,1,0,0,0,71.25,1,1065,1,1,1,1,1,1,2.63,1,14,10.4,1,133,55.44,1,976,8.47,1,98,0,0,0,0,0,0,11.28,0,77,11.28,0,77,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,5,2,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"CEMPINI MARCO;CORTESE MARIO;GIOVACCHINI FRANCESCO;MOISE MATTEO;VITIELLO NICOLA","1;1;1;1;1","AZIENDA OSPEDALIERO UNIVERSITARIA PISANA;SCUOLA SUPERIORE DI STUDI UNIVERSITARI E DI PERFEZIONAMENTO SANTANNA","1;1","49 MATHEMATICAL SCIENCES;4904 PURE MATHEMATICS","2;1",NA,NA,NA,NA,"A61H1/02;B25J9/00;F16H25/20","1;1;1","A61H1/0277;A61H1/0281;A61H2201/0157;A61H2201/1215;A61H2201/14;A61H2201/1481;A61H2201/1616;A61H2201/1638;A61H2201/1671;A61H2201/1676","1;1;1;1;1;1;1;1;1;1",1,2626812,175120.8,4,15,7,1,0,"AZIENDA OSPEDALIERA UNIVERSITARIA PISANA;CHARITÉ - UNIVERSITY MEDICINE BERLIN;DÉLÉGATION PARIS 11;FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE CASIMIRO MONDINO;ISTANBUL UNIVERSITY;KIEL UNIVERSITY;LEIDEN UNIVERSITY MEDICAL CENTER;MAASTRICHT UNIVERSITY;MEDICAL UNIVERSITY OF VIENNA;NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS;PASTEUR HELLENIC INSTITUTE;SANQUIN;SORBONNE UNIVERSITY;UNIVERSITY HOSPITAL SCHLESWIG-HOLSTEIN;UNIVERSITY OF AMSTERDAM","1;1;1;1;1;1;1;1;1;1;1;1;1;1;1","EUROPEAN COMMISSION","1","COALITION S;EC & ERC - EUROPEAN UNION","1;1","HORIZON-MSCA-2022-DN-01 (CALL FOR PROPOSAL);HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA DOCTORAL NETWORKS (FUNDING SCHEME);HORIZON.1.2 - MARIE SKŁODOWSKA-CURIE ACTIONS (MSCA) (PROGRAMME)","1;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3204 IMMUNOLOGY","1;1","AUTOIMMUNE DISEASE;CLINICAL RESEARCH;RARE DISEASES","1;1;1",NA,NA,"2.1 BIOLOGICAL AND ENDOGENOUS FACTORS","1",NA,NA,NA,NA,"A01 CLINICAL MEDICINE","1",NA,NA,39,"FRONTIERS;AMERICAN ASSOCIATION FOR CANCER RESEARCH;KARGER PUBLISHERS;ZENODO;TAYLOR & FRANCIS GROUP","24;5;5;4;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;3202 CLINICAL SCIENCES;3201 CARDIOVASCULAR MEDICINE AND HAEMATOLOGY;31 BIOLOGICAL SCIENCES;3204 IMMUNOLOGY;3105 GENETICS;52 PSYCHOLOGY;3212 OPHTHALMOLOGY AND OPTOMETRY;3213 PAEDIATRICS;3215 REPRODUCTIVE MEDICINE;47 LANGUAGE, COMMUNICATION AND CULTURE;49 MATHEMATICAL SCIENCES;51 PHYSICAL SCIENCES;5202 BIOLOGICAL PSYCHOLOGY;3208 MEDICAL PHYSIOLOGY;42 HEALTH SCIENCES;4704 LINGUISTICS;5105 MEDICAL AND BIOLOGICAL PHYSICS;5204 COGNITIVE AND COMPUTATIONAL PSYCHOLOGY","70;13;11;8;7;6;4;3;2;2;2;2;2;2;2;1;1;1;1;1","CLINICAL RESEARCH;CANCER;CARDIOVASCULAR;HEART DISEASE;DIGESTIVE DISEASES;RARE DISEASES;BRAIN DISORDERS;DIABETES;LUNG;NEUROSCIENCES;PEDIATRIC;AUTOIMMUNE DISEASE;BEHAVIORAL AND SOCIAL SCIENCE;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;GENETICS;INFANT MORTALITY;LIVER DISEASE;PEDIATRIC RESEARCH INITIATIVE;PERINATAL PERIOD - CONDITIONS ORIGINATING IN PERINATAL PERIOD;REHABILITATION","17;10;10;9;7;4;3;3;3;3;3;2;2;2;2;2;2;2;2;2","CANCER;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;INFLAMMATORY AND IMMUNE SYSTEM;REPRODUCTIVE HEALTH AND CHILDBIRTH;NEUROLOGICAL;RENAL AND UROGENITAL;SKIN","11;8;3;2;2;1;1;1","6.1 PHARMACEUTICALS;2.1 BIOLOGICAL AND ENDOGENOUS FACTORS;2.4 SURVEILLANCE AND DISTRIBUTION;5.1 PHARMACEUTICALS;5.5 RADIOTHERAPY AND OTHER NON-INVASIVE THERAPIES;7.1 INDIVIDUAL CARE NEEDS","11;4;1;1;1;1","CLINICAL;BIOMEDICAL;HEALTH SERVICES & SYSTEMS;POPULATION & SOCIETY","10;6;1;1","CLINICAL MEDICINE AND SCIENCE;BASIC SCIENCE","26;6","LIVER CANCER;NOT SITE-SPECIFIC CANCER;STOMACH CANCER;BREAST CANCER;GALLBLADDER CANCER;LUNG CANCER","4;4;4;1;1;1",NA,NA,20,2.9,1293.8,5,109.9,1,0,5,1,7,0,0,6,0,18,2,0,0,0,0,0,0,18,2,0,20,0,0,0,0,0,0,0,0,0,"United States;Denmark;Germany;Italy","6;2;1;1","32 BIOMEDICAL AND CLINICAL SCIENCES;3202 CLINICAL SCIENCES;3211 ONCOLOGY AND CARCINOGENESIS;52 PSYCHOLOGY;5202 BIOLOGICAL PSYCHOLOGY;3214 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES;3204 IMMUNOLOGY;40 ENGINEERING;4003 BIOMEDICAL ENGINEERING;42 HEALTH SCIENCES;4203 HEALTH SERVICES AND SYSTEMS;4205 NURSING","17;10;4;4;4;2;1;1;1;1;1;1","CLINICAL RESEARCH;CLINICAL TRIALS AND SUPPORTIVE ACTIVITIES;CANCER;PATIENT SAFETY;PREVENTION;CARDIOVASCULAR;RARE DISEASES;BREAST CANCER;DIABETES;DIGESTIVE DISEASES;HEART DISEASE;NUTRITION;BIOMEDICAL IMAGING;BRAIN DISORDERS;HEMATOLOGY;NEUROSCIENCES;AGING;ASSISTIVE TECHNOLOGY;AUTOIMMUNE DISEASE;BEHAVIORAL AND SOCIAL SCIENCE","20;18;7;7;5;4;4;3;3;3;3;3;2;2;2;2;1;1;1;1","CANCER;CARDIOVASCULAR;METABOLIC AND ENDOCRINE;NEUROLOGICAL;RENAL AND UROGENITAL;STROKE","7;3;3;1;1;1","6.1 PHARMACEUTICALS;5.1 PHARMACEUTICALS;4.2 EVALUATION OF MARKERS AND TECHNOLOGIES;5.3 MEDICAL DEVICES;6.3 MEDICAL DEVICES;6.4 SURGERY","14;4;2;1;1;1","BREAST CANCER;COLON AND RECTAL CANCER;ESOPHAGEAL / OESOPHAGEAL CANCER;KIDNEY CANCER;LEUKEMIA / LEUKAEMIA;LIVER CANCER;MYELOMA;PANCREATIC CANCER","4;1;1;1;1;1;1;1","5.4 SYSTEMIC THERAPIES - CLINICAL APPLICATIONS;4.3 TECHNOLOGY AND/OR MARKER TESTING IN A CLINICAL SETTING;5.2 LOCALIZED THERAPIES - CLINICAL APPLICATIONS;3.1 INTERVENTIONS TO PREVENT CANCER: PERSONAL BEHAVIORS THAT AFFECT CANCER RISK;5.5 COMBINATIONS OF LOCALIZED AND SYSTEMIC THERAPIES;6.1 PATIENT CARE AND SURVIVORSHIP ISSUES","5;2;2;1;1;1"
"AOU_PISANA",2024,597,19.9061976549414,2.72026800670017,0.367610837438424,0.209380234505863,0.226130653266332,0.11892797319933,0.591289782244556,0,270,130,36,35,0.45,0.22,0.06,0.06,0.88,0.921908392537407,0.418760469011725,0.95142378559464,4.89675007190108,0.475832510613423,0.428231627296588,0.505503439649781,0.494537563603711,"CHIARA CREMOLINI;SARA LONARDI;MAURIZIA ROSSANA BRUNETTO;GIANLUCA MASI;NICOLA MONTEMURRO;GIULIO ZUCCHELLI;LUCA GALLI;FRANCESCA BERGAMO;FILIPPO PIETRANTONIO;CATERINA VIVALDI;FEDERICO COCCOLINI;LORENZO ANTONUZZO;RICCARDO MORGANTI;MARCO DE CARLO;MARCO FALCONE;MANUEL DE JESUS ENCARNACIÓN RAMÍREZ;MARTA MOSCA;GIUSEPPE FORNARINI;FEDERICA MARMORINO;MARIO SCARTOZZI","29;25;23;22;22;19;18;17;17;16;16;15;15;14;14;14;13;13;12;12","MARCO FALCONE;NICOLA MONTEMURRO;GIULIO ZUCCHELLI;MARCO DE CARLO;ANGELO GEMIGNANI;RICCARDO MORGANTI;CHIARA CREMOLINI;LORENZO GHIADONI;MANUEL DE JESUS ENCARNACIÓN RAMÍREZ;MAURIZIA ROSSANA BRUNETTO;GIUSY TISEO;MARTA MOSCA;DANILO MENICUCCI;ROSSELLA ELISEI;FEDERICO COCCOLINI;NICCOLÒ RICCARDI;RAFFAELE DE CATERINA;SARA LONARDI;FABIO DI MARTINO;ANDREA DI CORI","1.91;1.89;1.72;1.55;1.53;1.39;1.38;1.36;1.35;1.23;1.21;1.13;1.11;1.09;1.06;1.05;1.02;0.97;0.95;0.95","CHIARA CREMOLINI;MAURIZIA ROSSANA BRUNETTO;GIANLUCA MASI;NICOLA MONTEMURRO;GIULIO ZUCCHELLI;LUCA GALLI;CATERINA VIVALDI;FEDERICO COCCOLINI;RICCARDO MORGANTI;MARCO DE CARLO;MARCO FALCONE;MANUEL DE JESUS ENCARNACIÓN RAMÍREZ;MARTA MOSCA;FEDERICA MARMORINO;FABIO DI MARTINO;LORENZO GHIADONI;LORENZO FORNARO;ANDREA DI CORI;LUCA SEGRETI;MARCO MARIA GERMANI","29;23;22;22;19;18;16;16;15;14;14;14;13;12;12;11;11;11;11;10","MARCO FALCONE;NICOLA MONTEMURRO;GIULIO ZUCCHELLI;MARCO DE CARLO;ANGELO GEMIGNANI;RICCARDO MORGANTI;CHIARA CREMOLINI;LORENZO GHIADONI;MANUEL DE JESUS ENCARNACIÓN RAMÍREZ;MAURIZIA ROSSANA BRUNETTO;GIUSY TISEO;MARTA MOSCA;ROSSELLA ELISEI;FEDERICO COCCOLINI;NICCOLÒ RICCARDI;RAFFAELE DE CATERINA;FABIO DI MARTINO;ANDREA DI CORI;STEFANO MASI;ANTONIO MATRONE","1.91;1.89;1.72;1.55;1.53;1.39;1.38;1.36;1.35;1.23;1.21;1.13;1.09;1.06;1.05;1.02;0.95;0.95;0.94;0.94","MARCO TUCCORI;CHIARA CREMOLINI;CARLA CARNOVALE;DANIELE SARTORI;ELISABETTA POLUZZI;EMANUEL RASCHI;PAOLA MARIA CUTRONEO;SALVATORE CRISAFULLI;VERA BATTINI;FEDERICO COCCOLINI;SARA LONARDI;NICOLA MONTEMURRO;FEDERICA MARMORINO;LORENZO FORNARO;FAUSTO CATENA;GIANLUCA MASI;CAROLINA ALVES COSTA SILVA;GUIDO KROEMER;LAURENCE ZITVOGEL;LISA DEROSA","51;42;41;41;41;41;41;41;41;33;31;27;25;25;24;24;22;22;22;22","MARCO TUCCORI;CHIARA CREMOLINI;FEDERICO COCCOLINI;NICOLA MONTEMURRO;FEDERICA MARMORINO;LORENZO FORNARO;GIANLUCA MASI;LUCA GALLI;CATERINA VIVALDI;MARCO FALCONE;MAURIZIA ROSSANA BRUNETTO;RICCARDO MARCONCINI;ANNA SONIA PETRONIO;FABIO DI MARTINO;MARCO FERRARI;MARCO GIANNELLI;FABIOLA PAIAR;MARCO DE CARLO;PAOLO CHIARUGI;ANTONIO CHELLA","51;41;33;27;25;25;24;19;16;15;14;14;12;12;12;12;11;11;11;10","CHIARA CREMOLINI;NICOLA MONTEMURRO;GIANLUCA MASI;MAURIZIA ROSSANA BRUNETTO;GIULIO ZUCCHELLI;FEDERICO COCCOLINI;LUCA GALLI;CATERINA VIVALDI;RICCARDO MORGANTI;FEDERICA MARMORINO;FABIO DI MARTINO;LORENZO FORNARO;MARCO DE CARLO;MARCO FALCONE;MARCO MARIA GERMANI;CRISTINA GIANNINI;ANNA SONIA PETRONIO;FABIOLA PAIAR;FRANCA MELFI;GIUSY TISEO","28;21;20;20;19;18;18;15;13;12;11;11;11;11;10;9;8;8;8;8","MEDICINE;BIOLOGY;COMPUTER SCIENCE;PHYSICS;CHEMISTRY;PSYCHOLOGY;MATHEMATICS;POLITICAL SCIENCE;ENGINEERING;ECONOMICS;MATERIALS SCIENCE;PHILOSOPHY;SOCIOLOGY;GEOLOGY;ART;HISTORY;BUSINESS;ENVIRONMENTAL SCIENCE;GEOGRAPHY","570;122;64;58;39;34;24;23;22;19;14;12;12;10;5;5;4;2;1","INTERNAL MEDICINE;SURGERY;ONCOLOGY;CARDIOLOGY;PATHOLOGY;GASTROENTEROLOGY;INTENSIVE CARE MEDICINE;RADIOLOGY;GENETICS;PSYCHIATRY;CANCER RESEARCH;GENERAL SURGERY;IMMUNOLOGY;ENDOCRINOLOGY;ENVIRONMENTAL HEALTH;ARTIFICIAL INTELLIGENCE;BIOCHEMISTRY;OPTICS;PALEONTOLOGY;PEDIATRICS","432;158;136;86;83;72;66;59;53;47;41;39;37;33;30;29;29;29;27;27","CANCER;DISEASE;CHEMOTHERAPY;GENE;COHORT;RANDOMIZED CONTROLLED TRIAL;POPULATION;RETROSPECTIVE COHORT STUDY;ADVERSE EFFECT;CONFIDENCE INTERVAL;HEPATOCELLULAR CARCINOMA;ATRIAL FIBRILLATION;CLINICAL TRIAL;HEART FAILURE;PROSPECTIVE COHORT STUDY;INCIDENCE (GEOMETRY);OBSERVATIONAL STUDY;THYROID;VIRUS;QUALITY OF LIFE (HEALTHCARE);TRANSPLANTATION","132;77;49;42;41;39;31;29;22;21;20;19;19;19;19;18;17;17;17;16;16","COLORECTAL CANCER;IMMUNOTHERAPY;BEVACIZUMAB;BREAST CANCER;CLINICAL ENDPOINT;HAZARD RATIO;THYROID CANCER;MULTICENTER STUDY;BLADDER CANCER;LIVER TRANSPLANTATION;EJECTION FRACTION;METASTASIS;PHENOTYPE;CATHETER ABLATION;CHRONIC HEPATITIS;MUTATION;PROGRESSION-FREE SURVIVAL;GENOTYPE;INFECTIOUS DISEASE (MEDICAL SPECIALTY);INTERIM ANALYSIS;SORAFENIB;WARFARIN","44;36;19;19;16;14;14;11;10;10;9;9;9;8;8;8;8;7;7;7;7;7","NIVOLUMAB;IRINOTECAN;PEMBROLIZUMAB;CORONAVIRUS DISEASE 2019 (COVID-19);OXALIPLATIN;CETUXIMAB;UROTHELIAL CARCINOMA;HBSAG;LENVATINIB;METASTASECTOMY;RIVAROXABAN;ANTIRETROVIRAL THERAPY;DNA METHYLATION;FUNCTIONAL MITRAL REGURGITATION;KRAS;METASTATIC BREAST CANCER;MILAN CRITERIA;NEOADJUVANT THERAPY;REGORAFENIB;SINGLE-NUCLEOTIDE POLYMORPHISM;SYSTEMIC THERAPY","19;9;9;7;7;6;6;5;5;5;5;4;4;4;4;4;4;4;4;4;4",";HUMANS;FEMALE;MALE;MIDDLE AGED;AGED;ADULT;RETROSPECTIVE STUDIES;TREATMENT OUTCOME;ITALY;AGED, 80 AND OVER;RISK FACTORS;ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;PROGNOSIS;LIVER NEOPLASMS;PROSPECTIVE STUDIES;YOUNG ADULT;ADOLESCENT;ANTIBODIES, MONOCLONAL, HUMANIZED;SURVEYS AND QUESTIONNAIRES","387;207;129;124;96;87;79;48;44;39;38;20;19;18;17;17;16;13;13;13","MANAGEMENT OF VALVULAR HEART DISEASE;ADVANCEMENTS IN COLORECTAL CANCER RESEARCH;ATRIAL FIBRILLATION;HEPATOCELLULAR CARCINOMA;DIAGNOSIS AND TREATMENT OF BLADDER CANCER;EPIDEMIOLOGY AND MANAGEMENT OF NAFLD;HEPATITIS B INFECTION AND TREATMENT;PANCREATIC CANCER RESEARCH AND TREATMENT;MANAGEMENT AND DIAGNOSIS OF THYROID CANCER;RENAL CELL CARCINOMA;CANCER IMMUNOTHERAPY;GASTRIC CANCER RESEARCH AND TREATMENT;CHOLANGIOCARCINOMA;GENETICS AND TREATMENT OF INFLAMMATORY BOWEL DISEASE;MYASTHENIA GRAVIS AND THYMIC TUMORS RESEARCH;PARTICLE THERAPY FOR CANCER TREATMENT;PELVIC FLOOR DISORDERS;COMPLICATIONS AND TECHNIQUES IN THYROID SURGERY;DIAGNOSIS AND TREATMENT OF LUNG CANCER;EFFECTS OF BARIATRIC SURGERY ON OBESITY AND DIABETES","26;18;16;13;11;10;10;10;9;9;8;7;6;6;6;6;6;5;5;5","TREATMENT;METASTATIC COLORECTAL CANCER;TRANSCATHETER AORTIC-VALVE REPLACEMENT;CLINICAL ENDPOINT;ATEZOLIZUMAB;ATRIAL FIBRILLATION;PROSTHETIC VALVES EVALUATION;RADIOFREQUENCY ABLATION;STROKE (ENGINE);BIOMARKERS FOR IMMUNOTHERAPY;BREAST CANCER;HEPATOCELLULAR CARCINOMA;MITRAL REGURGITATION;ANTICOAGULANT THERAPY;CATHETER ABLATION;METASTATIC GASTRIC CANCER;PROGRESSION-FREE SURVIVAL;VALVULAR REGURGITATION;CANCER IMMUNOEDITING;CARDIAC IMAGING","34;22;18;17;11;11;11;11;10;9;9;9;9;8;8;8;8;8;7;7","COLORECTAL CANCER;METASTATIC COLORECTAL;HEPATOCELLULAR CARCINOMA;ATRIAL FIBRILLATION;HEART FAILURE;CELL CARCINOMA;CHRONIC HEPATITIS;OBSERVATIONAL STUDY;BREAST CANCER;RENAL CELL;COHORT STUDY;LUNG CANCER;MULTICENTER STUDY;THYROID CANCER;CANCER MCRC;CANCER PATIENTS;LIVER TRANSPLANTATION;BULEVIRTIDE MONOTHERAPY;MACHINE LEARNING;MITRAL REGURGITATION;PATIENTS PTS;PATIENTS TREATED;PHASE II;RETROSPECTIVE STUDY;UROTHELIAL CARCINOMA;BARIATRIC SURGERY;BILIARY TRACT;CARCINOMA RECEIVING;CLINICAL PRACTICE;EDGE-TO-EDGE REPAIR","24;21;16;13;13;12;12;11;10;10;9;9;9;8;7;7;7;6;6;6;6;6;6;6;6;5;5;5;5;5","CLINICAL PRACTICE;GENETIC TESTING;CROSSREF PUBMED;PUBMED SCOPUS;PATIENTS TREATED;PATIENTS UNDERGOING;COLORECTAL CANCER;GENETIC COUNSELING;CLINICAL REMISSION;ADVERSE EVENTS;SURVIVAL OS;HR CI;CLINICAL TRIALS;CONSECUTIVE PATIENTS;BLOOD PRESSURE;LYNCH SYNDROME;MINIMALLY INVASIVE;CLIN ONCOL;LYMPH NODE;ONCOL -CROSSREF;PROGRESSION-FREE SURVIVAL;SURVIVAL PFS;CLIMATE CHANGE;COMPUTED TOMOGRAPHY;ENDOSCOPIC REMISSION;LUNG CANCER;SIGNIFICANT DIFFERENCES;BREAST CANCER;DISEASE ACTIVITY;DISEASE PROGRESSION","37;33;32;32;30;27;25;23;22;21;21;20;19;19;17;17;16;15;15;15;15;14;13;13;13;13;13;12;12;12",4,0.01,1,3.2,3.2,3.2,4,4,4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,5,5,5,0,0,0,0,0,0,3,3,3,0,0,0,0,0,0,1,1,1,0,0,0,2,2,2,0,0,0,0,0,0,0,0,0,6,6,6,6,6,6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
